Investigation of mechanisms of drug resistance in colorectal cancer: a proteomic and pharmacological study using newly developed drug-resistant human cell line subclones by Duran, M. Ortega
 University of Bradford eThesis 
This thesis is hosted in Bradford Scholars – The University of Bradford Open Access 
repository. Visit the repository for full metadata or to contact the repository team 
  





INVESTIGATION OF MECHANISMS OF DRUG 
RESISTANCE IN COLORECTAL CANCER:                    
A PROTEOMIC AND PHARMACOLOGICAL 
STUDY USING NEWLY DEVELOPED                      





 M. ORTEGA DURAN 









Investigation of mechanisms of drug               
resistance in colorectal cancer:                                      
a proteomic and pharmacological                                     
study using newly developed                                   
drug-resistant human cell line                          
subclones 
 
                                 Mario Ortega Duran 
 
                          Submitted for the Degree of 
                               Doctor of Philosophy 
 
      Faculty of Life Sciences 
                                University of Bradford 






Mario Ortega Duran 
Investigation of mechanisms of drug resistance in colorectal cancer:          
a proteomic and pharmacological study using newly developed drug-
resistant human cell line subclones 
Keywords: Colorectal cancer, 5-Fluorouracil, Oxaliplatin, Irinotecan,              
Drug resistance, Proteomics, SILAC, chemotherapy, protein interactions, 
chemosensitivity assays 
Despite therapeutic advances, colorectal cancer still has a 45% mortality rate, 
and one of the most crucial problems is the development of acquired resistance 
to treatment with anticancer drugs.  
Thus the aims of this project are to develop drug-resistant colon cancer cell 
lines in order to identify mechanisms of resistance for the most commonly drugs 
used in colorectal cancer: 5-fluorouracil, oxaliplatin, and irinotecan. 
Following evaluation of drug sensitivity to these agents in an initial panel of 
eight colorectal cancer cell lines, 3 lines (DLD-1, KM-12 and HT-29) were 
selected for the development of 5-FU (3 lines), oxaliplatin (2) and irinotecan (1) 
resistant sublines by continuous drug exposure, with resistance confirmed using 
the MTT assay. Consistently resistant sublines were subject to a „stable isotope 
labelling with amino acids in cell culture‟ (SILAC) approach and a MudPIT 
proteomics strategy, employing 2D LC and Orbitrap Fusion mass spectrometric 
analysis, to identify novel predictive biomarkers for resistance. An average of 
3622 proteins was quantified for each resistant and parent cell line pair, with on 
average 60-70 proteins up-regulated and 60-70 down-regulated in the drug 
resistant sublines. The validity of this approach was further confirmed using 
immunodetection techniques.    
These studies have provided candidate proteins which can be assessed for 
their value as predictive biomarkers, or as therapeutic targets for the modulation 
of acquired drug resistance in colorectal cancer. 
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1 General Introduction 
1.1  Colorectal Cancer 
Cancer is defined as the abnormal cell proliferation and the uncontrolled growth 
of cells due to a malignant process called neoplasia. Neoplasm is derived from 
the Greek words "neo" meaning new and "plasma" that means “formation” 
(Schwab 2008). When a malignant neoplasia occurs in the large intestine, it is 
called colon cancer, and when the malignant neoplasm occurs 16 cm or less 
distance from the anocutaneous line it is called rectal cancer (Schwab 2008). 
1.1.1 Colorectal Cancer Epidemiology 
Colorectal cancer (CRC) is the third most common cancer in the world after 
lung and breast cancer and the fourth most common cancer in the UK after 
breast, lung, and prostate cancer respectively (Kufe, Pollock et al. 2003). In the 
most recently available global figures from 2012, according to the GLOBOCAN 
2012 project, new CRC cases were estimated to be 1,361,000 (746,000 in men 
and 614,000 in women) (Ferlay, Soerjomataram et al. 2015). Almost 55% of the 
cases occur in developed regions. However, mortality is lower in developed 
regions (694,000 deaths, 8.5% of the total) than in the underdeveloped regions 
of the world with poor sanitary conditions, lack of access to treatments, and 
worst life expectancy (52% of the total deaths) (Ferlay, Soerjomataram et al. 
2015). Age is an important factor in CRC incidence, being the highest incidence 
rates in older men and women. Around 45% of CRC cancer cases are 
diagnosed in people aged 75 years and over, and 95% were diagnosed in 
people aged 50 and over (Kufe, Pollock et al. 2003). Data also shows 
differences according to sex, with around 75 and 58 new CRC cases for every 
100,000 males and females in the UK, respectively (Coley 2004).   
1.1.2 Stages of CRC 
Cell turnover constantly occurs in normal cells of the colon under healthy 
conditions (Rando 2006). During this renewal process of colorectal cells, 
hyperproliferation may occur on the surface of the colon wall, this abnormal 
growth of cells can form a mass of cells known as polyp (Kufe, Pollock et al. 
2003). There are two kinds of polyps: benign or malignant. A benign polyp does 
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not contain any tumour cells inside, can be removed by surgery, and it cannot 
spread to other parts of the body. Malignant polyps do have tumour cells inside 
and they have an abnormal genomic stability, so they can proliferate 
uncontrollably.  
The intestinal glands in the colon are often referred to as colonic crypts. Colon 
crypts are formed from different types of cells. Colorectal cells show specific 
colon crypt location that is related with their features and their differentiation 
level (Fig. 1.1). A crypt contains multiple types of cells: enterocytes that absorb 
water and electrolytes, goblet cells which secrete mucus, enteroendocrine cells 
that secrete hormones, and stem cells at the base of the gland. 
Hence tumour features depends on the biological origin of the cells from where 
the tumour is derived. Most of the heterogeneity at a genetic and transcriptional 
levels found in patients may be observed among the individual CRC cell lines 
used in research (Fig. 1.1). Different CRC cell lines classification are discussed 
in detail below in Chapter 2, section 2.2.  Anguraj Sadanandam et al., 
developed a sorting system to classified CRC in five subtypes according to their 
gene profiling (Sadanandam, Lyssiotis et al. 2013). These five subtypes of CRC 
tumours and cell lines are shown below. 
1) Goblet-like: CRC cells defined by high mRNA expression of goblet-specific 
MUC2 and TFF3. This cell subtype has a high differentiated phenotype. 
2) Enterocyte: CRC cells defined by high mRNA expression of enterocyte-
specific genes. 
3) Stem-like: CRC cells defined by high expression of Wnt signalling targets 
plus stem cell, myoepithelial and mesenchymal genes and low expression of 
differentiation marker. 
4) Inflammatory: CRC cells marked by comparatively high expression of 
chemokines and interferon related genes. CRC samples classified in this group 
normally are associated with MSI status.  




Once the malignant tumour appears, independently of the CRC tumour subtype, 
CRC is classified depending on the level of spread and proliferation, which are 
crucial factors to the success of the invasion process. There are four stages of 
CRC classification, which depend on the survival prognosis for the patient and 
they are described below. Moreover, there is an additional "Stage 0", also called 
carcinoma in situ, which has the best prognosis (Fig. 1.1). 
Stage I – Tumoural mass is localized on the surface of the colon or on the 
surface of the rectum (Fig. 1.1). The cancer is located in the innermost lining of 
the colon or rectum or slightly growing into the muscle layer.  
Stage II –Tumoural mass is entering into the wall of the colon or it has grown 
through the muscle layer of the rectum (Fig. 1.1). 
Stage III - Cancer has penetrated through the wall and it has spread to at least 
one lymph gland in the area close to the colon (Fig. 1.1). 
Stage IV - Cancer has overflowed the lymph glands and it has spread to 
somewhere else in the body, usually into the liver or lung (Fig. 1.1). It is also 
known as advanced CRC. 
For 90% of cases, the survival rate of patients who have been diagnosed with 
stage I is 5 years. However, survival rate decreases to 35-60% if the diagnostic 






Figure 1.1: Different CRC staging. The number of the stage depends on both cancer 
location and cancer spreading. Figure adapted from  (Medico, Russo et al. 2015) and 
from (Terese Winslow LLC, U.S.Govt. 2011). 
1.2 Treatments for CRC: Surgery, radiotherapy, and chemotherapy 
Once a patient has been diagnosed with CRC there are three main treatments: 
surgery, radiotherapy, and chemotherapy. In most cases, a combinational 
treatment of surgery with both radiotherapy or/and chemotherapy is used in 
CRC patients. 
1.2.1 Surgery 
Surgery is always the essential primary treatment for CRC patients. Surgery is 
relatively straightforward in the early stages of CRC and tumours can be 
removed using a colonoscope for guidance (Lacy, Garcia-Valdecasas et al. 
2002). A colonoscope is a long thin flexible tube with a light and a video camera 
attached to its end. The camera transmits the image to a monitor, where 
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doctors can see the inside of the colon. Once the tumour is located, it will be 
removed by surgeons. However, if the tumour has spread into the muscle area 
close to the wall of the colon, a bigger piece of the colon region needs to be 
removed. So, advanced cases require a partial colectomy (Lacy, Garcia-
Valdecasas et al. 2002). After removal of the section of the colon affected by 
cancer, the two remaining portions of the colon are connected and this is called 
anastomosis. Even though surgery is the main treatment for CRC patients, this 
treatment does not always get rid of all the tumour completely (Rodriguez-Bigas 
MA 2003). This is because surgery leaves small clusters of tumour cells that 
cannot be removed or cannot be detected on scans or other tests. Some 
months after surgery, these cancer cells can grow up and proliferate again. If 
the time taken to reappearance of the related cancer symptoms is three months 
or less, the regrowth is referred to as cancer progression by doctors (Kufe, 
Pollock et al. 2003). However, if a patient shows absence of symptoms for at 
least a year before the new regrowth of tumours, the regrowth is referred to as 
cancer recurrence. Therefore, to prevent recurrence and progression of CRC 
after surgery, there are two additional treatments which are normally used to 
complement surgery: radiotherapy and chemotherapy (Kufe, Pollock et al. 2003, 
Rodriguez-Bigas MA 2003, Schwab 2008).  
1.2.2 Radiotherapy 
X-Rays and gamma rays emit ionising radiation energy that is enough to ionise 
atoms, molecules and cause double-strand breaks of DNA. It is called ionising 
radiation because it forms ions by removing electrons from atoms and 
molecules of the cells it passes through. Ionising radiation removes an electron 
from the water inside the cells and free radicals are created. During ionising 
processes, large amounts of damaging free radicals are released. Free radicals 
are unstable molecules and highly reactive due to the presence of an unpaired 
electron that allows them to donate an electron to or accept an electron from 
other molecules, increasing cell damage (Olive 1998, Kufe, Pollock et al. 2003). 
The value of radiotherapy as a cancer treatment lies in the fact that tumours 
often have defective radiation repair pathways, whereas normal cells and 
normal tissues keep a higher capacity to recover from radiation damage (Lliakis 
1991, Olive 1998, Kufe, Pollock et al. 2003). Improvements in radiotherapy 
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applied to CRC patients are taking place over the last decade. There are three 
main types of radiotherapy used in CRC patients- (1) External-beam radiation 
therapy: the radiation is focused on the CRC cancer from an external machine 
and it last from few days to weeks. (2) Internal radiation therapy 
(brachytherapy): a radioactive source is put inside rectum in rectal cancer 
patients, hence adverse effects of radiotherapy in other parts of the body is 
decreased. (3) Systemic radiation therapy: a radioactive substance is injected 
into blood system to travel through the blood to locate and destroy tumoural 
cells. Radiotherapy may be used either before or after an operation to improve 
the success of the surgery or in some cases to alleviate specific symptoms 
caused by cancer (Ismaili 2011, van Gijn, Marijnen et al. 2011).  X-ray radiation 
can be used before surgery to damage the tumour tissue, which would make 
easier to remove the tumour during surgery (van Gijn, Marijnen et al. 2011), but 
also it can be used after surgery in order to decrease the recurrence of cancer 
(van der Meij, Rombouts et al. 2016).  
1.2.3 Chemotherapy 
Chemotherapy is a treatment based on the use of chemical compounds in order 
to damage cancer cells to avoid their spreading and proliferation. Although 
there are different types of chemotherapy, most drugs act during specific 
phases of the cell cycle to stop cells dividing or to cause cell death (Kufe, 
Pollock et al. 2003, Schwab 2008). Normally, chemotherapy is used after 
surgery to avoid the recurrence of cancer (Schrag, Cramer et al. 2001). But, 
chemotherapy can be used before both radiotherapy to make tumour cells more 
sensitive to radiation and before surgery by debulking of tumour, decreasing 
tumour size as much as possible (Nordlinger, Sorbye et al. 2008). Despite the 
broad range of chemotherapies developed to treat CRC patients. There is a 
lack of knowledge in how CRC patient responses differ from patients and 
tumours (Schwab 2008, Group 2012). Chemotherapy has different effects on 
cancer cells with different genomic backgrounds and drug response prediction 
is one of the main issues that need to be answered. Main widespread most 
used chemotherapy agents in CRC patients are discussed and classified below.  
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1) Alkylating agents that act by attaching an alkyl group to DNA by crosslinking 
guanine nucleobases in DNA double-helix strands forming strands unable to 
separate. These drugs are cell-cycle non-specific and normally act during the 
resting phase of cells (Fu, Calvo et al. 2012),  for example, cisplatin and 
oxaliplatin (OXA). Cisplatin cytotoxic effect occurs by its hydrolysis generating a 
highly reactive charged platinum complex [Pt(NH3)2ClH2O]
+ which binds to 
genomic and mitochondrial DNA and produces inhibition of replication and 
transcription processes leading to cell death (Fuertes, Alonso et al. 2003). OXA 
undergoes non enzymatic conversion in physiological solutions resulting into 
reactive species such as dichloro (1,2-diaminocyclohexane) platinum (II) 
(DACHPt), which covalently binds with DNA and macromolecules. Forming 
monoadducts guanine initially, but eventually, OXA attaches simultaneously to 
two nucleotide bases resulting in DNA cross-links between adjacent adenine 
and guanines which cause inhibition of both DNA replication and transcription 
(Kweekel, Gelderblom et al. 2005). 
2) Cell-cycle specific inhibitors as irinotecan (IRI) (Shi, Hui et al. 2014), 
doxorubicin, and paclitaxel. IRI and doxorubicin, are topoisomerase I (Topo I) 
and topoisomerase II (Topo II) inhibitors, respectively. 
3) Antimetabolites are molecules very similar to natural substances which are 
normally presented within the cell and that are required for cellular metabolism. 
Antimetabolites have a cell-cycle specific effect (Tiwari 2012) such as                          
5-fluorouracil (5-FU) that acts as cell-cycle specific by inhibition of Thymidylate 
synthase (TS), a key enzyme in the creation of thymine required for synthesis of 
DNA and RNA. 
Additionally, there are targeted molecules cancer therapies. Targeted therapies 
act on specific molecular targets that are associated with cancer, whereas 
previous chemotherapies mentioned above, act on all rapidly dividing normal 
and cancerous cells. Targeted therapies are designed to block tumour cell 
proliferation (cytostatic) through a specific target (Perez-Herrero and 
Fernandez-Medarde 2015). Two new molecularly-targeted agents are 
Cetuximab (Erbitux) and Panitumumab (Vectibix) that target Epidermal growth 
factor receptor (EGFR). EGFR is a receptor protein with three domains, one 
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external domain, a second domain in the cellular membrane and an internal 
domain. EGFR presents a ligand-induced internalization response with EGF 
and this process mediates signal pathways involved in cell differentiation and 
cell overgrowth (Pettigrew, Kavan et al. 2016). 
To understand how chemotherapy works, it is essential to know what kind of 
mechanisms can turn a normal cell into a tumour cell. Chemotherapy normally 
works by targeting the fast growth of tumour cells. 
During normal health conditions, the turnover of colon epithelial occurs every 
five days. Normally, intestinal epithelial cells are self-renewed by stem cells that 
grow under microenvironment influence (Mathonnet, Perraud et al. 2014). In 
2000, Hanahan and Weinberg published the six Hallmarks of Cancer (Hanahan 
and Weinberg 2000). These authors tried to summarize the complexity of 
cancer in six crucial features of any tumour cell. They thought that these six 
basics hallmarks could explain how a normal cell can be transformed into a 
protumoural cell. In 2011 a newly revised paper was published by Hanahan and 
Weinberg with four additional new hallmarks described (Hanahan and Weinberg 
2011). So, there are ten hallmarks in cancer that are: self-sufficiency in growth 
signals, evading growth suppressors, evading apoptosis signals, evading the 
immune system, alterations in cellular metabolism, genomic instability, 
sustained angiogenesis, activating tissue invasion and metastasis, promoting 
inflammation (Hanahan and Weinberg 2000, Kufe, Pollock et al. 2003, Hanahan 
and Weinberg 2011). The transformation of normal cells to cancer cells 
normally is mediated by some of these hallmarks shown above.  
Normal epithelial cells die by apoptosis and new cells replace them during 
normal cell cycle process. This process is regulated by extracellular and 
intracellular signals that allow the body to renew its cells when they have died 
(Schwab 2008). Colon homeostasis is carried out under this carefully regulated 
process. The loss of homeostatic balance can change into a malignant 
environment that affects growth inhibition, apoptosis, and carcinogenesis 
processes. Carcinogenesis requires the accumulation of different epigenetic 
and genetic alterations that converge in the abnormal growing of colorectal cells 
(Schumacher, Nehmann et al. 2012, Mathonnet, Perraud et al. 2014).  
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Angiogenesis and stem cell characteristic of limitless replicative potential are 
the two major hallmarks of carcinogenesis in CRC and therefore they have 
been the two main targets during the development of novel therapeutic 
treatments (Mathonnet, Perraud et al. 2014). Mutations and alterations in these 
hallmark areas can converge in ineffective therapies and chemotherapy 
resistance (Hanahan and Weinberg 2011). 
Chemotherapy treatment used with each patient depends very much on 
individual‟s specific circumstances and on the type and the stage of cancer 
(Hanahan and Weinberg 2000). Chemotherapy can be administered by different 
routes depending on the place where the tumour area is found and depending 
on the nature of the chemical compound used. Some chemotherapeutic agents 
are contained in capsules and pills, so the chemotherapy can be administered 
orally. A benefit of oral chemotherapy is that it can be ingested by the patient at 
home as another conventional treatment. Chemotherapy can be administered in 
liquids orally, tablets, by intramuscular injections, by intravenous injections (IV) 
or using cannulas (Kufe, Pollock et al. 2003). Duration of chemotherapy 
treatments can take weeks or months. In most of the cases, the patient is 
treated with different chemotherapy drugs in order to improve treatment 
effectiveness (Kufe, Pollock et al. 2003).  
1.2.3.1 Common chemotherapeutics used in CRC 
For more than 60 years, several chemical agents have been extensively used in 
the fight against CRC (Kufe, Pollock et al. 2003). However, this thesis has been 
focused on the most widely used drugs in CRC patients that are: 5-FU, OXA 
and IRI. The mechanism of action and known mechanisms of resistance to 
these three agents will be explained further in detail in their respective Chapters 
3-5, dedicated specifically for each drug. 
1.2.3.1.1 5-FU 
The use of chemotherapy in CRC started in the 1950s when 5-FU was first 
used for advanced CRC patients (Fig. 1.2) (Watson 1964, Ferlay, 
Soerjomataram et al. 2015). 5-FU is an analogue of uracil that once is 
incorporated into DNA and RNA causes cell death by cytotoxicity (Longey 
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2003). Mechanism of action of 5-FU and mechanisms of resistance to 5-FU are 
discussed in greater detail in Chapter 3, section 3.1.1 and 3.1.2. Treatment with 
5-FU consists of a 5-FU dose of 444 mg/m2 injected once daily for 4 successive 
days. Then, a single dose of 370 to 555 mg/m2 is injected per week (Jung, 
Jeung et al. 2007, 2016). Normally, 5-FU is used with folinic acid (leucovorin). 
Leucovorin 20 mg/m2 is administered by injections followed by 5-FU at 425 
mg/m2 in 5 days treatments repeated at 4-week intervals, this chemotherapy 
treatment was approved by the U.S (2016) Food and Drug Administration (FDA) 
in 1991 (Fig. 1.2) (Jung, Jeung et al. 2007). In 2005, a new prodrug of 5-FU 
called capecitabine (Xeloda® Tablets, made by Hoffman-LaRoche Inc.) was 
approved by the FDA in combination with OXA (Hoff, Ansari et al. 2001, Van 
Cutsem, Twelves et al. 2001) as a single treatment for stage III CRC patients 
(Fig. 1.2), showing a higher effectiveness than 5-FU (Van Cutsem, Hoff et al. 
2004). The recommended dose of capecitabine is 1250  mg/m2 administered 
orally twice daily for 2 weeks followed by a 1 week rest period given as 3-week 
cycles during 6 months (Pentheroudakis and Twelves 2002, 2016).  
1.2.3.1.2 OXA 
Another conventional drug used in CRC patients is OXA. OXA is a             
platinum-based drug, which damages the tumour cell by covalent and 
irreversible binding to the negative charges of the DNA (Alcindor and Beauger 
2011). Mechanism of action of OXA and mechanisms of resistance to OXA are 
discussed in greater detail in Chapter 5, section 5.4.3 and 5.4.4. OXA was 
approved in 2004 by FDA to be used in combination with 5-FU and leucovorin 
for adjuvant treatment for stage III CRC patients (Fig. 1.2) (Jung, Jeung et al. 
2007, 2016).  
1.2.3.1.3 IRI 
Another standard treatment for CRC patients is IRI. It is a camptothecin 
derivative. IRI is hydrolyzed by carboxylesterase to an active metabolite, SN-38 
(7-ethyl-10-hydroxycamptothecin) which is conjugated by hepatic uridine 
diphosphate glucuronosyl transferase to SN-38 glucuronide (SN-38G) a Topo I 
inhibitor that causes cell death by apoptosis and it was approved in 1996 for 
advanced CRC patients (Fig. 1.2) (Liu, Desai et al. 2000). Mechanism of action 
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of IRI and mechanisms of resistance to IRI are discussed in greater detail in 
Chapter 4, section 4.4.3 and 4.4.4.  Folfox (folinic acid, 5-FU, and OXA) was 
approved in 2004 (Fig. 1.2) for stage III CRC patients. Treatment is a 
combination of OXA, 5-FU and leucovorin. 
In 2011, Capox (Xelox) (Capecitabine and OXA) was approved to be used in 
stage III and advanced CRC patients (Fig. 1.2) (Diaz-Rubio, Evans et al. 2002). 
Treatment is administered every 21 days, usually for up to 8 cycles as follows: 
Day 1) OXA 130 mg/m2. Followed by 1-14 days of Capecitabine 1,000 mg/m2 
twice daily (Diaz-Rubio, Evans et al. 2002, 2016). 
Finally, FOLFIRI (folinic acid, 5-FU, and IRI) was approved in 2012 (Fig. 1.2). It 
is a combinational treatment of IRI (180 mg/m² injected over 90 min) with folinic 
acid (400 mg/m² [or 2 x 250 mg/m²] over 120 min), followed by 5-FU (400–500 
mg/m²) then 5-FU (2400–3000 mg/m² over 46 h (Klingbiel, Saridaki et al. 2015). 
This cycle is typically repeated every 2 weeks (2016).  
 
 
Figure 1.2: Drug-approval timeline for chemotherapy treatments in CRC patients. 
 
1.3 A review of the known mechanisms of resistance in CRC 
chemotherapy 
 
CRC has a 45% mortality rate due to failings in CRC therapies and one of the 
main barriers to therapeutic success is the development of acquired resistance 
to anticancer drugs (Kufe, Pollock et al. 2003). Chemotherapy resistance is the 
acquired ability of cancer cells to evade the effects of chemotherapeutics 
agents. Most chemotherapy drugs are targeted to specific proteins, so 
mutations or changes in these proteins could result in a reduction in the 
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effectiveness of the drug (Zahreddine and Borden 2013, Housman, Byler et al. 
2014). These changes can be inherently presented in tumours before any 
chemotherapy treatment is administered, or they can be acquired during 
treatment. The main mechanisms that can converge in drug resistance in 
human tumours are: drug efflux, cell epigenetics changes, cell death inhibition, 
DNA repair system failures, drug target alterations and drug inactivation 
(Zahreddine and Borden 2013, Housman, Byler et al. 2014). Tumour‟s 
predisposition to develop these mechanisms differs according to their diverse 
genomic and proteomic features. Therefore, it is necessary to select the best 
drug treatment to use for each patient according to the molecular differences of 
the tumour.  
It is important to know about the genetic profile of the tumour because the 
expression of some specific proteins can play an essential role in sensitivity and 
prognosis during drug treatment, and expression of a specific group of genes 
can be correlated with patient survival as it has been observed in CRC 
(Housman, Byler et al. 2014). Additionally, cross-resistance must be borne in 
mind before the selection of a drug. Cross-resistance can occur when a 
mechanism of resistance for a particular drug converges with resistance for 
another different drug (Zahreddine and Borden 2013). For example, cross-
resistance to gemcitabine (Gem) occurs in HCT116 cell line with acquired 
resistance to decitabine (DAC) by decreasing of Deoxycytidine kinase (dCK), an 
enzyme that phosphorylates deoxyribonucleosides deoxycytidine (Hosokawa, 
Saito et al. 2015). 
 
The complex mechanisms of resistance in CRC cell lines are not completely 
understood and this lack of knowledge is still an issue in cancer research. 
However, as stated above, some mechanisms of resistance are known. These 
known mechanisms of resistance can be considered in two different groups:  
 
1) Mechanisms of multi-drug resistance (MDR) that are reviewed below. 




1.3.1 Known mechanisms of MDR 
MDR is a broad term that includes a high number of molecular strategies that 
tumour cells use to avoid the effects of cytostatic drugs. There exists a high 
number of different cellular mechanisms able to develop MDR.                             
These mechanisms include: changes in membrane transporters (Gottesman 
and Pastan 1993, Scotto 2003), deregulation in autophagy or alteration in 
survival process (Kumar, Zhang et al. 2012), and changes in chromosomal 
instability that can converge in polyploidy (Coward and Harding 2007, 
Erenpreisa, Salmina et al. 2015). These known mechanisms of resistance are 
described in more detail below. 
1.3.1.1 Mechanisms of MDR mediated by membrane transporters 
Under normal extracellular and intracellular environment conditions in cell 
physiology, membrane transporters such as solute carriers (SLC) and ATP-
binding cassette (ABC) transporters can transport and pass solutes, 
macromolecules, and ions into and out of cells. In some unusual environments, 
for example under chemotherapy treatment conditions, extracellular matrix 
microenvironment may be remodelled and some transporters can pump drugs 
outside the cell too (Gottesman and Pastan 1993, Scotto 2003). SLC is a group 
of membrane proteins which includes 43 families and 298 transporter genes 
that mediate the transporter and control uptake and efflux processes of crucial 
compounds such as inorganic ions, nucleotides and amino acids (Hediger, 
Romero et al. 2004). Further, ABC transporters which include 8 subfamilies and 
49 ABC genes can mediate transport of different substances such as lipids, 
carbohydrates, ions and xenobiotics compounds (Hediger, Romero et al. 2004). 
To achieve this aim, membrane transporters use energy from the hydrolysis of 
ATP (Li and Shu 2014). This transport generates and maintains electrochemical 
ion gradients across membranes of the cell and it also can act by itself as a self-
defence mechanism of the cell by actively transporting toxic substances. Drugs 
can be pumped out from the cell to the extracellular space by these transporter 
proteins (Hediger, Romero et al. 2004). So, the cytotoxic agent inside the cell 
tends to decrease due to the efflux by itself and the decrease in both the influx 
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process of the agent into the cell and the cell permeability (Gottesman and 
Pastan 1993).  
Frequently, MDR is identified by a high increase in the expression of ABC 
transmembrane transporters like P-glycoprotein (Pgp) (MDR1) and the 
overexpression of the multidrug resistance-related protein (MRP1) (Gottesman 
and Pastan 1993, Scotto 2003, Schumacher, Nehmann et al. 2012). MDR1 is a 
170 kDa transmembrane glycoprotein. It is one of the best characterized 
proteins involved in avoiding the cytotoxic effects of multiple drugs on tumour 
cells (Mechetner, Kyshtoobayeva et al. 1998, Perez-Herrero and Fernandez-
Medarde 2015). It is overexpressed in malignant cells in order to remove 
chemotherapeutic drugs such as IRI from the cells by an active pathway  (Xu 
and Villalona-Calero 2002). However, the specific role that transmembrane 
transporters play during the development of drug resistance mechanisms is still 
unknown. Focusing on MDR1, CRC cell lines with low levels of MDR1 protein 
were more sensitive to drugs and high levels of MDR1 was an important factor 
during establishment of resistant sublines (Kramer, Weber et al. 1993).  
Other studies have shown that MDR1 positive HT 29 CRC cells proliferate 
much slower than MDR1 negative cells and metastasize less frequently in 
severe combined immunodeficiency (SCID) mice models (Schumacher, 
Nehmann et al. 2012). A deceleration of cell growth could be a mechanism of 
resistance against any drug whose target was the proliferation process. In 
addition, HT 29 CRC cell line with high expression of MDR1 would have more 
time to repair damages in DNA, because MDR1 cells proliferate slower than 
MDR1 negative cell lines.  
Whilst the MDR1 transporter accepts amphipathic cationic compounds and 
neutral compounds as substrates  (Chu, Suzuki et al. 1999),  the MRP1 
transporter family are organic anion transporters that transport anionic drugs 
and neutral drugs. Normally, MRP1 mediates glutathione S-conjugate export 
pump, playing its main role in the glutathione S-conjugates transporting and in 
the transport of glutathione disulfide to the extracellular space, taking a very 
important part in detoxification and defence against oxidative stress (Chu, 
Suzuki et al. 1999). Moreover, it has been shown that ABC proteins can play an 
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important role in camptothecins efflux. It has been demonstrated that both 
MDR1 and MRP1 overexpression are involved in the active efflux of IRI and its 
activated form SN-38 (Chu, Suzuki et al. 1999). Some tumour suppressor 
proteins such as p53 can repress the expression MDR1 and MRP1 proteins (Xu 
and Villalona-Calero 2002, Cai, Miao et al. 2013). Furthermore, decreasing p53 
expression is correlated with MRP1 expression in CRC cancer (Scotto 2003) 
and some p53 mutations can activate MDR1 promotor (Scotto 2003). Another 
gene involved in drug transporter regulation is c-MYC. c-MYC is a gene that 
encodes a transcription factor involved in cell cycle progression, apoptosis and 
cellular transformation  (Kugimiya, Nishimoto et al. 2015). Besides, p53 
regulates ABCB5 (MRP5) expression, another transmembrane transport protein 
which is involved in development of resistance to 5-FU in CRC cell lines 
(Kugimiya, Nishimoto et al. 2015). 
Finally, MDR1 and MRP1 are not the unique members of the ABC family that 
can act like transporters and mediate resistance to cytotoxic agents used in 
CRC therapy, like camptothecins and CPT-11 (IRI) (Chu, Suzuki et al. 1999). 
An additional identified ATP-binding cassette transporter is the breast cancer 
resistance protein (BCRP), that is overexpressed in colon, breast, gastric, and 
ovarian cancer cell lines (Maliepaard, van Gastelen et al. 2001). BCRP 
recognizes and transports a large number of anticancer agents (IRI, SN-38,               
9 amino camptothecin (9-AC) and topotecan) and increases MDR expression 
that mediates efflux of toxic chemical compounds (Ismaili 2011). BCRP is 
involved in camptothecins resistance and its inhibition by  GF120918 (a BCRP 
inhibitor) overcomes the resistant phenotype in human ovarian tumours 
(Maliepaard, van Gastelen et al. 2001). BCRP has been described also as a 
stem cell marker (Nakanishi and Ross 2012).  
To sum up, overexpression of certain family ABC transporter proteins such as 
MRP1, MDR1, and BCRP play crucial roles in the active excretion and efflux of 
chemical agents involved in CRC therapy and consequently, they are potential 
targets for modulation of pharmaceutical therapy (Gottesman and Pastan 1993).  
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1.3.1.2 Mechanisms of MDR mediated by autophagy 
In addition to ABC transporter proteins, autophagy has been implicated in MDR  
(Kumar, Zhang et al. 2012). Autophagy is a normal physiological process in the 
cells that maintains cellular homeostasis. Autophagy regulates protein and 
organelle degradation which may be necessary for generate energy to enable 
continuous cell survival and promote the turnover process of the cells. So, 
baseline levels of autophagy maintain cellular homeostasis and genomic 
integrity (Ryter, Cloonan et al. 2013). Furthermore, autophagy can mediate 
apoptosis and cell death. Autophagy is activated by cells, mainly in response to 
homeostatic stress but also in cellular stress conditions when cells require 
increases in metabolic demand (White 2008).  Autophagy promotes progression 
of tumours by stimulation of cell survival process (Ryter, Cloonan et al. 2013). 
Therefore, autophagy can be considered as a pro-survival mechanism and can 
be used by cancer cells to develop chemotherapy and radiotherapy resistance  
(Lu and Harrison-Findik 2013). In 2010, Jie Li et al., showed that the use of 5-
FU can stimulate resistance by autophagy in CRC cell lines in vitro and in vivo 
(Li, Hou et al. 2010). Consequently, autophagy must be studied as an 
alternative new target for CRC therapy. 
1.3.1.3 Mechanisms of MDR mediated by polyploidy 
Polyploidy is a 2-fold increment or more in the number of the normal set of 
paired (homologous) chromosomes of a cell. Cancer cells can develop 
polyploidization after treatment with some drugs that act by damaging DNA and 
mitotic checkpoints (Cortés, Mateos et al. 2004). Polyploid cells can have 
alterations in the p53 pro-apoptotic pathway, and p53 stimulates p21 protein 
that plays a crucial role avoiding cell division. Besides, p53 regulates 
mechanisms of senescence and its alteration can converge into cancer stem 
cells (CSCs) phenotypes involved in mechanism of resistance to different drugs 
as 5-FU (Coward and Harding 2007, Paschall, Yang et al. 2016). Hence, 
polyploidy is a potential mechanism of resistance to cytotoxic chemotherapy.    
1.3.1.4 Mechanisms of MDR mediated by cancer stem cells 
Cancer stem cells (CSCs) are a very small proportion of the tumour mass and 
can increase their own population by self-renewal (Schwab 2008). CSCs have 
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the capacity to differentiate into heterogeneous lineages of cancer cells. 
Furthermore, CRC stem cells secret a large number of growth factors that 
encourage angiogenesis, which play an important role in tumour 
microenvironment that is involved in CRC progression and metastasis 
(Mathonnet, Perraud et al. 2014). Colorectal CSCs have been shown to take 
part in resistance to chemotherapeutic treatments. Mainly, the resistance of 
CSCs is due to the fact that CSCs have self-renew capacity and show 
overexpression of multidrug transporters involved in resistance to drugs used in 
CRC. Additionally, CSCs show a high level of anti-apoptotic proteins, so they 
have the capacity to deregulate signalling pathways targeted by chemotherapy 
drugs  (Housman, Byler et al. 2014, Mathonnet, Perraud et al. 2014, Vidal, 
Rodriguez-Bravo et al. 2014). Finally, there is evidence that colorectal CSCs 
can develop resistance to drugs by autocrine IL-4 expression. IL-4 is a cytokine 
that inhibits apoptotic signalling. Hence, colon CSCs with high levels of IL-4 can 
avoid the apoptosis caused by 5-FU and OXA (Rich and Bao 2007, Todaro, 
Perez Alea et al. 2008).   
1.4   Experimental approaches for identification of novel mechanisms of 
resistance in CRC 
1.4.1 Understanding of cancer resistance through genomics 
CRC is caused by mutations in multiple genes. Development of resistance to 
chemotherapy agents is also derived from new mutations at the genetic level. A 
global project known as The Human Genome Project (HGP) started in 1990 to 
identify genes that are involved in cancer and abnormal cell development 
(Collins and Mansoura 2001). DNA models with the most frequent variants were 
established using blood samples from healthy people and used to build DNA 
"libraries”. After this achievement, during the last ten years, researchers have 
focused on the analysis and comparison of DNA sequencing of healthy samples 
and many different types of cancer cells (Sjöblom, Jones et al. 2006, 
Consortium 2012). The main idea was to find which mutations are common for 
most of the cancers or those that are more frequently detected in specific 
cancers, such as CRC and breast cancer (Sjöblom, Jones et al. 2006). The next 
step is to know what functions the mutated genes have in CRC. With these 
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approaches, the idea is to build a network map to identify the genetic mutations 
involved in each cancer (Collins and Barker 2007, Hudson, Anderson et al. 
2010) in order to develop the best chemotherapy for each type of tumour 
(McLeod and Evans 2001, Efferth and Volm 2005, Nelson, Wegmann et al. 
2012).  
The main features of CRC cells are genomic instability and accumulation of 
genetic alterations in comparison with normal colorectal cells (Lengauer, Kinzler 
et al. 1998, Fodde, Smits et al. 2001, Grady 2004, Pino and Chung 2010). 
Therefore the most crucial goal of genomics is to identify which of these 
changes are relevant to study (Greenman, Stephens et al. 2007). Tumours are 
formed by cells whose genetics is constantly changing and that respond to a 
microenvironmental stimulus such as chemotherapy (Kreso, O'Brien et al. 
2013). This ongoing change makes possible for a sensitive CRC cell line to 
evolve into in a resistant subline (Kreso, O'Brien et al. 2013).  Mutations that 
cause incapacity of the cell to repair mutations contribute to spreading genomic 
instability and genetic variability of new mutations that may result in 
chemotherapy treatment failures (Pino and Chung 2010). Hence, these 
mutations in regulatory genes such as BCL2 or KRAS and tumour suppressor 
genes such as TP53 play a crucial role in drug resistance development during 
chemotherapy treatment (Scherf, Ross et al. 2000, Violette, Poulain et al. 2002, 
Loupakis, Ruzzo et al. 2009). 
It is known that the total length of the human genome is over 3 billion base pairs 
with around 20,000 to 25,000 encoding genes expressing protein (Fig. 1.3) 
(Consortium 2004). The entire set of proteins in an organism or a cellular 
system is called the proteome. Proteomics is the study of the proteins in a 
biological system, through their identification, modification, quantification and 
localization (Yarmush and Jayaraman 2002). Human proteome is integrated by 
around 18,097 different proteins according to Bernhard Küster from The 
Technical University of Munich (Wilhelm, Schlegl et al. 2014). Similar results 
from Akhilesh Pandey from Johns Hopkins University established that around 
17,294 different proteins are present in the human body (Mathivanan, Ahmed et 
al. 2008). However, this number may be higher as there are protein pathways 
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from the extensive use of alternative pre-mRNA splicing in humans that 
provides the ability to build a very large number of modular proteins (Fig. 1.3) 
(Seo and Lee 2004). Mutations and splicing variants play a crucial role 
increasing the functional diversity of the proteome over time and across the 
tissues that generate variants of the basic protein form (Nilsen and Graveley 
2010). As a consequence, the Human Proteome Organization  (HUPO) 
estimates there are around 500,000 different proteins in the human body (Fig. 
1.3) (Collins and Mansoura 2001).  
          
Figure 1.3: Proteome Complexity. The increasing complexity of the human proteome 
compared with the simplicity of the human genome. Figure adapted from 
Science.energy.gov/ber/ 
1.4.2 Understanding genomics through proteomics 
As discussed above, genomics is complemented and expanded in complexity 
by proteomics (Fig. 1.3). Despite the fact that all human cells contain the 
information for the whole human genome, only a small number of these genes 
are expressed in each type of cell according to its functionality. There is no 
eukaryotic cell that expresses all its genome simultaneously and not all genes 
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are expressed in all cells. It depends on the type of cell and the external or 
intracellular signal pathways that the cell receives. Depending on these signals, 
cells will express a proportion of its genome. Post-translational modifications 
(PTMs) of the proteins may affect their structure, localization, and functionality. 
So, most of proteins are found as multiple forms and this information can be 
investigated through proteomics. There is only one genome for each cell line, 
however, each cell line exhibits different proteomes which change with time 
(Cohen, Geva-Zatorsky et al. 2008, Ly, Ahmad et al. 2014). Genomics helps to 
map the human genome to determine risk factor from a disease, while 
proteomics determines information about the proteins and the current state of a 
disease (Ly, Ahmad et al. 2014).  
For the last sixty years, most of the approaches used to study proteins have 
focused on the study of specific target proteins. So, studying multiple proteins 
has been taken a high costs in time and money resources. However, during the 
last twenty years, proteomics approaches have enabled a global, simultaneous 
overview of multiple proteins. This advance has been possible thanks to the 
interaction of various scientific disciplines as molecular biology, biochemistry, 
physics and bioinformatics (Tyers and Mann 2003). 
1.4.3 Understanding of cancer resistance through proteomics 
Cancer resistance is a complex problem derived from alterations of normal 
cellular proteins functions and these alterations may occur as consequence of 
different molecular biology processes. 
1.4.3.1 Mutational processes  
DNA sequence can suffer from a permanent change that is known as a 
mutation. One type of mutation is the point mutation that results from a change 
of one or two nucleotides at a single location in the DNA sequence. There are 
two types of point mutations: the base substitution, which happens when a 
nucleotide base is switched out with another base, and secondly the frameshift 
mutation, which occurs when a nucleotide base is added (insertion) or removed 
(deletion) from the DNA sequence. During insertion mutations one or few 
nitrogenous bases are added to the DNA sequence, so making DNA sequence 
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longer and altering codon sequences. In deletion mutations, one or a few bases 
are removed resulting in a shortening in the DNA sequence and these also can 
affect to codons. Mutations can affect coding region of DNA sequence, which is 
translated to form proteins and may lead to important changes at protein level. 
These changes in DNA coding sequences affect proteins at different levels such 
as spatial expression, temporal expression, protein–protein interaction (PPIs), 
PTMs, protein turnover process and at the protein expression level.  
1.4.3.2 Transcriptional and Post-transcriptional processes  
Additionally, there are different issues that affect protein levels and are not a 
consequence of mutational processes. These multiple and different regulation 
steps that can affect protein levels are shown below.  
i) Transcriptional regulation process: it is regulated by transcription factors 
(TFs), proteins synthesized in cytoplasm that migrate into the nucleus and 
interact with specific sequence of genes in the DNA and activate transcription. 
Hence, any potential change in a transcription factor protein can affect its 
regulated genes. (e.g., transcription factor p38 blocks the ability of Ras or Raf to 
activate the transcription function of NF-κB, altering protein kinase signalling 
pathways (Baldwin 2001)).  
ii) Post-transcriptional regulation process: after gene transcription, its regulation 
can still occur affecting its protein product through different post-transcriptional 
processes which are summarised below (e.g., alternative splicing of UMPS can 
mediate acquired 5-FU resistance in CRC cell lines (Griffith, Mwenifumbo et al. 
2013)). 
   - RNA processing: Alternative splicing. 
   - RNA stability: Exclusion or inclusion of regulatory elements that play a role in    
RNA stability; Premature stop codon. 
   - Translational: General translation; Regulatory elements in 5' UTR (e.g., 




  -  Protein turnover/modification:  Differential half-lives of the same protein 
isoforms under different conditions  (e.g., ubiquitination directing target proteins 
for proteasomal degradation (Ciechanover 1998)). 
1.4.3.3 Protein alterations modelling chemotherapy resistance 
As described above, some changes caused by mutations in DNA coding 
sequences affect spatial expression of proteins. Changes in spatial expression 
of proteins play an important role in chemotherapy resistance. For example, 
some resistant cancer cells show abnormal patterns of surface receptors such 
as CD95 and TRAIL (Johnstone, Ruefli et al. 2002). Frequently, these receptors 
may receive signals from neighbouring cells or from the microenvironment. 
These signals may be related to activation of apoptotic pathways or activation of 
the immune system. For example the absence of tumour necrosis factor related 
apoptosis-inducing ligand (TRAIL), a member of the tumour necrosis factor 
(TNF) superfamily, correlated to resistance to the inhibitor imatinib mesylate in 
melanoma and resistance to antibodies that target death receptors in breast 
cancer (Mahalingam, Szegezdi et al. 2009, Twomey, Kim et al. 2015). 
Therefore, lack of these apoptotic receptors may result in an interruption of pro-
apoptotic signalling pathways (Twomey, Kim et al. 2015). Furthermore, TRAIL-
receptor endocytosis or up-regulation of apoptosis inhibitors may inhibit the 
signalling of caspase cascade, converging in a resistance phenotype 
(Mahalingam, Szegezdi et al. 2009). 
Other protein changes involved in chemotherapy resistance are related to 
protein-protein interactions (PPIs). PPIs are defined as the physical interactions 
or molecular relationships that two or more proteins have between each other in 
a living system (De Las Rivas and Fontanillo 2010). The whole map of PPIs in a 
live organism is called the interactome (Stumpf, Thorne et al. 2008).                    
It has been estimated that the human interactome contains around 650,000 
PPIs involved in biological human body processes (Stumpf, Thorne et al. 2008, 
De Las Rivas and Fontanillo 2010). There are many different groups of proteins 




TFs are molecules and proteins that take part in the regulation process of gene 
expression by DNA-Protein interaction and PPIs with other proteins.  One of the 
best known TFs involved in cancer is the tumour protein p53 (TP53) (Petitjean, 
Mathe et al. 2007). p53 is a tetrameric complex. Each subunit of the complex 
consists of four domains: C-terminal domain, DNA binding domain, 
tetramerization domain and N-terminal domain (Muller and Vousden 2013). The 
tetrameric p53 complex binds to p53 consensus DNA sequences by the binding 
domain (Muller and Vousden 2013) and mediates the transcription of specific 
genes by RNA Polymerase II. It is known that p53 mutations are presented with 
high frequency in most cancers: 50% in colorectal (Li, Zhou et al. 2015), 
ovarian, oesophageal, lung, larynx, head and neck cancers and around 5% in 
cervical cancer, sarcoma, testicular cancer, malignant melanoma, and primary 
leukaemia (Petitjean, Mathe et al. 2007). These mutations in p53, cause 
changes in the expression of p53 dependant genes and at PPI level as occurs 
with the complexes p53/p21, MDM2/p53 and hDM2/p53 (Petitjean, Mathe et al. 
2007).  
TFs as p53 are especially relevant due to the PPI networks and DNA-binding 
regions where they are involved. DNA-binding proteins such as p53 play a key 
role in repression and stimulation of transcription of a broad range of genes 
involved in multiple biological processes that can be potentially involved in drug 
resistance. Some p53 target genes are involved in cell cycle control, such as 
p21WAF1/CIP1, GADD45, WIP1, MDM-2, EGFR, PCNA, CyclinD1, CyclinG, TGF-α 
and 14-3-3 sigma (Muller and Vousden 2013). Other p53 dependent genes are 
involved in DNA repair like GADD45, PCNA, and p21WAF1/CIP1 (Muller and 
Vousden 2013).  Another group of p53 regulated genes involved in apoptosis 
are: BAX, Bcl-L, FAS1, FASL, IGF-BP3, PAG608, DR5/KILLER, GML, P2XM, 
TSP-1 and BAI1 (Muller and Vousden 2013). Finally, some p53 dependent 
genes are involved in cellular stress response like TP53TG1, CSR, and PIG3 
that also can act as a mediator of drug resistance (Muller and Vousden 2013). 
Alterations in the expression of these proteins, which are involved in crucial 
biology functions of a healthy cell, may result in an uncontrolled growth of the 
cell that will increase tumoural features like aggressive growth, invasion, 
proliferation, development of cancer stages or development of resistant 
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phenotypes and survival pathways (Muller and Vousden 2013). Due to the large 
number of genes regulated by p53 activity, mutations in p53 can play a variable 
role in tumour sensitivity responses to chemotherapy (Breen, Heenan et al. 
2007).  
Other somatic changes that alter proteins involved in drug resistance occur at 
PTMs level. Once the polypeptides chain is synthesised by ribosomes to form 
the protein, but before becoming the mature protein, it may undergo 
modifications. These PTMs include, amongst others, glycosylation, 
phosphorylation, lipidation, methylation, acetylation, and proteolysis and are 
shown below. 
i) Glycosylation consists of the addition of sugar groups that alter the folding 
and conformation of proteins (Shental-Bechor and Levy 2008). Glycosylation is 
a frequent modification in membrane proteins involved in drug transporters and 
membrane surface receptors proteins. Glucosylceramide synthase (GCS) has 
been found to be overexpressed in doxorubicin- and cisplatin-resistant breast 
cancer, CRC, and leukaemia cells (Liu and Li 2013). GCS is an enzyme that 
catalyzes ceramide glycosylation (Liu and Li 2013). Drug treatments increase of 
ceramide that initiates processes of proliferation arrest, apoptosis, and 
autophagy. Overexpression of GCS is a cellular response that by ceramide 
glycosylation can arrest these cellular processes, and thereby protect cancer 
cells from apoptosis. Ceramide glycosylation has been observed in 
development of resistance to doxorubicin, anthracyclines, Vinca alkaloids, and 
taxanes drugs in breast cancer (Liu, Han et al. 2001). In CRC cell lines, 
increasing of GCS expression has been found during drug resistance 
acquisition, in SW-620 colon cell line with 121 fold resistance to doxorubicin and 
1.33 fold GCS expression in HCT-8/VCR  cell line with 4.5 fold resistance to 
cisplatin (Liu and Li 2013).  
ii) Phosphorylation consists of binding of phosphate to proteins, as occurs with 
Src protein, which can be switched from an inactive to an active state through 
control of its phosphorylation state. Normally GCS overexpression is correlated 
with MDR1 levels in cell lines and tumours resistance to drugs (Liu, Gupta et al. 
2010). MDR1 up-regulation by GSC occurs via Src kinase and β-catenin 
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signalling pathways. But up-regulation of MDR1 only occurs under both GSC 
overexpression and phosphorylated Src state conditions. However, the 
complete understanding of this mechanism is unknown, and the unique 
evidence is that blocking of GSC decreases MDR1 expression (Liu, Gupta et al. 
2010).  
iii) Lipidation is adding a lipid component into amino acids.                                     
This modification is normally present in proteins involved in interactions in 
mitochondrial, lysosomal, and plasma membranes. Lipidation modifications 
enhance the hydrophobic character of the proteins and are crucial during 
autophagosome formation. An increase in the number of autophagosomes have 
been observed in HT 29 and HCT116 CRC resistant sublines to 5-FU (Kumar, 
Zhang et al. 2012, Sui, Kong et al. 2014). Additionally, activation of 
autophagosome biogenesis promotes CRC cells survival and this fact has been 
demonstrated by using autophagy inhibitors that may reverse the resistant 
phenotype in CRC cells (Li, Hou et al. 2010, Sui, Kong et al. 2014, Zhang, 
Kumano et al. 2014).  
iv) Methylation consists of the addition of a methyl group (-CH3) into the amino 
acids by methyltransferase enzyme. This PTM is involved in gene expression 
regulation. So, DNA methylation patterns of unregulated cell lines may be found 
with hypomethylation and hypermethylation changes. In gastric cancer patients, 
DNA hypomethylation of some multidrug transporter proteins such as MDR1 
was observed, while DNA hypermethylation was found in genes related to 
apoptosis pathways (Baker and El-Osta 2003, Hervouet, Cheray et al. 2013). 
But the most important methylation occurs in histones. Histone methylation 
causes modification of enzymes associated with tumourigenesis and drug 
resistance. Increases of H2A/H4R3me2 and the two associated enzymes 
PRMT1, PRMT5, have been associated with poor prognosis in prostate cancer 
patients (Seligson, Horvath et al. 2005). Furthermore, expression of 
H3K9me2/3, KMT1, KMT8, KDM1, KDM3, KDM4 have been found increased in 
lymphoma (Braig, Lee et al. 2005) and H3K9me3 with increasing of KMT1, 
KMT8, KDM3, KDM4 in treatment with 5-aza-2′deoxycytidine (5-Aza-CdR) in 
bladder cancer cells (Nguyen, Weisenberger et al. 2002). Also, the use of 
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histone methyltransferase inhibitors is starting to be used to reverse epigenetic 
mechanisms that drive into drug resistance (Lachner, O'Sullivan et al. 2003). 
v) Acetylation process consists of adding an acetyl functional group onto 
specific amino acids. Main acetylation process involved in cancer is related to 
acetylation of histones. Histones are responsible for maintaining chromatin 
shape and structure. Histone acetylation occurs at the amino-terminal tale of the 
histone and it plays a key role in regulation of gene expression. Histone 
acetylation is controlled by the balance of two families of enzymes: Histone 
acetyl transferases (HATs) and histone deacetylases (HDACs). Under histone 
acetyl transferase activity, histones are acetylated and the chromatin structure 
is opened giving access to TFs to stimulate gene expression. There are two 
main types of acetylation in histones. On the one hand, lysine acetylation is a 
reversible PTM of proteins and plays a key role in regulating gene expression 
but with unknown role in cancer resistance. On the other hand, N-acetylation 
consists of the substitution of N-terminal methionine by an acetyl group during 
transcriptional process. Methionine aminopeptidase enzyme cleavages the N-
terminal methionine and the acetyl group replacement is mediated by N-
acetyltransferase enzymes (Marks, Rifkind et al. 2001). Regarding cancer 
resistance, there are histone deacetylase inhibitors (HDACIs), like PCI-24781 
which targets HDAC enzyme of colon carcinoma cells changing the global 
histone acetylation pattern (Marks, Rifkind et al. 2001, Banuelos, Banáth et al. 
2007). HDACIs have been studied for use in MDR in CRC as a novel class of 
anti-tumour drug (Wang, Huang et al. 2016). 
vi) Proteolysis is the process by which a protease enzyme breaks an inactivated 
protein (zymogen form of a protein) to activate the protein. However, the role of 
proteolysis in cancer resistance is unknown. 
1.4.3.4  Proteomics approaches to identify mechanisms of resistance in 
cancer 
Emergence of high-throughput proteomics technology has shed light on the 
complex picture of the mechanisms of drug resistance in cancer. Proteomics 
can be applied to characterizing the mechanisms of drug resistance and to 
identify biomarkers for predicting drug response to chemotherapy. A brief 
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summary of main methods for protein separation and quantification are 
described below. Some of the proteomics approaches which have previously 
been used in identification of mechanisms of resistance in cancer are 
summarized in Table 1.1. 
Proteomics      
approach 
Drug Type of Cancer 
Mechanism 
of resistance 
Author & Publication 
SDS-PAGE             
TOFMS 
Camptothecin Prostate  
Up-regulation of 
ANXA1, GAL3, GST 
Urol Int. 2006 (Hasegawa, 
Mizutani et al. 2006) 









Proteomics 2017 (CRUZ, 
COLEY et al. 2017) 
TOFMS Paclitaxel Non-small-cell lung  
Up-regulation of MET, 
DPP4, PTPRF 
Expert Rev Proteomics  
(Cho 2016) 
SILAC Doxorubicin Breast  
Up-regulation of TKs 
family 
Mol Cell Proteomics 
(Stebbing, Zhang et al. 
2015) 
SDS-PAGE                    
ESI-Q-TOFMS 
Docetaxel Naso-pharyngeal  
Up-regulation of ENO1, 
CNE-2R 
Anticancer Drugs  (Peng, 
Gong et al. 2016) 
SDS-PAGE 






Therapeutics  (Ginés, 
Bystrup et al. 2015) 
SDS-PAGE              
Label-free                         
LC-MS/MS 
5-FU Colorectal 
Up-regulation of NQO1, 
PRDX, and Down-
regulation of CTNNB, 
RhoA 
Proteomics  (Bauer, 
Lambert et al. 2012) 
Table 1.1: Proteomics approaches previously used in discovery of mechanisms of 
resistance in cancer. Key: Time-of-flight mass spectrometry (TOFMS), Electrospray 
ionization (ESI), Sodium dodecyl sulphate polyacrylamide gel electrophoresis          
(SDS-PAGE), Liquid chromatography tandem-mass spectrometry (LC-MS/MS). 
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Most proteomics approaches are used to separate, identified and quantified 
proteins. A brief summary of main methods for protein separation and 
quantification are described below. 
1.4.3.4.1 Proteomics separation approaches 
Proteins exhibit different biophysical and electrostatic properties based on the 
sequence of constituent amino acids. These properties can be exploited to 
separate proteins for subsequent analysis. The traditional proteomics strategy 
to identify proteins is based on protein separation of a sample by one and two-
dimensional polyacrylamide gel electrophoresis which enable proteins to be 
isolated in a band or spot for identification by mass spectrometry.  
One dimensional gel electrophoresis is used to separate proteins based on their 
molecular weights, after unfolding and linearisation of proteins by using of 
chaotropes such as urea and thiourea, and an anionic detergent as sodium 
dodecyl sulphate (SDS). Proteins with lower molecular weights migrate faster 
than proteins with high molecular weights through the polyacrylamide gel 
(Brunelle and Green 2014) (Shi and Jackowski 1998). 
Two-dimensional gel-based separation (2D-PAGE) approach can be used to 
separate proteins through the Isoelectric point (pI) of proteins  (O'Farrell 1975). 
pI is the pH at which the peptide or protein have a net charge of zero. Using  an 
immobilised pH gradient in an isoelectric focusing (IEF) gel it is possible to 
separate proteins based on their pI, when an electric current is passed across 
the gel.  Initially, all proteins are anions with negative charge but when they 
achieve their pI, proteins acquire neutral charge and they stop their movement 
through the electric field. The IEF gel than then be transferred to an SDS-PAGE 
gel for separation based on molecular weight, separating proteins in two 
dimensions. However, in this thesis a proteome screening method is required to 
identify as many proteins as possible, to identify novel biomarkers of drug-
response. 
Hence, Shotgun or Mudpit proteomics was the main approach used in this 
research to obtain an overview of proteome expression in resistant and 
sensitive cell lines. Shotgun proteomics is an indirect measurement method to 
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identify and quantify proteins through peptides derived from proteolytic digestion 
of intact proteins. This global proteomics approach was used to identify and 
quantify as many proteins as possible in resistant and sensitive cell lines. This 
approach required the use of multidimensional chromatographic separation to 
reduce complexity of protein lysates. In this work, columns of strong cation 
exchange (SCX) were utilised as separation technique. The different protein 
lysate fractions obtained by SCX separation contain different groups of proteins 
which are subsequently identified by mass spectrometric analysis in a database 
search.  
1.5 Mass spectrometry 
A mass spectrometer is an instrument to measure the mass and charge of 
molecules to determine their structures. Mass spectrometer ionises molecules 
and then transfer them to an analyser which separates them based on mass 
and/or charge and then detects the separated ions. Proteins and peptides are 
polar, non-volatile, and thermally unstable species that require an ionisation 
approach to transfer them into a gas phase without a high degradation of the 
molecule. To positively ionise a molecule consist of adding a proton or removing 
an electron from the molecule. Protein and peptides form a protonated molecule 
[M + H]+ which produces a peak at an m/z value of M + 1, where M is the mass 
of the analyte. 
The transformation from protein and peptide ions in solution to ions in the gas 
phase is mostly commonly achieved by electrospray ionisation (ESI) in 
combination with heated auxiliary gas. ESI can analyse the mass of polar 
compounds in excess of 100,000 Da (Ashton, Beddell et al. 1994).  
An electrospray needle creates droplets that are electrically charged at their 
surface as a liquid emerges from an interface connected to an High-
performance liquid chromatography (HPLC) system. In electrospray, charge 
density at the surface of the droplets increases as solvent evaporates, while an 
auxiliary gas helps solvent evaporation from the droplets. The electrical charge 
density at the surface of the droplets increases until reaching a critical point 
known as the Rayleigh stability limit. At this point, the droplets divide into 
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smaller droplets because the electrostatic repulsion is greater than the surface 
tension. Finally, electrostatic repulsion ejects sample ions from the very small, 
highly charged droplets into the gas phase. The sample ions enter the mass 
spectrometer through the ion transfer tube where they are analysed according 
to their mass-to-charge (m/z) ratio.  
There are two main types of mass spectrometers used for proteomics, primarily 
depending on how the samples are prepared (gel electrophoresis or liquid 
chromatography): Time-of-Flight Mass Spectrometer and Quadrupole-Orbitrap 
Mass Spectrometer. 
a) Time-of-Flight Mass Spectrometer 
In the ToF Mass Spectrometer, which most frequently employs matrix-
associated laser desorption ionisation (MALDI), ions are formed by firing a 
pulse of laser-generated photons at the samples. Singly charged ions of same 
kinetic energy, but different m/z ratio, are separated by time of flight over an 
identical path between the ion source and the detector. Heavy particles travel 
more slowly and arrive at the detector later than light particles. 
b) Quadrupole-Orbitrap Mass Spectrometer 
The Quadrupole-Orbitrap Mass Spectrometer was used for data presented in 
the thesis. Once the ionised analytes have entered into the mass spectrometer, 
they pass through an ion accelerator and a mass filtering quadrupole that 
consists of four parallel metal rods forming an electric passage. The trajectory 
of flight of ions during travelling between the four rods is affected by the applied 
voltages from the rods. The mass spectrum is obtained by monitoring ions' 
movement through the quadrupole filter voltages and that depends on the ions 
m/z ratios. 
After the ionised sample has crossed the linear ion accelerator and the mass 
filter, parent ions will enter the Orbitrap analyser via the C-trap. Before starting 
the analysis of any sample, an initial injection of a fixed number of ions of a 
known compound is analysed for a robust internal calibration of each spectrum. 
Finally, specific parent ions are ejected through a lenses system from the C-
Trap to the Orbitrap (Fig. 1.4).  
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Once parent ions have entered the Orbitrap, the central electrode of the 
Orbitrap is charged by voltage. Due to the electrode voltage, parent ions are 
forced to oscillate with different frequencies of the trapped ions as they move 
across the trap spindle and drawing different orbits around the Orbitrap. Each 
peptide has different harmonic oscillation frequencies which are derived from 
their particular m/z values. After ions with different m/z ratio have entered into 
the Orbitrap and move far enough from the outer electrodes, the voltage on the 
central electrode is stabilised and the detection can occur. According to the 
parent ion intensity, a parallel quantification of peptide abundance may be 
carried out to quantify peptide abundance in the sample.  
After parent ion isolation, they are fragmented by collision-induced dissociation 
in a neutral gas phase, normally helium, nitrogen or argon. During the collision, 
some of the kinetic energy is converted into internal energy which results in 
bond breakage and the fragmentation of the molecular ion into smaller 
fragments. These fragment ions are detected at the ion trap (Fig. 1.4). 
Comparisons of m/z fragment ion spectra are used in an algorithm that allows 
performing database searches which lead to peptide identification. The data 
acquired by the Orbitrap, is transferred to a database search engine, such as 
Mascot to compare the experiment spectra with an in silico database of all 




Figure 1.4: Schematic diagram of an Orbitrap mass spectrometer and Orbitrap 
Analyser. Figure adapted from © Thermo Fisher Scientific. 
1.5.1 Approaches in quantitative proteomics 
Three main approaches are Multiple Reaction monitoring (MRM) / Parallel 
reaction monitoring (PRM), Isobaric Tags for Relative and Absolute Quantitation 
(iTRAQ) and Stable Isotope Labelling by Amino acids in Cell culture (SILAC), 


























High yield, Robust, 
Sensitive and simple 
Available for cell/tissue culture only, 




type of samples, 
Good quantitation 
Required high amount of protein, 




Required low amount 
of protein, High 
proteome coverage, 
Low cost (avoid 
labelling) 
High instrumentation quality, High 
abundance of proteins required, 
Incomplete digestion introduce error, 
More than one experiment required 
for multiple analysis 
Table 1.2: Main advantages and disadvantages of main Gel-Free proteomics 
approaches. 
1.5.2 Multiple reaction monitoring (MRM) and Parallel reaction monitoring 
(PRM) 
MRM has high sensitivity, high selectivity, and robust quantification to identify a 
target peptide with a high confidence. MRM is a label-free method that makes 
possible to quantify hundreds of proteins by analysis of fragments from specific 
proteotypic peptides ionized (Fig. 1.7) (Rauniyar 2015). Fragmentation of ions is 
carried out in the gas phase by Higher-energy collisional dissociation (HCD) 
(Rauniyar 2015). Ions are accelerated by electrical potential to high kinetic 
energy until hitting against neutral molecules as helium, nitrogen or argon. Ions 
are fragmented and distributed in different clusters according to their masses to 
eliminate background and interferences. In MRM method, samples are 
processed independently, and once mass spectrum analysis has been done on 
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a single product ion selected, results of relative abundance of specific peptides 
will be compared between two or more samples (Fig. 1.7) (Rauniyar 2015). 
However, PRM method is a variant of tandem mass spectrometry (MS/MS), 
where detection of all product ions occurs in parallel, in a single analysis using a 
high resolution mass spectrometer, known as Orbitrap mass analyser (Zhou 
and Yin 2016). The method required adding of synthetic peptide standards to 
prepare calibration curves for relative quantification, alternatively, stable isotope 
labelled standard peptides can be added to the sample for absolute 
quantification as occurs with the SILAC approach used in the thesis. 
It is the main method to quantify protein relative abundances in mammalian 
cells (e.g., MCF-7 breast and SW480 CRC cell lines have been investigated by 
PRM to identify altered proteins involved in metabolic processes (Drabovich, 
Pavlou et al. 2012, Kim, Lin et al. 2015, Rauniyar 2015). 
1.5.3 Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) 
iTRAQ is proteomics relative quantification technique based on the labelling of 
peptides with a compound that produces isobaric fragments, or reporter ions, 
that are detected only under MS/MS or MS3 conditions. Isobaric reagents used 
for chemical labelling contain an amino-reacting group, a balance group and a 
reporter group (Fig. 1.5) (Seligson, Horvath et al. 2005). Firstly, isobaric 
reagents are used to label the amino groups of the peptides. These isobaric 
reagents are an N-methyl reporter group with different masses and an N-
hydroxysuccinimide ester group that reacts with the amines of the peptides to 
be attached (Seligson, Horvath et al. 2005). Each isobaric reagent has an 
additional balance group giving the same final mass to all peptides, 
independently of the N-methyl reporter group attached to the peptide. All 
peptides are labelled according to their specific masses (Seligson, Horvath et 
al. 2005). iTRAQ labelled samples are analysed by mass spectrometry in 
MS/MS mode to generate (a) fragments from the peptide and (b) fragments 
from the reporter ions, the intensities of which enable relative quantification 
(Seligson, Horvath et al. 2005) (Fig. 1.7).  iTRAQ has been successfully used to 
find that low expression level of β-catenin combined with the up-regulation of 
Calcyclin binding protein (CacyBP) promote metastatic processes in CRC: 1140 
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unique proteins were identified in SW480 and SW-620 CRC cell lines and, 147 
of those proteins showed significant changes in expression between healthy 
and metastatic cells (Ghosh, Yu et al. 2011). 
              
Figure 1.5: Isobaric reagent used in iTRAQ methodology. Figure adapted from         
© Ross PL, Huang YN, et al., (2004). 
1.5.4 Stable Isotope Labelling by Amino acids in Cell culture (SILAC) 
This proteomics study has been carried out using stable isotope labelling by 
amino acids in cell culture (Seligson, Horvath et al. 2005, Zhang, Xu et al. 2014) 
(SILAC), a relative quantification and label method. SILAC was described 
initially by Pratt et al., in 2002 (Pratt, Robertson et al. 2002). The principle of 
SILAC is based on replacement of the natural (light isotopes) amino acids with 
(Seligson, Horvath et al. 2005) isotopes with higher mass number than the 
original atom called heavy isotope- amino acids.  An isotope is an atom of an 
element with higher or lower number of neutrons than the original chemical 
element, but with the same number of protons and electrons than original 
element. The physicochemical properties and features of light and heavy 
isotopes are equal. Hence, the only difference between the original atom and its 
isotope is related to mass number that can be detected by a mass spectrometer 
(Seligson, Horvath et al. 2005). 
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To make possible the replacement of light amino acids with heavy amino acids 
that contain heavy isotopes, cells need to take the heavy amino acids from their 
medium (Fig. 1.6) (Zhang, Xu et al. 2014).  To be sure that cells take heavy 
(labelling) amino acids from the medium, just essential amino acids are selected 
for labelling in SILAC experiments (Seligson, Horvath et al. 2005). An essential 
amino acid is an indispensable amino acid that cannot be synthesized by cells 
and is limited by special pathophysiological conditions. There are nine amino 
acids that humans cannot synthesize: phenylalanine, valine, threonine, 
tryptophan, methionine, leucine, isoleucine, lysine, and histidine. Arginine is 
also used during labelling process because it is a semiessential or conditionally 
essential amino acid that is used by cells during proteins biosynthesis. 
Normally, to carry out SILAC experiments, the 12C and the 14N element are 
chosen to produce the stable isotopes 13C and 15N by adding an extra neutron 
into the atoms of the element (Fig 1.6). Stable isotopes will form part of the 
heavy amino acids (Fig. 1.6). 
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Figure 1.6: Light / Heavy lysine and arginine amino acids for SILAC approach.                             
© Thermo Fisher Scientific. 
Labelled amino acids presented in SILAC media can be metabolically 
incorporated by cells, which will use them during peptide biosynthesis. 
Maintaining cells in media with heavy amino acids (heavy medium) during more 
than six doublings will lead to the incorporation of heavy peptides into most of 
the proteins of the cells that will show the isotope labelling (Fig. 1.7) (Seligson, 
Horvath et al. 2005, Zhang, Xu et al. 2014). Finally, proteomics study of the 
cells starts with the lysis of the cells and the extraction of the proteins (Fig. 1.7) 
(Zhang, Xu et al. 2014). Later, proteins will be digested into peptides and a 
mass spectrometer will make possible to discern peptides from cells growth in a 
heavy amino acids medium from cells growth in a normal light medium (Fig. 1.7) 
(Seligson, Horvath et al. 2005). The relative abundance of the labelled and non-
labelled peptides will correspond to the amount of protein present in the cells of 
the study. SILAC approach has been used to quantify and analyse different 
proteome expression in normal bladder cells and bladder cancer cells, 3721 
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proteins were identified and 110 proteins were found with different expression 
levels (Zhang, Xu et al. 2014, Yang, Xu et al. 2015). SILAC in CRC has been 
used to study secretome in CRC metastatic cells (Barderas, Mendes et al. 
2013, Zeng, Yang et al. 2013)  and combined with microarray analysis to study 
changes of mRNA expression (Kaller, Liffers et al. 2011, Zhang, Xu et al. 2014). 
Advantages of SILAC over iTRAQ and label-free approaches have been shown 




Figure 1.7: Summary scheme of main quantitative proteomics approaches used to 
identify mechanisms of resistance in cancer. Graphic adapted from © Thermo Fisher 




1.6 Aims & Objectives 
As has been reviewed in this introduction (see section 1.3), and it will be see in 
Chapters 3-5, CRC acquired resistance depends on the drug‟s mechanism of 
action and the capacity of the cells to reduce the pathway-targeted anticancer 
effect of drugs. So, most of the molecular mechanisms of resistance that are 
known are based on the biochemistry and metabolism of these drugs. However, 
overall five-year survival rate for CRC (stage II-III) is 45%. Hence, it is probable 
that there exist unknown mechanisms of  acquired resistance to therapy. 
Therefore, the main aim of this Ph.D. project is focused on developing new 
drug-resistant human subclones which can be used to identify these novel 
mechanisms of resistance in CRC, and also as experimental models for 
evaluation of novel therapies which may overcome drug resistance that would 
explain the lack of success in the current chemotherapies strategies in CRC. 
To achieve this aim, the objectives of this research will be as follows: 
1) Selection of suitable cell lines for development of resistant sublines from a 
CRC cell line panel. 
2) Establishment of drug resistant sublines of the CRC lines for one of the three 
most common CRC chemotherapeutics, 5-FU, IRI, OXA and characterise cell 
lines for cross-reactivity with other anti-cancer agents. 
3) Identification of novel mechanisms of drug resistance using a proteomic 
approach. 
4) Validation of the proteomics results using immunodetection techniques to 
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Selection of CRC cell lines 








2 Selection of CRC cell lines for use in resistance studies 
One of the leading causes of high mortality rate in advanced CRC is acquired 
resistance to therapeutic treatment. 5-FU, IRI and OXA are the main 
postoperative treatments for CRC patients. In order to identify new mechanisms 
of resistance, three different CRC cell lines were chosen to establish more than 
three resistant sublines by continuous exposure to 5-FU, IRI and OXA.  
2.1 Heterogeneity of CRC cell lines 
To choose the three most relevant CRC cell lines to be used during 
development of resistant sublines by long-term drug exposure,  it is necessary 
to know what differences in growth rate, attachment features, shape, size and 
genetic background are presented in different CRC cell lines. One of the main 
advantages of working in cell culture is maintaining homogeneity of cell lines. 
Knowing cell lines growth features allows synchronizing cells at different stages 
of the cell cycle in a culture, bringing to the same phase different types of cell 
lines which differ in term of growth rates. This makes possible to compare 
chemical compounds or drugs on specific cell lines at a specific stage of the cell 
cycle, increasing consistency and reproducibility of results. 
Molecular heterogeneity observed in patients is maintained in CRC cell lines 
and it may be observed when CRC cell lines are classified in different subtypes 
according to their gene expressions and transcriptional features. There are five 
different classifiers which differ from algorithms used to establish different 
subtypes of CRC cell lines. However, the CRC-assigner (CRCA) classification 
system established by Sadananman et al., showed the highest overlap with all 
other classifiers (Sadanandam, Lyssiotis et al. 2013). Enzo Medico et al. also 
found that main mutations in oncogenes (KRAS, NRAS, BRAF, PIK3CA, PTEN)  
found in the clinic, were represented in the same proportion in a sample 
collection of 103 CRC cell lines (Medico, Russo et al. 2015). Genetic 
background and mutation landscape of four commonly altered oncogenes in the 
clinic are shown in Table 2.1. Molecular heterogeneity between the eight CRC 
cell lines analysed, may partially explain differences among the anti-proliferative 




2.2 Criteria for selection of a cell line for resistance studies 
There are many drugs that are used to treat CRC patients (see Chapter 1,              
Fig. 1.2). Usually, combinations of several of these drugs are used in order to 
enhance the effects of the chemotherapy. Most of these chemotherapies are 
based on the combination of the three most used drugs in CRC patients that 
are: IRI, 5-FU, and OXA (Kufe, Pollock et al. 2003, Ismaili 2011) (Fig. 2.1) and 
their chemical structures are shown below (Bandrés, Zárate et al. 2007).  
 
Figure 2.1: Chemical structures of three conventional drugs used in CRC 
chemotherapy. 
Whilst the principal mechanisms of resistance for these three conventional 
drugs are known and explained in three dedicated chapters for each one of the 
drugs studied: 5-FU, IRI and OXA (see Chapters 3-5), there is still a lack of 
knowledge on how CRC tumours develop resistance to chemotherapy  as is 
observed, in part, from the high mortality rate of the disease in advanced CRC 
patients (Hammond, Swaika et al. 2016). 
To make possible the measurement and comparisons of the anti-proliferative 
effect of three different drugs on eight different CRC cell lines, characterization 
of growth curves rate during cell culture were carried out for all CRC cell lines 
used. 
Initially, cell culture requires to authenticate that the eight CRC used in the 
present thesis show the specific features expected from the database online 
sources as National Center for Biotechnology Information (NCBI), The 
American Type Culture Collection (ATCC), and The International Cell Line 
Authentication Committee (ICLAC). A summary background information on the 
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eight CRC cell lines used is displayed in Table 2.1. This step is crucial to avoid 
misidentification and cross-contamination problems. To avoid common mistakes 
during cells passaging in cell culture, each time a new flask or tube with cells 
was used it was labelled with three marks: cell line name, date and researcher 
initials.       
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Cell Line Disease 
Cell subtype 
Sadanandam et al. 
classification 
Age / Gender TP53 Status MSI Status KRAS AA change BRAF AA change PIK3CA AA change 
COLO 205 Stage IV CR adenocarcinoma Goblet  70 years, Male WT MSS WT p.V600E WT 
DLD-1 Stage III CR adenocarcinoma Stem  45 years, Male p.S241F MSI p.G13D WT p.E545K 
HT 29 - CR adenocarcinoma Goblet  44 years, Female p.R273H MSS WT p.V600E WT 
SW-620 Stage III CR adenocarcinoma Transit amplifying  51 years, Female p.R273H MSS p.G12V WT WT 
LS 174T Stage II CR adenocarcinoma Goblet  58 years, Female WT MSI p.G12D WT p.H1047R 
KM 12 Stage II CR adenocarcinoma Goblet  - - MSI WT WT WT 
HCC 2998 - CR adenocarcinoma Goblet  - p.R213F MSS p.A146T WT WT 
HCT 116 - CR adenocarcinoma Stem  48 years, Male WT MSI p.G13D WT p.H1047R 
Table 2.1: Background information about eight CRC cell lines used in MTT assays. Abbreviations: MSI microsatellite instability, MSS 
microsatellite stable (Woerner, Yuan et al. 2010, Ahmed, Eide et al. 2013). WT wild type, AA amino acid, - Unavailable data          
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2.3 Material and Methods 
Selection of CRC cell lines to be used in development of cancer resistant 
sublines by continuous exposure to 5-FU, IRI, and OXA requires different 
material and methodologies, as described below.  
2.3.1 Drugs 
IRI and OXA were purchased from Selleckchem (Houston, USA) and stored         
at -20°C, whilst 5-FU was obtained from Sigma-Aldrich (Poole, UK) and stored 
at room temperature (RT). For cellular analyses, compounds were prepared as 
stock solutions in dimethyl sulfoxide (DMSO) obtained from Sigma-Aldrich 
(Poole, UK). Approximately 3 mg of IRI, 3 mg of 5-FU and 4 mg of OXA were 
accurately weighed out and dissolved in 100 μl of DMSO to give a stock 
solution (Table 2.2). After ensuring compounds were completely dissolved in 
the DMSO by vortexing, they were aliquoted into 50 μl aliquots which were 
stored at -20°C until use. Then, aliquots were used to make up 1 ml and or 100 
μl of a 3 mM DMSO solutions to be used in Thiazolyl Blue Tetrazolium Bromide 
(MTT) cell proliferation or cytotoxicity assays, or for developing drug-resistant 
cell lines. MTT was obtained from Sigma-Aldrich (Poole, UK). 1000 μl of 300 
μM solutions of all compounds were made up and are shown in Table 2.2. 
Dilutions were vortexed thoroughly to ensure that the compound was fully 
dissolved. Later, 50 μl of each solution were aliquoted into labelled sterile 0.5 ml 
Eppendorf tubes that were stored at -20°C until be used during MTT assay. For 
MTT working solutions, 100 mg of MTT stock was dissolved in 20 ml of Maxima 
water, passed through a 0.2 μm filter and stored at 4°C.  
Compound 
name 
Mol. Wt. Amount 
(mg) 
x mM DMSO used 
(DMSO concentration) 
5-FU 130.08 3.42 26.29 100 μl 
(DMSO 0.114%) 
IRI 586.68 2.98 50.79 100 μl 
 (DMSO 0.006%) 
OXA 397.29 4.44 111.76 100 μl 
 (DMSO 0.003%) 
Table 2.2: Initial stock solutions of the drugs used during MTT assays. 
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2.3.2 Cell lines 
All human colon adenocarcinoma cell lines COLO 205, DLD-1, HT 29, SW-620, 
LS 174T, KM 12, HCC 2998, and HCT 116 were provided by European 
Collection of Cell Cultures (Salisbury, UK) and American Type Culture 
Collection (ATCC) (Manassas, Virginia, USA) (see Table 2.1 for details of the 
cell lines).  
2.3.3 Cell culture media 
The cells were maintained in RPMI 1640 culture medium supplemented with 
10% (v/v) fetal bovine serum (FBS), 1 mmol/L sodium pyruvate, 2 mmol/L of L-
glutamine and incubated at 37°C in 5% CO2. Dulbecco‟s phosphate-buffered 
saline (PBS) obtained from Severn Biotech Ltd. (Kidderminster, UK) was used 
for washing during passaging. All products were provided from Sigma-Aldrich 
(Poole, UK). 
2.3.4 Characterisation of cell growth and cell seeding density 
optimisation by MTT assay 
Growth curve profiles of eight CRC cell lines studied were plotted. Different cell 
lines have different doubling times, and they were calculated to maintain cell 
lines between 30‐85% confluency in logarithmic (Log) phase under drug 
exposure conditions for as long as possible during 4 days of treatment. Growth 
curve profiles were determined using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) salt which is soluble in water and it was 
added to each assay well (Barderas, Mendes et al. 2013).  After an incubation 
time of 4 h, MTT was reduced into formazan by mitochondrial dehydrogenase 
enzyme that is found activated only in living cells. Formazan is an insoluble 
crystal with a purple colour. Formazan can be solubilized in DMSO and 
quantified by spectrophotometric reader using the absorbance of its purple 
coloured solution (van Meerloo, Kaspers et al. 2011, Barderas, Mendes et al. 
2013) at 540nm wavelength. So, the reaction of dehydrogenase enzyme 
reflects the number of viable cells and it can be used as measure of the number 
of viable cells present and to test the anti-proliferative effect of a drug. 
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Serial dilutions of each one of the eight different CRC cell lines were prepared 
and tested using the MTT assay during 6 days. Cells were seeded at nine 
different initial seeding density concentrations into 96-well plates containing 200 
μl of complete RPMI 1640 medium and placed under standard incubator 
conditions. Plates were removed for analysis of cell growth at different times 
over the 6 days incubation period.  Supernatants were removed and 200 μl of 
the MTT solution [2 ml MTT stock solution to 18 ml of complete RPMI 1640 
medium] were added to each well. Plates were incubated at RT, 5% CO2,                 
for 4 h. Finally, MTT supernatant was removed and 150 μl of the DMSO was 
added to solubilise the crystals of formazan. Absorbance values for the resulting 
solutions were read at 540 nm on a Thermo Scientific Multiskan EX from 
Thermo Scientific (Loughborough, UK). Graphs were plotting using GraphPad 
Prism 5.0 (GraphPad Software, Inc., San Diego, USA) and Microsoft Office 
Excel Ver. 3. 2013 (Chicago, USA). 
2.3.5 CRC cell lines chemosensitivity panel using the MTT assay 
To characterise the anti-proliferative effect of 5-FU, OXA, and IRI compounds 
commonly used in the clinic for treatment of CRC in a panel of eight CRC cell 
lines, MTT assays were carried out. In vitro evaluation of the response profile of 
eight human CRC cell lines to these three chemotherapeutic agents were 
established for 96 h of continuous exposure. For an initial seeding concentration 
of 1x104 cells/ml in a cell doubling time rate about 20-24 h,  96 h is a time long 
enough to duplicate the cells population 3-fold and achieve the Log phase in the 
culture at the 4th day. Cell lines used were DLD-1; HT 29; SW-620; COLO 205; 
LS 174T; KM 12; HCC 2998 and HCT 116.  
Based on growth curve profile results to reach Log phase at day 4th, adjusted 
cell seeding density optimised concentrations in 180 μl of growth medium 
suspension were inoculated into each test well of a 96-well plate and incubated 
overnight (O/N) at 37 °C (Table 2.3). Cell attachment occurs within 24 h of initial 
seeding, and so the drug was added after 24 h. A range of drug concentrations 
was made up in cell culture medium and 20 μl of test chemotherapeutic agents 
and control solutions were added into each well. Additionally, the maximum final 
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DMSO concentration during drug dilution was not greater than 0.25% solution 
that causes toxicity to the cells (Barderas, Mendes et al. 2013). 
Following addition of drugs, the plates were incubated for a further 96 h under 
standard conditions and then analysed by MTT as described in the previous 
section (Fig. 2.2). 
The chemosensitivity of each cell line to each drug was measured by 
determining three different inhibitory concentrations (ICs). The IC50, IC75, IC90, 
values are defined as the drug concentration that inhibits cell growth by 50%, 
75%, and 90% compared with the growth of untreated control cells, 
respectively. So, percentages of survival of drug-treated cells were evaluated 
using absorbance values of untreated cells as control and absorbance of 
treated cells using the following equation: 
           
  ̅                      ̅                
 ̅                     ̅                
 * 100 
Three independent experiments of 4 replicates were carried out for each drug 
concentration, with each one of the eight CRC cell lines studied. Graph plotting 
and ICs were calculated using GraphPad Prism 5.0 (GraphPad Software, Inc., 





































 1 2 3 4 5 6 7 8 9 10 11 12 
A  #1 #1 #1 #1 #1 - - - - -  
B  #1 #1 #1 #1 #1 - - - - -  
C  #1 #1 #1 #1 #1 - - - - -  
D  #1 #1 #1 #1 #1 - - - - -  
E  #2 #2 #2 #2 #2 #3 #3 #3 #3 #3  
F  #2 #2 #2 #2 #2 #3 #3 #3 #3 #3  
G  #2 #2 #2 #2 #2 #3 #3 #3 #3 #3  
H  #2 #2 #2 #2 #2 #3 #3 #3 #3 #3  
Table 2.3: Dimensional scheme of the 96-well plates. Distribution of drugs 
concentrations, control and blanks used during the evaluation of CRC cell lines to IRI 
(#1), OXA (#2), and 5-FU (#3) using MTT assay. 




Figure 2.2: Fragmented picture of a 96-well plate. Example of MTT assay used for 
evaluation of the chemosensitivity to IRI (#1), OXA (#2), and 5-FU (#3) by in DLD-1 
cell line, as it has been described in Table 2.3. 
2.3.6 Statistical analysis of MTT assay 
Effect of each drug on the viability of CRC cell lines was measured by MTT 
assay. Cells in Log phase were exposed to indicated concentrations of different 
drugs and after 4 days cell survival was determined by MTT assay.  Results are 
expressed as the means ± SD of 3 independently repeated experiments. 
Statistical analyses Student‟s t-test: * p≤0.05, ** p≤0.01, *** p≤0.001, **** 
p≤0.0001 was selected to compare the sensitivity for IC50 value among 
sensitive-parent cell line and resistant subline. If necessary, data were 
logarithmically converted into a normal distribution of variables to remove 
heterogeneity of variance before analysis. 
- 53 - 
 
2.4 Results  
2.4.1 Cell seeding density optimisation by MTT assay 
To be confident with cell density concentration seeded, linear regression growth 
curves for day 0 for the eight CRC cell lines studied were done. A highly 
significant linear relationship between number of cells seeded and MTT 
absorbance signal is clearly seen for all cell lines used during Day 0 (Fig. 2.3). 
After confirmation of MTT values for initial cell density concentrations, growth 
curves profiles allow choosing the best cell concentration to reach the Log 
phase at day 4th for chemosensitivity assays using MTT (Fig. 2.4).   
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Figure 2.3: Linear regression growth curves for day 0 for the eight CRC cell lines 
studied. A highly significant linear relationship between number of cells seeded and 
MTT absorbance signal is clearly seen for all cell lines used during Day 0. 
Based on growth curve profile results to reach Log phase at day 4th, (Figure 2.4) 
adjusted cell seeding density optimised concentrations of 1x104 cells/ml          
(DLD-1, HT 29, SW-620, LS 174T), 2x104 cells/ml (COLO 205, KM 12, HCC 
2998) and 5x103 cells/ml (HCT 116) were used as optimal cell seeded 
concentrations during chemosensitivity curve profiles by MTT assay.  
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Figure 2.4: MTT Growth curve profiles for eight CRC cell lines. Coloured in red, 
optimal cell seeded concentrations for each CRC cell line to reach Log phase at day 4
th
 
and that was used during chemosensitivity MTT assays. 
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2.4.2 Chemosensitivity curve profile of eight CRC cell lines  
Three screening panels to study cytotoxicity effect of 5-FU, IRI and OXA on 
eight different CRC cell lines were done. To make this possible, the eight CRC 
cell lines were evaluated using five different drug exposure concentrations. After 
four days under drugs conditions, percentage of cell survival was measured by 
MTT assay (Fig. 2.5). Results were expressed in terms of survival and IC50, 
IC75, and IC90 values. The ICs values were obtained by straight-line projection 
from y-axis coordinates where cell survival was 50%, 25% and 10% to the x-
axis. Interpolation with x-axis shows the respective concentrations of drug to 
achieve IC50, IC75, and IC90 values, respectively, for each CRC cell line.  
2.4.2.1 Chemosensitivity curve profile to 5-FU  
Calculation of ICs values of the eight CRC cancer cell lines to 5-FU after 96 h 
exposure to the 5-FU compound by growth inhibition assay.  
 
Figure 2.5: Graphs of Growth Inhibition Assays Results for eight CRC cell lines to         








IC50  (µM) IC75 (µM) IC90 (µM) 
COLO 205 4.6  ± 1.0 22.39 ± 0.5 >30  
DLD-1 3.7 ±  0.5 15.0 ± 3.5 >30  
HCC 2998 2.66  ± 0.5 > 30.0  >30  
HCT 116 4.78 ± 1.2 7.94 ± 0.1 14.13 ± 0.1 
HT 29 2.99 ± 1.1 18.62 ±  0.7 >30  
KM 12 2.79 ± 0.2 7.59 ± 0.1 30 ± 0.1 
LS 174T 5.62 ± 0.2 12.88 ± 1.0 30 ±  0.2 
SW-620 6.37 ± 1.1 30.0 ± 1.1 >30  
Table 2.4: Results for ICs values of eight CRC cell lines to 5-FU. Means ± SD are 
summarized. The highest sensitivity to 5-FU is showed in red colour [5-FU] ≤ 5 µM; 
intermediate sensitivity to 5-FU is showed in grey colour 5 µM < [5-FU] < 30 µM and 
lowest sensitivity to 5-FU is showed in green colour [5-FU] ≥ 30 µM. 
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2.4.2.2 Chemosensitivity curve profile to IRI 
Calculation of ICs values of the eight CRC cancer cell lines to IRI after 96 h 
exposure to the compound by growth inhibition assay is shown in Figure 2.6 
below. Additionally, results were summarised in Table 2.5. 
 
Figure 2.6: Graphs of Growth Inhibition Assays Results for eight CRC cell lines to 














IC50  (µM) IC75 (µM) IC90 (µM) 
COLO 205 1.79  ± 0.7 2.99 ± 0.8 30 ± 0.0 
DLD-1 3.3  ± 0.7 8.0 ± 0.0 30 ± 0.0 
HCC 2998 2.07  ± 0.2 21.88 ± 0.2 >30 
HCT 116 1.28 ± 0.5 2.79 ± 0.0 15.85 ± 0.2 
HT 29 2.06 ± 0.1 6.89 ±  1.1 25.70 ± 2.6 
KM 12 3.37 ± 0.0 16.60 ± 0.0 30 ± 0.1 
LS 174T 0.32 ± 0.0 1 ± 0.5 >30 
SW-620 0.78 ± 0.1 2.18 ± 0.2 26.3 ± 4 
Table 2.5: Results for ICs values of eight CRC cell lines to IRI. Means ± SD are 
shown. The highest sensitivity to IRI is showed in red colour [IRI] ≤ 5 µM; intermediate 
sensitivity to IRI is showed in grey colour 5 µM < [IRI] < 30 µM and lowest sensitivity 
to IRI is showed in green colour [IRI] ≥ 30 µM. 
2.4.2.3 Chemosensitivity curve profile to OXA 
Calculation of ICs values of the eight CRC cancer cell lines to OXA after 96 h 
exposure to the compound by growth inhibition assay. The calculation of ICs 
values by interpolation was complicated, specifically for HCC 2998, HCT 116 
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and LS 174T to OXA due to the high anti-proliferative effect of this drug on 
these cell lines for the initial range of concentration (0.1 μM – 30 μM) (Fig. 
2.7a). Hence, the growth inhibition assay was repeated using a lower range 
concentration of OXA, specifically among 0.001 μM – 10 μM range of 
concentration, instead of 0.1 μM – 30 μM (Fig. 2.7b). Results were summarised 
in Table 2.6. 
 
Figure 2.7: Graphs of Growth Inhibition Assays Results for eight CRC cell lines to 
OXA.  (a) Initially, the range concentration used of OXA was from 0.1 µM to 30 µM.  
(b) New OXA doses from 0.001 to 10 µM were diluted to achieve the IC50, IC75 and 
IC90 values of HCC 2998, HCT 116 and LS 174T. All values are averages of at least 
four independent experiments performed in triplicate. 
 





IC50  (µM) IC75 (µM) IC90 (µM) 
COLO 205 0.22  ± 0.1 2.01 ± 0.5 22.88 ± 0.0 
DLD-1 2.7  ± 0.3 28.0 ± 1.7 >30 
HCC 2998 0.72  ± 0.4 7.3 ± 1.0 >10 
HCT 116 2.1± 0.2 5.57 ± 0.1 10 ± 0.0 
HT 29 1.46 ± 0.2 3.02 ±  0.7 16.98 ± 0.1 
KM 12 1.79 ± 0.6 30 ± 0.0 >30 
LS 174T 2.4 ± 0.1 5.72 ± 0.1 10 ± 0.0 
SW-620 6.68 ± 0.2 9.62 ± 0.8 30 ± 0.0 
Table 2.6: Results for ICs values of eight CRC cell lines to OXA. Means ± SD are 
displayed. The highest sensitivity to OXA is showed in red colour [OXA] ≤ 5 µM; 
intermediate sensitivity to OXA is showed in grey colour 5 µM < [OXA] < 30 µM and 
lowest sensitivity to OXA is showed in green colour [OXA] ≥ 30 µM. 
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2.5 Discussion  
2.5.1 Discussion of CRC cell lines growth and cell seeding density 
optimisation by MTT assay 
Evaluation of linearity for formazan crystal formation for the eight CRC cell lines 
was carried out. At day 0 each specific cell line shows a linear relationship 
between cell density and absorbance and hence the assay can be used with 
confidence with each specific cell line (Fig. 2.3). A good linear relationship was 
seen with R2 values greater than 0.95 for all cell lines tested (Fig. 2.3).  
All growth curves obtained from eight CRC cell lines by MTT assay shown three 
clearly differentiated phases during cells growth. First phase known as "Lag" 
phase where cells start recovering from the passaging effect. A second phase, 
the "Log" phase were cells growth exponentially and a final "Plateau" phase 
where the confluence of cells limit the expansion of cells within the flask. 
All CRC cell lines used grew attached to the flask surface forming monolayer 
cultures. Except for COLO 205 cell line, as it was expected from ATCC 
database source. COLO 205 cell line grew to form aggregates in suspension 
with clusters of rounded cells floating in the medium and only a few groups of 
cells grew weakly attached to the plastic surface from the flask. 
MTT readings for Day 1, Day 2, Day 3, Day 4 and Day 5 were carried out. The 
eight CRC cells showed similar growth rates achieving 1 unit of absorbance 
during the fourth day when the initial concentration of cells seeded was close to 
1x104cells/ml in each well. Despite the similarities in the growing rates, three 
different subgroups were seen: firstly, HCT 116 showed the fastest growth rate, 
following by DLD-1, HT 29, LS 174T, SW-620 and finally, COLO 205, HCC 
2998, KM 12, which showed the slowest growth rates (Fig. 2.4). Hence, 
different optimal initial cell seeded concentrations to achieve a 1.000 unit on 
absorbance during optical density reading at 540nm wavelength after 4 days of 
growing were selected to be used during cellular chemosensitivity assays          
(Fig. 2.4). 
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2.5.2 Discussion of chemosensitivity curve profiles 
The aim of this project is to clarify the knowledge about unknown molecular 
mechanisms involved in CRC resistance to conventional chemotherapy. To 
achieve this aim, the establishment of drug resistant CRC sublines is required. 
New drug resistant sublines can be used both in vitro and in vivo for screening 
novel therapeutics and to identify predictive biomarkers of drug response in 
CRC. Initially, a chemosensitivity screen was carried out using a panel of eight 
CRC cell lines. 
 
Evaluation of the response curve profile of eight CRC cell lines to three 
conventional chemotherapeutic drugs showed appreciable differences both 
among the eight cell lines studied and among the three drugs used. However, 
there are some considerations that must be borne in mind to interpret the 
information related to IC50, IC75, IC90. Researching cancer by in vitro cell culture 
experiments lets researcher control experimental factors. These factors 
included physicochemical microenvironment elements in the culture such as 
pH, temperature, humidity, oxygen levels, osmolarity, and nutrients 
concentration. Additionally, homogeneity of cells is easily maintained and cells 
can be stored in liquid nitrogen with cryopreservation medium such as DMSO. 
Hence, cell samples with both different number of passages and different fold-
change in resistance may be stored to be used in future studies during the 
development of resistant sublines. Nevertheless, technical factors such as cell 
culture conditions, number of cell passages, solvent used to make up drug 
dilutions may interfere with the final experiment results. 
 
Different results in values for ICs among drugs in the same cell line could 
depend on the mechanism of action of the drug. For example, OXA is a 
platinum drug that damages DNA by the induction of DNA lesions, forming 
interstrand cross-links with the binding of two guanine, or less frequently, a 
guanine-adenine base pair as it will be described in Chapter 5, section 5.1.1.  
Consequently, a cytotoxic effect occurs and inhibition of the proliferation of 
cancer cells happens (Alcindor and Beauger 2011). The prevention of cell 
proliferation has a so strong effect that can be lethal for all kind of tumour cells, 
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so the high sensitivity of the eight cell lines to this drug could be due to the OXA 
mechanism of action by binding to DNA, leading to guanine-guanine or 
adenine-guanine intra-strand crosslinks. Its consequence is blocking DNA 
synthesis and escaping recognition by the mismatch repair enzyme complex. 
This mechanism of action could be involved in chemotherapy side effect as 
healthy human cells could die by OXA cytotoxic effect too (Rabik and Dolan 
2007). 
 
The epigenetic and genetic background of a cell line may play key roles in 
chemosensitivity and resistance to different drugs. Drug chemosensitivity may 
be affected by specific gene mutations that can confer resistance to mutated 
cell lines. Experts disagree regarding a specific methodology to use for CRC 
cell line classification (Ahmed, Eide et al. 2013, Sadanandam, Lyssiotis et al. 
2013). There exist some classifications based on genetic origin, MSI, CpG 
island methylator phenotype (CIMP) and hotspots mutations in oncogenes. 
Concerning oncogenes and genes associated with chemoresistance a key 
protein is p53. TP53 gene is the most frequently mutated gene in CRC cells this 
issue is observed in Table 2.1. Among the eight CRC cell lines studied in the 
present project: HCT 116 and LS 174T are known to present TP53 wild type 
and a higher sensitive to OXA, while DLD-1, HT 29 and SW-620 have mutations 
at TP53 gene and they are less sensitive to OXA (Table 2.1)  (Martinez-Cardús, 
Martinez-Balibrea et al. 2009). This difference in response can be due to the 
main function of TP53, which induces apoptosis when DNA damage caused by 
OXA cannot be repair. DLD-1, HT 29 and SW-620 cell lines would avoid 
activation of pro-apoptotic pathways by TP53. Other frequently mutated genes 
in CRC are KRAS, PIK3CA, BRAF, and PTEN (Ahmed, Eide et al. 2013). 
 
Different molecular and genomic backgrounds of the eight CRC cell lines 
studied could be involved in the chemosensitivity response to the drugs. For 
example, DLD-1, HCT 116 and LS 174T cell lines showed some of the lowest 
sensitivities to 5-FU (Table 2.4), although all CRC cell lines showed the lowest 
sensitivity to this drug, it is known that these three cell lines show the MSI 
phenotype (Ahmed, Eide et al. 2013) (see Table 2.1) and consequently, their 
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DNA mismatch repair system is not working normally. MSI is presented in 15% 
of CRC tumours and it has been related to 5-FU resistance in CRC (Sinicrope 
and Sargent 2012). So, it could be interesting to know if the low sensitivity of 
DLD-1, HCT 116 and LS 174T to 5-FU is due to the failure in DNA mismatch 
repair (MMR) system. Moreover, SW-620, HCT 116 and LS 174T have a low 
sensitivity to 5-FU, but they present a high sensitivity to IRI and OXA drugs. 
Previously published results of drug sensitivity in CRC, showed that COLO  205 
was more sensitive to 5-FU than DLD-1 or HCT 116 (Jung, Jeung et al. 2007). 
However, in the present study, it is seen that COLO 205 shows lower sensitivity 
to 5-FU than DLD-1 and HCT 116 (Table 2.4). Differences with previous results 
may be the result of differences in cell culture conditions such as exposure 
times, cell concentrations and drug dose used. Result shown in this thesis 
makes sense if it is kept in mind that COLO 205 was isolated in 1975 by T.U. 
Semple, et al. from a patient who had been treated with 5-FU for 4-6 weeks 
(Semple, Quinn et al. 1978, Paillas, Causse et al. 2012).  Cells of the patient 
were exposed to 5-FU during the chemotherapeutic period. So, tumour cells 
were growing in a 5-FU environment over treatment time. It is possible that 
during this time, patient‟s COLO 205 CRC cells started to develop some 
mechanisms of resistance to the 5-FU drug that may be noticed in the final 
patient-derived cell line. So, it is important to know the background of both cell 
line and patient as far as possible, in order to keep in mind how different 
variations can affect to the experimental design. 
 
Another fact that shows the importance of knowledge of the nature of the cell 
line used in the experiment can be extracted from HCT 116 MTT results. During 
growth curves profiles assays, HCT 116 showed the highest growth in normal 
conditions (Fig. 2.4). Besides, HCT 116 cell line shows the highest sensitivity to 
5-FU and OXA, among the eight CRC cell lines studied (Table 2.4) (Table 2.6). 
Both agents damage DNA, affecting stabilisation and activation of p53 that can 
activate genes involved in apoptosis pathways. In this way, the more a cell 
proliferates, the more its DNA suffers from a drug effect. Studies have shown 
that cells during S-phase are 1000-fold more susceptible to camptothecins as 
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OXA (Shah and Schwartz 2001). Hence, the time taken for cells to complete a 
cycle can be an important factor to keep in mind.  
 
Finally, a possible toxicity effect of DMSO was studied. A 0.4% concentration of 
DMSO was necessary for making up 1000 μl of a 300 μM solution for IRI. No 
cytotoxic effect of DMSO (0.4% concentration) was found. 
Finally, based on chemosensitivity curve profiles of the eight CRC cell lines and 
discussion here displayed, cell lines DLD-1, KM 12 and HT 29 were selected to 
generate resistant sublines to 5-FU, OXA and IRI. These three cell lines 
showed the lowest sensitivity among all three drugs, hence development of high 
drug resistance phenotypes from these three parent cell lines may be possible. 
They also showed the best correlation in increasing of cell survival with 
increasing drug concentration (IC50, IC75, and IC90) (Table 2.4-6). Hence, these 
three cell lines are expected to file a progressive response within the ten 
months that cells are expected to be growing under drug conditions.  
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3 Identification of new mechanisms of resistance to 5-FU  
3.1 Introduction  
5-FU is a heterocyclic aromatic organic compound analogue of uracil, which is 
used before or after surgery at any stage of CRC patients (Longey 2003). The 
structural study of 5-FU showed that this drug crystallises adopting a hydrogen-
bonded sheet structure with four molecules in its asymmetric unit (Hulme, Price 
et al. 2005). The specific structure of the 5-FU, which is similar to the uracil, 
makes possible the incorporation of 5-FU into DNA and RNA during nucleoside 
metabolism and converges into cytotoxicity and cell death (Zhang, Yin et al. 
2008). 
3.1.1 Mechanisms of action of 5-FU 
5-FU is converted by two main different routes into several active metabolites in 
mammalian cells. A scheme of mechanism of action of 5-FU is shown below. 
 
Figure 3.1: Metabolic conversions and mechanisms of action of 5-FU. The enzymes 
involved in these reactions are: (1) orotate phosphoribosyltransferase (OPRT); (2) 
uridine phosphorylase (UP); (3) thymidine phosphorylase (TP); (4) uridine kinase (UK); 
(5) thymidine kinase 1 (TK1); (6) thymidylate synthase (TS); (7) dihydrofolate 
reductase; (8) dihydropyrimidine dehydrogenase (DPD); (9) ribonucleotide reductase 
(RR); (10) 5’-nucleotidases and phosphatases. Metabolic pathways are depicted as solid 
lines. The inhibition of TS by FdUMP is depicted as a broken line with a minus sign 
(Peters, Backus et al. 2002). 
- 69 - 
 
The main activation route for 5-FU activation is the conversion in 
fluorodeoxyuridine (FUdR), which is then phosphorylated to fluorodeoxyuridine 
monophosphate (FdUMP) by thymidine kinase (TK1) (Fig. 3.1) (Peters, Backus 
et al. 2002) or converted to FdUDP by ribonucleotide reductase (RR). A second 
alternative route is the conversion of FdUMP directly from 5-FU by uridine 
phosphorylase (UP) and uridine kinase (UK). The stable 5-FdUMP forms a 
complex by its union with the enzyme thymidylate synthase (TS) (Fig. 3.1) 
(Peters, Backus et al. 2002). Consequently, the inhibition of deoxythymidine 
monophosphate (dTMP) production occurs. dTMP is an essential element for 
DNA repair and replication processes. So, a decreasing of dTMP level causes 
cytotoxicity and cell death (Fig. 3.1) (Peters, Backus et al. 2002, Longey 2003). 
Alternatively, dihydropyrimidine dehydrogenase (DPD) mediates conversion of 
5-FU to dihydrofluorouracil (DHFU) which is a rate-limiting step of 5-FU 
catabolism in normal and tumour cells. 
From Figure 3.1, it may be interpreted that some anticancer drugs such as 5-FU 
require metabolic activation, and thus cancer cells can develop resistance 
through decreased drug activation. Additionally, active metabolites of drugs 
which target multiple enzymes and that cause damage to multiple molecular 
pathways may be more useful to carry out the cytotoxic function. However, they 
may also be more susceptible to different mechanisms of resistance that can 
appear to decrease drug effects.  
3.1.2 Known mechanisms of resistance to 5-FU 
3.1.2.1 Mechanisms of resistance to 5-FU related to thymidylate synthase 
One of the best known mechanisms of resistance to 5-FU is related to the TS 
enzyme. After binding of FdUMP to TS protein, a new stable complex is formed. 
The new stable ternary complex blocks access of dUMP to the nucleotide-
binding site and inhibiting dTMP synthesis. So, an increase in the expression of 
TS can be by itself a potential mechanism of resistance to 5-FU. There exist 
multiple elements which can play a role in TS induction: target-associated 
resistance, pharmacokinetic resistance or decreased accumulation of activated 
metabolites (Peters, Backus et al. 2002).            
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It is unclear if the mRNA-mediated induction of TS occurs at the 
postranscriptional level. Nevertheless, it is known that TS mRNA-bound enzyme 
is an autoregulatory translation model and that ligand-bound enzyme is more 
stable than TS ligand-free enzyme (Forsthoefel, Peña et al. 2004). The binding 
of TS mRNA to the enzyme produces conformational changes, normally in the 
C-terminal domain in the TS molecule. These changes increase the stabilisation 
and half-life of the enzyme. An increase in TS levels could affect the dose of the 
drug that is needed to induce cell death by TS inhibition and consequently, 5-
FU may lose its effectiveness. Therefore, ligand binding can be a possible 
mechanism of resistance to TS-directed drugs (Forsthoefel, Peña et al. 2004).  
Another possible mechanism of resistance related to TS could be TS over-
expression, which has been found in CRC drug-resistant sublines, but not in the 
drug-sensitive parent lines (Wang, McLeod et al. 2007). TS overexpression 
could be described as an additional molecular mechanism responsible for 5-FU 
resistance, with an increase in TS expression resulting in an increase in the 
target protein of 5-FU. So, higher doses of the drug would be required to kill 
cells with overexpression of TS (Wang, McLeod et al. 2007). 
Concerning 5-FU resistance mediated by TS, it is thought that interferon 
gamma (IFNγ) can act as a suppressor for TS resistance. IFNs are a 
glycoprotein family known as cytokines. IFNs are classified into three types: 
type I (IFNα, IFNβ), type II (IFNγ) and type III (IFNλ). They have different 
peptide sequences and contribute to the protective defences of the immune 
system (Rando 2006). During the activation of IFNγ, the mechanism of 
resistance to 5-FU mediated by TS induction can be avoided. New data suggest 
that the antitumour effect of 5-FU can be enhanced by IFNγ, due to its 
suppressing effect against the overexpression of TS. It was found that a 
combinational chemotherapy of 5-FU and IFNγ showed better results in 
stopping tumour growth than 5-FU alone (Chu, Zinn et al. 1990). 
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3.1.2.2 Mechanisms of resistance to 5-FU related to dihydropyrimidine 
dehydrogenase 
Another mechanism involved in 5-FU resistance is due to an increase in 
dihydropyrimidine dehydrogenase (DPD) activity and the corresponding 
catabolism of 5-FU (Fig. 3.1). DPD metabolises the nucleobases uracil and 
thymine, but also some chemotherapy drugs such as 5-FU that are similar to 
these pyrimidines may be metabolised by DPD activity too (Zhang, Yin et al. 
2008). Studies in mice using an HT 29 human CRC xenograft model have 
shown that following treatment of mice with 5-FU, the tumours that showed the 
highest levels of DPD expression had the fastest growth rate (Zeng, Yang et al. 
2013). Therefore, a possible mechanism of resistance to 5-FU could be 
mediated by DPD upregulation (Zeng, Yang et al. 2013). In the same way, it 
has been shown that tumours with low DPD expression are sensitive to 5-FU 
and an increase in DPD mRNA expression is directly related to the resistance 
capacity of the cells against the 5-FU drug in CRC tumours (Milano, Etienne et 
al. 1999, Zeng, Yang et al. 2013).  
3.1.2.3 Mechanisms of resistance to 5-FU related to microsatellite 
instability 
Apart from TS and DPD, there are other proteins not directly involved in 5-FU 
metabolism that play a role in the resistance to 5-FU. For example, tumour cells 
with microsatellite instability (MSI) caused by defective MMR system have been 
related to less sensitivity to 5-FU in vitro in contrast to non-MSI cells, despite 
the availability to misincorporate similar amounts of 5-FU into the DNA of the 
cells (Tajima, Hess et al. 2004, Sinicrope and Sargent 2012). One of the 
proteins involved in 5-FU resistance via DNA repair, it is the protein Smug1 that 
repairs single- and double-stranded DNA by removing uracil from DNA and 
base excision. Qian An et al. (An, Robins et al. 2007) suggested that Smug1 
could mediate a protective mechanism or cell survival strategy by excision of 5-
FU that had previously been incorporated into DNA  (Wang, McLeod et al. 
2007). So, high Smug1 levels is a potential mechanism of resistance to 5-FU in 
tumours and Smug1 may be used as a predictive biomarker for poor 5-FU 
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response and it will allow selecting a better treatment for these patients (Wang, 
McLeod et al. 2007). 
3.1.2.4 Mechanisms of resistance to 5-FU related to cell cycle 
Moreover, cell cycle perturbations may be implicated in development of 5-FU 
resistance. The cell cycle can decelerate, delaying the incorporation of cytotoxic 
molecules into DNA (Moore, Houghton et al. 2011). This process is mediated by 
proteins such as CDK2, Cyclin D3 or Cyclin A that were reduced in both 
resistant H630 CRC cell lines and resistant T47D breast cancer cell lines (Guo, 
Goessl et al. 2008). These proteins are mediators of the delay in G1 and G1/S 
cell cycle phase and can affect DNA synthesis time (Guo, Goessl et al. 2008). 
The prevention of incorporation of 5-FU metabolites into DNA can give enough 
time to allow the cells to repair the misincorporated nucleotides (Moore, 
Houghton et al. 2011). Guo and his colleagues (Guo, Goessl et al. 2008) 
studied cell cycle alterations in colon and breast resistant sublines to 5-FU. 
They found that cells remained in G1 for a longer time, and they took more time 
to change between G1/S phases (Guo, Goessl et al. 2008). 
3.1.2.5 Mechanisms of resistance to 5-FU related to ATP synthase 
The main mechanism of action of 5-FU is inhibition of TS that reduces dTMP 
production causing changes at ATP/dTTP ratio levels which are required for 
DNA synthesis and repair, resulting in lethal DNA damage (Danenberg 1977). 
At the ATP synthase level, down-regulation may lead to cellular events 
responsible for 5-FU resistance. A study carried out by Shin YK et al. (Shin, Yoo 
et al. 2005) showed that a decrease in the expression levels of the α subunit of 
mitochondrial F1F0-ATP synthase and the reduction in the expression of other 
ATP synthase complex subunits happened in resistant cell lines that showed to 
be less sensitive to 5-FU (Shin, Yoo et al. 2005). Consequently, when ATP 
synthase activity is decreased, the intracellular ATP content is reduced. 
Moreover, these results were confirmed using an inhibitor of the ATP synthase 
called oligomycin A, which inhibits suppression of cell proliferation mediated by 
5-FU (Shin, Yoo et al. 2005). 
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3.1.2.6 Mechanisms of resistance to 5-FU related to reactive oxygen 
species 
Finally, another mechanism of resistance to 5-FU is the cellular adaptive 
response to reactive oxygen species (ROS). Oxidative stress is one of the 
causes that can produce necrosis or apoptosis in cells. Apoptosis occurs after 
acute but persistent oxidative stress conditions leading to genomic instability, 
tumour progression and drug resistance (Hwang, Chung et al. 2007). Some 
tumour cells increase specific gene expression such as manganese superoxide 
dismutase (MnSOD), Bcl-2 and Prx I in oxidative stress conditions. Research 
carried out by Tae Hwang et al., (Hwang, Chung et al. 2007) showed that ROS 
plays an important role in human lung cancer progression and can induce drug 
resistance to a variety of anticancer agents such as 5-FU (Hwang, Chung et al. 
2007). Another recent CRC study demonstrated that the use of a double 
treatment of both 5-FU and antioxidants can be harmful due to the inhibitor 
effect that antioxidants have on Src protein (Fu, Yang et al. 2014). Src is a 
kinase that drives the apoptotic action of 5-FU via caspase-7 through its 
phosphorylation (Fu, Yang et al. 2014). 5-FU can induce ROS-dependent Src 
activation in CRC cells, so a failure of apoptosis via 5-FU could be a potential 
mechanism of resistance contributing to tumour development (Fu, Yang et al. 
2014). Additionally, in-depth studies have shown that reactive oxygen species 
modulator 1 (Romo1) siRNA treatment had positive results and high efficiency 
against 5-FU-induced ROS generation. Romo1 is a gene that encodes a 
mitochondrial membrane protein responsible for ROS production. At the same 
time, 5-FU induces an increase in mRNA levels of Romo1. So the use of a 
Romo1 siRNA to block Romo1 expression directly contributes to decrease ROS 
generation by 5-FU (Hwang, Chung et al. 2007). 
3.1.3 Aims & Objectives for 5-FU 
The main aims and objectives of this study were focused on developing new 
resistant sublines to 5-FU which could be used to explore novel mechanisms of 
resistance in CRC. This was achieved by the following objectives: 
1) Establish and characterise 5-FU resistant sublines for DLD-1, HT 29 and               
KM 12 cell lines in terms of sensitivity to 5-FU both in vitro and in vivo. 
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2) Identify novel mechanisms of 5-FU resistance using a proteomic approach. 
3) Validate the proteomics approach using immunodetection techniques. 
3.2  Material & Methods 
All materials used and methods were applied as described in Chapter 2 to study 
chemosensitivity curve profiles by MTT assay. Additionally, new methods used 
during development of resistant sublines and validation of proteomics approach 
by immunodetection techniques are detailed below. 
3.2.1 Establishment of resistant CRC cell lines 
CRC sublines with resistance to conventional drugs were established and 
derived from DLD-1, KM 12 and HT 29 parent cell lines by continuous exposure 
to increasing concentrations of 5-FU, IRI and OXA. Drug concentrations were 
increased at each step of resistance over a period of ten months. IC75 values 
were used as initial starting doses for DLD-1, KM 12 and HT 29 cell lines. As an 
example of the establishment of resistant cell line process, development of 
DLD-1 resistant subline to 5-FU is explained below (see figure 3.2).  
Firstly, DLD-1 parent cell line was split into a T25 flask (surface area 25 cm2) 
with RPMI 1640 complete medium plus the corresponding doses of the drug. 
Initial concentrations used for each drug was the IC75 (drug concentration that 
inhibits cell growth by 75%) and it was doubled each time. The drug exposure 
dose was increased until 250 μM was reached. 
For instance, in 5-FU case, the initial dose concentration of the drug in the flask 
was 15 μM (Fig. 3.2). (e.g., [15 μM] 5-FU initial dose was increased in 
successive concentrations of 2 x IC75, 3 x IC75 each 4-7 days. Passages were 
done once the confluence in the T25 flask was around 80%. In this way, after 
the first 2 weeks, the drug dose was increased from 15 μM to 60 μM (Fig. 3.2). 
Simultaneously, jointly at the same time with each new passage of DLD-1, an 
extra passage was done into a T25 flask with no drugs added, apart from the 
regular T25 flask with DLD-1 cell line in presence of 5-FU (Fig. 3.2). This 
parallel T25 untreated flask with cells with the same number of passage that 
treated cells was based on the idea to be able to assess the effects that the 
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passage number has on MTT assay and proteomics results. Development of 
resistant sublines by higher exposure dose to the drug is a procedure that takes 
time and it is known that passage number has effect in cells (Chang-Liu and 
Woloschak 1997, Pronsato, La Colla et al. 2013). After a long period of time (10 
months) with DLD-1 growing under drug conditions, changes in IC50 value are 
expected. The IC50 of resistant sublines are expected to be higher than the IC50 
value of the DLD-1 parent cell line that has been maintained in drug-free 
medium. So, the drug sensitivity was examined by the MTT assay as described 
in Chapter 2, section 2.3.5 (Table 3.2) each time that parent DLD-1 cell line was 
exposed to a higher dose of the drug. Further, at each step of resistance to 5-
FU, a T75 flask (surface area 75 cm2) was split with no drug added in order to 
freeze down for cryovials and cell freezing (Fig. 3.2). Cells were stored at 
different stages of resistance development process by freezing the cells in 
medium containing 10% DMSO, using cryovials and storing them in liquid 
nitrogen at -196°C.The reason for this was to avoid a loss of samples due to 
unexpected events such as contamination of cell cultures and power cuts in the 
facilities.  
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Figure 3.2: Scheme showing the protocol used to establish DLD-1 resistant cell line 
to 5-FU from the parent DLD-1 CRC cell line. On the left, a parallel passaging of 
initial parent cell line was done in free-conditions media to detect potential changes 
caused by passaging effect during development of resistant sublines (right side).   
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3.2.2 Microscopy studies  
Resistant and parent-sensitive cell lines were examined using x40 objective 
magnification under Light-Olympus CK2 Inverted Microscope (Tokyo, Japan) 
and pictures were taken using Lumascope 488 Series obtained from Etaluma 
Inc. (Carlsbad, USA). 
3.2.3 Development of drug-resistant xenograft CRC models in nude mice 
to confirm stability of DLD-1 5-FU subline 
10 week old male athymic nude mice (Envigo Ltd. Balackthom, UK) were used 
to develop subcutaneous xenograft models. Mice were maintained under 
pathogen-free conditions throughout-in facilities approved by the Home Office to 
meet all current regulations and standards of the United Kingdom.                         
All procedures were carried out under a United Kingdom Home Project License, 
following UK National Cancer Research Institute Guidelines for the Welfare of 
Animals. 
1x106 cells in a volume of 100 µl of DLD-1 5-FU [250] resistant subline and 
DLD-1 parent cell line were injected subcutaneously in both right and left flanks 
of 12 nude mice. Once tumours were palpable, then therapy commenced 
(designed day 0). 5-FU was administered to the treatments groups as a single 
intraperitoneal injection at 100 mg/Kg on day 0. For comparison, a control group 
was left untreated. Tumour volume using callipers and animal body weight were 
recorded frequently, and normalised to the respective volume on the initial day 
of treatment. Mann-Whitney U tests were conducted to determine the statistical 
significance of any differences in growth rate (based on tumour volume doubling 
time) between control and treated groups.  
3.2.4 SILAC and Cell culture media 
Cell culture was carried out as described in Chapter 2, section 2.3.3, but also a 
new cell culture technique was applied four quantitative proteomics 
characterization. Characterisation of resistant cell lines was carried out using a 
stable isotope labelling amino acids in cell culture (SILAC) based approach as 
follows: DLD-1, KM 12 and HT 29 CRC parent cell lines were SILAC-labelled 
with 50 mg of L-Arginine-HCl (13C6, 
15N4) and 50 mg of L-Lysine-2HCl                    
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(13C6, 
15N2) by culturing them for 8 passages in 500 ml of RPMI media for 
SILAC with 10% (v/v) dialyzed FBS and incubated at 37°C in 5% CO2. This 
number of passages was done to ensure incorporation of isotope label was as 
close to 100% as possible. 115 mg of  L-Proline was added to prevent the 
metabolic conversion of heavy arginine to heavy proline, causing inaccuracy 
during comparison between the light and heavy peptides ion signal (Van Hoof, 
Pinkse et al. 2007). All products were obtained from Thermo Fisher Scientific 
(Loughborough, UK).  
Cells were split into T25 flasks using 1x104 cells/ml during first 5 passages. Last 
3 passages were done using T75 flasks. The medium was replaced every 4 
days, until cells reached 65–75% confluency, when cells were passaged. So 
cells were maintained in Log phase growing (between 30‐80% confluency) for 
as long as possible during all passaging. Finally, cells were collected from an 
80% confluent T75 flask by trypsinisation. Long and low generation controls 
plus the resistant subline were compared with the SILAC-labelled samples 
collected. 
3.2.5 General quantitative proteomics approach 
The approach proposed to identify proteomic changes in CRC resistant sublines 
using mass spectrometry by SILAC approach was divided in three main stages 
which are summarized in three schemes below. After that, a detailed section of 
general material and methods used is described. 
1st Stage - Preparation of proteomics samples -  
A two-stage stable isotope labelling by amino acids in cell culture (SILAC) 
protocol was used to identify protein changes in CRC resistant sublines 
established in vitro (Fig. 3.3).  
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Figure 3.3: Diagram of experimental protocols and general strategy design.              
(a) Flowchart of SILAC approach showing the parent cell line growth in SILAC 
medium. (b) Parent cell line growth in drug-free medium to be used as low and long 
generation control during protein quantification. (c) Parent cell line growth under drug 
exposure conditions during establishment of CRC resistant sublines process. 
- 80 - 
 
 
2nd Stage – Protein extraction and Strong Cation Exchange 
Chromatography (SCX) -  
The flow chart shows the protocol used for cell lysis, protein extraction and 
proteins separation by SCX to be used in mass spectrometry analysis (Fig. 3.4). 
See sections 3.2.5.1 to 3.2.5.5 for details. 
 
Figure 3.4: Flowchart describing samples preparation before MS analysis. Initially, 
200 μg of light sample and 200 μg of heavy sample were combined to get 400 μg of 
L/H combined sample prior to protein digestion. L/H digested sample was separated in 
12 subsamples by SCX to be analysed in triplicate in Orbitrap Mass Spectrometer. 
3rd Stage – Protein quantification and data analysis - 
The flow chart shows the protocol used for data processing, filters, statistics and 
interpretation of proteomics data (Fig. 3.5). Each eluted subsample by SCX was 
analysed by Orbitrap Mass Spectrometer in triplicate and all identified peptides 
were used for protein identification. From all peptides detected during MS 
analysis, only the three best unique peptides were used for protein 
quantification. After protein quantification three filters were applied:  
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(1) only proteins quantified from unique peptides with 2 or more PSMs were 
used, (2) only master proteins were considered and (3) mascot score applied 
for p<0.05. Proteins only quantified in light or heavy sample were removed. 
Finally, Log2 transformation of raw data was done after normalized each single 
SILAC experiment. Multi SILAC datasets were formed by three single SILAC 
experiments (resistant subline, low generation control, long generation control) 
and Multi SILAC datasets were analysed under LIMMA and the 5th percentile 
criteria. See sections 3.2.5.6 to 3.2.5.8 for details. 
 
Figure 3.5: Flowchart describing quantification and proteomics analysis process. 
Unique peptides were used during protein quantification to avoid misidentifications of 
proteins. Automatic and manual filters were applied before data normalisation and 
transformation.   
3.2.5.1 Cell lysis and protein extraction 
Proteins for analysis were extracted from the cells using a Complete™, Mini 
Protease Inhibitor Cocktail with EDTA and containing 7M urea, 2M thiourea, 
0.4% CHAPS, 0.1% sodium dodecyl sulphate (SDS), 0.05% sodium 
deoxycholate in PBS (Severn Biotech Ltd., Kidderminster, UK)  at 4˚C and 
homogenized by sonication with a SH70G Sonicator from Philip Harris Scientific 
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(Lichfield, UK). Samples were centrifuged at 13,000 rpm for 25 min at 4˚C. All 
materials for protein extraction buffer were provided from Sigma-Aldrich (Poole, 
UK).  
3.2.5.2 Bradford Protein Assay 
Concentration of protein extracts was measured using Bradford protein assay 
kit (ThermoFisher, Loughborough, UK) (Bradford 1976). To carry out the 
Bradford assay, firstly five serial dilutions of 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 
0.125 mg/ml and 0.06 mg/ml were done from an initial concentration of 2 mg/ml 
albumin from bovine serum (BSA) and a 40 fold dilution was done for each cell 
line lysate sample. Secondly, 1.5 ml of Bradford assay reagent was added to 50 
µl of standards (BSA dilutions), blank and cell lysate and vortex following by 
incubation at RT for 15 min. Select SkanIt™ Software from Thermo Fisher 
(Loughborough, UK) was used to read absorbance at 595 nm wavelength using 
1ml of samples in plastic cuvettes on the Thermo Scientific Multiskan 
spectrophotometer. BSA reading values were used to yield a linear calibration 
curve over the entire BSA protein concentration range. Sample protein 
concentration was calculated by Y-axis intercept and its projection over X-axis. 
Graphs were generated using GraphPad Prism 5.0 (GraphPad Software, Inc., 
San Diego, CA).  
3.2.5.3 Protein digestion 
After the Bradford assay, 200 μg of light and 200 μg of heavy samples 
combinations were mixed prior to digestion. These 12 different samples were 
defined as 12 single SILAC experiments are summarised below. 
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Figure 3.6: Combinations of cell lines extracts to make up 12 different single 
SILAC experiments. A mix of 200 μg protein of light sample / 200 μg protein of heavy 
sample were used during mass spectrometry analysis. 
To the combined extracts, 1 ml of chilled acetone was added and stored O/N at 
-20ºC. The precipitates were then centrifuged at 13,400 rpm for 20 min at 4ºC, 
the supernatant decanted and the protein pellet lyophilised. Protein pellets were 
re-solubilised in 40 µl of 8 M urea. 1 μl of Dithiothreitol (DTT) 50mM, a reducing 
agent to disrupt disulfide bonds between cysteine residues and 1 μl of 
iodoacetamide (IAA) 100mM an alkylating agent to avoid sulfhydryl groups 
reforming. DTT and IAA were obtained from Sigma-Aldrich (Poole, UK).  
Digestion using 20 µl of  PierceTM trypsin protease (20 mg/ml) from Thermo 
Scientific (Loughborough, UK) was carried out O/N at 37˚C. 
3.2.5.4 MALDI mass spectrometry 
Before applying digests to SCX chromatography and desalting, protein 
digestion was confirmed as follows. 1 μl of Bruker matrix CHCA (LC MALDI) 
made up in 1 ml of 30% CH3CN and 0.01% TFA was deposited on the MALDI 
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plate. An aliquot of 1 µl sample was diluted 10 fold in 10% acetonitrile (ACN) 
from Sigma-Aldrich (Poole UK) and added on the matrix. Secondly, 1 μl of 
matrix was deposited on the sample to be analysed using Ultraflex Matrix 
Assisted Laser Desorption/Ionization (MALDI) tandem Mass Spectrometer from 
Bruker Daltonics (Bremen, Germany). Data was acquired in reflector mode 
using 1000 shots for MS and 2000 shots for MS/MS. 
3.2.5.5 SCX chromatography and desalting 
Digested samples were collect as 12 fractions from SCX chromatography. The 
ISOLUTE® SCX column from Biotage (Hengoed, UK) was equilibrated with 
loading buffer (LB). The column was equilibrated with LB of 10mM potassium 
di-hydrogen phosphate (KH2PO4) (pH=3) in 25% acetonitrile (ACN) from Sigma-
Aldrich (Poole, UK) was used for SCX. The sample (400 μg of digested mix) 
was applied and washed initially with LB followed by washing with 11 LB 
gradient to remove non-binding components, which was retained as a flow 
through fraction. Peptides were eluted sequentially with incremental increases 
in KCl (in LB) (Table 3.1). The flow through and eluted samples were diluted 4-
fold with 2% acetonitrile, 0.1% formic acid desalted using C18 columns from 
Kinesis (Cambridgeshire, UK) before lyophilisation as follow.  Initially, ZipTip 
columns were equilibrated using three times 20 ul of 100% methanol and three 
times 20 ul of Buffer A (2% ACN, 0.1% formic acid). These steps act as a 
gradient for the mini-column, which wets the resin and conditions it to be ready 
to bind peptides prior to sample loading. Load the sample was done by pipetting 
the protein digest up and down (discarding it back into its tube) 10 fold diluted  
(1 ul Sample + 9 ul of Buffer A). ZipTip were washed three times using Buffer A 
and finally, sample was eluted using Buffer B (100% ACN, 0.1% formic acid). 
Lyophilisation was done at 45ºC aqueous mode of Genevac Centrifugal 
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Buffer 
LB + KCl (mg) 
mM Volume Fraction 
LB+30 mg 30.0 22.4 E1 
LB+60 mg 60.0 44.7 E2 
LB+90 mg 90.0 67.1 E3 
LB+120 mg 120.0 89.5 E4 
LB+150 mg 150.0 111.8 E5 
LB+180 mg 180.0 134.2 E6 
LB+250 mg 250.0 186.4 E7 
LB+300 mg 300.0 223.7 E8 
LB+500 mg 500.0 372.8 E9 
LB+700 mg 700.0 521.9 E10 
LB+1000 mg 1000.0 745.5 E11 
Table 3.1: Making up of 11 elution buffers used during SCX chromatography for 
protein separation. 
3.2.5.6 Data acquisition 
A preliminary quality control step to check SILAC labelling efficiency prior to 
SCX chromatography and SCX fractionated samples were analysed on an 
Orbitrap Fusion™ Tribrid™ Mass Spectrometer connected with Ultimate 3000 
HPLC. Each SCX fraction was resuspended in 30 μl of 0.1% formic acid (FA), 
sonicated for 5 min in a Ultrawave 50 ultrasonic bath (Wolf Laboratories, York, 
UK), and centrifuged at 14,500 rpm, for 1 min. An aliquot (10 μl) of the fraction 
was used during Mass spectrometer analysis. Each SCX fraction was run in 
triplicate on the LC-MS as shown below (Fig. 3.7).  
Digested peptides were washed on a C18 Trap-column (300 μm x 5 mm, 100 A),  
at a flow rate 300 nl/min for 4 min then transferred C18 Analytical-Column            
(75 μm x 50 cm, 2 μm, 100 A) at temperature 40˚C. C18 columns were provided 
by Thermo Scientific (Loughborough, UK). Peptides were eluted by using 
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Solvent A (2% ACN, 0.1% FA) and Solvent B (100% ACN, 0.1% FA). Total run 
time was 120 min using a gradient of solvent B: 0 min at 5%, 5 min at 7%, 65 
min at 25%, 80 min at 45% and 85 min at 85%. Column cleaning was 
performed during 20 min with 85% solvent B and equilibration of column was 
performed during 15 min with 5% solvent B. Eluted peptides were subject to a 
Spray voltage at 2000 V and heated capillary Full MS scan in the Orbitrap was 
followed by the MS/MS scans of the ions selected from the MS spectrum in the 
Orbitrap (HPLC-MS).  
MS analysis of eluted peptides was conducted through Xcalibur™ 4.0 Software 
with Foundation 3.1 SP1 (Thermo Scientific) package with Chromeleon™ 7.2 
Chromatography Data System software on Orbitrap Fusion™ from Thermo 
Fisher Scientific (Loughborough, UK).  Mass resolution was 120,000 between 
350 and 1,500 m/z with the maximum injection time was 100 ms. All MS/MS 
acquisition was performed on the Ion-trap, in top speed mode with 3 s cycle 
time, a dynamic exclusion (±5 ppm) of 50-60 s, intensity threshold 5,000, with 
parent charge states 2+ to 7+ were sequentially fragmented by collision-induced 
dissociation with a normalised collision energy of 35%. A maximum of 200 ms 
ion injection time was allowed. 
3.2.5.7 Protein identification and quantification 
MS spectra generated were analysed in the Mascot  2.4 Database Manager 
search algorithm (Matrix Science, London, United Kingdom) using the human 
database from UniProt (SwissProt) 2016 with records of 551,705 functional 
proteins.  
All proteins were classified based on the protein Mascot scores of each single 
SILAC experiment analysis. Mascot software uses a probability-based scoring, 
where a "high" score is a "low" probability for false protein identification. Scores 
are given in -10 x Log10 (p) and p is the value of absolute probability.                     
A probability of 10-20 thus becomes a score of 200.The protein identified with 
the most accuracy based on matches using mass values and peptide mass 
fingerprinting receives the highest score. Finally, a confidence threshold is 
selected for the rest of proteins identified. For a 95% confidence, the software 
shows the lowest score to establish the confidence threshold at p<0.05.  
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For example, selecting proteins with Mascot scores higher than “x” and 95% 
confidence (p<0.05), a wrong protein identification of a protein with a mascot 
score higher than “x”, it is expected to occur at random with a frequency of less 
than 5%. Consequently, the lower the expectation value for a wrong 
identification is, the higher the mascot score attached to the protein is. 
The peptide and protein SILAC ratios were determined using fixed modifications 
for SILAC peptide pairs searches with fixed L-Arginine-HCl (13C6, 
15N4) and L-
Lysine-2HCl (13C6, 
15N2) modifications.  Modifications from the quantitative 
method was SILAC (2 Lysine (K) + 8 Arginine (R)) = + 10 [Mass-shift]. Search 
parameters included; up to 2 missed trypsin cleavage, MS mass tolerance of 10 
ppm and MS/MS mass tolerance of 0.6 Da were selected. Dynamic 
modifications included were Oxidation (M) and Deamidated (NQ). 
Carbamidomethyl (C) was established such as static modification. Confidence 
threshold was established for p<0.05 and all proteins identified with p≥0.05 
were excluded from analysis and not included in the list of quantified proteins. 
Identified proteins were quantified by tracking pairs of peptides signals (light 
and heavy) in the ion chromatogram using Proteome Discoverer™ 2.1 software 
from Thermo Fisher Scientific (Loughborough, UK). The Proteome Discoverer™ 
Protein quantitation was carried out by the SILAC approach. Master proteins 
were defined as those with two or more unique peptide identification and two or 
more peptide SILAC ratios from the total triplicate analyses for all SCX fractions 
(i.e. 36 LC-MS profiles). Software determined the SILAC ratios from the signal 
intensities of the light SILAC peptide (containing 12C6
14N4-Arg) and the paired 
heavy SILAC peptide (containing 13C6
15N4-Arg). Master proteins were defined 
as those with two or more unique peptide identification and two or more peptide 
SILAC ratios from the total triplicate analyses for all SCX fractions (i.e. 36 LC-
MS profiles).   
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Figure 3.7: Diagram with a brief description of the SILAC-approach protocol 
applied for protein quantitation. After combination of 200 μg of light and heavy 
samples, mixed sample was digested and separated in 12 subsamples by SCX. Each 
single SILAC experiment was analysed in triplicate by MS. After filtering, results from 
single SILAC sample for each resistant subline and results from single SILAC samples 
for its two controls (low and high passage) were grouped to form a multi SILAC 
dataset. A total of 6 multi SILAC dataset were generated to be analysed under “R” and 
“Cluster analysis”. 
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Single SILAC experiment ratios were determined from the average of the three 
best peptide ratios. Three examples of MS spectrum and MS/MS spectrum of 
peptides are illustrated below. 
 
Figure 3.8: Increased expression in resistance. (a) MS spectrum showing more 
intense light than heavy mass signals of the peptide YCKPSWIFGFVAK from the 
Tensin-4 (TNS4) and (b) MS/MS spectrum used to identify YCKPSWIFGFVAK and 
the fragment matching sequence (highlighted in yellow and blue).  




Figure 3.9: No change in expression. (a) MS spectrum showing similar intense light 
and heavy mass signals of the peptide IDQLEGDHQLIQEALIFDNK from the protein α 
actin-1(ACTN1)  and (b) MS/MS spectrum used to identify 
IDQLEGDHQLIQEALIFDNK and the fragment matching sequence (highlighted in 
yellow and blue). 




Figure 3.10: Decreased expression in resistance. (a) MS spectrum showing lower 
intense light than heavy mass signals of the peptide DLPLLFR from the protein D-3-
Phosphoglycerate Dehydrogenase (PHGDH) and (b) MS/MS spectrum used to identify 
DLPLLFR and the fragment matching sequence (highlighted in yellow and blue). 
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3.2.5.8 Bioinformatics and statistical analysis of quantitative proteomics 
data 
Raw single SILAC results were subjected to median normalisation and Log2 
transformation to enable cross-experiment comparison during multi SILAC 
datasets study. Three single SILAC experiments (resistant cell line, low and 
long generation controls) were used to generate multi SILAC datasets in Venn 
diagrams. Venn diagrams were created with web tool provided by the University 
of Pretoria through Bioinformatics and Evolutionary Genomics department 
following website http://bioinformatics.psb.ugent.be/ and retrieved from 
November, 2016. All commonly quantified proteins in resistant and parent cell 
lines (multi SILAC dataset) were classified into three groups in terms of 
expression relative between single SILAC experiments. Three groups defined 
were “Not altered proteins” (N), “up-regulated proteins” (U) and “down-regulated 
proteins” (D) using two different statistical methods. 
1. The first method was based on multi SILAC datasets analysis by R, 
using linear models and differential expression for microarray data 
studies (LIMMA) (Ritchie, Phipson et al. 2015) (Fig. 3.11). LIMMA was 
introduced as an empirical Bayes approach that specifically allowed 
developing a realistic distribution of biological variances. LIMMA 
statistical is based on the use of the full data to shrink the observed 
sample variances towards a pooled estimate. Results of LIMMA are 
more stable with a higher and powerful inference compared to ordinary t-
tests particularly when the number of samples is small (Kammers, Cole 
et al. 2015). LIMMA has been used in more than 6000 citations in the last 
ten years and in hundreds of proteomic experiments (Brusniak, 
Bodenmiller et al. 2008, Margolin, Ong et al. 2009, Ting, Cowley et al. 
2009, Jankova, Chan et al. 2011, Zhao, Li et al. 2013).  A fold change 
and its associated p-value were calculated for each protein according to 
their significant different ratio expressions between the resistant subline 
and its two related control cell lines with a high and a low number of 
passages. This information was summarized in a Volcano plot of LIMMA-
modelled proteomics data. The data for all proteins are plotted as Log2 
fold change versus the −Log10 of the adjusted p-value.  
- 93 - 
 
 
2. Proteins from multi SILAC datasets were clustered using the 5th 
percentile criteria of Log2 normalized ratios distribution to classify all 
proteins in the three different responses defined above. Hence, 10% of 
the most altered proteins of each sample (5% up-regulated (U) and 5% 
down-regulated (D) proteins) were considered changed, whilst the 
remaining 90% were considered unaltered. Cluster analysis was 
performed for sets of experiments to define groups of like-responding 
proteins (e.g., Fig. 3.23). 
Those proteins classified as altered using the 5th percentile cluster analysis and 
with a significant p-value (p<0.05) obtained from LIMMA analysis were selected 
for further bioinformatics analysis. 
R Script for LIMMA test 
 
Figure 3.11: R script to perfom multi SILAC dataset analyses. 
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3.2.5.9 Data analysis of altered proteins expression in resistant sublines 
Initially, STRING was used to predict functional interactions of up-regulated and 
down-regulated proteins in resistant sublines. Links between proteins were 
defined as "Known interactions, experimentally determined" (pink colour), 
"Known interactions, database" (blue colour), "Protein neighbourhood" (green 
colour), "Proteins frequently mentioned together" (yellow colour) and "Co-
expression" (grey colour) (Von Mering, Huynen et al. 2003).  
Secondly, protein networks from STRING were modified based on EnrichNet 
(Network-based gene and protein set enrichment analysis) and GO (Biological 
Process ontology) results (Tsui, Chari et al. 2007, Liu and Ruan 2013). Proteins 
were classified into 5 different biological processes groups that contain proteins 
that may mediate drug response and drug resistance. These 5 biological 
processes were: (1) apoptotic and anti-apoptotic pathways, (2) DNA repair 
process, (3) drug and small molecules metabolism, (4) intracellular protein 
transport, (5) cellular membrane transporters and membrane organization (Tsui, 
Chari et al. 2007, Liu and Ruan 2013). Finally, significantly altered proteins 
were used to build up the Venn diagrams that show common up-regulated and 
significantly down-regulated protein in sublines resistant to the same drug.  
3.2.6 Validation of relative protein expression levels identified by 
proteomics 
Protein extract quality control was performed by SDS-PAGE and validation of 
proteomic results was performed by Western blotting (WB).  
3.2.6.1 SDS-PAGE 
Whole cell lysate from each single SILAC experiment (20 μg) was separated by 
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5 ml Solution 
Components 
Stacking gel 6% Separating gel 12% 
H2O 1.95 ml 0.75 ml 
30% Acrylamide mix 1 ml 2 ml 
10% SDS 0.05 ml 0.05 ml 
10% ammonium 
persulfate 
0.05 ml 0.05 ml 
TEMED 0.004 ml 0.002 ml 
Tris 
0.5 M Tris/HCl 
(pH 6.8) 1.95 ml 
1.5 M Tris 
(pH 8.8) 1.95ml 
Table 3.2: Composition of the SDS-PAGE gels used in these studies. 
Mini-gels (100mm x50mm x1mm) were used, with a 6% stacking gel, 12% 
separating gel and 10-well comb. PageRuler™ Plus Prestained Protein Ladder 
(5-250kDa MW range) from Thermo Scientific (Loughborough, UK) was used as 
a guide during protein separation in electrophoresis (SDS-PAGE) and WB for all 
proteins validated. Protein Ladder was loaded in the first well in all gels followed 
by all remaining cell lysate samples. An initial voltage of 50 mV was applied to 
the tank with the gel and the buffer for 15 min and then increased to 150 mV for 
1 h. Running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) was 
stored at RT and diluted to 1x before use.  
Gel transferring was done by Wet electroblotting (Tank transfer). The gel was 
placed in a “transfer sandwich” (filter paper-gel-membrane-filter paper), 
cushioned by pads and pressed together by a support grid after air-bubbles 
removing. Transfer was performed with an ice pack and at 4°C to mitigate the 
heat produced. Proteins were transferred from the gel matrix to a Hybond-P 
nitrocellulose blotting membrane (0.45 µm) (Sciences, Germany) using constant 
Amperage of 300 mA for 2 h. Protein presence in membrane after blotting was 
confirmed by Ponceau S solution provided by Sigma-Aldrich (Poole, UK). Stock 
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transfer buffer (39 mM glycine, 48 mM Tris base, 0.04% SDS, pH 8.3) prepared 
by adding 29.275 g of glycine, 58.147 g of Tris and 4 g of SDS into 1000 ml of 
distilled water.  Stock transfer buffer was stored at 4˚C and was used to prepare 
working transfer buffer by adding 100ml of stock transfer buffer and 200 ml of 
methanol into 700 ml of distilled water. 
3.2.6.2 Western blotting 
Antibody labelling was carried out after blocking for 1 h at RT using blocking 
buffer (0.416% mM Tris (pH 7.6), 10% Tween-20, 5% (w/w) skimmed milk 
(Marvel, Premier Food, UK). Details of the primary antibodies used in the 
studies are detailed below in Table 3.3. A monoclonal Anti-β-Actin (A2228) 
(mouse IgG2a isotype) at 1:7000 dilution from Sigma-Aldrich (Poole, UK) was 
used as a protein identification control. 
 

















Abcam® ab157107 Primary Polyclonal IgG Rabbit Aa 692-742 of Human CD44 Mouse, Rat, Human 1:2000 
Has not yet been 
referenced 
GeneTex® GTX114872 Primary Polyclonal IgG Rabbit Centre region of Human UMPS Human, Rat, Mouse 1:2000 
Has not yet been 
referenced 
Abcam® EPR14545 Primary Polyclonal IgG Rabbit Aa 176-403 of Human VPS4 Human, Mouse, Rat, 1:2000 
(Shtanko, Nikitina et al. 
2014) 
Abcam® TS63 Primary Monoclonal IgG1 Mouse Human CD63 protein Human 1:500 
(Nakase, Kobayashi et al. 
2015) 
Sigma-Aldrich® A2228 Primary Monoclonal IgG2a Mouse 
N-terminal end of the β-isoform of 
actin 








Polyclonal IgG Rabbit Mouse IgG Mouse 1:5000 (White, Jansen et al. 
2015) 
Table 3.3: List of antibodies and their features used in WB and IF experiments. 
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After primary antibody incubation O/N, the membrane was washed three times 
for 10 min each using TBS wash buffer after adjusting pH at 7.6. After the 
membrane was washed, it was incubated for 1 h in 2 ml of the secondary 
antibody in blocking at 1:5000 dilution (Table 3.3). After secondary antibody 
incubation, a further three washes for 10 min each using TBS wash buffer were 
performed before protein revelation.  
For protein labelling development, the ECL™ Prime WB System (GERPN2232) 
kit from Sigma-Aldrich (Poole, UK) was used. Briefly, the blot was exposed to 
ECL reagents (A and B) for two minutes at RT before being enveloped in a hard 
plastic sheet. After removing excess reagent, the membrane was covered in a 
transparent plastic wrap. Then, in the dark room, the blot was exposed to hyper 
film ECL for a variable time ranging from 10 seconds to 15 min depending on 
the antibody. Hyperfilm was developed using Multi-grade rapid developer 
solution (ILFORD) for up to 3 min, followed by distilled water to remove the 
excess developer solution and at the end, the blot was fixed using the Rapid 
film fixer for 5 min. 
3.3 Results  
3.3.1 Establishment of DLD-1, HT 29 and KM 12 drug resistant cell lines 
to 5-FU 
After ten months of episodic drug exposure, DLD-1 5-FU [250μM] resistant 
subline, KM 12 5-FU [60μM] resistant subline and HT 29 5-FU [60μM] resistant 
subline were established. An example of the progressive development of 
resistance is shown for DLD-1 5-FU (Fig. 3.12a). 
Resistance indices were evaluated according to the relative resistance for 
pretreated cell lines with  5-FU in comparison with parent cell lines, defined by 
the ratio of IC50 of the resistant subline to the IC50 of the sensitive parent cell 
lines. Several criteria were set for successful establishment of a resistant line: 
the 5-FU resistant subline had to show stable growth and proliferation in culture 
medium with a drug concentration higher than the IC50 of the parent cell line: the  
sublines must maintain 5-FU resistance following the cell freezing and 
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defrosting process, and a new resistant subline must retain resistance 
phenotype after growth during at least one month in a drug-free medium. Under 
these conditions  
After ten months of episodic drug exposure, DLD-1 5-FU [250µM] resistant 
subline, KM 12 5-FU [60µM] resistant subline, and HT 29 5-FU [60µM] resistant 
subline were successfully established. Three independent chemosensitivity 
curve profiles for DLD-1 parent and DLD-1 pretreated with 5-FU cell lines were 
carry out to measure progressiveness of resistance phenotype development 
process. An example of the progressive development of resistance is shown for 
DLD-1 5-FU (Fig. 3.12a). 
IC50 values were calculated and are shown in figure 3.12b for DLD-1 5-FU, in 
figure 3.13a for KM 12 5-FU, and in figure 3.13b for HT 29 5-FU resistant 
sublines. Important differences of IC50 values were observed between the 
original parent cell lines and the 5-FU resistant sublines which have been 
growing under 5-FU. DLD-1 5-FU [250μM] resistant subline was around 130.2 
fold change resistant to 5-FU than DLD-1 parent cell line (Fig. 3.12b). Whilst, 
KM 12 5-FU, and HT 29 5-FU is 3.2-fold change (Fig. 3.13a) and 3.5-fold 
change in resistance (Fig. 3.13b) in comparison to KM 12 and HT 29 parent cell 
lines respectively.  
Visual comparison of resistant sublines and parent-sensitive cell lines under 
microscope at 40x magnification showed both an increase in size and in 
number of cells with irregular shapes around the monolayer clusters formed by 
5-FU resistant sublines on the flasks surface (Fig. 3.14-3.15).  5-FU resistant 
sublines showed colonies more tightly packed than for parent cell lines. 
Additionally, DLD-1 5-FU resistant subline showed higher size on average and 
more irregular shapes than initial parent DLD-1 cell lines. 
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Figure 3.12: Chemosensitivity curve profiles for DLD-1. (a) Three independent 
chemosensitivity curve profiles for DLD-1 parent and DLD-1 pretreated with 5-FU cell 
line during establishment of DLD1 5-FU resistant subline (b) DLD-1 no pretreated cell 
lines and DLD-1 5-FU resistant subline with 5-FU during 70 generations were exposed 
to 5-FU [0.3-400 µM] doses during 96 h. MTT assays were performed in three 
independent experiments. Graphs show the cell survival of DLD-1 5-FU resistant 
subline against different 5-FU concentrations.  The difference in IC50 among DLD-1 
parent cell line and DLD-1 5-FU resistant subline was highly significant with 130.2-fold 
change (**** p≤0.0001). Error bars showing standard deviations between replicates are 
displayed too. 
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Figure 3.13: Chemosensitivity curve profiles for KM12 and HT 29. (a) KM 12 
parent cell line and KM 12 5-FU resistant subline during 50 generations and (b) HT 29 
parent cell line and HT 29  5-FU resistant subline with 5-FU during 48 generations were 
exposed to 5-FU [0.03-100 µM] doses during 96 h. MTT assays were performed in 
three independent experiments. Graphs show the cell survival of KM 12 and HT 29 
pretreated and non-pretreated cell lines against different 5-FU concentrations. The 
difference in IC50 among parent cell line and resistant 5-FU sublines is highly 
significant in both experiments (p≤0.0001). A 3.2-fold change and a 3.5-fold change 
difference in IC50 were found in the KM 12 5-FU [60] and HT 29 5-FU [60] resistant 
sublines respectively (**** p≤0.0001). Error bars showing standard deviations between 
replicates are displayed too. 
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Figure 3.14: DLD-1 cells growth in normal media. In the upper part, freshly isolated 
cells from (a) DLD-1 5-FU resistant subline and (b) DLD-1 parent-control cell line. 
Difference in cells size is clear under the microscope. In the lower part, confluent 
monolayer clusters of (c) DLD-1 5-FU resistant subline cells showed colonies more 
tightly packed than for (d) DLD-1 parent-control cells growing in RPMI medium. 
Several colonies of CRC cells have attached and started to spread on the T25 flasks 
after four days. Scale Bar size = 200 µm. 
200 µm 
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Figure 3.15: KM 12 and HT 29 cells growth in normal media. In the upper part, 
freshly isolated cells from (a) KM 12 5-FU resistant subline and (b) KM 12 parent cell 
line. Difference in cells shape is clear under the microscope. In the lower part, confluent 
monolayer clusters of (c) HT 29 5-FU resistant subline cells and (d) HT 29 control 
parent cells growing in RPMI medium on the T25 flasks after four days.                           
Scale Bar size = 200 µm 
3.3.2 Characterisation of cell growth for DLD-1, KM 12 and HT 29 
resistant sublines to 5-FU 
To confirm results obtained by MTT and to test if the number of passage of the 
flask could have some effect on the MTT assay, a growth curve analysis was 
200 µm 
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done for all resistant sublines to 5-FU established. Growth rate and capacity to 
proliferate was measured for resistant sublines (Fig. 3.16). Growth curves were 
done using an initial concentration of 1x104 cells/ml. No significant differences in 
growth curve were found during the study of three resistant sublines to 5-FU. 
 
Figure 3.16: MTT Growth curve profiles. During 5 days of 1x10
4
 cells/ml 
concentrations seeded for (a) DLD-1 parent cell lines and DLD-1 5-FU resistant 
subline; (b) KM 12 parent cell lines and KM 12 5-FU resistant subline; (c) HT 29 parent 
cell lines and HT 29 5-FU resistant subline. No significant differences (p>0.05) were 
found in growth curve profiles between parent and resistant sublines during 5 days after. 
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3.3.3 Evaluation of cross-resistance in the DLD-1 5-FU subline by MTT 
Cross-resistance is the capacity of cancer cells to withstand different drugs by 
one or more mechanisms of action like the increasing of ABC transporters, 
polyploidy, autophagy (see Chapter 1; section 1.3). Due to the lack of 
knowledge related to cross-resistance mechanisms in chemotherapy, a further 
study of collateral loss of sensitivity to eight chemotherapy agents used in CRC 
was carried out. 
During the cross-resistance study, eight different standard agents were used 
covering a wide range of mechanisms of action and probably different 
mechanisms of resistance. The eight drugs were: 5-FU, OXA, IRI, carmustine, 
cisplatin, colchicine, doxorubicin, and paclitaxel. According to their different 
mechanisms of action, these drugs can be classified into three groups 
described in Chapter 1, section 1.2.3. 
- Antimetabolites like 5-FU that acts as cell-cycle specific by interfering with 
synthesis of DNA and RNA (Tiwari 2012). 
- Alkylating agents such as carmustine, cisplatin, and OXA that act during rest 
phase of the cell causing cross-links in DNA. So, they are cell cycle non-specific 
(Fu, Calvo et al. 2012).  
- Plant alkaloids like colchicine, IRI, doxorubicin and paclitaxel that act at cell-
cycle specific points. Colchicine and paclitaxel inhibit microtubule assembly 
(Bombuwala, Kinstle et al. 2006), whilst doxorubicin, and IRI are topoisomerase 
II and topoisomerase I inhibitors, respectively, that act during phases of cell 
division (Biondi, Fusco et al. 2013, Shi, Hui et al. 2014).  
Evaluation of cross-resistance in DLD-1 5-FU and DLD-1 parent cell line was 
carried out by a chemosensitivity study using MTT assay as it has been 
described in Chapter 2, in sections 2.3.5 and 2.3.6. 
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None of the eight compounds studied showed such as spectacular differences 
in resistance as 5-FU. However, some fold changes in resistance were 
observed in some of the drugs tested. Without considering the resistance fold 
change to 5-FU, the highest fold change (2.6-fold) was found to OXA, but not to 
cisplatin, despite the fact that both agents have similar mechanisms of action 
(see Chapter 5, section 5.4.1). Additionally, a 2.3-fold change in resistance was 
observed to IRI and carmustine. A small 1.9-fold change was observed to 
Colchicine, whilst in doxorubicin, cisplatin, and paclitaxel no activity in 
resistance was found.  
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Figure 3.17: MDR profile conferred by DLD-1 5-FU resistant subline and DLD-1 
parent cell line. The 96 h cytotoxicity assays were performed with eight different 
drugs: (a) 5-FU, (b) OXA, (c) IRI, (d) doxorubicin, (e) carmustine, (f) colchicine, (g) 
cisplatin and (h) paclitaxel. Curves are representative of separate experiments in 
triplicate.  Relative resistance values were obtained by dividing the IC50 value of the 
resistant DLD-1 5-FU resistant subline by the IC50 value of the DLD-1 parent cell line.                                                                                                                                                                                   
(*p≤0.05; ** p≤0.01; *** p≤0.001; ****p≤0.0001). 
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3.3.4 DLD-1 5-FU subline maintains tumourigenicity and drug resistant 
phenotype when grown in vivo 
To further confirm the permanency of the acquired 5-FU drug resistance in the 
DLD-1 5-FU subline, the cells were implanted by subcutaneous injection in 
immunodeficient mice and treated with 5-FU.  
It was observed that tumourigenicity was maintained in the DLD-1 5-FU [250] 
subline, although it appeared to grow slower than the DLD-1 parent cell line 
xenograft models (Figure 3.18 and Table 3.4), mirroring the in vitro findings.  
In terms of response to 5-FU treatment, negligible toxicity was seen for both 
models with maximum bodyweight losses of 7% and 9% for DLD-1 parent cell 
line and DLD-1 5-FU resistant subline xenograft models respectively. For 5-FU 
treated groups, a significant (p≤0.01) delay of 4.6 days in tumour growth was 
seen for the DLD-1 parent line-derived xenografts, whilst DLD-1 5-FU resistant 
subline did not show any significant response (p>0.05) (Fig. 3.18 and Table 
3.4). This suggests that the resistant phenotype has been maintained in vivo 
and it can be used in future studies. 
Cells injected Treatment 





DLD-1 P=65 Untreated - - 3 
DLD-1 P=65 5-FU 4.6 P<0.01 7 (day 3) 
DLD-1 
5-FU[250] 
Untreated - - 1 
DLD-1 
5-FU[250] 
5-FU 0 p>0.05 ns 9 (day 3) 
Table 3.4: Results of xenograft mice models. Measures obtained for tumour growth 
and body weight in untreated mice and treated mice derived from DLD-1 5-FU and 
DLD-1 parent cell line. Development of xenograft models was done by Cooper PA 
under HO project licence number 40/3670. 
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Figure 3.18: Relative tumour volume curves of xenograft mice were done with or 
without 5-FU treatment. (a) Significant differences were found in growth under 
treatment in xenograft models derived from DLD-1 parent cell line but (b) not in 
xenograft derived from DLD-1 5-FU, which showed resistance to the treatment. (c) 
Relative % bodyweight of mice bearing sensitive DLD-1 cells with or without 5-FU 
treatment and (d) relative % bodyweight of mice bearing resistant DLD-1 cells with or 
without 5-FU treatment. No significant differences were found in body weight. 
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3.3.5 Protein extraction and Bradford protein assays 
Three independent Bradford assays were done for each cell lysate sample to 
calculate the volume required to obtain 200 µg of protein to be applied during 
proteomic analysis. Four examples of Bradford assays results are shown below 
(Fig. 2.8) and final protein amounts extracted from all samples is summarised in 
table 2.7. 
 
Figure 3.19: Examples of protein concentration measurements of 4 different cell 
lines. (a) DLD-1 RPMI P=9; (b) DLD-1 SILAC P=9; (c) DLD-1 RPMI P=65 and (d) 
DLD-1 5-FU [250] P=70 resistant subline by Bradford assay using BSA in a serial 
dilution (mg/ml). All samples were 40 fold diluted. 
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                                   All initial samples were 40 fold diluted 
Cell line Sample 
Protein extracted 
μg 
Volume required for 
Acetone ppt 
(200 µg of protein) 
DLD-1 SILAC P=9  (Heavy sample) 4379.00 8.86 µl 
DLD-1 RPMI P=9 5675.67 10.4 µl 
DLD-1 RPMI P=65 1175.19 9.19 µl 
DLD-1 5-FU [250] P=70 2790.00 6.74 µl 
DLD-1 OXA [250] P=60 1720.17 10.92 µl 
DLD-1 IRI [200] P=55 270.47 17.74 µl 
KM 12 SILAC P=9 (Heavy sample) 5994.63 6.47 µl 
KM 12 RPMI P=9 3756.26 7.66 µl 
KM 12 RPMI P=55 3457.07 11.22 µl 
KM 12 5-FU [60] P=50 2703.40 10.65 µl 
KM 12 OXA [40] P=45 801.65 15.97 µl 
HT 29 SILAC P=9  (Heavy sample) 7634.03 5.08 µl 
HT 29 RPMI P=9 6590.00 5.89 µl 
HT 29 RPMI P=57 3579.88 8.04 µl 
HT 29 5-FU [60] P=48 3300.84 
8.73 µl 
Table 3.5: Summary table with the total amount of protein extracted from CRC 
cell lines. The volume required for 200 μg of protein that was used during proteomic 
analysis to combine in the single SILAC samples. P = passage number. 
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3.3.6 Identification of proteome changes in DLD-1, HT 29 and KM 12 
resistant sublines to 5-FU using mass spectrometry by SILAC 
approach 
Before starting the analysis of protein expression, the labelling incorporation 
efficiency was measured to avoid incomplete isotope labelling due to amino 
acid conversion problems that could affect quantification. After nine doublings, a 
small aliquot of proteins digested from SILAC cell lines was analysed to 
determine the efficiency of incorporation. In the three cases: DLD-1, KM 12 and 
HT 29 cell lines grown in SILAC achieved >98% incorporation of labelled amino 
acid into their proteins, as recommended in previous publications on this 
technique (Ong and Mann 2006, Waanders, Hanke et al. 2007). A figure with 
total number of labelled proteins identified in a small aliquot of SILAC sample is 
shown below. 
 
Figure 3.20: Summary graph and table with labelling efficacy incorporation 
detected in a small aliquot of digested SILAC sample. SILAC achieved >98% 
incorporation of labelled amino acid into proteins. 
Proteins from the complete 2DLC MS datasets were quantified as described in 
Chapter 3, section 3.2.5.6 and identified in at least two of three independent 
injections on the mass spectrometer in both heavy (labelled) and                              
light (no labelled) samples. All proteins in each single SILAC experiment were 
quantified using the best three peptide-spectrum matches (PSMs) to define 
each master protein form. But if there were less than 3 PSMs identifying the 
protein, then the two best PSMs were used for quantification. 
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All proteins with a Mascot score less than 95% confidence were excluded from 
the list of identified proteins during single SILAC experiments. Lowest Mascot 
score used in single SILAC experiments was established by Mascot software 
























 >31 >30 >31 >28 >28 >28 >28 >28 >28 
Table 3.6: Lowest Mascot scores used during proteomics analysis for single SILAC 
experiment samples during identification of altered proteins in 5-FU response. 
From the full profiling of passage controls, SILAC controls and resistant cell 
lines a total of 3x107 MS/MS (product ions), 6.5x106 PSMs, 1.1x105 peptides 
and 57450 proteins were obtained. Each single resistant cell line result was 
compared to its low and long generation control to form the multi SILAC 
dataset. Multi SILAC datasets were used to identify: (a) proteins commonly 
identified and (b) those proteins significantly changed due to resistance.  
The total number of proteins quantified in three multi SILAC datasets for 5-FU 
were similar, with the total number of commonly quantified proteins shown in 
the centre (Fig. 3.21). For complete protein lists identities see Appendix 
Proteomics results in CD along with this thesis.  
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Figure 3.21:Venn diagrams results of multi SILAC datasets in 5-FU. The number of 
proteins commonly quantified between the two parent cell lines of (a) DLD-1; (b) KM 
12; (c) HT 29  with a high and a low number of passages and in their respective drug-
resistant sublines to 5-FU. 
3.3.7 Protein quantification and results of the MS analysis  
Analysis of proteomics data was performed as described in sections 3.2.5.7 and 
3.2.5.8. This process requires normalization and transformation of single SILAC 
experiment raw data, followed by multi SILAC dataset (Fig 3.21) analyses using 
(a) a LIMMA algorithm in “R” software and (b) Cluster analysis. Finally, 
STRING, EnrichNet and GO data analysis platforms were used to identify the 
most significant altered proteins found in resistant sublines.  
3.3.7.1 Raw data normalization and transformation 
Initially, median normalization was performed to remove systematic biases from 
the data before statistical methods are applied (see Proteomic results included 
in CD Appendix). Normalization was followed by Log2 transformation of the 
normalized SILAC-ratio data, to enable cross-experiment comparison between 
different SILAC experiments. Frequency distributions of commonly quantified 
proteins were plotted in  Figure 3.22.  Distribution of Log2 SILAC-ratio proteins 
in resistant sublines exceeded parent cell lines proteins distribution. This 
difference in data distribution may be presumably caused by drug effects, these 
trends were observed in the multi SILAC datasets. Surprisingly, KM 12 5-FU 
multi SILAC dataset showed a more extended proteins distribution than         
DLD-1 5-FU dataset, which contrary showed a higher resistance fold change 
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during MTT assays (Fig. 3.12b and Fig. 3.13). This difference may be attributed 
to the type of altered proteins in different resistant sublines. Although                     
DLD-1 5-FU subline shows a lower number of altered proteins than KM 12 5-
FU, proteins altered in DLD-1 5-FU may be directly involved in 5-FU response, 
while altered proteins in KM 12 5-FU may not taking part in 5-FU response.  
 
Figure 3.22: A histogram view of superimposed fold change distributions of the 
total number of proteins commonly quantified in resistant sublines to 5-FU.         
(a) DLD-1, (b) KM 12 and (c) HT 29 compared with their respective parent and 
sensitive cell lines after Log2-transformation and normalisation of experimental SILAC-
ratio data (L/H). 
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3.3.7.2 R-LIMMA analysis  
5-FU Multi SILAC datasets were analysed by R, using LIMMA. A fold change 
and its associated p-value were calculated for each protein according to their 
significant difference in ratio expressions between the resistant subline and its 
two related control parent cell lines (with a high and a low number of passages).  
This information was summarized in a Volcano plot of LIMMA-modelled 
proteomics data (Fig. 3.23). Volcano plots summarise all proteins commonly 
quantified in 5-FU resistant sublines compared to parent cell lines. The data for 
all proteins commonly quantified were plotted as normalized Log2 fold change 
versus the −Log10 of the adjusted p-value. Orange dot line is at p=0.05 and 
proteins above it represent significantly altered proteins in resistant sublines. 
Red and green dots represent up- and down-regulated proteins respectively, 
with FDR adjusted p<0.001. Vertical black dot lines are positioned at 1 and -1, 
corresponding to 2-fold change in up-regulated and down-regulated proteins 
respectively. A summary table containing significantly altered proteins from 
Volcano plots is shown below. 
 
Resistant cell 
lines to 5-FU 
Significant              
Up-regulated 
Proteins 






DLD-1 105 112 5,79% 
KM 12 301 419 20.39% 
HT 29 32 89 3.42% 
Table 3.7: Significantly up-regulated (Fold change ≥ 2) and down-regulated (Fold 
change ≤ 2) proteins in resistant cell lines to 5-FU. 
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Figure 3.23: Volcano plots showing the distribution of significantly down- and up-
regulated proteins following LIMMA modelling in 5-FU multi SILAC datasets. 
Criteria for significance are a 2-fold change for the (a) DLD-1 5-FU, (b) KM 12 5-FU, 
and (c) HT 29 5-FU sublines compared to the parent data, with p<0.05. Key: Red-
Upregulated, Green – Downregulated proteins, Grey-Unaltered and non-significant 
proteins. 
- 118 - 
 
 
Log2 fold changes and their respective p-value were calculated using LIMMA. 
However, fold change calculated is a measure of how much the abundance of 
commonly quantified proteins differs from initial parent cell lines to a final 
protein value in resistant sublines. This measure does not differentiate how 
significant the fold change is, estimated from a biological point of view. So, a 
further clustering classification was done based on the highest group of proteins 
altered just in resistant sublines but not in parent cell lines. Proteins of each 
sample were ordered from the highest to the lowest according all normalized 
Log2 ratio data from SILAC results.  
3.3.7.3 Cluster analysis 
Cluster analysis using a 5th percentile threshold was performed (as described in 
section 3.2.5.7), for 5-FU multi SILAC datasets (Table. 3.8). Of the 27 possible 
different response combinations, the largest group for each cell line was the 
group “NNN” containing unaltered proteins under any of the 3 conditions. 
Encouragingly the smallest groups of proteins were those exhibited apparent 
sporadic response combinations (for example group “ DNU”). Relevant proteins 
for discussion were obtained from clusters of proteins that only were increased 
or decreased in 5-FU resistant sublines with no change in SILAC and passage 
controls (NNU and NND). These proteins are shown in  Figure 3.24, along with 
the unchanged NNN clusters.  
The significantly altered proteins in DLD-1 5-FU, KM 12 5-FU and HT 29 5-FU 
resistant sublines are shown in Tables 3.9 - 3.14. 
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Table 3.8: Thresholds for protein status in 5-FU multi SILAC datasets were 
established using a 5
th
 percentile criteria. From the column of  “Status Sum-up”  in 
the table, only the proteins which remain as unaltered (brown) in both parent cell lines 
and with an altered status (green or red) in the resistant subline were considered to be 
studied as altered proteins involved in drug-resistance. 
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DLD-1  5-FU 
Cluster analysis for DLD-1 5-FU resistant subline showed similar results to 
those observed during “R” LIMMA analysis (see Fig. 3.23a). The highest 
number of proteins remain unaltered in both parent cells lines, whilst DLD-1           
5-FU shows a high symmetry in (a) up- and (b) down-regulated proteins fold 
change dispersion. 
Detailed results for significantly altered proteins in DLD-1 5-FU resistant subline 
are summarized in Tables 3.9 and 3.10. Log2 SILAC results for DLD-1 5-FU / 
DLD-1 SILAC P=9 ratio and p-values from R analysis of resistant and control 
cell lines are included. 
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Figure 3.24: Cluster analysis for DLD-1.  Proteins were classified using 5
th
 percentile 
threshold for significantly (a) up-regulated proteins; (b) unaltered proteins; (c) down-
regulated proteins in DLD-1 5-FU and unaltered in sensitive parent-control cell lines 
DLD-1 P=9 and DLD-1 P=65. 






MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value              
1 HDAC3 O15379 48.8 12.6 4 3 54 3.11 0.001
2 NME3 Q13232 19.0 10.1 4 1 84 2.64 0.001
3 NFAT5 O94916 165.7 9.1 25 7 605 2.51 0.005
4 SPAST Q9UBP0 67.2 11.9 26 4 266 2.18 0.010
5 JUND P17535 35.2 24.2 8 4 217 2.15 0.014
6 STK39 Q9UEW8 59.4 26.8 58 6 758 2.13 0.008
7 RAB2B Q8WUD1 24.2 43.1 92 2 1159 2.08 0.002
8 AGRN O00468 217.1 19.3 92 20 1344 1.91 0.024
9 STAM2 O75886 58.1 13.3 19 4 250 1.90 0.003
10 C1orf116 Q9BW04 63.9 31.3 67 10 846 1.83 0.002
11 FSCN1 Q16658 54.5 55.2 235 20 3488 1.83 0.060
12 PITPNA Q00169 31.8 35.9 52 6 685 1.82 0.003
13 LOC107984056 P54278 95.7 3.8 10 2 113 1.74 0.008
14 AKAP13 Q12802 307.4 22.1 109 30 1148 1.64 0.035
15 FECH P22830 47.8 40.4 80 11 463 1.59 0.016
16 TBC1D17 Q9HA65 72.7 7.6 9 2 158 1.56 0.004
17 TAOK1 Q7L7X3 116.0 11.3 38 6 196 1.52 0.013
18 GSDMD P57764 52.8 34.7 67 11 643 1.50 0.007
19 CDKN2AIPNL Q96HQ2 13.2 31.0 8 2 163 1.48 0.084
20 SVIL O95425 247.6 17.2 109 23 1035 1.47 0.025
21 NAGLU P54802 82.2 26.9 61 12 561 1.45 0.038
22 POLR2M Q6EEV4 15.1 25.0 21 2 417 1.44 0.089
23 SEPTIN10 Q9P0V9 52.6 55.1 189 19 2328 1.43 0.010
24 SYTL2 Q9HCH5 104.9 27.2 99 17 626 1.42 0.004
25 APP P05067 86.9 24.8 103 14 1122 1.39 0.009
26 Hsp40 Q96KC8 63.8 13.7 31 5 512 1.39 0.004
27 EIF2AK4 Q9P2K8 186.8 7.4 22 7 340 1.34 0.091
28 ROMO1 P60602 8.2 21.5 26 1 674 1.34 0.021
29 GALK1 P51570 42.2 42.1 105 12 1801 1.30 0.053
30 RNF13 O43567 42.8 18.4 7 3 49 1.27 0.029
31 PIK3C2A O00443 190.6 12.2 59 14 484 1.25 0.038
32 IGF2BP3 O00425 63.7 36.8 162 13 2216 1.24 0.016
33 MAN2B1 O00754 113.7 19.7 67 13 658 1.23 0.047
34 GGT1 P19440 61.4 16.9 42 7 524 1.23 0.076
35 DDAH2 O95865 29.6 36.5 32 6 405 1.18 0.022
36 UBE3C Q15386 123.8 19.3 39 12 350 1.17 0.010
37 CNOT10 Q9H9A5 82.3 15.9 37 7 297 1.17 0.034
38 ITGA3 P26006 116.5 15.6 100 11 1338 1.16 0.006
39 RABL3 Q5HYI8 26.4 22.0 13 3 142 1.16 0.007
40 NOL3 O60936 22.6 60.6 42 7 781 1.12 0.029
41 GOPC Q9HD26 50.5 34.6 67 10 619 1.11 0.058
42 PAWR Q96IZ0 36.5 36.2 67 10 1184 1.11 0.072
43 PRKCD Q05655 77.5 7.5 14 3 158 1.10 0.034
44 CORO7 P57737 100.5 28.6 64 12 864 1.09 0.028
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Table 3.9: Results of high SILAC-ratios for single SILAC DLD-1 5-FU 
experiment. p-value from multi SILAC dataset analysed by LIMMA is 
included. 
 
45 AMDHD2 Q9Y303 43.7 37.4 46 8 324 1.09 0.047
46 TMED4 Q7Z7H5 25.9 25.1 48 3 428 1.09 0.036
47 ASPH Q12797 85.8 30.7 156 15 1983 1.09 0.011
48 CCDC53 Q9Y3C0 21.2 26.3 13 3 264 1.07 0.024
49 LOC102724023 P30042 28.2 36.9 87 6 665 1.05 0.029
50 DCTN3 O75935 21.1 10.8 14 1 298 1.04 0.037
51 CHURC1 Q8WUH1 16.1 28.1 18 3 178 1.04 0.030
52 VPS16 Q9H269 94.6 17.5 45 8 266 1.00 0.050
53 SYNRG Q9UMZ2 140.6 13.2 46 11 757 1.00 0.035
54 HIP1 O00291 116.1 21.2 88 16 1202 1.00 0.068
55 TRIP4 Q15650 66.1 22.0 27 6 201 0.98 0.089
56 MYADM Q96S97 35.3 7.1 23 1 625 0.97 0.064
57 DOCK6 Q96HP0 229.4 8.7 38 10 489 0.95 0.066
58 INF2 Q27J81 135.5 41.3 366 35 5976 0.94 0.031
59 VPS36 Q86VN1 43.8 29.3 40 9 196 0.94 0.031
60 ACADVL P49748 70.3 49.8 249 26 4775 0.93 0.010
61 SEC24D O94855 112.9 24.4 59 14 450 0.93 0.026
62 ACSF3 Q4G176 64.1 17.9 25 6 260 0.93 0.077
63 DYNLT3 P51808 13.1 35.3 29 2 623 0.93 0.034




MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value            
1 HELZ P42694 218.8 7.2 16 7 166 -5.17 0.000
2 VPS45 Q9NRW7 65.0 11.9 30 6 377 -4.83 0.000
3 VPS52 Q8N1B4 82.2 16.7 25 7 264 -3.91 0.003
4 GPD1L Q8N335 38.4 8.8 13 2 565 -3.32 0.004
5 TOMM20 Q15388 16.3 17.2 9 2 122 -2.68 0.001
6 UMPS P11172 52.2 40.4 79 12 1367 -2.57 0.002
7 ARHGAP32 A7KAX9 230.4 19.5 76 19 956 -2.56 0.001
8 AMACR Q9UHK6 42.4 26.7 47 6 600 -2.53 0.020
9 MASTL Q96GX5 97.3 9.3 10 4 180 -2.29 0.002
10 PDS5B Q9NTI5 164.6 8.6 26 6 226 -2.20 0.002
11 C2orf72 A6NCS6 30.5 11.9 11 2 85 -2.16 0.002
12 TUBB4B P68371 49.8 73.0 4561 1 66661 -1.97 0.008
13 FDXR P22570 53.8 38.9 75 12 770 -1.96 0.021
14 SCRIB Q14160 174.8 20.5 99 17 817 -1.95 0.007
15 EMC4 Q5J8M3 20.1 22.4 15 4 202 -1.76 0.020
16 RAP1GDS1 P52306 66.3 23.9 50 9 1010 -1.75 0.009
17 CBX5 P45973 22.2 44.0 72 5 1668 -1.67 0.004
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Table 3.10: Results of low SILAC-ratios for single SILAC DLD-1 5-FU 
experiment. p-value from multi SILAC dataset analysed by LIMMA is included. 
 
 
18 SLC5A6 Q9Y289 68.6 3.8 6 2 138 -1.65 0.013
19 SPTLC3 Q9NUV7 62.0 6.0 3 2 58 -1.63 0.006
20 CDCP1 Q9H5V8 92.9 13.5 53 10 278 -1.59 0.014
21 DHCR24 Q15392 60.1 22.1 98 10 849 -1.53 0.032
22 AP3S1 Q92572 21.7 7.8 18 1 239 -1.51 0.045
23 PABPC4 Q13310 70.7 36.2 385 10 7754 -1.51 0.006
24 HAS1 Q92839 64.8 1.4 12 1 281 -1.51 0.006
25 WDR18 Q9BV38 47.4 14.4 30 5 340 -1.50 0.014
26 SLC3A2 P08195 68.0 46.8 344 24 6878 -1.48 0.026
27 TEX10 Q9NXF1 105.6 8.4 45 5 367 -1.43 0.016
28 MYD88 Q99836 33.2 25.0 7 4 46 -1.43 0.040
29 CLPTM1 O96005 76.0 16.1 38 6 924 -1.41 0.028
30 H2AFY2 Q9P0M6 40.0 10.2 79 1 511 -1.37 0.025
31 HMGCS1 Q01581 57.3 53.5 247 18 3706 -1.32 0.009
32 SMARCD2 Q92925 58.9 24.7 34 7 280 -1.26 0.016
33 AP3B1 O00203 121.2 15.5 106 13 1119 -1.26 0.019
34 PELP1 Q8IZL8 119.6 19.6 121 13 1093 -1.25 0.020
35 CGN Q9P2M7 136.3 11.6 53 8 495 -1.23 0.024
36 TAMM41 Q96BW9 51.0 19.5 29 6 177 -1.21 0.033
37 P4HA2 O15460 60.9 18.9 51 6 644 -1.21 0.019
38 ACSL4 O60488 79.1 19.1 33 7 435 -1.21 0.036
39 AGO1 Q9UL18 97.2 13.9 26 4 176 -1.20 0.019
40 AP3M1 Q9Y2T2 46.9 33.3 50 8 597 -1.18 0.026
41 RPL7L1 Q6DKI1 28.6 14.2 13 3 168 -1.18 0.013
42 MYBBP1A Q9BQG0 148.8 24.5 174 27 1908 -1.15 0.012
43 NDUFAF3 Q9BU61 20.3 19.0 9 3 67 -1.15 0.009
44 LBP-1a Q9NZI7 60.5 6.5 40 1 593 -1.14 0.010
45 TCTN3 Q6NUS6 66.1 1.3 2 1 37 -1.13 0.020
46 PTPN6 P29350 67.5 27.9 41 10 281 -1.12 0.029
47 LARP1 Q6PKG0 123.4 26.7 94 14 780 -1.10 0.013
48 EMC8 O43402 23.8 36.2 49 5 467 -1.10 0.049
49 TRIM28 Q13263 88.5 58.3 675 29 9525 -1.07 0.016
50 MINA Q8IUF8 52.8 18.1 33 7 254 -1.06 0.010
51 AK6 Q9Y3D8 20.0 14.5 9 2 177 -1.02 0.019
52 PMPCA Q10713 58.2 29.1 116 11 964 -1.01 0.044
53 TKT P29401 67.8 47.0 659 20 10387 -1.01 0.031
54 ATP1B3 P54709 31.5 32.6 83 8 882 -0.99 0.035
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KM 12 5-FU 
Cluster analysis results for KM 12 5-FU are shown in Figure 3.25. Detailed 
results for significantly altered proteins in KM 12 5-FU resistant subline are 
summarised in Tables 3.11 and Table 3.12. Log2 SILAC results for KM 12 5-FU 
/ KM 12 SILAC P=9 ratio and p-values from R analysis of resistant and control 
cell lines are included. 
Cluster analysis for KM 12 5-FU resistant subline showed similar results to 
those observed during “R” LIMMA analysis (see Fig. 3.23b). The highest 
number of proteins remain unaltered in both parent cells lines, whilst KM 12 5-
FU shows a higher number of down-regulated proteins than up-regulated 
proteins. 
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Figure 3.25: Cluster analysis for KM 12.  Proteins were classified using 5
th
 percentile 
threshold for significantly (a) up-regulated proteins; (b) unaltered proteins; (c) down-
regulated proteins in KM 12 5-FU and unaltered in sensitive parent-control cell lines 
KM 12 P=9 and KM 12 P=55. 






MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value               
1 PYGM P11217 97.0 17.8 159 2 1686 5.95 -
2 ISG15 P05161 17.9 44.8 117 7 1764 4.30 0.006
3 B2M P61769 13.7 47.1 46 4 526 4.11 0.003
4 TAP1 Q03518 87.2 24.8 65 10 1193 3.91 0.008
5 Hsp110 Q92598 96.8 47.7 261 33 4315 3.70 0.000
6 STAT1 P42224 87.3 47.9 448 29 7843 3.64 0.001
7 GNS P15586 62.0 32.1 50 11 640 3.33 0.017
8 LIMA1 Q9UHB6 85.2 40.6 177 24 2043 3.25 0.000
9 MYH14 Q7Z406 227.7 43.9 873 75 14550 3.19 0.001
10 PLSCR1 O15162 35.0 21.7 45 4 968 3.12 0.089
11 EPPK1 P58107 555.3 54.3 436 63 5764 3.12 0.002
12 SRC P12931 59.8 38.2 54 10 815 3.03 0.002
13 ACACA Q13085 265.4 28.3 158 43 1875 3.03 0.001
14 ERMP1 Q7Z2K6 100.2 21.9 79 12 891 2.76 0.005
15 EFNB1 P98172 38.0 26.0 25 5 242 2.73 0.084
16 GRN P28799 63.5 32.9 138 10 1591 2.72 0.018
17 LGALS3BP Q08380 65.3 36.8 501 15 9580 2.69 0.021
18 CHMP2A O43633 25.1 11.7 29 3 1212 2.55 0.001
19 ARHGAP18 Q8N392 74.9 18.4 42 10 671 2.53 0.004
20 SCAMP2 O15127 36.6 10.6 20 4 604 2.48 0.043
21 STIM1 Q13586 77.4 28.3 77 13 531 2.47 0.004
22 PSMB9 P28065 23.3 30.1 34 5 513 2.45 0.012
23 BAIAP2 Q9UQB8 60.8 42.2 72 14 967 2.36 0.012
24 ABCC3 O15438 169.2 12.9 65 13 713 2.35 0.001
25 ACAD9 Q9H845 68.7 25.3 75 13 1178 2.30 0.002
26 IPO7 O95373 119.4 19.9 127 16 1413 2.30 0.001
27 MGLL Q99685 33.2 16.2 7 3 37 2.28 0.002
28 APLP2 Q06481 86.9 11.0 35 5 240 2.28 0.005
29 ST14 Q9Y5Y6 94.7 21.8 74 12 968 2.26 0.010
30 GPRC5A Q8NFJ5 40.2 21.3 58 6 599 2.24 0.001
31 GNAI2 P04899 40.4 52.1 113 9 1099 2.19 0.004
32 HPCAL1 P37235 22.3 31.1 38 5 386 2.17 0.001
33 C1orf116 Q9BW04 63.9 29.6 46 9 475 2.16 0.159
34 CNPY3 Q9BT09 30.7 21.2 47 4 379 2.15 0.007
35 IGF2R P11717 274.2 19.9 84 28 692 2.12 0.018
36 TMUB1 Q9BVT8 26.2 12.6 16 2 103 2.08 0.895
37 REPIN1 Q9BWE0 63.5 2.6 10 1 124 2.07 0.002
38 RAC1 O96013 64.0 26.4 56 7 375 2.07 0.007
39 CHCHD6 Q9BRQ6 26.4 23.8 27 3 224 2.06 0.002
40 GSTK1 Q9Y2Q3 25.5 61.1 190 10 1949 2.04 0.011
41 NEU1 Q99519 45.4 29.9 36 7 237 2.04 0.026
42 NSDHL Q15738 41.9 49.3 104 15 1199 2.01 0.003
43 AGK Q53H12 47.1 36.0 46 10 612 1.98 0.005
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44 PSMB10 P40306 28.9 33.3 37 4 738 1.97 0.033
45 ASAP2 O43150 111.6 26.8 52 14 726 1.96 0.002
46 TRIM56 Q9BRZ2 81.4 13.1 21 7 198 1.94 0.021
47 NPC2 P61916 16.6 41.1 60 4 405 1.93 0.008
48 DDAH2 O95865 29.6 36.5 74 6 1572 1.90 0.006
49 ABHD12 Q8N2K0 45.1 39.4 68 9 676 1.89 0.017
50 MYADM Q96S97 35.3 12.1 16 3 448 1.89 0.007
51 ACP2 P11117 48.3 8.5 20 3 91 1.86 -
52 CNDP2 Q96KP4 52.8 56.4 184 19 1927 1.86 0.003
53 ACOT13 Q9NPJ3 15.0 30.7 18 3 299 1.86 0.021
54 PCCB P05166 58.2 28.0 34 10 307 1.84 0.034
55 CLN6 Q9NWW5 35.9 11.3 31 3 240 1.84 0.003
56 USP8 P40818 127.4 9.7 20 7 252 1.83 0.068
57 GALNS P34059 58.0 16.3 19 7 150 1.82 0.071
58 CLPTM1L Q96KA5 62.2 15.8 33 5 163 1.82 0.013
59 NT5C3A Q9H0P0 37.9 50.9 74 15 1089 1.82 0.047
60 NUDT3 O95989 19.5 35.5 19 4 108 1.82 0.037
61 RAP2C Q9Y3L5 20.7 42.6 15 3 402 1.81 0.003
62 SLC9A3R1 O14745 38.8 34.9 104 8 789 1.78 0.002
63 TNS4 Q8IZW8 76.7 19.3 23 7 229 1.75 0.051
64 PRKAR1A P10644 43.0 17.3 27 5 452 1.75 0.030
65 SQSTM1 Q13501 47.7 57.3 228 15 3175 1.74 0.018
66 IVD P26440 46.3 29.8 76 8 1111 1.74 0.005
67 CTSD P07339 44.5 50.0 506 18 9602 1.73 0.433
68 TP53 P04637 43.6 36.1 44 6 465 1.72 0.008
69 RNMT O43148 54.8 30.7 47 9 618 1.72 0.012
70 ABCF1 Q8NE71 95.9 19.5 70 14 1117 1.71 0.069
71 TFAM Q00059 29.1 22.0 44 5 576 1.70 0.019
72 FAM49B Q9NUQ9 36.7 40.7 206 11 3204 1.68 0.002
73 TEAD1 P28347 47.9 12.0 11 3 98 1.67 0.025
74 PSMB8 P28062 30.3 49.3 62 10 735 1.66 0.139
75 PARP4 Q9UKK3 192.5 13.0 48 14 716 1.66 0.002
76 SPTLC2 O15270 62.9 34.2 86 10 1194 1.65 0.032
77 NUDT4 Q9NZJ9 20.3 41.1 45 6 353 1.65 0.012
78 AHNAK Q09666 628.7 73.6 2961 283 31255 1.65 0.003
79 SPOUT1 Q5T280 42.0 15.2 26 3 278 1.63 0.006
80 PDCD6 O75340 21.9 37.7 69 6 1188 1.63 0.004
81 VAPA Q9P0L0 27.9 34.5 87 5 860 1.63 0.003
82 USP14 P54578 56.0 51.6 165 18 2267 1.63 0.003
83 TMEM43 Q9BTV4 44.8 42.5 52 9 508 1.62 0.001
84 PARVA Q9NVD7 42.2 19.1 20 7 434 1.61 0.020
85 SGPL1 O95470 63.5 34.3 112 11 1478 1.58 0.458
86 CYB5A P00167 15.3 42.5 50 5 245 1.58 0.006
87 RAD50 Q92878 153.8 23.2 104 22 701 1.58 0.021
88 LAMP2 P13473 44.9 4.9 28 2 213 1.57 0.029
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Table 3.11: Results of high SILAC-ratios for single SILAC KM 12 5-FU 
experiment.  p-value from multi SILAC dataset analysed by LIMMA is included.              
*- Protein not quantified in at least one control sample. 
 
89 PIP4K2C Q8TBX8 47.3 24.7 34 8 803 1.57 0.085
90 COASY Q13057 62.3 21.3 50 8 464 1.56 0.006
91 MRE11 P49959 80.5 34.9 102 18 1143 1.56 0.004
92 LIG3 P49916 112.8 19.2 60 14 871 1.56 0.003
93 ADAM10 O14672 84.1 32.9 110 15 1272 1.56 0.003
94 NNT Q13423 113.8 24.3 73 17 1063 1.56 0.429
95 SDF2 Q99470 23.0 29.9 50 4 630 1.56 0.068
96 SAMHD1 Q9Y3Z3 72.2 56.1 213 29 3347 1.55 0.205
97 S100A13 Q99584 11.5 29.6 16 2 159 1.54 0.404
98 FAM129B Q96TA1 84.1 49.7 323 22 3165 1.54 0.002
99 WASL O00401 54.8 18.2 14 5 159 1.54 0.018
100 EIF2AK2 P19525 62.1 38.1 171 17 2809 1.53 0.147
101 MYO6 Q9UM54 149.6 37.3 199 39 2593 1.53 0.002
102 BCAP31 P51572 28.0 14.2 49 5 805 1.52 0.033
103 CORO1B Q9BR76 54.2 39.1 192 12 2352 1.51 0.012
104 NUP153 P49790 153.8 28.3 69 21 681 1.51 0.005
105 CAPG P40121 38.5 31.32 141 7 2300 1.50 0.003
106 PSAP P07602 58.1 47.3 308 18 3773 1.50 0.165
107 ISOC2 Q96AB3 22.3 72.7 95 8 1383 1.49 0.066
108 EXOC4 Q96A65 110.4 18.8 46 12 466 1.49 0.023
109 GDF15 Q99988 34.1 18.2 12 3 118 1.49 0.417
110 TM9SF3 Q9HD45 67.8 11.9 37 6 255 1.49 0.018
111 SRPRA P08240 69.8 35.1 74 15 850 1.47 0.007
112 ANXA4 P09525 35.9 67.4 338 22 6665 1.45 0.021




MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value              
1 PRKAR2B P31323 46.3 17.7 28 2 473 -7.33 -
2 PPP1R1B Q9UD71 22.9 58.8 54 7 582 -6.57 0.000
3 ARG2 P78540 38.6 29.9 19 6 333 -6.07 0.000
4 CA2 P00918 29.2 48.8 87 11 963 -5.90 0.000
5 FSCN1 Q16658 54.5 47.5 115 16 1543 -5.75 0.000
6 TFF3 Q07654 8.6 22.5 6 1 101 -5.53 0.000
7 CRYM Q14894 33.8 10.8 9 2 82 -4.93 0.000
8 UBXN7 O94888 54.8 20.4 31 6 300 -4.80 0.038
9 CNN3 Q15417 36.4 32.2 28 7 242 -4.37 0.000
10 VIM P08670 53.6 29.4 37 10 467 -4.10 0.001
11 CD109 Q6YHK3 161.6 15.8 45 14 759 -3.93 0.001
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12 PHGDH O43175 56.6 54.0 417 27 7013 -3.89 0.000
13 AHCYL1 O43865 58.9 18.1 31 3 259 -3.75 0.071
14 OXCT1 P55809 56.1 37.3 119 12 2444 -3.74 0.000
15 PLIN2 Q99541 48.0 16.9 9 4 80 -3.63 0.001
16 MAPRE2 Q15555 37.0 17.7 17 4 203 -3.60 0.000
17 PRAF2 O60831 19.2 16.9 15 3 279 -3.49 0.000
18 ASB9 Q96DX5 31.8 19.0 8 3 108 -3.49 0.003
19 HMGN5 P82970 31.5 21.6 46 4 831 -3.39 0.000
20 FAM98C Q17RN3 37.3 16.6 6 4 37 -3.34 -
21 PLEK2 Q9NYT0 39.9 24.1 23 4 136 -3.19 0.020
22 IQGAP2 Q13576 180.5 15.4 39 13 436 -3.18 0.001
23 CEMIP Q8WUJ3 152.9 8.3 15 7 32 -3.16 0.057
24 BDH2 Q9BUT1 26.7 16.3 9 3 146 -3.12 0.000
25 BAZ1A Q9NRL2 178.6 5.3 10 5 75 -3.08 0.017
26 S100A14 Q9HCY8 11.7 77.9 70 5 847 -3.06 0.000
27 RPL22L1 Q6P5R6 14.6 36.1 10 2 141 -2.94 -
28 KRR1 Q13601 43.6 12.6 17 4 236 -2.89 0.534
29 ALDH2 P05091 56.3 58.6 212 20 4848 -2.79 0.000
30 ALCAM Q13740 65.1 33.1 87 12 1123 -2.75 0.001
31 BLMH Q13867 52.5 26.4 21 7 202 -2.75 0.002
32 MUC5AC P98088 585.2 15.2 113 30 1034 -2.72 0.000
33 SOD2 P04179 24.7 42.8 109 6 1729 -2.72 0.001
34 KIF2C Q99661 81.3 30.6 60 13 836 -2.72 0.002
35 AGR2 O95994 20.0 57.1 371 8 5697 -2.69 0.001
36 EIF4EBP1 Q13541 12.6 63.6 24 4 198 -2.66 0.039
37 HLCS P50747 80.7 6.3 4 3 38 -2.59 0.774
38 PARP2 Q9UGN5 66.2 8.7 11 3 71 -2.58 0.003
39 LYN P07948 58.5 14.1 29 5 100 -2.58 0.001
40 ULBP2 Q9BZM5 27.4 11.8 4 2 83 -2.55 0.002
41 WRAP53 Q9BUR4 59.3 12.2 8 4 82 -2.54 0.003
42 TTC19 Q6DKK2 42.4 12.6 7 3 57 -2.50 -
43 MTA1 Q13330 80.7 15.4 19 5 250 -2.48 0.100
44 KIF20A O95235 100.2 10.6 17 5 287 -2.47 0.002
45 PACSIN3 Q9UKS6 48.5 21.5 8 5 137 -2.45 0.001
46 TRIM2 Q9C040 81.5 12.5 18 5 115 -2.39 0.001
47 UBASH3B Q8TF42 72.6 5.7 7 2 91 -2.36 0.662
48 FABP5 Q01469 15.2 70.4 426 12 5771 -2.34 0.003
49 MCRIP2 Q9BUT9 17.8 35.0 25 3 441 -2.34 0.075
50 ETFDH Q16134 68.5 10.0 5 3 88 -2.33 0.022
51 GAA P10253 105.3 12.5 32 8 353 -2.33 0.000
52 EYA3 Q99504 62.6 6.8 4 2 33 -2.28 -
53 PTER Q96BW5 39.0 31.5 31 7 281 -2.28 0.001
54 MVD P53602 43.4 29.5 40 7 353 -2.27 0.002
55 CDKN2AIP Q9NXV6 61.1 10.7 25 4 388 -2.27 0.077
56 Hsp40 Q96KC8 63.8 7.2 8 2 57 -2.24 -





57 FBXO30 Q8TB52 82.3 6.3 6 3 58 -2.23 0.019
58 OAT P04181 48.5 65.6 249 21 3799 -2.23 0.001
59 CDCA2 Q69YH5 112.6 4.6 11 3 102 -2.18 -
60 SNTB2 Q13425 57.9 4.3 11 2 215 -2.17 0.003
61 CORO1A P31146 51.0 7.8 9 2 134 -2.16 0.082
62 DNA P11388 174.3 32.0 242 30 3498 -2.15 0.003
63 CYCS P99999 11.7 46.7 77 8 293 -2.13 0.002
64 RIDA P52758 14.5 45.3 21 4 353 -2.13 0.001
65 TAMM41 Q96BW9 51.0 19.0 32 6 209 -2.11 0.002
66 MPC2 O95563 14.3 30.7 13 3 66 -2.11 0.008
67 MYO1E Q12965 127.0 13.4 26 9 184 -2.10 0.001
68 COPS7A Q9UBW8 30.3 20.7 13 3 222 -2.10 0.004
69 HCCS P53701 30.6 20.5 18 5 153 -2.09 0.001
70 KIF15 Q9NS87 160.1 3.6 5 3 86 -2.09 -
71 PRKCI P41743 68.2 20.1 26 6 103 -2.09 0.528
72 PLCD3 Q8N3E9 89.2 11.7 15 6 128 -2.09 -
73 FUT8 Q9BYC5 66.5 2.4 2 1 47 -2.08 0.001
74 HMGCS2 P54868 56.6 37.8 150 11 2623 -2.08 0.004
75 LUC7L Q9NQ29 43.7 21.0 79 4 509 -2.07 0.003
76 DPP4 P27487 88.2 18.1 54 11 592 -2.07 0.003
77 DDT P30046 12.7 83.1 226 9 2832 -2.05 0.002
78 KIF11 P52732 119.1 17.4 45 12 921 -2.05 0.012
79 C12orf43 Q96C57 28.2 26.3 15 4 68 -2.04 0.028
80 PRPS2 P11908 34.7 51.3 224 6 2879 -2.02 0.005
81 HSP90AA1 P07900 84.6 62.2 2383 35 39957 -1.99 0.006
82 ABHD17C Q6PCB6 35.8 14.0 8 3 82 -1.97 -
83 SLC25A4 P12235 33.0 42.6 148 3 2147 -1.97 0.003
84 PPID Q08752 40.7 41.6 56 10 810 -1.96 0.006
85 PBK Q96KB5 36.1 26.7 36 5 577 -1.95 0.007
86 UTP20 O75691 318.2 8.5 67 16 666 -1.93 0.013
87 PRPSAP2 O60256 40.9 41.2 82 8 589 -1.92 0.007
88 GLS O94925 73.4 37.7 143 17 1804 -1.91 0.007
89 GPD1L Q8N335 38.4 13.1 15 3 461 -1.89 0.021
90 SLC25A11 Q02978 34.0 19.4 44 5 864 -1.87 0.001
91 COQ5 Q5HYK3 37.1 30.9 13 6 120 -1.87 0.006
92 LARS Q9P2J5 134.4 42.4 337 39 4377 -1.86 0.159
93 GPHN Q9NQX3 79.7 16.7 18 7 263 -1.84 0.002
94 DDI2 Q5TDH0 44.5 47.6 55 11 315 -1.84 0.004
95 CKAP4 Q07065 66.0 40.9 138 18 2625 -1.84 0.000
96 TXNL4B Q9NX01 17.0 12.1 4 1 73 -1.83 0.027
97 TRUB1 Q8WWH5 37.2 22.6 8 4 30 -1.81 0.966
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Table 3.12: Results of low SILAC-ratios for single SILAC KM 12 5-FU 
experiment.  p-value from multi SILAC dataset analysed by LIMMA is included.              
*- Protein not quantified in at least one control sample. 
 
 
98 NCDN Q9UBB6 78.8 3.2 4 2 48 -1.80 -
99 GTPBP3 Q969Y2 52.0 14.8 11 4 152 -1.79 0.008
100 OGFOD1 Q8N543 63.2 18.8 28 7 335 -1.77 0.112
101 TSEN15 Q8WW01 18.6 33.3 12 3 146 -1.76 0.630
102 MTO1 Q9Y2Z2 79.9 5.3 8 2 41 -1.75 0.007
103 APOO Q9BUR5 22.3 23.2 22 3 291 -1.74 0.001
104 SMTN P53814 99.0 9.8 9 5 123 -1.74 0.003
105 ASF1B Q9NVP2 22.4 34.16 28 4 444 -1.74 0.016
106 PRMT5 O14744 72.6 22.0 88 11 816 -1.74 0.006
107 PYGL P06737 97.1 50.5 308 28 2911 -1.74 0.001
108 KLC1 Q07866 65.3 27.6 66 10 632 -1.74 0.018
109 APPL1 Q9UKG1 79.6 22.3 66 9 536 -1.74 0.032
110 EPB41L2 O43491 112.5 42.1 211 25 3561 -1.74 0.176
111 CDCA3 Q99618 29.0 6.7 9 1 211 -1.73 0.092
112 DUSP12 Q9UNI6 37.7 35.3 21 7 237 -1.73 0.008
113 HEATR3 Q7Z4Q2 74.5 12.5 42 7 407 -1.72 0.007
114 WDR77 Q9BQA1 36.7 35.7 108 7 1481 -1.72 0.010
115 DECR1 Q16698 36.0 34.3 134 8 1563 -1.71 0.001
116 PSAT1 Q9Y617 40.4 50.5 176 15 2215 -1.71 0.047
117 GGA1 Q9UJY5 70.3 12.2 12 3 107 -1.70 0.004
118 SLC3A2 P08195 68.0 42.5 364 21 6392 -1.69 0.007
119 SLC4A7 Q9Y6M7 136.0 5.8 11 4 172 -1.69 0.005
120 TTC38 Q5R3I4 52.8 19.8 10 6 73 -1.68 0.004
121 PRKAR2A P13861 45.5 44.1 119 12 2255 -1.68 0.004
122 CLASP2 O75122 141.0 8.7 39 5 362 -1.68 0.017
123 DFFA O00273 36.5 27.8 62 7 1115 -1.67 0.014
124 IMPDH2 P12268 55.8 45.5 283 19 5200 -1.66 0.050
125 QRSL1 Q9H0R6 57.4 15.0 17 5 219 -1.66 0.011
126 GUF1 Q8N442 74.3 4.3 5 2 61 -1.65 0.005
127 PDE12 Q6L8Q7 67.3 36.3 93 14 1281 -1.63 0.011
128 NCKIPSD Q9NZQ3 78.9 8.2 20 5 164 -1.63 0.004
129 BPNT1 O95861 33.4 42.2 103 11 1802 -1.62 0.001
130 MED4 Q9NPJ6 29.7 15.9 10 3 94 -1.61 0.008
131 COA6 Q5JTJ3 14.1 22.4 15 3 174 -1.61 0.008
132 HK2 P52789 102.3 21.4 41 12 388 -1.60 0.023
133 CIAPIN1 Q6FI81 33.6 39.7 88 9 676 -1.60 0.030
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HT 29 5-FU 
Cluster analysis results for HT 29 5-FU are shown in Figure 3.26. Detailed 
results for significantly altered proteins in HT 29 5-FU resistant subline are 
summarized in Tables 3.13 and 3.14. Log2 SILAC results for HT 29 5-FU / HT 
29 SILAC P=9 ratio and p-values from R analysis of resistant and control cell 
lines are included. 
Cluster analysis for HT 29 5-FU resistant subline showed similar results to 
those observed during “R” LIMMA analysis (see Fig. 3.23c). The highest 
number of proteins remain unaltered in both parent cells lines, whilst HT 29 5-
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Figure 3.26:  Cluster analysis for HT 29. Proteins were classified using 5
th
 percentile 
threshold for significant (a) up-regulated proteins; (b) unaltered proteins; (c) down-
regulated proteins in  HT 29 5-FU resistant subline and unaltered in sensitive parent-
control cell lines HT 29 P=9 and HT 29 P=57. 














Log2  Ratio:  
L/H
p-value             
1 GATA6 Q92908 60.0 2.4 3 1 228.03 3.13 0.012
2 PALD1 Q9ULE6 96.7 3.6 4 2 72.67 2.33 0.020
3 BET1 O15155 13.3 15.3 4 1 75.66 2.31 0.019
4 SQSTM1 Q13501 47.7 56.8 313 13 4032.1 2.26 0.085
5 OCLN Q16625 59.1 26.4 49 9 351.14 2.24 0.094
6 TFRC P02786 84.8 39.9 365 25 5250.2 2.21 0.029
7 ZNF609 O15014 151.1 5.2 15 3 37.317 2.21 0.034
8 TOR4A Q9NXH8 46.9 25.1 42 7 697.98 2.18 0.061
9 FUT4 P22083 59.0 7.4 8 3 139.4 2.13 0.142
10 B2M P61769 13.7 21.8 26 2 300.09 2.12 0.097
11 LDLR P01130 95.3 13.5 51 7 324.21 2.10 0.120
12 MAN2A1 Q16706 131.1 20.7 58 14 456.84 2.10 0.122
13 EPCAM P16422 34.9 33.8 280 7 4744.9 2.07 0.096
14 CHDH Q8NE62 65.3 37.0 68 13 694.09 2.04 0.070
15 ALDH1B1 P30837 57.2 44.7 120 16 1638.9 2.02 0.132
16 DST Q03001 860.1 1.5 12 6 35.05 2.01 0.049
17 NAGLU P54802 82.2 11.7 12 5 91.11 2.01 0.159
18 PARP14 Q460N5 202.7 7.3 26 9 163.82 2.01 0.160
19 REEP4 Q9H6H4 29.4 12.8 10 2 32.97 1.98 0.094
20 NFU1 Q9UMS0 28.4 21.3 26 4 255.21 1.96 0.172
21 TPMT P51580 28.2 33.5 35 6 465.85 1.95 0.119
22 SP100 P23497 100.4 14.9 48 7 579.91 1.95 0.125
23 TUBB3 Q13509 50.4 44.9 1366 3 20228 1.94 0.188
24 ADGRE5 P48960 91.8 10.5 41 5 369.95 1.92 0.067
25 HLA-A P05534 40.7 43.6 204 2 3630.8 1.89 0.031
26 PLSCR1 O15162 35.0 15.4 31 3 438.82 1.88 0.077
27 MAP3K4 Q9Y6R4 181.6 3.7 15 4 328.27 1.88 0.179
28 ADPGK Q9BRR6 54.1 25.6 82 7 535.46 1.88 0.275
29 TNFRSF21 O75509 71.8 8.2 19 4 461.38 1.87 0.262
30 METTL2B Q6P1Q9 43.4 13.8 20 3 401.68 1.85 0.038
31 ATL2 Q8NHH9 66.2 9.3 42 3 622.95 1.85 0.085
32 SPINT1 O43278 58.4 16.8 56 7 444.45 1.84 0.125
33 TIMM8B Q9Y5J9 9.3 13.3 11 1 259.49 1.83 0.140
34 ALG2 Q9H553 47.1 11.8 7 3 47.263 1.82 0.024
35 ERLIN1 O75477 38.9 33.8 37 6 623.78 1.82 0.219
36 HIBADH P31937 35.3 47.3 179 13 2573.2 1.79 0.108
37 APLP2 Q06481 86.9 15.2 74 7 449.57 1.78 0.023
38 HACD3 Q9P035 43.1 22.7 63 6 536.41 1.78 0.166
39 CPD O75976 152.8 22.8 122 19 1363.6 1.78 0.318
40 MYOF Q9NZM1 234.6 34.4 399 52 3611.6 1.77 0.069
41 GCAT O75600 45.3 29.6 24 7 419.49 1.77 0.091
42 GOLIM4 O00461 81.8 8.9 36 4 416.93 1.77 0.100
43 WBSCR22 O43709 31.9 20.6 28 3 258.82 1.77 0.222
44 AMDHD2 Q9Y303 43.7 30.6 38 8 186.7 1.76 0.076
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Table 3.13: Results of high SILAC-ratios for single SILAC HT 29 5-FU 
experiment. p-value from multi SILAC dataset analysed by LIMMA is included. 
 
 
45 CLN6 Q9NWW5 35.9 18.0 41 4 268.8 1.74 0.137
46 PLPP2 O43688 32.6 5.2 15 1 144.91 1.73 0.456
47 FDFT1 P37268 48.1 29.0 50 9 754.35 1.72 0.106
48 HK2 P52789 102.3 16.9 30 10 293.93 1.72 0.282
49 POLR1B Q9H9Y6 128.1 2.5 7 2 135.91 1.72 0.434
50 WDR74 Q6RFH5 42.4 34.0 37 9 421.14 1.71 0.244
51 ZNF830 Q96NB3 42.0 31.5 29 7 242.24 1.70 0.180
52 ATF7IP Q6VMQ6 136.3 7.6 18 5 40.115 1.69 0.025
53 SLC12A2 P55011 131.4 26.4 288 24 4031.3 1.68 0.259
54 CCDC51 Q96ER9 45.8 7.1 9 3 47.148 1.67 0.071
55 RRP7A Q9Y3A4 32.3 13.2 8 2 74.19 1.67 0.397
56 EFL1 Q7Z2Z2 125.4 12.8 19 7 274.18 1.66 0.327
57 RRP8 O43159 50.7 16.4 17 5 217.16 1.66 0.568
58 UTP14A Q9BVJ6 87.9 15.3 49 8 467.75 1.66 0.572
59 FTH1 P02794 21.2 39.9 31 5 253.34 1.65 0.026
60 NUDT1 P36639 22.5 16.2 8 3 131.42 1.65 0.299
61 SPOUT1 Q5T280 42.0 18.4 46 4 309.65 1.63 0.087
62 RNF114 Q9Y508 25.7 16.7 14 2 311.27 1.63 0.202
63 GALNT7 Q86SF2 75.3 21.2 49 8 908.11 1.63 0.298
64 RBBP5 Q15291 59.1 11.9 29 3 267.61 1.63 0.618
65 APP P05067 86.9 20.6 87 10 764 1.62 0.208
66 QSOX2 Q6ZRP7 77.5 20.8 66 8 904.48 1.62 0.311
67 DSG2 Q14126 122.2 33.8 198 17 2976.5 1.62 0.607




MW    
[kDa]






Log2  Ratio:  
L/H
p-value             
1 SMAD1 Q15797 52.2 5.8 11 1 144.4 -3.83 0.005
2 VPS45 Q9NRW7 65.0 14.0 38 5 397.99 -2.35 0.002
3 CRABP2 P29373 15.7 57.2 164 7 2285.9 -2.24 0.006
4 PLIN4 Q96Q06 134.3 9.2 13 5 85.675 -2.12 0.004
5 ANXA1 P04083 38.7 60.4 590 20 10910 -1.86 0.023
6 NCDN Q9UBB6 78.8 6.6 10 3 161.68 -1.83 0.008
7 SLC16A3 O15427 49.4 4.3 3 2 29.25 -1.82 0.003
8 SLFN5 Q08AF3 101.0 6.4 7 3 48.11 -1.69 0.043
9 CUL4B Q13620 103.9 13.8 56 6 515.33 -1.65 0.008
10 RASA1 P20936 116.3 11.9 46 8 410.58 -1.60 0.042
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11 PXMP2 Q9NR77 22.2 6.2 7 1 29.4 -1.55 0.006
12 ARL3 P36405 20.4 68.1 60 10 357.66 -1.55 0.026
13 LCN2 P80188 22.6 38.9 48 5 726.45 -1.49 0.006
14 FUCA1 P04066 53.7 16.5 51 5 584.23 -1.40 0.039
15 RDH10 Q8IZV5 38.1 14.1 11 3 95.04 -1.37 0.029
16 PLA2G4A P47712 85.2 4.8 10 2 119 -1.36 0.025
17 TUBB6 Q9BUF5 49.8 21.5 1448 1 13443 -1.33 0.006
18 S100A16 Q96FQ6 11.8 44.7 16 3 321.49 -1.30 0.034
19 DHRS3 O75911 33.5 13.6 3 2 59.24 -1.29 0.037
20 MBNL2 Q5VZF2 40.5 11.5 30 1 92.241 -1.23 0.062
21 CD55 P08174 41.4 21.3 65 5 695.28 -1.20 0.052
22 ALDH1A1 P00352 54.8 56.3 972 25 14234 -1.17 0.010
23 PGM1 P36871 61.4 28.1 50 11 872.09 -1.17 0.047
24 TROVE2 P10155 60.6 27.0 74 9 1148.6 -1.15 0.044
25 ZNFX1 Q9P2E3 220.1 2.2 4 2 40.88 -1.14 0.095
26 C17orf49 Q8IXM2 17.9 19.8 5 2 101.21 -1.11 0.024
27 RTF1 Q92541 80.3 9.0 15 5 315.09 -1.05 0.026
28 CSNK1D P48730 47.3 13.5 21 4 235.1 -1.04 0.017
29 EPHX1 P07099 52.9 38.7 136 10 1002 -1.04 0.139
30 NME3 Q13232 19.0 20.1 14 2 119.83 -1.03 0.056
31 EPPK1 P58107 555.3 55.0 1072 74 16423 -1.02 0.074
32 LYPLA2 O95372 24.7 37.7 75 5 850.15 -1.00 0.045
33 TSEN15 Q8WW01 18.6 10.5 8 1 133.67 -1.00 0.074
34 BTF3L4 Q96K17 17.3 19.0 14 2 190.24 -0.98 0.053
35 CLPP Q16740 30.2 23.1 45 4 1211.6 -0.97 0.064
36 ENO2 P09104 47.2 61.8 358 12 8367.2 -0.97 0.115
37 S100P P25815 10.4 78.9 55 4 344.1 -0.95 0.022
38 BPNT1 O95861 33.4 30.2 46 7 765.77 -0.90 0.028
39 SERPINB8 P50452 42.7 22.2 48 4 232.91 -0.90 0.097
40 RAP1GDS1 P52306 66.3 19.4 44 7 523.94 -0.87 0.028
41 FTO Q9C0B1 58.2 18.6 27 6 426.54 -0.85 0.193
42 NRDC O43847 131.5 9.2 21 7 84.31 -0.83 0.143
43 TMSB4X P62328 5.1 43.2 4 1 32.2 -0.83 0.144
44 QSOX1 O00391 82.5 8.8 25 5 132.78 -0.83 0.210
45 IQGAP3 Q86VI3 184.6 8.4 45 7 507.27 -0.81 0.052
46 SH3GLB1 Q9Y371 40.8 15.1 35 5 142.6 -0.80 0.053
47 TSTD1 Q8NFU3 12.5 12.2 10 1 63.65 -0.80 0.164
48 CAPZA1 P52907 32.9 62.2 406 10 3689.5 -0.78 0.031
49 OGFR Q9NZT2 73.3 22.9 98 11 1260.1 -0.78 0.070
50 GNL1 P36915 68.6 16.1 59 7 641.52 -0.78 0.199
51 40787 Q9NVA2 49.4 33.3 97 5 802.4 -0.78 0.218
52 CTSD P07339 44.5 42.2 493 12 8415.3 -0.77 0.153
53 GYS1 P13807 83.7 25.1 67 13 299.32 -0.77 0.220
54 PGD P52209 53.1 42.7 256 13 4029.8 -0.75 0.014
55 RBM15B Q8NDT2 97.1 6.4 4 3 31 -0.75 0.021
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Table 3.14: Results of low SILAC-ratios for single SILAC HT 29 5-FU 
experiment. p-value from multi SILAC dataset analysed by LIMMA is included. 
3.3.7.4 Bioinformatics analysis of proteins significantly changed due to 
resistance 
Proteins classified as significantly altered by (a) 5th percentile cluster analysis 
and (b) p-values (p≤0.05) from LIMMA analysis were selected for network 
analysis by STRING (Protein-Protein Interaction Network) (see section 3.2.5.8). 
Initially, STRING analysis was applied to identify relationships between proteins 
significantly altered in resistant sublines. For each resistant subline set results, 
proteins were classified according to five biological processes which may 
mediate drug response and drug resistance 1) apoptotic process, 2) DNA repair 
process, 3) metabolism of drugs and small molecules, 4) intracellular protein 
transport and 5) cellular membrane transport and cell membrane organization 
56 CAP1 Q01518 51.9 37.1 276 14 3910.4 -0.75 0.045
57 NDUFA11 Q86Y39 14.8 37.6 9 3 166.39 -0.74 0.013
58 GLRX P35754 11.8 43.4 27 4 392.86 -0.74 0.240
59 SSU72 Q9NP77 22.6 31.4 13 5 36.1 -0.73 0.016
60 TAGLN3 Q9UI15 22.5 14.1 4 1 107.25 -0.73 0.132
61 UBA6 A0AVT1 117.9 26.8 124 19 1439 -0.72 0.038
62 PHPT1 Q9NRX4 13.8 44.0 113 6 702.09 -0.72 0.127
63 NAXD Q8IW45 36.6 36.3 37 6 447.08 -0.72 0.372
64 PNPLA2 Q96AD5 55.3 8.5 16 2 147.82 -0.71 0.030
65 ASAH1 Q13510 44.6 18.5 18 5 251.82 -0.71 0.037
66 EFHD2 Q96C19 26.7 37.1 116 9 1798.9 -0.71 0.101
67 HERC4 Q5GLZ8 118.5 12.9 25 8 59.75 -0.70 0.025
68 TESC Q96BS2 24.7 24.3 17 4 161.05 -0.70 0.069
69 WFS1 O76024 100.2 7.9 12 4 124.2 -0.69 0.037
70 DPYSL2 Q16555 62.3 61.2 224 20 3036.6 -0.69 0.043
71 RABGGTA Q92696 65.0 2.6 13 1 103.48 -0.69 0.127
72 LRSAM1 Q6UWE0 83.5 11.2 15 5 73.86 -0.69 0.228
73 NECAP2 Q9NVZ3 28.3 22.4 22 3 226.84 -0.67 0.087
74 HP1BP3 Q5SSJ5 61.2 4.7 9 2 87.315 -0.66 0.030
75 RNPEP Q9H4A4 72.5 39.2 250 19 2645.9 -0.66 0.037
76 TAGLN2 P37802 22.4 66.8 459 10 8778 -0.66 0.064
77 RHOC P08134 22.0 43.0 189 1 2337.3 -0.66 0.076
78 LZIC Q8WZA0 21.5 28.9 7 3 71.875 -0.65 0.071
79 SRSF4 Q08170 56.6 12.3 66 4 604.38 -0.64 0.028
80 WDR1 O75083 66.2 53.6 531 19 8712.8 -0.64 0.056
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processes. This is based on molecular functions identified by GO and pathway 
analysis for selected proteins using EnrichNet (Fig. 3.28-3.30). Furthermore, 
significantly altered proteins were used to build up Venn diagrams to show 
common significantly up-regulated and significantly down-regulated protein in 
different resistant sublines to 5-FU (Fig. 3.27). Commonly up-regulated and 
down-regulated proteins are presented at the intersection of the Venn diagrams 
and they will be discussed in detail further in the section 3.4.3.2. 
3.3.8 Cross-cell line related protein responses to 5-FU resistance 
 
Figure 3.27: Venn diagrams showing common significantly altered 
proteins in 5-FU resistant sublines. (a) Up-regulated and (b) down-regulated 
proteins using 5th percentile threshold in three different resistant CRC sublines 
to 5-FU.  
Common significantly altered proteins presented in at least two of the three 
resistant sublines to 5-FU are shown in the table 3.15. Additional information 
relating to two important proteins that may be playing a crucial role in 5-FU 
resistance (CD44, UMPS) which were significantly altered but unique to DLD-1 
5-FU cell line have been included in the table too. Uniquely altered proteins 
from the three resistant sublines were used to develop three different protein 
network model of 5-FU resistance and they are shown below.  
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Figure 3.28: Proteomic network model for DLD-1 5-FU. Significantly altered proteins obtained by modification on EnrichNet and GO from 
the initial bubble map obtained in STRING. Coloured circles group proteins by functionality. Not grouping proteins are commonly altered 
proteins in at least other resistant 5-FU subline and not linking to other proteins. Dotted arrows indicate the most relevant proteins with known 
functions which may be involved in response to 5-FU. All significantly altered proteins not linked by STRING software with other altered 
proteins or presented altered just in one of the 5-FU resistant sublines, were removed from the model. Key: Green arrow: significantly down-
regulated protein; Red arrow: significantly up-regulated protein. 
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Figure 3.29: Proteomic network model for KM 12 5-FU. Significantly altered proteins obtained by modification on EnrichNet and 
GO from the initial bubble map obtained in STRING. Coloured circles group proteins by functionality. Not grouping proteins are 
commonly altered proteins in at least other resistant 5-FU subline and not linking to other proteins. Dotted arrows indicate the most 
relevant proteins with known functions which may be involved in response to 5-FU. All significantly altered proteins not linked by 
STRING software with other altered proteins or presented altered just in one of the 5-FU resistant sublines, were removed from the 
model. Key: Green arrow: significantly down-regulated protein; Red arrow: significantly up-regulated protein. 
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Figure 3.30: Proteomic network model for HT 29 5-FU. Significantly altered proteins obtained by modification on EnrichNet and GO from the 
initial bubble map obtained in STRING. Coloured circles group proteins by functionality. Not grouping proteins are commonly altered proteins in 
at least other resistant 5-FU subline and not linking to other proteins. Dotted arrows indicate the most relevant proteins with known functions 
which may be involved in response to 5-FU. All significantly altered proteins not linked by STRING software with other altered proteins or 
presented altered just in one of the 5-FU resistant sublines, were removed from the model. Key: Green arrow: significantly down-regulated 
protein; Red arrow: significantly up-regulated protein. 
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Table 3.15: Commonly significantly altered proteins in at least two of three 5-FU resistant sublines. Proteins were used to identify new 
mechanisms of resistance involved in resistance to 5-FU. Additionally, some relevant proteins as CD44 and UMPS with a potential role to 
develop resistance to 5-FU are included.   
Key: Red - Significantly up-regulated protein, Green – Significantly down-regulated protein, # - protein not quantified.
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3.3.9 Verification of experimental fold changes using housekeeping-
control proteins  
From clustering analysis, unsurprisingly the largest group of proteins was seen 
to be the group of proteins not changed in any of the three samples (SILAC 
control, passage control and resistant experiment) across the 3 different cell 
lines.  A total of 1793 proteins were quantified commonly unchanged in all 9 
samples studied (3 cell lines x 3 types of sample (low passage control, high 
passage control and resistant subline)). To verify the accuracy of any 
proteomics finding discussed, the fold change of some housekeeping proteins 
were analysed to ensure that significantly altered proteins changed expression 
only due to the drug effect. These housekeeping proteins were selected as 
control proteins whose expression should not to be influenced by the drug 
under study, and its functionality should be normal among all CRC samples 
used including both parent cell lines and resistant sublines. ß-actin, tubulin or 
GAPDH are housekeeping proteins frequently used in proteomics studies 
(Ferguson, Carroll et al. 2005), however were discarded due to lack of 
quantification during Mass spectrometer analysis. Information related to the 
seven housekeeping control proteins used is shown in the table 3.16 below.  
Housekeeping proteins selected were: 
1)  Peptidyl-prolyl cis-trans isomerase A (PPIA) promotes folding of proteins and 
it catalyses the cis-trans isomerization of proline in oligopeptides (Camilloni, 
Sahakyan et al. 2014). PPIA participates in the cell-virus interaction (Hopkins 
and Gallay 2015). Cells-virus interaction is not expected to be presented during 
cell culture conditions for any sample. 
2)  ADP-ribosylation factor 3 (ARF3) is a GTP-binding protein that functions as 
an allosteric activator of the cholera toxin catalytic subunit, that it is not 
expected to affect this study (Kahn and Gilman 1986).  
3) Hypoxia up-regulated protein 1 (HYOU1) is a protein involved in 
cytoprotective cellular mechanisms triggered by oxygen deprivation. Oxygen 
levels are not expected to be altered as cell culture conditions remain the same 
for all cell lines (Semenza 2002). 
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4) ATP synthase subunit d, mitochondrial (ATP5H) is a mitochondrial 
membrane ATP synthase which has been used in different previous 
publications as housekeeping protein (Leyva, Bianchet et al. 2003). 
5) Osteoclast-stimulating factor 1 (OSTF1) activated during bone resorption 
processes and enhances osteoclast formation and activity. These processes 
are not expected to be altered in CRC cell lines under any drug effect 
(Roodman 1999) 
6) Heme oxygenase 2 (HMOX2) is a heme oxygenase that plays its main role in 
the spleen, where senescent erythrocytes are sequestrated and destroyed. Any 
of these processes is expected to change in CRC under drug effects (Stocker 
and Perrella 2006). 
7) Cytoskeleton-associated protein 5 (CKAP5) regulates microtubule dynamics 
and organization and it has been used in previous studies as housekeeping 
proteins (Li, Finley et al. 2002). 
Once control proteins were selected, the summary Table 3.16 was done, 
containing SILAC-ratio raw data and normalised Log2 SILAC-ratio data. Last 
two columns show the fold change for the protein obtained during LIMMA 
analysis where relative protein abundance in resistant subline was compared 
with the relative protein abundance in both parent control cell lines and the 
corresponding "p-value". A "p-value" lower than 0.05 means that no significant 
differences were found between the resistant subline and parent cell lines in 
relative abundance for the specific protein. No significant changes were found in 
any of the seven control proteins studied (Table. 3.16). 
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Table 3.16: Control proteins that are unaltered by drug effects and which were used to evaluate the success of SILAC approach and 
statistical analysis applied to 5-FU resistant sublines. Log2 fold change of all control proteins were found close to zero in the three 5-FU 
resistant sublines when they were compared to its respective parent-control cell lines. A Log2 fold proximaly to 0, means that levels of the 
proteins quantified  were similar in light and heavy samples.  
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3.3.10 Validation of proteomics findings using Western Blotting for 2 
proteins with identified altered expression profiles, CD44 and UMPS 
In order to validate the findings of the quantitative proteomics methodology, 2 
proteins whose expressions were identified as being up-regulated in the 5-FU 
resistant sublines, were further investigated using immunodetection techniques. 
Expression of CD44 (Fig. 3.31) and UMPS (Fig. 3.32)  selected proteins was 
further analysed using WB. Validation of quantitative proteomics results was 
necessary to support from SILAC-approach and LIMMA analysis. CD44 protein 
was selected due to its role in chemoresistance in different types of cancer, 
included CRC (Fanali, Lucchetti et al. 2014), whilst UMPS was selected 
because it mediates the initial step in the metabolism of the drug 5-FU and it 
has been related to 5-FU drug response (see section 3.1.2.1) (Griffith, 
Mwenifumbo et al. 2013). 
CD44 Western blot analysis of DLD-1 parent and resistant subline showed a 
single band of 81 kDa molecular weight, which was most intense in the DLD-1 
5-FU resistant subline sample. Band intensities were adjusted relative to ß-
actin, which was analysed as a house-keeping protein. After correction for 
cross-experiment variations, the ratios for CD44, closely matched the SILAC 
data (Fig. 3.31b-c). Similar results were obtained for CD44 Western blot 
analysis of HT 29 parent and resistant sublines which showed the most intense 
single band of 81 kDa molecular weight in HT 29 5-FU and a second intense 
single band of 81 kDa molecular weight in HT 29 P=9. WB results for the CD44 
ratios closely matched with previous SILAC data (Fig. 3.31h-i).  However, 
different results were found for KM 12 analysis that showed the two most 
intense bands for CD44 in KM 12 parent cell lines but no band for CD44 was 
found in KM 12 5-FU which showed a poor matched with previous SILAC data 
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Figure 3.31: WB results for CD44. (a) (d) (g) WB analysis of the presence of CD44 
was performed for resistant sublines DLD-1, KM 12 and HT 29 to 5-FU.  A WB 
example used to estimate CD44 abundance containing both β-actin results and MDA-
MB 231 cell line positive for CD44 which were used as control during WB.  Table 
showing p-values obtained from WB by t-test statistics analysis. (b) (e) (h). Relative 
expression of CD44 abundance in the indicated samples was divided between CD44 
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abundance in SILAC sample, as it had been done during SILAC protocol to estimate 
SILAC-ratios (L/H).  (c) (f) (i) Bar graphs obtained from SILAC approach with Log2 
(SILAC-ratios) data for each sample and a table showing p-values obtained from 
SILAC approach by LIMMA statistics analysis. Data are presented as mean; an asterisk 
represents significant differences (p<0.05). 
UMPS Western blot analysis of DLD-1 parents and resistant subline showed 
two bands of 52 kDa and 33 kDa molecular weights in DLD-1 P=65 and DLD-1 
5-FU. 33 kDa band was most intense in DLD-1 5-FU resistant subline than in 
DLD-1 P=65. While DLD-1 P=9 showed a single band of 52 kDa molecular 
weight. Band intensities were adjusted relative to ß-actin, which was analysed 
as a house-keeping protein. After correction for cross-experiment variations, the 
ratios for UMPS did not match with the SILAC data (Fig. 3.32a,b). A new WB 
analysis was carried out based on the Microarray study of the ratio between the 
two isoforms identified as it was done in the article published in The 
Pharmacogenomics Journal (January 2012) where authors demonstrated that 
the ratio of isoform A to B was 25.6 in MIP101 sensitive cells and 0.85 in 
MIP/5FU resistant sublines (Fig. 3.32c). This new results presented were similar 
in ratio abundance to previous results described by M. Griffith et al.: relative 
ratio abundance of UMPS isoform A / UMPS isoform B was close to 1 in DLD-1 
5-FU resistant subline and the highest abundance of UMPS isoform A was 
found in long generation control obtained from WB in this thesis (Fig. 3.32d). 
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Figure 3.32: (a) WB analysis for UMPS in DLD-1 5-FU. Additionally, an 
immunoblot example used to estimate UMPS abundance containing both β-actin results 
and A549 cell line positive for UMPS which were used as control during 
immunoblotting. (b) Bar graph obtained from Log2 SILAC-ratios data for each sample 
and table showing p-values obtained from SILAC approach by LIMMA statistics 
analysis. Data are presented as mean; an asterisk represents significant differences 
(p<0.05). (c) The ratio of isoform A to B was 25.6 in MIP101 cells and 0.85 in MIP/5-
FU cells. Data obtained from microarray hybridization and analysis of microarray data 
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on the ALEXA splicing microarray platform by M. Griffith et al. (Griffith, 
Mwenifumbo et al. 2013). (d) New results presented in this thesis which are similar in 
ratio abundance to previous results described by M. Griffith et al,: Relative ratio 
abundance of UMPS isoform A / UMPS isoform B was close to 1 in DLD-1 5-FU 
resistant subline and the highest abundance of UMPS isoform A was found in both two 
DLD-1 parent cell lines obtained from WB in this thesis. 
3.4 Discussion  
Three different resistant cell lines to 5-FU models were established, and were 
used to increase our understanding of how CRC cells develop resistance to 5-
FU. 5-FU resistant sublines for 3 cell lines, DLD-1, KM 12 and HT 29, were 
developed by continuous 5-FU exposure, and resistance fold changes of 130.2, 
3.2 and 3.5 respectively were achieved. Differences in resistance fold change 
can be caused by genomic background of the initial parent cell lines and cellular 
sensitivity to 5-FU effects may differ between different cell lines. Additionally, 
establishment of resistant sublines is a long process (more than 10 months), so 
during this period of time new randomly and different mutations appear and 
these can have different roles in 5-FU response. Hence, new alterations in 
proteins expression will progressively lead the development of a resistant 
phenotype. Additionally, according with results here presented, the number of 
altered proteins is not representative of the total resistance fold change 
achieved by a resistant subline. Hence, the molecular functions of altered 
proteins and their potential roles in 5-FU response, appear to be most relevant 
than the total number of proteins during establishment of resistance sublines. 
This issue can be observed from results obtained for KM 12 5-FU which was 
the resistant subline with more altered proteins, although its resistance fold 
change was low.  However, DLD-1 5-FU showed the highest resistance fold 
change even though the total number of altered proteins was not so high.                 
Due to high differences in resistance fold change between DLD-1 5-FU and the 
other two sublines, DLD-1 5-FU was selected for development of xenograft 
models which will be used in future studies of mechanisms of resistance to 5-
FU in vivo. Once 5-FU resistant sublines were developed they were analysed 
proteomically using a stable isotope labelling with amino acids in cell culture 
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(SILAC)-approach and Orbitrap Fusion™ Tribrid™ Mass Spectrometry analysis, 
to identify new biomarkers of drug resistance.  
3.4.1 Evaluation of cross-resistance in the DLD-1 5-FU subline 
Significant cross-resistant effects were observed for DLD-1 5-FU [250] resistant 
subline to OXA, IRI, carmustine and colchicine (Fig. 3.17b,c,e,f). Similar results 
for 5-FU and IRI cross-resistant effect were found in 2014 by John Boyer et al., 
with HCT 116 resistant cell line to 5-FU that showed a 2 fold resistant 
phenotype to IRI than parent HCT116 cell line [347]. Special attention requires 
the cross-resistance effect observed with DLD-1 5-FU resistant subline to OXA 
drug. These findings are similar to results obtained by Nikolaos A. Dallas et al., 
which showed cross-resistance to OXA in a HT 29 resistant subline to 5-FU 
[348]. Together, these findings suggest the presence of common mechanisms 
of resistance to 5-FU and OXA drugs that could be relevant for the clinical 
treatment of CRC patients. OXA and 5-FU combination therapy is normally 
used in advanced CRC patients and although initial outcomes for patients show 
benefits, appearing of resistance to combination therapy occurs later.                 
So, studying of proteomics behind this cross-resistance process could help to 
prevent this clinical problem. Although it is important to highlight that these 
results are specific for a single resistant subline to 5-FU and it may not be 
extrapolated to general terms.    
Results from DLD-1 resistant subline to 5-FU shows that the use of 5-FU in 
combination with any of the drugs that  show cross-resistance as OXA, IRI, 
carmustine and colchicine could converge into the failure of the combinational 
therapy (Fig. 3.17b,c,e,f).  
Researcher partnerships could create data platforms using CRC cell lines and 
cross-resistance studies in vitro and in vivo, that may help to understand the 
cross-resistance process. Establishment of cross-resistance guides of 
successful combinational therapies would avoid cross-resistance problems and 
it will promote working on personalized combinational therapies based on the 
presence of specific mechanisms of resistance in each patient. 
- 153 - 
 
3.4.2 Development of drug resistant xenograft models 
Whilst in vitro models of acquired resistance are useful in exploring 
mechanisms of resistance, they do not take into account influence of other cells 
and factors in the tumour microenvironment. For this reason, it is useful to show 
that the resistance phenotype can be maintained in an in vivo situation, which 
more closely mimics the clinical situation. The subcutaneous xenograft model is 
the first step in this direction but still, further studies need to be done to solve 
few issues. The main issue is that high passage parent cell line phenotype from 
original cancer cells has not been studied. Hence, potential differences in high 
and low passaging are not shown during in vivo models. 
Recently trend of the use of patient-derived xenograft model is increasing, as 
the use of xenograft model derived directly from the patient primary tumour 
isolated during surgery. But also issues are present during trying to establish 
drug resistant sublines due to limited passaging in animal models.  
During the thesis here presented, clearly demonstrated maintenance of 
resistant phenotype in vivo for this particular cell line was found. Without 5-FU 
therapy the volume growth times for the sensitive or resistant tumours were 
similar. However, under 5-FU treatment, xenograft tumours from DLD-1 parent 
cell lines grew slower than xenograft tumours from DLD-1 5-FU (Fig. 3.18).  
In vivo studies are important for understanding metastatic process where 
resistant phenotypes are maintained leading to failures during chemotherapy 
treatment in different regions of the body with resistant tumours, a high problem 
presented frequently in the metastatic breast cancer (Coley 2008) and 
metastatic colorectal carcinomas (Benhattar , Cerottini et al. 1996). So in 
conclusion, xenograft model may be used to validate novel mechanisms of 
resistance in a complete organism and as initial method of study new targets for 
new chemotherapy after in vitro resistant sublines development. 
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3.4.3 Mechanisms of resistance to 5-FU identified by proteomics 
3.4.3.1 Bradford protein assays 
After the establishment of resistant sublines, cell lysis and protein extraction 
were carried out for these new resistant cell sublines developed  and for their 
long and low generation controls. Additionally, proteins were extracted from 
SILAC labelled parent cell lines for each cell line to be used during SILAC-
approach. According to results previously shown in Table 3.6, amount of 
proteins extracted from each samples were similar and volumes were high 
enough to use the 200 µg of proteins required to build up the mixed SILAC-
samples by combination of the Light/Heavy samples.  
3.4.3.2 Significantly altered proteins seen in more than one 5-FU resistant 
subline 
Due to the lack of commonly altered proteins in resistant sublines, a deeper 
study of uniquely altered proteins in each particular resistant subline to 5-FU 
was done and discussed in section 3.4.3.3. 
3.4.3.2.1 Up-regulated proteins of DLD-1 5-FU and KM 12 5-FU (3) 
High significantly up-regulation was found for Myeloid-associated differentiation 
marker (MYADM) in the resistant sublines: DLD-1 5-FU, DLD-1 OXA, KM 12 5-
FU and KM 12 OXA. But no differences in MYADM expression was found 
neither in DLD-1 IRI, HT 29 5-FU resistant cell lines nor in any of the two parent 
control cell lines DLD-1, KM 12 and HT 29. MYADM is a protein that takes part 
in the organisation of endothelial cells surface and cell-cell junctions playing a 
role at the biological defense facing the vessel lumen. MYADM was described 
as a differentiation marker of stem cells and as an initial marker of CD34+ bone 
marrow myeloid cells derived from normal marrow cells. MYADM modulates 
selective permeability, such as mechanical forces, cytokine signalling, and cell–
cell interactions (Aranda, Reglero-Real et al. 2013). MYADM-GFP is located at 
the plasma membrane and in cell–cell junctions in confluent endothelial cells. 
MYADM distribution overlaps with filamentous actin and junctional markers, 
such as vascular endothelial (VE)-cadherin (Aranda, Reglero-Real et al. 2013). 
Interestingly, DLD-1 5-FU and KM 12 5-FU resistant sublines showed 
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differences during cell culture in cells distribution at the edge of the colony. Cell 
distribution of these two resistant cell lines gives a rounder shape border in 
contrast with HT 29 5-FU and control samples that show an irregular colony 
border (Fig 3.15). It has been observed that MYADM reduction induced the 
appearance of intercellular gaps, increasing cell membrane permeability. 
Similar results indicate that MYADM knockdown causes endothelial barrier 
dysfunction (Aranda, Reglero-Real et al. 2013). So, an increase of cell-cell 
junctions may act as physical barrier decreasing penetration of the drugs into 
cells by decreasing of cell membrane permeability. In 2005, during a microarray 
analysis of 298 genes using human melanoma cell lines, the overexpression of 
MYADM was associated with melanoma aggressiveness and progression and 
MYADM were defined as a prognostic factor in melanoma (De Wit, Rijntjes et 
al. 2005). A possible use of MYADM as a biomarker for promyelocytic leukemia 
cells was described in 2001 by Cui W. et al. Suggesting a role of MYADM 
during myelocytic leukemia development (Cui, Yu et al. 2001). 
MYADM regulates activation of the family proteins, ezrin, radixin, and moesin 
(ERM proteins) that are the best-known connectors between plasma 
membrane, transmembrane receptors, and the subcortical actin cytoskeleton. 
ERM proteins increase cell permeability and they have been observed 
phosphorylated and activated under MYADM silencing in Human Umbilical Vein 
Endothelial Cells (HUVEC), promoting the inflammatory response (Aranda, 
Reglero-Real et al. 2013). ERM proteins co-localize with CD44 at actin filament-
plasma membrane interaction sites, associating with CD44 via their N-terminal 
domains and with actin filaments via their C-terminal domains. 
Interestingly CD44 is a transmembrane receptor protein found overexpressed in 
DLD-1 5-FU and HT 29 5-FU resistant sublines and it has been related to poor 
prognosis, aggressiveness by EGFR modulation in breast cancer (Bellerby, 
Smith et al. 2016). Additionally, CD44 is known to be a cell surface biomarker of 
cancer stem-like cells (CSLCs). Tumour cells with CSCs properties have the 
potential to proliferate through self-renewal and they are able to survive 
chemotherapy. CD133 and CD24 are CSCs markers that normally are co-
expressed with CD44 and that have been associated with CRC resistance. 
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However, CD133 and CD24 were not detected during proteomics screening in 
any sample (Sahlberg, Spiegelberg et al. 2014, Bonneau, Rouzier et al. 2015). 
CD44 acts as a receptor for hyaluronic acid, which activates intracellular 
survival pathways and it is involved in proliferation, differentiation, and motility. 
CD44 has been associated with chemoresistance in different types of cancer, 
included CRC (Hiraga, Ito et al. 2013, PYLVÄS-EEROLA, Liakka et al. 2016, 
Xia and Xu 2016). CD44 protein was found up-regulated in DLD-1 5-FU and 
DLD-1 OXA resistant subline. Although no clear evidence about a differentiation 
role of CD44 in resistant sublines was found because CD44 ratios expressions 
were irregular along all subsamples, so no conclusions were established. 
However, the insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) 
was found significantly up-regulated in DLD-1 5-FU resistant subline. IGF2BP3 
binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs and to 
sequences in the 3'-UTR of CD44 mRNA. Significantly up-regulation of the 
androgen-regulated gene protein receptor (SARG) was also found in DLD-1 5-
FU and  KM 12 5-FU, than in DLD-1 and KM 12  parent cell lines (Steketee, 
Ziel-van der Made et al. 2004). Despite the lack of knowledge about this specific 
androgen receptor, the relevance of androgen receptors (AR) has been one of 
the main targets of prostate cancer therapies during last years. Furthermore, 
AR overexpression and mutations have been studied as mechanisms of cancer 
resistance during anti-AR therapies. So, the potential role of SARG as CRC 
biomarker must be studied. 
Other protein significantly up-regulated in 5-FU resistant samples was N(G), 
N(G)-dimethylarginine dimethylaminohydrolase 2 (DDAH2).  DDAH2 is a protein 
that inhibits the nitric oxide synthase (NOS) enzyme. NOS mediates the 
production of nitric oxide from arginine. This conversion from arginine to NOS 
mainly occurs in vascular endothelium tissues that are rich in arginine like 
gastrointestinal tract, kidney, and urinary bladder (Uhlén, Fagerberg et al. 
2015). It is known that levels of NOS enzyme are variable according to arginine 
availability within the cell microenvironment. Nitric oxide production by NOS 
may play a protector role in the vascular endothelium as a vasodilator and 
antiplatelet agent. It is known that under vascular endothelium damage 
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conditions, the level of nitric oxide decreases and the production of 
vasoconstrictor molecules increases. Colorectal cell lines were exposed to drug 
agents during resistant cell lines development and an increase in DDAH2 
expression may be a response to decreasing nitric oxide levels by NOS enzyme 
inhibition. Nitric oxide has been proposed as an inhibitor of cell proliferation in 
endothelium so a decrease of nitric oxide levels in resistant cells by NOS 
inhibition through DDAH2 overexpression may have a proliferation effect. A 
complementary result of NO decreasing by NOS inhibition is the up-regulation 
of the enzyme ferrochelatase (FECH) in DLD-1 5-FU subline. The main role of 
FECH is to catalyse the ferrous insertion into protoporphyrin IX. FECH enzyme 
is inhibited by NO and the overexpression of FECH may be a consequence of a 
decreasing at the NO levels caused by inhibition of NOS by DDAH2 (Furukawa, 
Kohno et al. 1995). Studies about nitric oxide signalling pathways and NO 
production has been considered to be therapeutic beneficial too (Choudhari, 
Chaudhary et al. 2013, Vasudevan and Thomas 2014). Recently, DDAH2 
overexpression has been considered as a poor prognosis factor for initial stages 
of lung adenocarcinoma and it has been related with angiogenesis and 
invasiveness (Shiozawa, Iyama et al. 2016). Hasegawa et al. reported that 
DDAH2 stimulates expression of VEGF through the transcription factor Sp1 in 
vascular endothelial cells. VEGF was not identified during initial proteomics 
screening, whilst Sp1 do not show any expression change in resistant samples 
to 5-FU (Hasegawa, Wakino et al. 2006). DNA methylation of DDAH2 and its 
overexpression at gene level have been suggested as differentiation marker 
from neural stem cells to embryonic stem cells (Bäckdahl, Herberth et al. 2009). 
However, the role of DDAH2 overexpression in CRC is still unknown. 
3.4.3.2.2 Up-regulated proteins of HT 29 5-FU and KM 12 5-FU (1) 
The unique significantly up-regulated protein found in HT 29 5-FU and KM 12 5-
FU samples was the amyloid β precursor-like protein (APLP2). However, 
APLP2 was not detected in DLD-1 5-FU subline, so a WB should be done to 
confirm if APLP2 may be an important marker of 5-FU in CRC. APLP2 is 
together with amyloid β A4 protein (APP) and the amyloid-like protein 1 
(APLP1) part of the amyloid precursor protein (APP) family.  APP was found up-
regulated in DLD-1 5-FU, DLD-1 OXA, DLD-1 IRI and HT 29 5-FU resistant 
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sublines in contrast with the four DLD-1 and HT 29 generation controls. APLP1 
was not detected in any sample during the proteomics analysis. Despite the 
high lack of knowledge about physiological functions of APLP2 and APLP1 
proteins. It is known that APP family is expressed in gastrointestinal tumours. 
APP family members have been proposed to be transported to the cell 
membrane where they act in cell-cell interaction, cells adhesion, and metastatic 
processes. A high expression of APLP1 over APLP2 expression has been 
described as a feature of neuroendocrine tumours (Arvidsson, Andersson et al. 
2008). APLP2 have been described as crucial protein in many kinds of cancers: 
prostate, breast, colon, thyroid, lung, nasopharynx, and gastrointestinal cancer 
(Pandey, Sliker et al. 2016). APLP2 plays a role in synaptic plasticity, promoting 
neurite outgrowth and differentiation, neural cell motility and copper 
homeostasis, has also been shown to regulate development of the brain by 
regulating migration and differentiation of neural stem cells (Srivastava, 
Khurana et al. 2012). APLP2 has been related with radioresistance in pediatric 
Ewing's sarcoma (EWS) and in human cervical carcinoma HeLa cell line. As 
APLP2 expression decreases the expression of MHC class I molecules in EWS 
cancer this may inhibit and interfere with cell lysis mediated by T-cell. EWS is a 
cancer presented in bones, cartilage or nerves. EWS is characterised by the 
presence of a high chromosomal translocation with high capacity to develop 
resistance to therapy (Peters, Yan et al. 2013).   
3.4.3.2.3 Down-regulated proteins of DLD-1 5-FU and KM 12 5-FU (3) 
Three different proteins were found significantly down-regulated in DLD-1 5-FU 
and KM 12 5-FU sublines. One of these proteins was 4F2 cell-surface antigen 
heavy chain (SLC3A2). SLC3A2 is a protein that plays a role in metal ion 
homeostasis and toxicity with a high activity during up-taking of methylmercury 
(MeHg). SLC3A2 transmembrane protein transporter regulates intracellular 
calcium levels and transports L-type amino acid, playing a role in nitric oxide 
synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-
arginine. So, SLC3A2 down-regulation and DDAH2 up-regulation (previously 
described as NOS inhibitor) together could be involved in a mechanism of 
resistance against 5-FU by decreasing of nitric oxide levels in two different CRC 
cell lines DLD-1 5-FU and KM 12 5-FU. Previous literature supports the idea of 
- 159 - 
 
nitric oxide as chemotherapy resistance factor in neuroblastoma cell lines. This 
mechanism of resistance is has been proposed to be related to MYC inhibition 
and an enhancement of ABC transporters activity and overexpression (Porro, 
Chrochemore et al. 2010). Previous publications led by Weiming Xu and his 
team showed the relevance of NO levels for cell cytotoxicity. High levels of 
iNOS expression may be cytostatic or cytotoxic for tumour cells, whereas lower 
activity can have the opposite effect and promote tumour growth in MCF-7 and 
ZR75 breast cancer cell lines (Liu and Xu 2013).  
Another significantly down-regulated protein in DLD-1 5-FU and KM 12 5-FU 
resistant cell lines is the phosphatidate cytidyltransferase mitochondrial 
(TAMM41). TAMM41 is an enzyme that catalyses the formation of CDP-
diacylglycerol (CDP-DAG) from phosphatidic acid (PA) in the mitochondrial 
inner membrane. Required for the biosynthesis of the dimeric phospholipid 
cardiolipin that stabilises supercomplexes of the mitochondrial respiratory chain 
in the mitochondrial inner membrane (Swan, Maxwell et al. 2015). 
The third significantly down-regulated protein involved in 5-FU resistance was 
the Glycerol-3-phosphate dehydrogenase 1-like protein (GPD1L). GPD1L plays 
a role in the regulation of cardiac sodium current and decreases enzymatic 
activity that results in an increase in glycerol 3-phosphate. Glycerol 3-phosphate 
activates the DPD1L-dependent SCN5A phosphorylation pathway, which may 
ultimately lead to decreased sodium current; cardiac sodium current may also 
be reduced due to alterations of NAD(H) balance induced by DPD1L (Valdivia, 
Ueda et al. 2009). Apart from DLD-1 5-FU and KM 12 5-FU, GPD1L was found 
down-regulated in DLD-1 IRI resistant subline too. 
3.4.3.2.4 Down-regulated proteins of DLD-1 5-FU and HT 29 5-FU (2) 
Only two significantly down-regulated proteins were commonly found in DLD-1 
5-FU and HT 29 5-FU.The first protein was Rap1 GTPase-GDP dissociation 
stimulator 1 (RAP1GDS1) factor that participates in activation of G proteins like 
Rap1a/Rap1b, RhoA, RhoB, and KRas. RAP1GDS1 promotes GDP/GTP 
exchange reaction by stimulating GDP dissociation from G-proteins (Kikuchi, 
Kaibuchi et al. 1992).  
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The second protein down-regulated was the vacuolar protein sorting-associated 
protein 45 (VPS45) (5) that plays a role in vesicle-mediated protein trafficking 
from the Golgi stack through the trans-Golgi network (Rajasekariah, Eyre et al. 
1999).  Some recent studies in yeast show that methylmercury toxicity depends 
directly on the activity of both the endosome transport and the vesicular trans-
Golgi trafficking network. Increasing of trans-Golgi network factor as VPS45 
increases sensitivity of yeast to methylmercury and down-regulation of 
endosome trans-Golgi transport increase the resistance phenotype in yeast 
model (Hwang, Murai et al. 2014). However, no evidence of VPS45 role has 
been described in cancer drug resistance or CRC. 
3.4.3.2.5 Down-regulated proteins of KM 12 5-FU and HT 29 5-FU (3) 
The enzyme 3'(2'), 5'-bisphosphate nucleotidase 1 (BPNT1) was found 
significantly down-regulated in both KM 12 5-FU and HT 29 5-FU resistant 
sublines. BPNT1 mediates conversion of adenosine 3'-phosphate 5'-
phosphosulfate (PAPS) to adenosine 5'-phosphosulfate (APS) and 3'(2')-
phospho- adenosine 5'- phosphate (PAP) to AMP (Spiegelberg, Xiong et al. 
1999). However, the role of BPNT1 is unknown in cancer. 
The other significantly down-regulated protein was the neurochondrin (NCDN) 
factor. NCDN is involved in nervous system development and its main function 
is to act as promotor of surface localization of GRM5 to increase neural signal 
transduction. It is important to regulate melanin concentration by its interaction 
with MCHR1 that interferes with G protein-coupled signal transduction pathways 
(Francke, Ward et al. 2006). 
3.4.3.3 Significantly altered proteins unique to one of the 5-FU resistant 
sublines 
Whilst some proteins were consistently altered across the cell lines (see Fig. 
3.27), in the majority of cases the altered proteins were unique to one cell line. 
This confirms the heterogeneity seen in CRC, and why molecular 
characterisation of an individual patient´s tumour is important in developing 
therapeutic strategies. In this section, the findings for each one of the three cell 
lines are discussed. In considering potential novel mechanisms of resistance, 
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since this process is usually the outcome of longer-term processes involving a 
net of proteins and different biological pathways, and not a single protein or 
pathway, this will be focused on 5 biological processes: 1) apoptotic and anti-
apoptotic pathways, 2) DNA repair process, 3) drug and small molecules 
metabolism, 4) intracellular protein transport, 5) cellular membrane transporters 
and membrane organization. 
A summary table containing unique proteins altered in 5-FU resistant sublines 
derived from DLD-1, KM 12 and HT 29 is shown below (Table 3.17). Most 
relevant up-regulated proteins were classified based on the specific literature 
background of the protein in two groups: 
1) Altered proteins by direct effect of 5-FU exposure: apoptotic mechanism, 
stress proteins… 
2) Altered proteins by indirect effect of 5-FU exposure:  DNA repair, drug 
transport, drug metabolism, exocytosis, vesicle formation… 
 Indirect effect of  5-FU  Direct effect of  5-FU  
DLD-1 5-FU 
ACSF3, NOL3, LGMN, 
EHBP1L1, GAA, LAMP1, 
LAMP2, RAB2B, SEC24D, 
HID1, MUC5AC,  ITGA3, 
CD44, MAC-2-BP, MDR1, 
ATP7B, FSCN1, SYTL2 
FAS, FADD, NFAT5, TAOK1, 
PRKCD, PAR-4, PMS2,  
HSP27, UMPS, GGT1, 
TMED4,  
KM 12 5-FU 
ERMP1, CHMP2A, IPO7, 
LGALS3BP, EFNB1, SRC, 
STAT1 
PYGM, NT5C3A, GNAI2, 
HSPH1, STIM1, PLSCR1 
HT 29 5-FU BET1, TFRC, FTH1 GATA6 
Table 3.17: Up-regulated proteins identified in 5-FU resistant sublines. 
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3.4.3.3.1 DLD-1 5-FU  
3.4.3.3.1.1 Apoptotic process (1) 
Among the three resistant sublines, DLD-1 5-FU showed the highest number of 
proteins altered in pro-apoptotic and anti-apoptotic pathways.  
From DLD-1 5-FU results, one of the most significantly up-regulated proteins 
was the nucleolar protein 3 (NOL3) (ARC). NOL3 has two isoforms. Whilst 
isoform 1 participates in the regulation of the splicing process of the 
arginine/serine-rich SRp30c protein, isoform 2 is a repressor of the apoptotic 
process that avoids cell death. Inhibition of apoptosis by NOL3 is mediated by 
blocking of tumour necrosis factor receptor superfamily (FAS) and its FAS-
associated death domain (FADD) interaction protein. FAS and FADD proteins 
were found up-regulated in DLD-1 5-FU resistant subline as a possible 
consequence of the 5-FU cytotoxicity effect (Park, Yoon et al. 2002). NOL3 
overexpression in CRC has previously been related to activation of DNA repair 
mechanisms and suppression of apoptotic pathways mediated by caspase 
activity (Tóth, Meinrath et al. 2016). 
Argonaute-1 (AGO1) (EIF2C1) is involved in mRNA silencing leading to down-
regulation of different gene expression such as RNA Pol ll. Silencing of target 
genes is mediated by argonaute proteins by mRNA degradation and 
translational repression of mRNA. AGO1 binds to RNA Polymerase II (RNA Pol 
II) interfering with RNA Pol II transcription (Huang, Zheng et al. 2013) and 
hence down-regulation of AGO1 may unbalance gene expression of different 
proteins directly involved in cancer pathways such as BRCA2, RAD51, BCL-2, 
and p21 (Mondal, Pal et al. 2016). Genomic deregulation and increasing 
expression of genes as RNA Pol II would mediate drug resistance in DLD-1 5-
FU subline. Interestingly, two mediators of RNA polymerase II, the transcription 
MED9 and MED31 were also found up-regulated in DLD-1 5-FU. Results 
presented here correlate with a similar previous study in CRC patients that 
showed how somatic mutations which involved repression and down-regulation 
of AGO2, may contribute to development of MSI state by increasing mutations 
and alterations that may lead to cancer development (Kim, Oh et al. 2010). 
Another important finding related to RNA Pol II in DLD-1 5-FU was the up-
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regulation of the nuclear factor of activated T-cells 5 (NFAT5). NFAT5 showed a 
positive regulation of transcription from RNA polymerase II promoter. NFAT5 is 
a protein involved in cell regulation under osmotic stress conditions (L pez-
Rodr  guez, Aramburu et al. 2001). Additionally, NFAT5 plays a crucial role 
during intestinal cells differentiation. It has been demonstrated that NFAT5 
inhibition by siRNA blocks Caco-2 and HT 29 intestinal cells differentiation 
process and increasing of NFAT5 has been observed in intestinal mucosa with 
high differentiation (L pez-Rodr  guez, Aramburu et al. 2001). 
Significant up-regulation of serine/threonine-protein kinase (TAOK1), which is 
involved in the p38/MAPK14 stress-activated MAPK cascade, and the DNA 
damage response, was also observed in DLD-1 5-FU. TAOK1 mediates G2/M 
transition during DNA damage (Raman, Earnest et al. 2007) and activates p38, 
a protein also found overexpressed in the DLD-1 5-FU subline. Hence, TAOK1 
overexpression would be expected in cells that have been grown under DNA 
damage conditions over a prolonged period. However, TAOK1 activity in CRC 
has not previously been studied. 
Similar effects were found with protein kinase C δ type (PRKCD), which was 
found significantly up-regulated in DLD-1 5-FU. PRKCD is a pro-apoptotic 
protein that is activated during DNA damage-induced apoptosis. Under 
oxidative stress conditions which may be similar to drug treatment, PRKCD 
interacted with CHUK/IKKA proteins and promoted phosphorylation of 
p53/TP53. An alternative regulation of apoptosis by PRKCD is mediated by 
activation of MAPK11 or MAPK14.The treatment of HCT 116 CRC cell line with 
5-FU caused up-regulation of PRKCD in line with our observations (Mhaidat, 
Bouklihacene et al. 2014). 
Serine/threonine-protein kinase PRKC (Par-4) (PAWR) is a pro-apoptotic 
regulator of WT1 protein, a transcription factor with proline/glutamine-rich DNA-
binding domain and regulator of p53. Par-4 protein is inactivated in CRC cell 
lines under normal conditions however it is up-regulated in CRC cell lines after 
5-FU treatment. Par-4 activity is also increased by Src inhibition using  Src 
kinase inhibitors in vitro (Kline and Irby 2011). Therefore, an increasing of Par-4 
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expression may be a consequence of continuously 5-FU treatment that 
promotes apoptotic pathways in CRC cell lines.  
3.4.3.3.1.2 DNA repair process (2) 
Two related proteins to DNA repair process were found significantly up-
regulated in DLD-1 5-FU subline, transcription factor jun-D (JUND) and AP-1 
complex-associated regulatory protein (Berger and Shaul 1991). The role of AP-
1 in CRC is to increase the expression of drug transporter proteins like MDR1 
(Guan, Zhao et al. 2016), which was also up-regulated in DLD-1 5-FU subline. 
Mismatch repair endonuclease PMS2 that forms part of the post-replicative 
DNA mismatch repair system (MMR) was also up-regulated. PMS2 causes 
single-strand breaks close to the mismatch point and thus creates new entry 
points for the exonuclease EXO1 which degrades the strand containing the 
mismatch. Therefore, PMS2 plays a crucial role in DNA damage signalling. 
PMS2 may arrest the cell cycle and this may derivate into apoptotic pathways in 
case of serious DNA damage occurring in CRC cell lines exposed to excess 5-
FU (Adamsen, Kravik et al. 2011). The up-regulation of PMS2 may play a role in 
assisting MMR system to DNA damage caused by the 5-FU active metabolite. 
Additionally, it has been demonstrated that overexpression of PMS2 contributes 
to DNA damage toleration in mammalian cells causing MMR system 
deregulation (Gibson, Narayanan et al. 2006).  
3.4.3.3.1.3 Drug and small molecules metabolism (3) 
Several proteins in metabolism showed a significantly change in expression 
under 5-FU conditions. One of these proteins significantly overexpressed in 
DLD-1 5-FU  is the heat shock protein 27 (HSP27). HSPs proteins are 
evolutionarily conserved molecules synthesised by cells in response to heat or 
chemical stress, conditions equivalent to prolonged drug exposure. HSP27 
shows a negatively regulation of apoptotic process, which is activated by anti-
cancer drugs or under oxidative stress conditions (Heinrich, Donakonda et al. 
2016).  Previous multiple studies reflect an important protective effect by HSP27 
on CRC cell lines when they were treated with 5-FU while HSP27 
phosphorylation and down-regulation return the 5-FU sensitive phenotype in 
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CRC cells (Wong, Wong et al. 2008, Matsunaga, Ishii et al. 2014, Lu, Sun et al. 
2016).  Additionally, HSP27 has been described as a biomarker for resistance 
to cisplatin in ovarian cancer cell lines and HSP27 inhibition can reverse 
resistance in vitro (Wong, Wong et al. 2008). 
Among all significantly down-regulated proteins in DLD-1 resistant subline to 5-
FU, the uridine monophosphate synthase (UMPS) (OPRT) is involved directly in 
the conversion of 5-FU into active metabolites with anticancer properties. 5-FU 
can be metabolised into 5-fluorouridine monophosphate (FUMP) by UMPS. 
FUMP is essential for its metabolic conversion into deoxyuridine triphosphate 
(dUTP) and 5-fluorouridine triphosphate (FUTP). dUTP cytotoxicity effect occurs 
after its incorporation into DNA causes irreparable cell damage during DNA 
synthesis and DNA repair (Muhale, Wetmore et al. 2011). Additionally, FUTP 
misincorporation into different RNA structures causes cell death by alteration of 
cellular metabolism and homeostasis (Ghoshal and Jacob 1994). Recently, it 
has been discovered that UMPS isoforms A and B are crucial during the 
development of resistance to 5-FU. Expression of isoform B occurs in a high 
percentage of resistant tumours by splicing of exon 2, while, high levels of 
isoform A are predominant in 5-FU sensitive cell lines. Moreover, M Griffith et 
al. showed that protein relative expression levels of UMPS isoforms A and B 
might have an effect on 5-FU resistant outcomes (via an unknown molecular 
mechanism) (Griffith, Mwenifumbo et al. 2013). Similarly, expression levels of A 
and B isoforms were feature of the proteomics results for DLD-1 resistant 
sublines. WB results generated as part of our study showed a strong signal for 
two isoforms of UMPS in the resistant subline DLD-1 5-FU and a weak signal 
for one of the two isoforms in DLD-1 P=65 parent cell line. However, the second 
isoform was not detected in DLD-1 P=9 parent cell line. After analysis of UMPS 
isoforms levels in DLD-1 Set, it was observed that similar expression levels 
were presented in the resistant subline DLD-1 5-FU but no in the parent cell 
lines that were sensitive to 5-FU. So, similar results to M Griffith et al., studies 
were found. 
Two enzymes involved in lipid metabolism were found significantly up-regulated 
in DLD-1 5-FU too. One was the acyl-CoA synthetase family member 3 
- 166 - 
 
(ACSF3) protein and the second was the enzyme known as the very long-chain 
specific acyl-CoA dehydrogenase (ACADVL). ACSF3 activates the synthesis of 
fatty acid in mitochondria by metabolising malonate and methylmalonate while 
ACADVL protein is involved in the β-oxidation of fatty acids in mitochondria. 
A different and intriguing finding was the up-regulation of gamma-
glutamyltranspeptidase 1 (GGT1). GGT1 is a protein involved in reduction of 
glutathione to cysteine,  a stress marker (Fentiman 2012) and its up-regulation 
may be related to the 5-FU treatment as consequence of an increasing of 
oxidative stress in cells due to continuous drug treatment. GGT1 
overexpression has been linked to risk of a poor prognosis in cervical cancer 
patients and associated with invasiveness features of melanoma cell lines and 
mouse xenograft models (Corti, Franzini et al. 2010). Recently, GGT1 was 
identified as an important factor and potential marker of CRC progression from 
stage-III to stage-IV. Hence, the role of GGT1 in CRC resistance warrants 
further investigation (Palaniappan, Ramar et al. 2016). 
3.4.3.3.1.4 Intracellular protein transport (11)  
Some proteins significantly up-regulated proteins found in DLD-1 5-FU, there 
are some whose molecular functions are related to the endomembrane system:  
endoplasmic reticulum (ER), Golgi apparatus, and lysosomes. These proteins 
involved in vesicle production and trafficking inside the cells are particularly 
relevant due to possible roles in drug resistance. Vesicles formed inside the 
cells could act as drug containers, which would decrease the free drug 
concentration inside cells. Main cellular structures available to act as drug 
containers are lysosomes and storage vesicles. Lysosomes are especially 
interesting due to the function they play during catabolism of biomolecules. 
Lysosomes contain a large number of different enzymes such as hydrolases 
that digest proteins, nucleic acids, lipids and other biomolecules. These 
enzymes could limit the bioavailability by drug degradation. Lysosomal drug 
sequestration of hydrophobic weak base drugs (Duvvuri and Krise 2005) and 
consequently lysosomal drug storage has been recently described by 
Zhitomirsky and Assaraf. Lysosomal drug storage converges into an increase of 
the number and size of lysosomes inside cells. Further, drug transporters from 
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the ABC superfamily were found localized on lysosomes membrane and 
involved in the active transport of drugs into the lysosome (Zhitomirsky and 
Assaraf 2016). In the same way, another drug transporter known as ATP7B was 
defined as necessary for copper-dependent lysosomal exocytosis (Peña, 
Coblenz et al. 2015).  All these recent findings indicate lysosomes are potential 
mediators of drug resistance. Among the proteins found significantly up-
regulated in DLD-1 5-FU resistant subline, 11 are associated with lysosome an 
exosome formation and whose relevance in 5-FU resistance is summarised in 
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Protein Name Main Function Role in Cancer Reference 
Cysteine proteinase legumain (LGMN) Exopeptidase activity Poor prognosis in CRC 
(Dall and Brandstetter 2013) and 
(Haugen, Boye et al. 2015) 
EH domain–binding protein 1–like 1 
(EHBP1L1) 
Late endosome and 
lysosomes formation 
Unknown 
(Zhen, Chunlei et al. 2014) and 
(Nakajo, Yoshimura et al. 2016)  
Lysosomal α –glucosidase (GAA) 
Hydrolysis of glycogen in 
lysosomes 
GAA inhibitors decrease CRC risk (Nakajo, Yoshimura et al. 2016) 
Lysosomal-associated membrane proteins 
(LAMP1, LAMP2) 
Constitute 50% of the 
lysosomal membrane 
LAMPs downregulation  inhibit 
proliferation in prostate cancer 
(Eskelinen 2006) and (Okato, Goto et 
al. 2016). 
 
Protein Rab-2B (RAB2B) 
Modulation of Golgi 
complex and exocytosis 
Unknown 
(Ostrowski, Carmo et al. 2010) and 
(Aizawa and Fukuda 2015)   
Sec24D 
Transport to the Golgi 
complex 
Unknown (Tang, Kausalya et al. 1999) 
VPS16 
Fusion of lysosomes with 
endosomes 
Unknown (Wartosch, Günesdogan et al. 2015) 
Components of the lysosome-related 
organelles complex 1 (BLOC-1) 
Synthesis of melanosomes Cisplatin resistance 
(Chen, Leapman et al. 2009) and  
(Chen, Valencia et al. 2006)  
HID1 protein 
Vesicle trafficking in 
secretory cell lines 
Unknown (Wang, Zhan et al. 2011) 
Mucins (MUC5AC and  MUC2) 
Protection and survival of 
epithelial cells 
Carcinogenesis in  CRC, MUC5AC 
inhibition repress migration in CRC 
(Kufe 2009), (Truant, Bruyneel et al. 
2003) and (Zhu, Long et al. 2016) 
Transmembrane emp24 domain-containing 
protein 4 (TMED4) 
Endoplasmic reticulum 
modulation under stress 
conditions 
Unknown (Hwang, Boswell et al. 2008) 
Synaptotagmin-like protein 2 (SYTL2) Exocytosis processes Biomarker in metastatic breast cancer 
Sung et al., 2016 (Sung, Han et al. 
2016) 
Table 3.18: Summary table showing significantly up-regulated proteins in DLD-1 
5-FU associated with lysosome an exosome formation. 
- 169 - 
 
3.4.3.3.1.5 Cellular membrane transporters and cell membrane 
organization (5) 
An important significantly up-regulated protein (but not included in the 10% of 
most altered proteins group) was CD44. CD44 is a transmembrane receptor 
protein found significantly overexpressed in DLD-1 5-FU resistant subline and it 
has been related to poor prognosis and aggressiveness by EGFR modulation in 
breast cancer (Bellerby, Smith et al. 2016). Additionally, CD44 is known to be a 
cell surface biomarker of CSCs. Tumour cells with CSCs properties have 
potential to proliferate through self-renewal and they are able to survive 
chemotherapy (Bonneau, Rouzier et al. 2015).  CD44 acts as a receptor for 
hyaluronic acid, which activates intracellular survival pathways and it is involved 
in proliferation, differentiation, and motility. Overexpression of CD44 in DLD-1 5-
FU was validated by WB and similar results to SILAC approach were obtained 
(see section 3.3.10). CD44 has been associated with chemoresistance in 
colorectal and ovarian cancer. It is known that in addition to its role as CSCs 
biomarker and hyaluronic acid receptor involved in stress response, CD44 may 
act as protector of drug transporters such as P-glycoprotein from ubiquitination 
(Hiraga, Ito et al. 2013, PYLVÄS-EEROLA, Liakka et al. 2016, Xia and Xu 
2016). Finally, CD117, also known as KIT, is another surface marker of 
embryonic stem cells that was found notably overexpressed in DLD-1 5-FU cell 
line but it has not been associated with 5-FU resistance.  
One more protein significantly up-regulated in DLD-1 5-FU and involved in cell 
membrane organizations was galectin-3 (Mac-2-BP). Mac-2-BP is a protein 
implicated in modulating cell–cell and cell–matrix interactions and participates in 
multiple extracellular functions like cell adhesion, migration, invasion, 
angiogenesis, immune functions, apoptosis, endocytosis and it has been found 
elevated in the serum of patients with cancer. So, it has been discussed as a 
biomarker of cancer progression (Bresalier, Mazurek et al. 1998, Marchetti, 
Tinari et al. 2002, Iacovazzi, Notarnicola et al. 2010).  Furthermore, Mac-2-BP 
has been considered as CSCs surface marker like CD44, previously described. 
Experiments in vitro evidence how subpopulations of DLD-1 with high levels of 
Mac-2-BP on its surface are more resistance to chemotherapeutic treatments 
like 5-FU, leucovorin, OXA and IRI (Ilmer, Mazurek et al. 2016). These evidence 
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of a crucial role of Mac-2 BP in CRC resistance are complemented by 
discoveries using 196 CRC patients where LGALS3BP overexpression in 
tumour tissue was defined as unique and independent prognostic factor of poor 
survival (Piccolo, Tinari et al. 2015).  Finally, one last protein found significantly 
up-regulated and with high interaction with Mac-2-BP protein was the integrin α-
3 (ITGA3). ITGA3 was found up-regulated in DLD-1 5-FU. ITGA3 promotes cell 
invasion and contributes to matrix degradation processes and invadopodia 
formation process (Mueller, Ghersi et al. 1999, Fukushi, Makagiansar et al. 
2004). Invadopodia promotes metastasis and may contribute to tumoural cell 
migration to distant sites of the body where chemotherapy agents show a lower 
effect (Stoletov and Lewis 2015). But no role of ITGA3 in CRC resistance has 
been described until now.  
Finally, fascin (FSCN1) is another interesting finding in DLD-1 5-FU. Main role 
of FSCN1 protein is to mediate in filopodia formation and distribution of actin 
filamentous fibres that play their crucial role during cell motility, cell-cell 
interaction and reorganization of the cytoskeleton (Yamashiro, Yamakita et al. 
1998, Chen, Yang et al. 2011). Up-regulation of FSCN1 gene has been 
reported previously in resistant gastric cell lines to 5-FU. The paper was 
published in 2014 and the methodology followed to develop resistant sublines in 
vitro was by the culture of gastric cancer cells for more than ten months in a 
medium containing 5-FU, so using a similar methodology to the protocol used in 
this thesis study. The current proteomics study findings complement the 
previous study of FSCN1 at the gene level under 5-FU conditions. In summary, 
use of overexpression of FSCN1 should be studied as a predictive biomarker 
for 5-FU resistance in cancer (Maeda, Ando et al. 2014). 
3.4.3.3.2 KM 12 5-FU  
The complexity of the protein network model for KM 12 5-FU was the highest in 
contrast with the rest of resistant sublines models developed. This fact can be 
consequence of different initial genomic background between CRC cell lines. 
Additionally, new changes in proteins expression occurred during establishment 
of CRC sublines can affect proteins involved in DNA repair process such as 
PARP2 (see section 3.4.3.3.2.2 below) and alterations in these proteins can 
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affect to the DNA repair process, causing further alterations in additional 
proteins and molecular pathways. The main problem was that significantly 
altered proteins selected by 5th percentile in KM 12 5-FU sample were too many 
to be shown in a single network of protein interaction. Additionally, the number 
of interactions between these proteins was higher than in remaining resistant 
models. So, percentile was decreased to 2.5th percentile criteria to develop a 
new protein network model of the 5% of most altered proteins which are 
discussed below.  
3.4.3.3.2.1 Apoptotic process (1) 
It is known that stress-induced cell death occurs as consequence of DNA 
damage and cytotoxic stress that happens during cell lines drug exposure. 
Stress-induced signals converge upon the mitochondria via regulation of BCL2 
family proteins. After BCL2 proteins activation, mitochondrial outer membrane 
permeabilization triggers the release of intramembrane space proteins including 
cytochrome c (CYCS), which permits assembly of a large multiprotein complex 
referred to as the apoptosome (Gupta, Cuffe et al. 2010). Significant down-
regulation of CYCS in DLD-1 5-FU may be affecting stress-induced cell death 
that occurs as consequence of 5-FU treatment through DNA damage. Inhibition 
of CYCS in resistant cell lines would avoid the apoptosome assembly and it 
would decrease apoptotic processes (Deegan, Saveljeva et al. 2014). 
Cytochrome c-type heme lyase (HCCS) is a protein that links covalently the 
heme group to CYCS which was found significantly down-regulated in KM 12 5-
FU too (Babbitt, San Francisco et al. 2014).  
Another important and significantly down-regulated protein that may be taking 
part in the development of resistance to 5-FU in KM 12 subline was the 
telomerase Cajal body protein 1 (WRAP53). WRAP53 mRNA regulates p53 
protein at the post-transcriptional level during DNA damage. Under 
chemotherapy conditions, the transcription of p53 is increased by WRAP53 
overexpression and this fact induces apoptosis of cells with DNA damage 
(Mahmoudi, Henriksson et al. 2016). In absence of WRAP53 or during down-
regulation of WRAP53, p53 levels could be decreased and tumour cells would 
proliferate with DNA damage, increasing tumour size and tumour heterogeneity. 
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3.4.3.3.2.2 DNA repair process (2) 
No significantly up-regulated protein involved in DNA repair was found in KM 12 
5-FU and the unique significantly down-regulated protein was the poly [ADP-
ribose] polymerase 2 (PARP2). PARP2 is involved in the base excision repair 
(BER) pathway (Schreiber, Amé et al. 2002), previous publications have shown 
that PARP2 is a protein which joins to DNA damage sites in cells to facilitate 
DNA repair process (Riccio, Cingolani et al. 2015). Additionally, recent studies 
with PARP2-deficient model organisms and cell lines, show sensitivity to 
several DNA damage agents. Hence, PARP inhibitors are now considered as a 
new treatment in cancer therapy (Murai, Shar-yin et al. 2012). According to the 
new data obtained here, it may be considered that a review of PARP proteins 
and their potential role as mediators of resistance to 5-FU should be done. 
3.4.3.3.2.3 Drug and small molecules metabolism (3) 
KM 12 5-FU showed a high number of altered proteins involved in drugs and 
small molecules metabolism. However, there is no clear evidence to link these 
up-regulated proteins to mechanisms of drug resistance in cancer. These 
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Mormeneo et al. 
2010)   
Cytosolic 5'-nucleotidase 
3A (NT5C3A 
CMP and m7GMP 
metabolism 
(Amici, Ciccioli et 
al. 2005)  
Guanine nucleotide-
binding protein G (i) 




(Cho and Kehrl 
2007)  
Subunit β type-10 of the 
proteasome (PSMB10) 
Mediates cleaving of 
peptides with Arg, Phe, 
Tyr, Leu, and Glu 
(Rouette, 
Trofimov et al. 
2016) 
Heat shock protein 105 
kDa (HSPH1) 
Prevents aggregation of 
denatured proteins 
(Shorter 2011) 
Table 3.19: Summary table with most significantly altered proteins seen in KM 12 
5-FU related to drug and small molecules metabolism. 
3.4.3.3.2.4 Intracellular protein transport (4)  
Most of the significantly up-regulated proteins found in KM-12 5-FU belong to 
the intracellular protein transport group. One of these up-regulated proteins was 
the stromal interaction molecule 1 (STIM1), previously discussed in more detail 
in section 3.4.3.2. 
Endoplasmic reticulum metallopeptidase 1 (ERMP1) is other significantly up-
regulated protein in KM 12 5-FU. ERMP1 is required for the organization of 
somatic cells and normal ovarian histogenesis, but no implications in cancer are 
known (Garcia-Rudaz, Luna et al. 2007). 
Charged multivesicular body protein 2a (CHMP2A) that is involved in 
multivesicular bodies‟ formation (MVBs) was found significantly up-regulated in 
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KM 12 5-FU too. CHMP2A is required for a normal function of endosomal 
sorting complex required for transport (ESCRT) of proteins. ESCRT proteins are 
involved in cellular functions related to membrane fission events such as: 
releasing of cytokines, mitosis, late anaphase processes (Guizetti, Schermelleh 
et al. 2011) and membrane fission activities through its interaction with VPS4 
protein, which was found increased in all resistant sublines except HT 29 5-FU 
(Obita, Saksena et al. 2007) (Vietri, Schink et al. 2015). Increasing of MVBs 
activity is being one of the main aims in cancer resistance fight, as it has been 
found evidence of MDR development in prostate cancer by increasing of MVBs 
and other extracellular vesicles (Soekmadji and Nelson 2015). However, no 
evidence of MVBs activity in CRC resistance has been established yet. 
Importin-7 (IPO7) (RanBP7) is a significantly up-regulated protein of KM 12 5-
FU. Previous studies of IPO7 show overexpression of IPO7 as a common 
feature in CRC cells. IPO7 main role is to transport nuclear receptors 
responsible for the nuclear import of histone H1 and ribosomal proteins. High 
mRNA levels of IPO7 show a positive correlation with high proliferation rate in 
colorectal tumour tissue, although the mechanism behind this IPO7 expression 
to mediate cell proliferation is still unknown (Li, Gyselman et al. 2000). Contrary 
to previous publications that found IPO7 repressed by p53 in the CRC cell line 
HCT116 (Golomb, Bublik et al. 2012), these proteomics results of KM 12 5-FU 
show higher levels of both IPO7 and p53 in the KM 12 5-FU resistant subline 
than in the sensitive parent cell line KM 12. 
3.4.3.3.2.5 Cellular membrane transporters and cell membrane 
organization (5) 
KM 12 5-FU analysis showed up-regulation in some proteins involved in cell 
membrane organisation and cell membrane transporters. Galectin-3-binding 
protein (LGALS3BP) is a protein that increases cell adhesion, promoting tumour 
cell aggregation that increases cancer progression and metastasis in the human 
melanoma cell line A375 (Sasaki, Brakebusch et al. 1998, Tinari, Kuwabara et 
al. 2001). While very little is known about how cell adhesion may contribute to 
drug resistance, cell adhesion is being one of the main issues of study under 
cellular biology and biomedical engineering fields (Khalili and Ahmad 2015). 
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Ephrin-B1 (EFNB1) is other significantly up-regulated protein that enhances cell 
adhesion via cell-cell signalling that has not been related to CRC yet. Although, 
it is known that inhibition of EFNB1 in vitro decreases tumour growth in head 
and neck squamous cell carcinomas (Vermeer, Colbert et al. 2013). 
In KM 12 5-FU, one of the most relevant significantly up-regulated proteins is 
the proto-oncogene tyrosine-protein kinase Src (SRC). Up-regulation of SRC 
can occur by mutations as consequence of DNA mutations affecting 
cytoplasmic kinase domains that constitutively active signalling involved in cell 
adhesion, cell cycle progression, apoptosis, migration, and transformation. SRC 
is also activated at the sites of cell-cell contact adherences junctions and 
phosphorylates substrates such as β-catenin (CTNNB1), delta-catenin 
(CTNND1), and plakoglobin (JUP) and SRC mediates phosphorylation of both 
STAT1 and STAT3 by epidermal growth factor (EGF), leading to increased DNA 
binding activity of these TFs (Vasilenko, Butylin et al. 2000). STAT1 was found 
significantly up-regulated in KM 12 5-FU, hence the value of this SRC-STAT1 
hypothesis acquires more relevance. STAT1 is a transcription factor that has 
been suggested as an anti-tumour target to avoid drug resistance. In the CRC 
cell line Colon26L5-Vec resistant doxorubicin, the inhibition of STAT1 returns 
the sensitive phenotype (Malilas, Koh et al. 2013). In the same way, a study 
using Stat1−/− mice showed that overexpression of STAT1 enhances a cell 
environment that promotes cell survival under genotoxic stress (Wang, Patsis et 
al. 2015). 
Phospholipid scramblase 1 (PLSCR1) was also found significantly up-regulated 
in KM 12 5-FU. PLSCR1 plays an important role during apoptosis by recognition 
of damaged cells by the reticuloendothelial system. Inhibition of PLSCR1 
protein by antiphospholipid scramblase 1 antibody has shown to have an anti-
proliferative effect in CRC cell lines in vitro (Chen, Chen et al. 2014). 
Additionally, PLSCR1 is thought to be involved in tumour proliferation because 
overexpression of PLSCR1 has been observed under EGF stimulation 
pathways (Sun, Nanjundan et al. 2002). However, PLSCR1 as a mediator of 
drug resistance has not been described yet. 
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3.4.3.3.3 HT 29 5-FU  
HT 29 5-FU was one of the resistant sublines that showed the lowest resistant 
fold change (3.5-fold) with only seven significantly up-regulated proteins. 
3.4.3.3.3.1 Apoptotic process (1) 
Only the transcription factor GATA-6 (GATA6) was found significantly up-
regulated in HT 29 5-FU. Previous studies using HT 29 cell line show that 
overexpression of GATA6 is involved in proliferation process (Gao, Sedgwick et 
al. 1998) and mediates radiotherapy resistance in vitro (Cai, Shen et al. 2014).  
3.4.3.3.3.2 DNA repair process (2), Drug and small molecule metabolism 
(3) and Intracellular protein transport (4)  
No significantly up-regulated proteins were found involved neither in DNA 
process nor in drug and small molecules metabolism in HT 29 5-FU. In contrast 
to all remaining resistant sublines, HT 29 5-FU was the unique resistant subline 
that did not show any significantly up-regulated protein involved in intracellular 
protein transport.  
Phosphoglucomutase-1 (PGM1) enzyme is a significantly down-regulated 
protein which catalyses the breakdown and synthesis of glucose (Bae, Kim et 
al. 2014). PGM1 activity may be decreased as result of constant exposure to 
drugs that decrease cell survival and cell proliferation. Tumour cells could be 
decreasing their metabolism and glycolysis pathways as consequence of a 
constant interaction with chemotherapy. Effects of 5-FU in glycolysis and 
glucose metabolism have been studied in A549 cell line (Zhao, Ren et al. 2014). 
So, the low fold change in the resistant sublines HT 29 5-FU may be explained 
as a resistance establishment step process where cells show a lower metabolic 
rate before they are available to develop a better consistent resistance that may 
be established after long time drug exposure. In the same way, previous studies 
with MCF-7 breast cancer cell lines showed that decreasing of glycolysis 
pathways can drive into an increasing of mitochondrial respiration that declines 
anti-proliferative effects of drugs such as carboplatin, OXA, 5-FU, camptothecin, 
doxorubicin, paclitaxel, docetaxel, and hydrogen peroxide  (Leung, Kim et al. 
2014). 
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Another significantly down-regulated protein is the dihydropyrimidinase-related 
protein 2 (DPYSL2) which has a role in neuronal polarity and axon growth. 
Although DPYSL2 has not been related to cancer, alterations in DPYSL2 
expression are involved in development of Alzheimer's disease (Natalia Silva, 
Furuya et al. 2013). 
3'(2')-5'-bisphosphate nucleotidase 1 (BPNT1) enzyme metabolises conversion 
of both PAPS to APS and PAP to AMP. Apart from KM 12 5-FU, BPNT1 protein 
was found significantly down-regulated in the resistant subline HT 29 5-FU and 
it will be discussed in more detail below in the Chapter 7, section 7.3.1.4. 
Vacuolar protein sorting-associated protein 45 (VPS45) plays a role in vesicle-
mediated protein trafficking from the Golgi stack through the trans-Golgi 
network (Rajasekariah, Eyre et al. 1999). Apart from HT 29 5-FU was found 
significantly down-regulated in the resistant subline DLD-1 5-FU and it has been 
discussed previously in section 3.4.3.2.4. 
Finally, a last significantly down-regulated protein was the ADP-ribosylation 
factor-like protein 3 (ARL3) is a small GTP-binding protein involved in 
transporting of lipid proteins and cilia signalling but its relevance in cancer is 
unknown (Fansa and Wittinghofer 2016). 
3.4.3.3.3.3 Cellular membrane transporters and cell membrane 
organization (5) 
Three significantly up-regulated proteins involved in membrane transport were 
found in HT 29 5-FU. One of these proteins was the BET1 homolog (BET1) 
protein. BET1 mediates vesicle transport along the cytoplasm from the 
endoplasmic reticulum (ER) to the Golgi apparatus, taking part in the fusion 
activity of transport vesicles to the Golgi apparatus membrane (Petrosyan 2015) 
(Wlodkowic, Skommer et al. 2009). Inhibition of transporting activity of vesicles 
from ER to Golgi apparatus has been previously used as a strategy to reverse 
fludarabine resistance phenotype in resistant chronic lymphocytic leukaemia 
(CLL) cells in vitro. The mechanism behind this loss of resistance resides in that 
the blocking of protein trafficking caused by brefeldin A treatment leads to 
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activation of caspases and increases sequestration of the survival factors 
APRIL and VEGF (Carew, Nawrocki et al. 2006).  
A second significantly up-regulated protein found in HT 29 5-FU  was the 
transferrin receptor protein 1 (TFRC). TFRC mediates iron uptake via 
endosomes internalization after ligand binding to the transferrin receptor that 
activates endocytosis of endosomes (Rothenberger, Iacopetta et al. 1987). In 
CRC cells levels of TFRC are related with proliferation rate of tumour cells 
(Okazaki, Matsunaga et al. 2010) and it has been considered as enhancer of 
platinum drugs delivery (Daniels, Delgado et al. 2006), especially for OXA 
(Suzuki, Takizawa et al. 2008). This new potential role for TFRC as a mediator 
of resistance discovered during our proteomics study, it is proposed as a point 
of disagreement. It looks clear that use of liposomes for platinum drugs delivery 
is having success in animal models, where drugs are maintained inside 
interstitial space during a long time (Maruyama 2011).  
Finally, the third protein significantly up-regulated included in membrane 
transport group and unique of HT 29 5-FU subline was the ferritin heavy chain 
(FTH1). FTH1 is another protein related to the previously discussed protein 
FTRC. After iron uptake mediated by FTRC, the protein FTH1 with ferroxidase 
activity mediates iron homeostasis and stores iron molecules in vesicles within 
cells (Wu, Polack et al. 1999). Although nothing is known about FTH1 role in 5-
FU and cancer resistance, the present proteomics analysis suggests that an 
increase in iron uptake activity could be associated with resistance to 5-FU. 
3.4.3.4 Significantly altered proteins seen in DLD-1 5-FU, HT 29 5-FU, and 
KM 12 5-FU resistant sublines 
RICTOR, FAM83B, TEP1, and GLCE proteins were quantified and showed a 
high light/heavy ratio in DLD-1 5-FU, HT 29 5-FU, and KM 12 5-FU resistant 
sublines during proteomics quantification. However, these proteins were not 
quantified in any of the six parent control samples. This lack of quantification in 
any of the six control samples may be due to the limit of quantification (LOQ) by 
the mass spectrometer. LOQ is one of the main challenges in proteomics 
quantification. A mass spectrometer requires a minimum quantity of peptides 
concentration to be reliable to detect, identify and quantify a protein. If the cell 
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sample does not achieve this minimum concentration of the protein to be 
identified by the mass spectrometer, the protein may not be detected by this 
technique. So, a further analysis of the protein by other technique as WB should 
be carried out to confirm these results.  
The protein FAM83B was discovered in 2012, this protein is an oncogene that 
acts at EGFR signalling pathway. FAM83B expression levels were associated 
with specific cancer subtypes, with increasing of tumour size and with patients 
survival decrease. FAM83B may act by EGFR direct activation or by the 
mediation of RAS/MAPK and PI3K/AKT/TOR signalling cascades in breast 
cancer cell lines and mice models (Cipriano, Graham et al. 2012, Lee, Meier et 
al. 2012, Cipriano, Miskimen et al. 2014). Overexpression of FAM83B was 
significantly associated with estrogen receptor– (ER-) and progesterone 
receptor–negative (PR-negative) breast tumours and poor outcome.                        
All evidence about FAM83 over the last years have increased the interest of the 
science community on this new oncogene that has been found up-regulated in 
the three different resistant sublines to 5-FU developed in vitro. 
Glucuronyl C5-Epimerase (GLCE) (HSepi) is an enzyme that mediates heparan 
sulfate (HS) and heparin biosynthesis by catalysing the epimerization of D-
glucuronic acid (GlcA) to L-iduronic acid (IdoA) at polymer level. HS is a 
negatively charged linear polysaccharide derived from proteoglycan (HSPG) in 
which two or three HS chains are attached to the cell surface or extracellular 
matrix proteins to mediate the selective binding and cellular internalisation of 
circulating soluble and insoluble extracellular ligands including growth factors 
and viral proteins. HS participates in multiple biological processes as tissue 
development, coagulation, angiogenesis and tumour metastasis. Other minor 
forms of membrane HSPG include ß-glycan and the V-3 isoform of CD44 
present on keratinocytes and activated monocytes (Qin, Ke et al. 2015).  
Telomerase-Associated Protein 1 (TEP1) is a component of the 
ribonucleoprotein complex responsible for telomerase activity which catalyses 
the addition of new telomerase on the chromosome ends. To find this protein 
up-regulated in all 5-FU resistant subsamples acquires a crucial importance due 
to its role during cell proliferation. The main role of telomerase is to maintain 
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telomere homeostasis and to protect telomeres damage (Olovnikov 1996). 
Telomerase is essential to let cells outgrowth and to maintain genomic integrity 
of telomeres (Gillis, Schuller et al. 2008). In humans, a high presence of 
telomerase occurs in telomeres from cells that need to maintain its proliferation 
activated after fetal development. Proliferating cells that keep its division and 
with a high presence of telomerase are stem cells, germ cells, hair follicles, 
activated lymphocytes.  In other cells such as epithelial cells, fibroblasts, 
endothelial cells and in the majority of healthy tissues, telomerase is presented 
at low levels with a low expression. While 80-90% of metastatic tumour cells 
show a very high expression of telomerase. Each time a cell is divided, it has 
been estimated that a cell loses around 150-200 base pairs per cell division 
before cell senescence and before cells death by apoptosis. This number was 
established in cell culture experiments using breast cancer cell lines (Jafri, 
Ansari et al. 2016). High levels of telomerase in resistant cell lines may explain 
the fact that resistant sublines show a bigger size than its respective sensitive 
parent cell line. A similar study about the effect that high passaging produces in 
DLD-1 colorectal cell lines in vitro, showed that long-term cultivation promotes 
telomere elongation and overexpression of MDR1 and MRP genes (Kuranaga, 
Shinomiya et al. 2001). In CRC, a high presence of telomerase has been 
described as a possible biomarker of resistance to radiotherapy (Shin, Foot et 
al. 2012, Bertorelle, Rampazzo et al. 2014). 
Additionally, its expression is related to vault components MVP, TEP1 and 
vPARP and their correlation to other MDR proteins in ovarian cancer. Vaults are 
ribonucleoprotein particles found in the cytoplasm of eucaryotic cells. The 13 
MDa particles are composed of multiple copies of three proteins: a Mr 100 000 
major vault protein (MVP) and two minor vault proteins of Mr 193 000 (vault 
poly-(ADP-ribose) polymerase) and Mr 240 000 (telomerase-associated protein 
1), as well as small untranslated RNA molecules of approximately 100 bases. 
Although the existence of vaults was first reported in the mid-1980s, no function 
has yet been attributed to this organelle. The notion that vaults might play a role 
in drug resistance was suggested by the molecular identification of the lung 
resistance-related (LRP) protein as the human MVP. Expression profiles of 
vault components MVP, TEP1, and vPARP and their correlation to other MDR  
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proteins in ovarian cancer (Mossink, van Zon et al. 2003, Szaflarski, Sujka-
Kordowska et al. 2013).  MVP was found up-regulated in KM 12 5-FU and KM 
12 OXA resistant sublines. 
3.4.4 Discussion of WB validation results for CD44 and UMPS in 5-FU 
In order to validate the findings of the quantitative proteomics methodology, 2 
proteins whose expressions were identified as being up-regulated in the 5-FU 
resistant sublines, were further investigated using immunodetection techniques.  
3.4.4.1 CD44 in resistant sublines to 5-FU 
CD44 was studied due to it has recently been discovered for its potential role as 
CSCs biomarker and it was found significantly up-regulated in DLD-1 5-FU 
resistant subline but not in DLD-1 parent samples (Fig. 3.31a). WB results 
obtained in DLD-1 5-FU, DLD-1 P=9, DLD-1 P=65 and DLD-1 SILAC P=9, 
indicate that the difference in bar graphs distribution between the WB results 
and the SILAC approach results is not great for DLD-1 Set. Unique differences 
are due to certain additional adjustments as the measurement and using the 
sample DLD-1 SILAC to estimate the relative abundance of CD44 protein in 
different samples. Additionally, using different experimental approaches, 
measures of SILAC samples to calculate the relative expression ratio and 
statistics analysis may increase differences between both results. However, in 
both cases (WB bar graph and SILAC bar graph) the general trend and profile 
of samples are maintained. In this way, in both experiments, CD44 relative 
expression in DLD-1 set of samples, was found from the highest to the lowest 
levels in the following order DLD-1 5-FU, DLD-1 P=65, and DLD-1 P=9. In both 
cases, a significantly up-regulation was found for CD44 in DLD-1 5-FU resistant 
subline. In KM 12 set of samples, WB results obtained in KM 12 5-FU, KM 12 
P=9, KM 12 P=55, and KM 12 SILAC P=9, indicate that the small differences in 
bar graphs distribution between the KM 12 WB results and the KM 12 SILAC 
approach results, is due to experimental technique differences (Fig. 3.31b).  
However, no significant differences in CD44 expression were found in KM 12 
resistant subline. Finally, WB results obtained in HT 29 5-FU, HT 29 P=9, HT 29 
P=57, and HT 29 SILAC P=9, indicate similarity in bar graphs distribution 
between the WB results and the SILAC approach results (Fig. 3.31c). A clear 
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high expression of CD44 was found in HT 29 5-FU, following by HT 29 P=9 in 
both experiments. Whilst, HT 29 P=65 showed the lowest expression of CD44 
in both cases too. 
3.4.4.2 UMPS DLD-1 
As it has been described above, in the section 3.4.3.3.1.3, levels between 
UMPS isoforms are important for the development of resistance to 5-FU in 
CRC. From initial mass spectrometry results, a significantly down-regulation in 
UMPS has been found in the resistant subline DLD-1 5-FU. However, initial WB 
results obtained do not show a significantly down-regulation in UMPS enzyme 
levels. Contrary to expectations, in DLD-1 5-FU sample a high expression of a 
second isoform of the enzyme UMPS was found (Fig. 3.32a). A further analysis 
was done by estimation of the relative expression ratio between the two 
isoforms of the enzyme UMPS found. Interestingly, as it has been described in 
previous publications the resistant subline DLD-1 5-FU showed the most similar 
levels between the two isoforms of UMPS (Fig 3.32c). So, it may be confirmed 
that data obtained from microarray hybridization and analysis of microarray data 
on the ALEXA splicing microarray platform by M. Griffith et al., and new relative 
ratio abundance of UMPS isoform A / UMPS isoform B found during the present 
thesis are similar (Fig. 3.32c,d). The unique difference was that SILAC-
approach did not show the same trend than WB and microarray data previously 
described.  
So, to understand the absence of any conceptual or visual similarity between 
WB results and SILAC approach results, a review of SILAC-ratio data obtained 
for UMPS was done. 
For WB study of UMPS in DLD-1 5-FU resistant subline, the GTX 114872 
UMPS antibody was used. The UMPS recombinant antibody encompasses a 
sequence within the centre region of human UMPS. However, the exact 
sequence is proprietary of GenteTex Antibodies. According to the observed 
target size in WB results (Fig. 3.32a), it can be confirmed that the two isoforms 
detected are the Isoform A: Length: 480; Mass (Da):52,22 and the Isoform B: 
Length:302; Mass (Da):33,05. The difference between Isoform A and Isoform B 
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is that Isoform B misses the 1-178 regions. However, antibody binding is not 
occurring to encompass this missing region as it is binding to the centre region.  
In conclusion, it is crucial to know both the amino acid sequence that it is used 
by the Orbitrap Analyser to quantify the proteins and the amino acid sequence 
recognized by the antibody during WB. This issue may cause failures in results 
similar during the comparison between WB and mass spectrometry results and 
it needs to be avoided by a properly antibody selection during WB validation. 
3.4.5 Conclusion 
Development of 5-FU resistant sublines was carried out by continuous drug 
exposure. Differences in resistance fold change may be because the initial 
parent cell lines have different genomic background and cellular sensitivity to 5-
FU effects may be different for each cell line. Additionally, establishment of 
resistant sublines is a long process (more than 10 months), so during this 
period of time, new randomly and different mutations appear in parent cell lines 
and these can have different roles in 5-FU response. Hence, final outcome in 
resistance fold change is the result of multiple cellular responses to 5-FU. All 
this genetic variability and different protein expressions, contribute to the 
development of different resistant phenotypes with different grades of 
resistance fold change.  
These differences explain why DLD-1 5-FU showed a 130.2 fold change whilst 
KM 12 5-FU and HT 29 5-FU showed fold change of 3.2 and 3.5, respectively. 
A further validation of resistant sublines establishment methodology was based 
on the development of mice xenograft models. In vivo results showed 
resistance maintained suggesting DLD-1 subline as a 5-FU resistant model. 
Validation of proteomics as a technique for identifying alterations in protein 
expression was carried out using Western Blotting for 2 proteins with identified 
altered expression profiles, CD44 and UMPS. Results from WB were in line with 
the initial results obtained by SILAC approach. The SILAC proteomic 
quantification approach is a robust and widely accepted method to quantify 
significant differences between two or more biological samples. This issue is 
confirmed as the SILAC-approach and analysis led to quantification of a similar 
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number of proteins (3500-4000) in the three cell lines (DLD-1, KM 12, HT 29) 
studied (Fig. 3.22). 
DLD-1 5-FU xenograft mice models developed (see Fig. 3.18) will be used to 
further validate by WB and immunohistochemistry (IHC) the observations 
obtained from in vitro studies. Tumour-derived cell lines may not completely 
recapitulate tumour microenvironment, hence in vivo models are important to 
employ to study processes such as angiogenesis and hypoxia. The role of 
myeloid cells and cell surface receptors in acquired resistance to anti-Vascular 
Endothelial Growth Factor (VEGF) therapy has been recently discovered (see 
Chapter 3, section 3.4.3.2.1) (Rosa, Monteleone et al. 2014). Hence, up-
regulated proteins involved in myeloid differentiation process such as NFAT5, 
MYADM and cell surface receptors such as CD44, SARG involved in 
proliferation and differentiation of intestinal colon cells, are some of the most 
interesting candidate altered proteins for further studies as targeted protein to 
avoid acquired resistance to 5-FU in CRC.  
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4 Identification of new mechanisms of resistance to IRI  
4.1  Introduction  
The prodrug IRI, 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy 
camptothecin (CPT-11), is a derivative of camptothecin. It is a cytotoxic 
quinoline alkaloid that acts as Topo I inhibitor (Liu, Desai et al. 2000).  
Topo I enzyme catalyses the relaxation of superhelical DNA. This is possible 
through cycles of transient single strand cleavage and its religation in the DNA 
duplex. Topo I cleaves and reseals the phosphodiester backbone of DNA in a 
repetitive process. The Topo I-DNA complex makes possible the passage of the 
single DNA and double DNA through the nicked DNA (Shao, Cao et al. 1999).  
4.1.1 Mechanisms of action of IRI 
IRI has S-phase-specific cytotoxicity because interacts with cellular Topo I–DNA 
complexes (Xu and Villalona-Calero 2002). The active form of IRI is SN-38) 
binds to Topo I-DNA complex and prevents religation of cleaved DNA complex. 
Once the SN-38-Topo I-DNA complex has been formed and collides with the 
advancing replication fork, the failure of the replication process happens and the 
formation of a double-strand DNA break occurs (Liu, Desai et al. 2000). This is 
the final and critical damage that causes the arresting of proteins of the 
replication fork in G2, which is arrested and delayed by DNA damage signalling 
during S-phase checkpoint, leading to apoptosis (Liu, Desai et al. 2000). Under 
high IRI concentration, cells that are not in S-phase may also die from IRI 
toxicity. This kind of anti-proliferative effect by high concentrations appears to 
be related to the damage at a transcriptional level, which converges into the 
activation of genes involved in apoptosis (Liu, Desai et al. 2000). 
4.1.2 Known mechanisms of resistance to IRI 
Metabolism of IRI is a complex process that involves the action of a large 
number of enzymes such as Carboxylesterase (CE), Topo I, Protein kinase 
ataxia telangiectasia mutated (ATM) (Rasheed and Rubin 2003), 
Serine/threonine protein kinase (ATR), DNA-dependent protein kinase (DNA-
PK). Alterations in regulation of these proteins and changes at expression level 
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in the Mitogen-Activated Protein Kinase (MAPK) (p38) or in the nuclear factor 
kappa B (NF-κB) may lead to resistance development to IRI. All roles of these 
factors in IRI resistance are known and are explained in detail below (Rasheed 
and Rubin 2003).  
4.1.2.1 Mechanisms of resistance to IRI related to carboxylesterase 
IRI is activated through its hydrolysis to SN-38, by CE. CE is a member of the 
carboxylesterase family which contains enzymes that take part in the hydrolysis 
or transesterification of various xenobiotics and drugs (Sanghani, Quinney et al. 
2003). Therefore a variation in CE expression can affect the IRI metabolism 
process. IRI resistance and low chemosensitivity to the drug are related to low 
CE expression in vitro (Guichard, Terret et al. 1999) and in the same way, CE 
gene expression is directly related to the inter-individual variation in therapeutic 
outcome of CRC patients when they are treated with IRI (Sanghani, Quinney et 
al. 2003). 
4.1.2.2 Mechanisms of resistance to IRI related to DNA damage 
There are some alterations in terms of DNA repairing effects that can lead to 
resistance to IRI. ATM, ATR, and DNA-PK activation show the highest activity 
during DNA damage detection and DNA repairing processes (Reinhardt, 
Aslanian et al. 2007). ATM is a protein kinase which is activated primarily by 
double-strand breaks (DSBs), while the chromatin binding protein kinase ATR is 
activated in response to persistent single-stranded DNA that is generated by 
DNA damage and by blocking proteins of the replication fork (Schwab 2008). 
The ATM/ATR kinases also activate by phosphorylation the checkpoint 
Chk1/Chk2 kinases, which consecutively can play critical roles acting like 
messengers during cell cycle checkpoints (Schwab 2008). Subsequently, they 
regulate the cell cycle control, DNA repair systems and cell survival (Reinhardt, 
Aslanian et al. 2007, Schwab 2008). 
4.1.2.3 Mechanisms of resistance to IRI related to p38α 
Related to SN-38, it has been shown that p38α phosphorylation is increased in 
SN-38 resistant clones derived from HCT 116 and SW480 CRC cell lines, 
suggesting that p38α activation might represent a general resistance 
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mechanism (Paillas, Boissière et al. 2011). This data was surprising because it 
was assumed that p38α activity induced the expression of pro-apoptotic 
proteins and acted as a tumour suppressor (Grossi, Peserico et al. 2014). Now, 
a recent publication showed similar results suggesting that MAPK p38α could 
act through two different pathways with completely different consequences in 
CRC. One of these pathways regulates the suppression effect of colitis-
associated tumour initiation (Fig. 4.1). Contrary, p38α stimulates proliferation 
and survival of transformed epithelial tumour cells, contributing to tumour 
burden (van Houdt, de Bruijn et al. 2010, Gupta, del Barco Barrantes et al. 
2014).  
The protumoural activity of p38α in CRC could be due to the capacity of p38α to 
stimulate CRC cell survival by enhancing DNA repair in response to 
chemotherapy and the autophagy pathway. Evidence for involvement in 
autophagy comes from a study which demonstrated that p38α mediates 
autophagy and cell death inhibition in CRC cells suggesting that p38α activation 
is essential for their survival (Fig. 4.1) (Paillas, Causse et al. 2012). These 
authors showed that the activation of the autophagy process by p38α was 
mediated by GABARAP gene activation. GABARAP is a gamma-aminobutyric 
acid A receptor that takes part in vacuoles and autophagosomes formation. 
Under low levels of p38α activity, the GABARAP gene is upregulated and cell 
death by autophagy occurs. So, the use of p38α inhibitors can cause cell death 
by autophagy (Fig. 4.1) (Comes, Matrone et al. 2007). 
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Figure 4.1: Schematic diagram of p38 role in proliferation and apoptosis in CRC. 
Non-tumoural cells with DNA damage activate DNA repair system, but if it is not 
possible to repair DNA, p38 activates some TFs such as p53, p21, Myc, etc which arrest 
the cell cycle at the G1/S phase by blocking of CDK2 and CyclinE interaction. 
Alterations and overexpression in p38 protein can deregulate this pro-apoptotic 
mechanism, increasing number of cells with DNA damage that are more likely to 
develop new malignant and resistant phenotypes.  
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4.1.2.4 Mechanisms of resistance to IRI related to Topoisomerase I 
Another crucial factor in IRI mechanism of action is Topo I. This enzyme is the 
natural target of Topo I inhibitors like IRI, so it is believed that the cellular levels 
of Topo I could be proportional to cellular sensitivity to IRI. It has been observed 
that in CRC resistant cell lines that have been exposed continuously to IRI 
treatment, the expression of Topo I was reduced in contrast to the IRI-sensitive 
parent cell line (Husain, Mohler et al. 1994). There is evidence that CRC cell 
lines express higher levels of Topo I than normal colon mucosa in xenografts 
(Giovanella, Stehlin et al. 1989). Additionally, Topo I overexpression has been 
suggested as a predictor for high sensitivity to the drug (Xu and Villalona-Calero 
2002). However, detailed knowledge about regulation of Topo I is needed, 
because the level of Topo I in cells depends on multiple molecular mechanisms 
that regulate the expression of the enzyme. Some studies in CRC tumours 
demonstrated that upregulation of Topo I mRNA increases Topo I in cell lines at 
the protein level (Husain, Mohler et al. 1994). Nevertheless, a clear relation 
between sensitivity to IRI and pre-treatment tumoural Topo I expression has not 
been established. 
Otherwise, studies in colon, breast and leukaemia cell lines have demonstrated 
that IRI can down-regulate Topo I through an ubiquitin/26S proteasome-
dependent system. The 26S proteasome is a complex protein formed by 31 
different subunits (Voges, Zwickl et al. 1999). This molecular machinery 
catalyses proteins degradation and it has been found activated as consequence 
of the formation of the Topo I-DNA and IRI complex (Voges, Zwickl et al. 1999, 
Desai, Li et al. 2001). Moreover, it is known that most of tumour cell lines show 
defects at some point during the degradation pathway of Topo I. In peripheral 
blood mononuclear cells of patients who have been previously treated with IRI, 
it has been found reduction of Topo I (Liu, Desai et al. 2000). As a result, it 
should be studied if the Topo I reduction can be used as a mechanism of 
resistance by normal cells against IRI therapy.  
4.1.2.5 Mechanisms of resistance to IRI related to NF-κB 
Finally, treatment with IRI can stimulate proliferation. This proliferative process 
is initiated by activation of NF-κB. This protein complex is a ubiquitous 
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transcription factor that controls the DNA transcription by regulation of a large 
number of genes involved in inflammation and immune response (Veiby and 
Read 2004). During first stages of protumoural cells development, NF-κB acts 
like a suppressor factor of the apoptotic cascade. It acts on the apoptotic 
cascade that can be suppressed by gene activation such as oncogenic Ras, 
tumour necrosis factor-α (TNF-α) and chemotherapy drugs as IRI. After this, the 
transcriptional factor activated can regulate chemoresistance by changes 
around the tumour area (Liu, Desai et al. 2000, Veiby and Read 2004).   
4.1.3  Aims & Objectives for IRI 
The main aims and objectives of this study were focused on developing new 
resistant sublines to IRI which could be used to explore novel mechanisms of 
resistance in CRC. This was achieved by the following objectives: 
1) Establish and characterise IRI resistant sublines for DLD-1 in terms of 
sensitivity to IRI in vitro. 
2) Identify novel mechanisms of IRI resistance using a proteomic approach. 
4.2 Material & Methods  
All general material and methods used were carried out as it has been 
previously described in Chapter 2 and Chapter 3. 
4.3 Results  
4.3.1 Establishment of DLD-1 drug resistant cell line to IRI 
An IRI resistant subline was established from DLD-1 by episodic exposure to 
IRI over a period of ten months (Fig. 4.2). The DLD-1 resistant IRI subline was 
maintained and growth in a drug-free medium over a month, keeping stability in 
IRI resistant phenotype. A significant increase of 1.7-fold change was found in 
DLD-1 IRI subline. Unfortunately, it was not possible to establish IRI-resistant 
sublines for KM 12 and HT 29 cell lines over the treatment period due to the 
high anti-proliferative effect of the drug in these two cell lines. 
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Figure 4.2: Chemosensitivity curve profiles for DLD-1. (a) Three independent 
chemosensitivity curve profiles for DLD-1 parent and pretreated DLD-1 IRI cell line 
during establishment of DLD1 IRI resistant subline. (b) DLD-1 no pretreated cell lines 
and DLD-1 IRI P=55, were exposed to IRI [0.03-100 µM] doses during 96 h. MTT 
assays were performed in three independent experiments. Graphs show the cell survival 
of DLD-1 pretreated and non-pretreated cell lines against different IRI concentrations. 
A significant difference of 1.7-fold change in IC50 was found between DLD-1 parent 
cell line and DLD-1 IRI resistant subline (**** p≤0.0001). Error bars showing standard 
deviations between replicates are displayed too. 
4.3.2 Characterisation of cell growth for DLD-1 IRI resistant subline 
To confirm results obtained by MTT and to test if the number of passage of the 
flask could have some effect on the MTT assay, a growth curve analysis was 
done for DLD-1 IRI resistant subline. Growth rate and capacity to proliferate 
was measured for resistant subline and parent cell line (Fig. 4.3). Growth curves 
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were done using an initial concentration of 1x104 cells/ml. No significant 
differences in growth rate were found in DLD-1 IRI resistant subline. 
 
Figure 4.3: MTT Growth curve profiles for DLD-1 parent cell line and DLD-1 IRI 
resistant subline. No significant difference (p>0.05) was found in growth curve 
profiles between parent and resistant subline. 
4.3.3 Identification of proteome changes in DLD-1 resistant subline to IRI 
using mass spectrometry by SILAC approach 
Results for DLD-1 IRI were obtained as it has been previously described for              
5-FU (see Chapter 3, section 3.3.6). Lowest Mascot score used in each sample 
were established by Mascot software for a 95 % confidence rate and these 











 >31 >30 >31 
Table 4.1: Lowest Mascot scores used during analysis of DLD-1 samples. 
Total number of proteins quantified in DLD-1 parent samples and DLD-1 IRI 
resistant subline are shown in a Venn diagram below (Fig. 4.4). Total number of 
commonly quantified proteins is shown within circles intersections. Complete 
protein lists are enclosed in a soft copy which is attached in a CD along with this 
thesis. 
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Figure 4.4: Venn diagram of multi SILAC dataset in DLD-1 IRI. Middle cells with 
the number of unique proteins commonly quantified in  DLD-1 long and low generation 
controls and DLD-1 IRI resistant subline are shown. 
4.3.4 Protein quantification and results of the MS analysis  
4.3.4.1 Raw data normalization and transformation 
Initially, after Log2 transformation of the normalized SILAC-ratio data, frequency 
distributions of commonly quantified proteins of parent cell lines (DLD-1 P=9, 
DLD-1 P=65) and DLD-1 IRI were plotting in figure 4.5. Distribution of Log2 
SILAC-ratio proteins in DLD-1 IRI overlays by little both parent cell lines 
distributions. This difference in data distribution may be presumably caused by 
IRI effects, which increases number of altered proteins in DLD-1 IRI treated cell 
line. 
 
Figure 4.5: A histogram overlaid fold change distribution of multi SILAC data set 
in DLD-1 IRI showing fold change distribution of proteins commonly quantified. 




lines to IRI 
Significant              
Up-regulated 
Proteins 






DLD-1 51 74 3.32% 
Table 4.2: Significantly up-regulated (Fold change ≥ 2) and down-regulated (Fold 
change ≤ 2) proteins in DLD-1 resistant subline to IRI. 
4.3.4.2  “R” LIMMA analysis 
DLD-1 IRI multi SILAC dataset was analysed by LIMMA as it has been 
described in Chapter 3, section 3.2.5.7. Proteins fold change between DLD-1 
IRI and DLD-1 parent cell lines were summarised in a Volcano plot below. The 
data for all proteins are plotted as Log2 fold change versus the −Log10 of the 
adjusted p-value (Fig. 4.6). 
 
Figure 4.6: Volcano plots showing the distribution of significantly altered proteins 
following LIMMA modelling in DLD-1 IRI. Criteria for significance are a 2-fold 
change for the DLD-1 IRI subline compared to the parent data, with p<0.05. Key: Red-
Upregulated, Green – Downregulated proteins, Grey-Unaltered and non-significant 
proteins. 
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Log2 fold changes and their respective p-value were calculated using LIMMA. 
Proteins of each sample were ordered from the highest to the lowest according 
to normalized Log2 ratio data from SILAC results before cluster analysis.  
4.3.4.3 Cluster analysis 
The ordered list of proteins was divided into three groups of proteins as it has 
been described in Chapter 3, section 3.2.5.7.  
Initial results containing all probable proteins status among DLD-1 IRI and DLD-
1 parent cell lines are shown in Table 4.3. Proteins unaltered in parent cell lines 
but also up-regulated or down-regulated in DLD-1 IRI subline were used to build 
the cluster analysis.   
Cluster analysis for DLD-1 IRI resistant subline showed similar results to those 
observed during “R” LIMMA analysis (see Fig. 4.6). The highest number of 
proteins remain unaltered in both parent cells lines, whilst DLD-1 IRI shows a 
high symmetry in (a) up- and (b) down-regulated proteins fold change 
dispersion. Detailed results are summarized in Table 4.4 and Table 4.5. 
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Table 4.3: Thresholds for protein status in DLD-1 IRI multi SILAC dataset of 
were established using a 5
th
 percentile criteria. From the column of  “Status Sum-up”  
in the table, only the proteins which remain as unaltered (N, brown) in both parent cell 
lines and with an altered status (D green or U red) in DLD-1 IRI resistant subline were 
considered to be studied as altered proteins involved in IRI drug-resistance. 
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Figure 4.7: Cluster analysis of DLD-1 IRI. Proteins were classified using  a  5
th
 
percentile criteria for significantly (a) up-regulated proteins; (b) unaltered proteins; (c) 
down-regulated proteins in sensitive parent cell lines DLD-1 P=9, DLD-1 P=65 and 
DLD-1 IRI resistant subline. 






MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value       
1 NGDN Q8NEJ9 35.9 24.1 17 4 135 4.67 0.000
2 USP48 Q86UV5 119.0 6.0 7 4 47 2.25 0.005
3 DHX57 Q6P158 155.5 7.7 28 5 307 2.23 0.007
4 RBM23 Q86U06 48.7 20.5 34 4 373 2.14 0.005
5 HELZ P42694 218.8 6.8 24 7 56 2.04 0.010
6 TSSC4 Q9Y5U2 34.3 9.4 13 3 94 1.92 0.008
7 FSCN1 Q16658 54.5 58.4 306 24 4586 1.87 0.058
8 ARFRP1 Q13795 22.6 15.4 3 2 113 1.78 0.009
9 LMO7 Q8WWI1 192.6 32.6 302 38 4419 1.56 0.008
10 RIOK1 Q9BRS2 65.5 25.7 24 9 299 1.54 0.111
11 SMC6 Q96SB8 126.2 9.0 18 6 140 1.48 0.008
12 Hsp40 Q96KC8 63.8 22.7 33 9 449 1.46 0.004
13 RPL29 P47914 17.7 9.4 33 1 913 1.44 0.043
14 ESRP2 Q9H6T0 78.4 25.3 53 10 536 1.42 0.060
15 BTF3L4 Q96K17 17.3 37.3 79 6 647 1.40 0.022
16 PHRF1 Q9P1Y6 178.6 4.9 26 5 217 1.40 0.089
17 IGFBP2 P18065 34.8 42.8 40 8 533 1.39 0.141
18 CENPF P49454 367.5 13.0 50 25 446 1.39 0.049
19 BOD1L1 Q8NFC6 330.3 4.7 39 7 451 1.37 0.079
20 NFKB2 Q00653 96.7 35.2 123 21 1188 1.37 0.062
21 Hsp40 O75190 36.1 23.3 25 6 430 1.37 0.055
22 DNA P49643 58.8 14.1 31 4 164 1.36 0.045
23 NDUFAF3 Q9BU61 20.3 44.6 39 5 624 1.35 0.030
24 PHF6 Q8IWS0 41.3 17.8 23 4 279 1.34 0.010
25 TIMM8B Q9Y5J9 9.3 33.7 12 2 235 1.33 0.067
26 TENM3 Q9P273 300.8 1.6 7 2 97 1.33 0.168
27 TRAPPC12 Q8WVT3 79.3 10.9 13 4 101 1.31 0.143
28 MRPL52 Q86TS9 13.7 42.3 32 2 365 1.28 0.081
29 INTS4 Q96HW7 108.1 6.1 10 3 72 1.27 0.011
30 VPS37A Q8NEZ2 44.3 14.1 13 3 222 1.24 0.011
31 RAD51 Q06609 36.9 18.6 27 4 393 1.24 0.161
32 AAMP Q13685 46.7 29.7 58 7 729 1.24 0.094
33 CHMP6 Q96FZ7 23.5 19.4 20 3 221 1.22 0.040
34 SEC24D O94855 112.9 17.8 42 11 492 1.22 0.014
35 CHD1 O14646 196.6 15.6 82 16 748 1.20 0.090
36 POM121C A8CG34 125.0 13.5 48 8 595 1.19 0.039
37 CIZ1 Q9ULV3 100.0 21.8 46 10 535 1.19 0.113
38 BCAR1 P56945 93.3 26.3 106 13 1126 1.19 0.069
39 RNF13 O43567 42.8 11.8 13 2 133 1.17 0.039
40 DNTTIP2 Q5QJE6 84.4 31.7 130 16 1309 1.16 0.143
41 MPP5 Q8N3R9 77.2 22.5 43 9 538 1.16 0.021
42 LIMD1 Q9UGP4 72.1 33.7 39 9 379 1.15 0.268
43 SPAST Q9UBP0 67.2 19.5 34 8 760 1.15 0.215
44 RHBDD1 Q8TEB9 35.8 11.1 11 2 431 1.13 0.008
- 200 - 
 
 
Table 4.4: Results of high SILAC-ratios for single SILAC DLD-1 IRI experiment. 
p-value from multi SILAC dataset analysed by LIMMA is included. 
 
45 ARHGAP5 Q13017 172.4 17.7 65 15 462 1.13 0.099
46 TWISTNB Q3B726 37.4 12.1 16 3 293 1.13 0.155
47 TIMMDC1 Q9NPL8 32.2 23.2 26 5 205 1.13 0.225
48 TIMM23 O14925 21.9 45.9 28 5 277 1.12 0.128
49 WDR73 Q6P4I2 41.7 14.6 12 3 74 1.12 0.148
50 ZNF428 Q96B54 20.5 23.9 18 3 408 1.11 0.104
51 SFSWAP Q12872 104.8 8.7 22 5 389 1.10 0.190
52 UHRF1 Q96T88 89.8 40.5 115 22 1218 1.10 0.114
53 CHMP2A O43633 25.1 11.7 21 3 713 1.09 0.337
54 EHD4 Q9H223 61.1 57.1 195 23 2995 1.08 0.049
55 SSU72 Q9NP77 22.6 42.3 46 8 624 1.08 0.099
56 NOP16 Q9Y3C1 21.2 32.6 62 5 543 1.08 0.152
57 KLK6 Q92876 26.8 30.3 29 4 293 1.08 0.058
58 PPWD1 Q96BP3 73.5 26.9 43 11 395 1.07 0.053
59 IL6ST P40189 103.5 11.1 32 6 339 1.07 0.014
60 C1orf122 Q6ZSJ8 11.5 46.4 8 3 133 1.06 0.074
61 RRS1 Q15050 41.2 32.1 86 13 921 1.05 0.214
62 MRPL24 Q96A35 24.9 17.6 14 3 318 1.04 0.020
63 BAIAP2L1 Q9UHR4 56.8 46.8 97 15 903 1.04 0.036
64 GATA6 Q92908 60.0 23.4 25 8 544 1.04 0.361
65 TNFRSF10A O00220 50.1 13.7 26 4 457 1.04 0.069
66 WDR74 Q6RFH5 42.4 42.1 71 11 1189 1.03 0.118
67 NFRKB Q6P4R8 138.9 8.6 21 6 189 1.03 0.099
68 ERBIN Q96RT1 158.2 26.6 110 22 1053 1.02 0.084
69 MDC1 Q14676 226.5 33.7 222 32 2509 1.02 0.267
70 Hsp70 P48723 51.9 11.9 15 5 95 1.01 0.015




MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value              
1 SPTLC3 Q9NUV7 62.0 6.5 4 2 52 -3.58 0.000
2 RNF2 Q99496 37.6 22.3 43 3 371 -3.56 0.003
3 EXOC2 Q96KP1 104.0 6.8 9 4 108 -3.09 0.001
4 NEDD4 P46934 149.0 11.4 33 8 257 -2.80 0.001
5 CANT1 Q8WVQ1 44.8 36.7 24 8 499 -2.30 0.004
6 AMACR Q9UHK6 42.4 29.3 42 7 555 -2.14 0.034
7 STX6 O43752 29.2 47.8 39 7 338 -2.06 0.005
8 ACY1 Q03154 45.9 24.0 28 6 241 -2.02 0.013
9 GPD1L Q8N335 38.4 17.4 15 5 407 -1.99 0.024
10 ANKFY1 Q9P2R3 128.3 26.1 124 18 1739 -1.99 0.004
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11 DPYSL3 Q14195 61.9 49.6 247 16 3926 -1.95 0.055
12 RNF213 Q63HN8 591.0 4.1 37 13 248 -1.89 0.029
13 VPS13C Q709C8 422.1 5.3 34 13 293 -1.82 0.010
14 AGL P35573 174.7 18.2 78 18 978 -1.77 0.019
15 GBAS O75323 33.7 19.9 32 4 201 -1.74 0.019
16 PSPH P78330 25.0 36.0 55 6 929 -1.73 0.094
17 KLC4 Q9NSK0 68.6 17.3 36 4 505 -1.73 0.048
18 NIPSNAP3A Q9UFN0 28.4 9.3 5 2 43 -1.72 0.074
19 FOCAD Q5VW36 199.9 1.3 8 2 110 -1.69 0.048
20 MIF P14174 12.5 36.5 304 4 4559 -1.68 0.091
21 GLB1 P16278 76.0 21.7 61 11 1127 -1.58 0.028
22 MRPL17 Q9NRX2 20.0 23.4 19 4 158 -1.57 0.068
23 ZZEF1 O43149 330.9 2.9 10 6 185 -1.55 0.011
24 LYPLAL1 Q5VWZ2 26.3 30.0 39 5 203 -1.53 0.017
25 URB1 O60287 254.2 7.8 54 12 222 -1.52 0.137
26 ITPR3 Q14573 303.9 13.0 77 19 659 -1.51 0.026
27 NGLY1 Q96IV0 74.3 17.3 20 6 108 -1.51 0.122
28 EIF4EBP1 Q13541 12.6 38.1 19 3 141 -1.49 0.046
29 PDCD4 Q53EL6 51.7 27.3 45 9 634 -1.49 0.012
30 TLN2 Q9Y4G6 271.4 8.1 76 6 980 -1.49 0.083
31 RAB3GAP2 Q9H2M9 155.9 8.7 46 9 520 -1.46 0.117
32 PFN2 P35080 15.0 36.4 83 5 1493 -1.44 0.085
33 MCU Q8NE86 39.8 24.8 55 7 202 -1.44 0.165
34 BLMH Q13867 52.5 18.5 23 5 300 -1.42 0.138
35 PDK3 Q15120 46.9 8.1 11 2 78 -1.42 0.168
36 ACSS2 Q9NR19 78.5 4.1 10 2 62 -1.42 0.028
37 SLC7A1 P30825 67.6 6.8 16 3 328 -1.41 0.103
38 WASH1 A8K0Z3 50.3 10.5 30 2 451 -1.41 0.010
39 PRKDC P78527 468.8 35.4 1309 129 18704 -1.41 0.030
40 HUWE1 Q7Z6Z7 481.6 20.6 390 52 5509 -1.41 0.038
41 PTER Q96BW5 39.0 41.8 72 10 700 -1.40 0.156
42 ALDH5A1 P51649 57.2 20.7 58 8 1194 -1.40 0.091
43 DOPEY2 Q9Y3R5 258.1 0.6 11 1 213 -1.40 0.088
44 IGF2R P11717 274.2 29.3 304 48 3216 -1.36 0.111
45 FDFT1 P37268 48.1 41.7 74 13 966 -1.35 0.040
46 NADP O75874 46.6 57.2 557 20 7653 -1.35 0.196
47 LSS P48449 83.3 23.0 83 13 1058 -1.35 0.204
48 SLC26A6 Q9BXS9 82.9 4.5 7 2 147 -1.34 0.165
49 PSMC5 P62195 45.6 54.4 482 20 8289 -1.33 0.169
50 DHCR7 Q9UBM7 54.5 11.4 20 4 500 -1.33 0.104
51 LCLAT1 Q6UWP7 48.9 7.5 14 2 106 -1.32 0.012
52 NAGA P17050 46.5 15.8 35 5 561 -1.31 0.021
53 MGST3 O14880 16.5 34.2 121 4 768 -1.31 0.139
54 PAFAH1B3 Q15102 25.7 42.9 71 6 686 -1.31 0.025
55 LRBA P50851 318.9 13.8 130 28 1384 -1.30 0.029
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Table 4.5: Results of low SILAC-ratios for single SILAC DLD-1 IRI experiment. 
p-value from multi SILAC dataset analysed by LIMMA is included. 
4.3.4.4 Bioinformatics analysis of proteins significantly changed due to 
resistance 
Only proteins classified in the altered group using the 5th percentile cluster 
analysis and with a significant p-value (p<0.05) obtained from LIMMA analysis 
were selected to develop a protein network model. Initially, STRING analysis 
was applied to identify relationships between proteins significantly altered in 
resistant sublines, based on molecular functions identified by GO and pathway 
analysis for selected proteins using EnrichNet (Fig. 4.8).  
56 ARL6IP5 O75915 21.6 20.2 88 4 1846 -1.29 0.207
57 DYNC1H1 Q14204 532.1 41.2 1624 156 20175 -1.28 0.044
58 MPP7 Q5T2T1 65.5 23.4 33 8 159 -1.28 0.015
59 DHRS1 Q96LJ7 33.9 14.7 11 2 96 -1.28 0.024
60 MBOAT7 Q96N66 52.7 8.7 32 3 759 -1.27 0.114
61 EXOC4 Q96A65 110.4 12.8 43 8 734 -1.27 0.037
62 THYN1 Q9P016 25.7 14.2 12 2 202 -1.26 0.064
63 FLOT2 Q14254 47.0 34.1 62 11 975 -1.26 0.137
64 EHBP1 Q8NDI1 139.9 7.4 19 5 308 -1.25 0.005
65 OSBPL8 Q9BZF1 101.1 18.6 36 10 245 -1.25 0.034
66 ABCD3 P28288 75.4 30.0 185 14 1994 -1.25 0.099
67 ABHD14B Q96IU4 22.3 34.8 97 5 901 -1.22 0.141
68 RAB1A P62820 22.7 60.0 252 3 4211 -1.22 0.202
69 CASP6 P55212 33.3 24.2 35 5 221 -1.21 0.097
70 COX2 P00403 25.5 20.7 61 4 519 -1.20 0.022
71 SCCPDH Q8NBX0 47.1 25.4 34 8 295 -1.20 0.145
72 NUP205 Q92621 227.8 10.7 77 14 473 -1.20 0.024
73 SACM1L Q9NTJ5 66.9 22.1 87 11 631 -1.19 0.055
74 ADH5 P11766 39.7 25.1 150 10 2009 -1.19 0.086
75 NIPSNAP1 Q9BPW8 33.3 27.5 103 6 916 -1.19 0.046
76 STT3B Q8TCJ2 93.6 9.4 66 8 849 -1.18 0.115
77 CMAS Q8NFW8 48.3 43.5 156 13 2368 -1.17 0.329
78 MTOR P42345 288.7 6.5 34 10 238 -1.17 0.091
79 G6PC3 Q9BUM1 38.7 6.1 6 1 193 -1.17 0.043
80 CRAT P43155 70.8 16.6 42 7 416 -1.16 0.310
81 MYO6 Q9UM54 149.6 39.2 462 43 5907 -1.15 0.018
82 EXD2 Q9NVH0 70.3 10.6 17 4 258 -1.15 0.096
83 RAB3GAP1 Q15042 110.5 19.0 86 13 857 -1.14 0.363
84 UGGT1 Q9NYU2 177.1 40.8 426 38 6704 -1.14 0.279
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Figure 4.8: The figure shows a proteomic network model for DLD-1 IRI. Significantly altered proteins obtained by modification on 
EnrichNet and GO from the initial bubble map obtained in STRING. Proteins were classified into different biological processes groups 
represented with a circle.  Dotted arrows indicate the most relevant altered proteins and its main function as mediator of drug resistance.  
Key: Green arrow: significantly down-regulated protein; Red arrow: significantly up-regulated proteins. 
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4.3.4.5 Verification of experimental fold changes using housekeeping-control proteins  
As it has been explained in Chapter 3, section 3.3.9, seven housekeeping control proteins were used to validate fold changes 
findings in DLD-1 IRI. Results for these seven housekeeping proteins are summarized in Table 4.6. 
 
Table 4.6: Control proteins that are unaltered by IRI effects and which were used to evaluate the success of SILAC 
approach and statistical analysis applied to DLD-1 IRI resistant subline. Log2 fold change of all control proteins were found 
close to zero in the unique IRI resistant sublines when they were compared to its respective parent-control cell lines. A  Log2 fold 
proximal to 0, means that levels of the proteins quantified were similar in light and heavy samples. 
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4.4 Discussion  
Development of resistant sublines from KM 12 and HT 29 parent cell lines was 
not possible. Failure during establishment of resistant sublines may be due to 
the high anti-proliferative effect that the drug had on KM 12 and HT 29 cell lines, 
which were more sensitive than DLD-1 during long-term (10 months) drug 
exposure times. Proteomics quantification results for DLD-1 IRI resistant subline 
were also similar in productiveness to the three previous results in 5-FU 
resistant sublines with a total of 3761 proteins quantified. From histograms, 
volcano plots and cluster analysis obtained, it was observed that DLD-1 IRI 
resistant subline was the subline with the lowest fold change (1.7-fold) 
according to MTT assay (Fig. 4.2b) and with the lowest number of significantly 
altered proteins (Fig. 4.6). 
A summary table containing proteins altered in DLD-1 IRI resistant subline is 
shown below. Most relevant up-regulated proteins were classified based on the 
specific literature background of the protein in two groups: 
1) Altered proteins by direct effect of IRI exposure as proteins involved in 
apoptotic mechanism and stress regulation. 
2) Altered proteins by indirect effect of IRI exposure as proteins related to DNA 
repair, drug transport, drug metabolism, exocytosis and vesicle formation. 






Table 4.7: Up-regulated proteins identified in 5-FU resistant sublines. 
4.4.1 Mechanisms of resistance to IRI identified by proteomics: 
Significantly altered proteins in DLD-1 IRI 
Among the three resistant sublines of DLD-1, DLD-1 IRI was the resistant 
subline with the lowest number of significantly up-regulated proteins. 
Additionally, DLD-1 IRI resistant subline showed the lowest fold change 
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resistant phenotype in comparison with DLD-1 parent cell line. Among 5% of the 
most significantly up-regulated proteins none was involved in drug metabolism 
and just one was found in anti-apoptotic proteins. Drug metabolism and 
avoiding of apoptotic pathways are essential steps during drug resistance 
metabolism in CRC. So, lack of up-regulated proteins belonging in these 
processes may be related to the lack of success during DLD-1 resistance 
development to IRI. 
4.4.1.1 Apoptotic process (1) 
One noteworthy significantly down-regulated protein  was the programmed cell 
death protein 4 (PDCD4). PDCD4 is a tumour suppressor that acts promoting 
apoptotic pathways. Decreasing of PDCD4 activity has been associated with 
resistance development in glioblastoma (Liwak, Jordan et al. 2013). PDCD4 
decreases tumour progression through cell cycle and cell proliferation regulation 
in CRC cells by down-regulation of MAP4K1 transcription. A direct 
consequence of MAP4K1 inhibition is blocking of c-Jun activation. Although it is 
clear that PDCD4 shows translational inhibition of target mRNAs, which 
suppress tumourigenesis. However, the mechanisms behind this process are 
still unknown (Allgayer 2010).  
Recent results from 2015 show that increasing of  PDCD4  levels in CRC cells 
increases 5-FU sensitivity by negative regulation of ABC transporters and 
negative regulation of surface stem cell markers as CD44 expression (Wu, Li et 
al. 2015). Therefore, a decreasing of PDCD4 expression could increase the 
ABC transporters and stem cell markers levels, driving cells to develop a 
resistant phenotype to drugs like IRI. Additionally, down-regulation of PDCD4 
drives in a decrease of paclitaxel toxicity in different human cancer cells (Xu, 
Dephoure et al. 2015). 
4.4.1.2 DNA repair process (2)  
Only the structural maintenance of chromosomes protein 6 (SMC6) was found 
significantly up-regulated in DNA repair process of DLD-1 IRI. SMC6 with SMC5 
together form a complex that mediates during formation of DNA double-strand 
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breaks by homologous recombination, a high expression of the SMC5 protein 
was found also in DLD-1 IRI. The SMC6-SMC5 complex is required for 
telomere maintenance during cell division (De Piccoli, Cortes-Ledesma et al. 
2006, Räschle, Smeenk et al. 2015). Nevertheless, no evidence of SMC5-
SMC6 protein expression has been related yet with chemotherapy resistance in 
cancer. Due to its role as a mediator of sister-chromatid recombination for DNA 
repair and maintenance of telomeres, the SMC5-SMC6 complex may be part of 
a mechanism of resistance to drugs and the inhibition of SMC5-SMC6 complex 
during chemotherapy treatment should be studied. 
4.4.1.3 Drug and small molecules metabolism (3) 
DLD-1 IRI did not show any significantly up-regulated protein involved in drug 
metabolism among the 10% of most altered protein. This issue may be related 
to the fact that the final resistant fold change of DLD-1 IRI was the lowest (1.7 
fold change). So, maybe the lack of altered proteins involved in drug 
metabolism may partially explain the lack of success during DLD-1 IRI 
establishment process. 
4.4.1.4 Intracellular protein transport (4)  
One significantly up-regulated protein was the ADP-ribosylation factor-related 
protein 1 (ARFRP1) that takes part in protein transport and lysosome vesicles 
formation (Vitale, Horiba et al. 1998).  
A second significantly up-regulated protein of DLD-1 IRI was the transport 
protein SEC24D that promotes the transport of secretory vesicles and vacuolar 
proteins from the endoplasmic reticulum to the Golgi complex (Tang, Kausalya 
et al. 1999).  
Finally, charged multivesicular body protein 6 (CHMP6) and vacuolar protein 
sorting-associated protein 37A (VPS37A) were also found significantly                    
up-regulated and their role is to mediate invagination and scission of the 
endosomes and lysosomes in experiments with the yeast Saccharomyces 
cerevisiae (Hurley and Hanson 2010). Up-regulation of SEC24D, CHMP6, 
VPS37A proteins together, increase transport of cell vesicles. Increasing of 
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vesicle transport has been described as a mechanism of drug resistance. It is 
based on the idea that cells may decrease drug levels inside the cells by 
collecting drug molecules within lysosomes and other vesicles that will be 
delivery to the extracellular space (Zhitomirsky and Assaraf 2016).  
4.4.1.5 Cellular membrane transporters and cell membrane organization 
(5) 
The unique significantly up-regulated protein related with transcellular 
membrane transport was the Rhomboid-related protein 4 (RHBDD1). RHBDD1 
has two main functions that may contribute to drug resistance developing. 
RHBDD1 inhibits the pro-apoptotic pathways in Human embryonic kidney cells 
293 (HEK 293T) (Wang, Guan et al. 2008), increasing exosome secretion that 
may increase both 5-FU and  FOLFOX resistance in CRC (Bigagli, Luceri et al. 
2016).  
4.4.2 Conclusion 
Among the three parent cell lines used, only DLD-1 developed a low acquired 
resistance to IRI. Hence, IRI was the drug with the highest anti-proliferative 
effect of all CRC cell lines studied (see Chapter 2, section 2.4.2.2). Initial IRI-
toxicity panel matches with the results of the establishment of resistant sublines, 
which only were successful with DLD-1 IRI development. Most of the 
significantly altered proteins seen in DLD-1 IRI sublines were more related to 
consequences of IRI effects than to cellular mechanisms of resistance to the 
drug. It would be interesting to study if hydroxylation of IRI (CPT-11) by 
carboxylesterase (CE) to the active metabolite SN-38 (see Chapter 4, section 
4.1.2.1) may be a limiting factor during development of resistant sublines to this 
drug. Protein expression levels of CE in parent and resistant sublines were not 
quantified during our proteomics study. The measurement of CE protein 
expression can be done by real-time PCR platforms, WB and immunostaining.           
It would be interesting to know if different expression levels of CE among all 
CRC cell lines studied are affecting the development of acquired resistance 
process, as under low levels of CE conditions IRI would not be activated and 
cells would not be affected by its anti-proliferative effect. 
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5 Identification of new mechanisms of resistance to OXA  
5.1 Introduction  
OXA (1,2-diaminocyclohexane-oxalate platinum) is the only member of the 
family of platinum analogues that shows activity against CRC (Rabik and Dolan 
2007). OXA has an oxalate ligand and a diaminocyclohexane ligand (DACH) 
that has replaced the amine group from cisplatin (André, Boni et al. 2004, 
Alcindor and Beauger 2011). Structural differences between the two molecules 
explain differences in OXA and cisplatin activity. The hydrogen bond formation 
between Pt-amine-hydrogens and surrounding bases of the DNA are different 
for cisplatin and OXA (Chaney, Ramachandran et al. 2009). Those differences 
in hydrogen binding patterns result in DNA conformational differences that allow 
selective recognition of OXA or cisplatin by different proteins that can play a role 
in toxicity and resistance of these drugs.  
5.1.1 Mechanisms of action of OXA 
The pathways of action of OXA are far from being fully known (Martinez-
Cardús, Martinez-Balibrea et al. 2009). DNA is the natural target of OXA and of 
the rest of platinum-based drugs. The DACH-Pt complex is critical for a high 
cytotoxicity and a high binding to cellular DNA by OXA (Woynarowski, 
Chapman et al. 1998). DACH-Pt reacts with the sulfhydryl and amino groups of 
proteins, DNA and RNA. Although OXA binds with all four DNA nucleobases, it 
predominantly forms adducts with adenine and guanine (Woynarowski, 
Chapman et al. 1998, Kerr, Shoeib et al. 2008).  DNA lesions and arrest of both 
DNA and RNA synthesis lead to a switching on of the damage sensor system of 
the cell. The activation of the DNA repair mechanism system converges in the 
activation of ATM and ATR proteins that results in the stabilization and 
activation of p53 that can subsequently activate genes involved in apoptosis 
pathways (Schwab 2008, Muller and Vousden 2013). OXA shows synergism 
when it is used together with other cytotoxic drugs as 5-FU, however additional 
in-depth studies are required to know more about these effects (Alcindor and 
Beauger 2011). 
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5.1.2 Known mechanisms of resistance to OXA 
5.1.2.1 Mechanisms of resistance to OXA related to membrane 
transporters   
There are multiple processes that may play a role in OXA resistance. The main 
mechanisms of resistance to OXA are related to membrane transporters that 
mediate the efflux of platinum agents out from the cell (Alcindor and Beauger 
2011). The main group of proteins that can act as transporter for cisplatin 
agents are the copper transporters, especially ATP7a and ATP7b (Komatsu, 
Sumizawa et al. 2000, Martinez-Cardús, Martinez-Balibrea et al. 2009, 
Martinez‐Balibrea, Martínez‐Cardús et al. 2009). In the case of ATP7a, high 
levels of this copper transporter have been found in cisplatin-resistant ovarian 
carcinoma cell lines after be treated with cisplatin and OXA (Samimi, Safaei et 
al. 2004). Further, an association between high levels of ATP7b transporter and 
a poor prognosis in CRC patients under OXA treatment has been found 
(Martinez‐Balibrea, Martínez‐Cardús et al. 2009).  
5.1.2.2 Mechanisms of resistance to OXA related to glutathione   
Other mechanisms associated with resistance to cisplatin drugs are related to 
intracellular glutathione (GSH) levels (Balendiran, Dabur et al. 2004). GSH is 
increased in cisplatin resistant ovarian cancer cell lines (Rabik and Dolan 2007). 
The increase of intracellular GSH in A2780 ovarian carcinoma cell line is 
caused by γ-glutamyl transpeptidase activity (El-Akawi, Abu-Hadid et al. 1996).  
γ-glutamyl transpeptidase is a cell surface enzyme that catalyses the transfer of 
the gamma-glutamyl moiety of GSH to an acceptor that may be an amino acid, 
a peptide or water (Yang, Faustino et al. 2000). The correlation between high 
levels of GSH and cisplatin resistance is due to that some membrane 
transporters require GSH as cofactor for substrate transporting, so an increase 
in GSH levels can make easier the transport of cisplatin drugs (Kuo 2009).  
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5.1.2.3 Mechanisms of resistance to OXA related to mitochondrial 
apoptotic pathway   
Finally, a recent study found that defects in the mitochondrial apoptotic pathway 
could contribute to resistance to OXA in CRC (Gourdier, Crabbe et al. 2004). 
This is because one of OXA‟s mechanisms of action is via Bax/Bak dependent 
mitochondrial apoptosis (Gourdier, Del Rio et al. 2002). Bax/Bak are pro-
apoptotic proteins that are activated by cell stress or DNA damage (Yang, 
Faustino et al. 2000). These proteins mediate the permeabilization of the 
mitochondria, an essential process for apoptosis. A mutation in Bax gene has 
been demonstrated to enable resistance in the HCT 116-R2 CRC cell line 
(Gourdier, Del Rio et al. 2002, Gourdier, Crabbe et al. 2004). 
5.1.3 Aims & Objectives for OXA 
Main aims and objectives of the investigation were focused on developing new 
resistant sublines to OXA to identify novel mechanisms of resistance in CRC, 
and use as experimental models for evaluation of novel therapies which may 
overcome drug resistance and will be carried out as follows: 
1) Select suitable cell lines for development OXA resistant sublines from a CRC 
cell line panel. 
2) Establish resistant sublines. 
3) Cell growth characterisation of DLD-1 OXA and KM 12 OXA 
6) Study of MDR mechanisms from KM 12 OXA by MTT. 
7) Identify novel mechanisms of OXA resistance using a proteomic approach. 
5.2 Material & Methods  
All general material and methods used were carried out as it has been 
previously described in Chapter 2 and Chapter 3. 
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5.3 Results  
5.3.1 Establishment of DLD-1 drug resistant cell lines to OXA 
OXA resistant sublines were established from DLD-1 and KM 12 parent cell 
lines by episodic exposure to OXA over a period of ten months. Evolve of DLD-
1 parent cell lines to DLD-1 OXA is shown by the interval between four 
successive different passages of DLD-1 parent cell line under OXA exposure 
conditions  (Fig. 5.1a). The DLD-1 OXA resistant subline was maintained and 
growth in a drug-free medium during a month, keeping stability in OXA resistant 
phenotype. Regarding HT 29 parent cell line, it was not possible establishment 
of its resistant subline as OXA cytotoxic effects on this cell line were too high 
during long-term drug exposure process. 
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Figure 5.1: Chemosensitivity curve profiles of OXA resistant sublines. Three 
independent chemosensitivity curve profiles for (a) DLD-1 parent and DLD-1 pretreated 
with OXA during establishment of DLD-1 OXA resistant subline. (b) DLD-1 no 
pretreated cell line and DLD-1 OXA P=60. (c) KM 12 no pretreated cell line and KM 
12 OXA P=30. All cell lines were exposed to OXA [0.03-100 µM] concentration during 
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96 h. MTT assays were performed in three independent experiments (mean ± SEM). 
Graphs show the cell survival of DLD-1 OXA and non-pretreated cell lines against 
different OXA concentrations. The difference in IC50 among DLD-1 non-pretreated 
parent cell line and DLD-1 OXA was 10.7-fold change (**** p≤0.0001). The difference 
in IC50 among KM 12 non-pretreated parent cell line and KM 12 OXA was 2.06-fold 
change and significant (*** p≤0.001). Error bars showing standard deviations between 
replicates are displayed too. 
5.3.2 Characterisation of cell growth for DLD-1 and KM 12 resistant 
sublines to OXA 
To confirm results obtained by MTT and to test if the number of passage of the 
flask could have some effect on the MTT assay, a growth curve analysis was 
done for the two resistant sublines to OXA established. Growth rate and 
capacity to proliferate was measured for OXA resistant sublines (Fig. 5.2). 
Growth curves were done using an initial concentration of 1x104 cells/ml.   
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Figure 5.2: MTT Growth curve profiles. (a) DLD-1 parent cell line and DLD-1 OXA 
resistant subline, and (b) KM 12 parent cell lines and KM 12 OXA resistant subline. No 
significant differences (p>0.05) were found in growth curve profiles between parent and 
resistant sublines. 
5.3.3 Evaluation of cross-resistance in the KM 12 OXA subline by MTT 
MDR was studied following same methodology previously described for DLD-1 
5-FU (see Chapter 3, section 3.3.3). So, to support with new knowledge related 
to cross-resistance mechanisms in OXA chemotherapy, a further study of 
collateral loss of sensitivity to eight chemotherapy agents used in CRC was 
carried out using the resistant sublines KM12 OXA (Fig. 5.3). 
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Figure 5.3: Cross-resistance profile conferred by KM 12 OXA and KM 12 parent 
cell line. The 96 h cytotoxicity assays were performed with eight different drugs: (a) 5-
FU, (b) OXA, (c) IRI, (d) doxorubicin, (e) carmustine, (f) colchicine, (g) cisplatin and 
(h) paclitaxel. Curves are representative of separate experiments in triplicate. Relative 
resistance values were obtained by dividing the IC50 value of the resistant KM 12 OXA 
resistant subline by the IC50 value of the KM 12 parent cell line.                                                
(*p≤0.05; ** p≤0.01; *** p≤0.001; **** p≤0.0001). 
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5.3.4 Identification of proteome changes in DLD-1 and KM 12 resistant 
sublines to OXA using mass spectrometry by SILAC approach 
Results for OXA resistant sublines were carried out as it has been previously 
described for 5-FU in Chapter 3, section 3.3.6. Lowest Mascot score used in 
each sample were established by Mascot software for a 95 % confidence rate 

















 >31 >30 >30 >28 >28 >28 
Table 5.1: Lowest Mascot scores used during analysis of OXA resistant sublines.  
Multi SILAC datasets of OXA resistant sublines were similar and is shown in 
two Venn diagrams below. The total number of commonly quantified proteins is 
shown within circles intersections. Complete protein lists are enclosed in a soft 
copy which is attached in a CD along with this thesis. 
 
Figure 5.4: Venn diagrams of multi SILAC datasets in OXA. (a) DLD-1 and (b) KM 
12 parent cell lines with a high and a low number of passages and their respective drug-
resistant sublines to OXA. These commonly up-regulated and down-regulated proteins 
presented at the intersection of Venn diagrams are discussed in detail further in section 
5.4.2.1. 
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5.3.5 Protein quantification and results of the MS analysis  
SILAC labelling method was used to determine changes in protein expression 
from parent cell lines and their resistant OXA subline.  
5.3.5.1 Raw data normalization 
Initially, after Log2 transformation of the normalized SILAC-ratio data, a 
histogram frequency distribution of  Log2 SILAC-ratio data figure for common 
proteins quantified in each set of parent cell lines (two parent cell lines with high 
and low number of passages and sensitive to 5-FU) and its respective resistant 
subline  established in vitro was carried out and they are shown below                  
(Fig. 5.5). Histogram relevance lies in the number of high Log2 SILAC-ratio 
proteins value for each sample, which should show lower values of Log2 SILAC-
ratio in proteins of parent cell lines than in resistant sublines that show an 
increase in Log2 SILAC-ratio caused by drug effects. These trends are observed 
in the two histogram views (Fig. 5.5) and they are useful to validate that the 
experimental procedure is replicable as it was expected.  
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Figure 5.5: A histogram view of overlaid fold change distributions of multi SILAC 
datasets in OXA. (a) DLD-1 and (b) KM 12 resistant sublines to OXA compared with 
their respective parent and sensitive cell lines after Log2-transformation and 











lines to OXA 
Significant              
Up-regulated 
Proteins 






DLD-1 153 109 7.05% 
KM 12 270 453 21.01% 
Table 5.2: Significantly up-regulated (Fold change ≥ 2) and down-regulated (Fold 
change ≤ 2) proteins in resistant cell lines to OXA. 
5.3.5.2  “R” LIMMA analysis 
OXA multi SILAC datasets were analysed by LIMMA. A fold change and its 
associated p-value were calculated for each protein according to their 
significant different ratio expressions between the OXA resistant sublines and 
its two related parent-control cell lines with a high and a low number of 
passages. This information was summarised in a Volcano plot of LIMMA-
modelled proteomics data. The data for all proteins are plotted as Log2 fold 
change versus the −Log10 of the adjusted p-value (Fig. 5.6). 
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Figure 5.6: Volcano plots showing the distribution of significantly down- and up-
regulated proteins following LIMMA modelling in OXA sublines. Criteria for 
significance are a 2-fold change for the (a) DLD-1 5-FU and (b) KM 12 5-FU sublines 
compared to the parent data, with p<0.05. Key: Red-Upregulated,                                   
Green – Downregulated proteins, Grey-Unaltered and non-significant proteins. 
Log2 fold changes and their respective p-value were calculated using LIMMA. 
Proteins of each sample were ordered from the highest to the lowest according 
to normalised Log2 ratio data from SILAC results.  
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5.3.5.3 Cluster analysis 
The ordered list of proteins was divided into three groups of proteins using a 5th 
percentile threshold of the total population as it has been previously described 
in Chapter 3, section 3.3.7.3. The most significantly altered proteins in OXA 
resistant sublines but which remain as unaltered in both parent samples under 
5th percentile criteria were used to build up a cluster analysis (Fig. 5.7 and          
Fig. 5.8). Significance was obtained from LIMMA analysis p-value. Finally, lists 
of the most significant high and low SILAC-ratios of proteins quantified in DLD-1 
OXA and KM 12 OXA resistant sublines were done (Table 5.4-5.7). 
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Table 5.3: Thresholds for protein status in DLD-1 and KM 12 multi SILAC 
datasets were established using a  5
th
 percentile criteria. From the column of  “Status 
Sum-up”  in the table, only the proteins which remain as unaltered (brown) in both 
parent cell lines and with an altered status (green or red) in the resistant sublines were 
considered to be studied as altered proteins involved in drug-resistance. 
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Cluster analysis results for DLD-1 OXA are shown in Figure 5.7. Detailed 
results for significantly altered proteins in DLD-1 OXA resistant subline are 
summarized in Tables 5.4 and 5.5. Log2 SILAC results for DLD-1 OXA / DLD-1 
SILAC P=9 ratio and p-values from R analysis of resistant and control cell lines 
are included. 
Cluster analysis for DLD-1 OXA resistant subline showed similar results to 
those observed during “R” LIMMA analysis (see Fig. 5.6a). The highest number 
of proteins remain unaltered in both parent cells lines, whilst DLD-1 OXA shows 
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Figure 5.7: Cluster analysis of DLD-1 OXA. Proteins were classified using 5
th
 
percentile threshold for significantly  (a) up-regulated proteins; (b) unaltered proteins; 
(c) down-regulated proteins in sensitive parent cell lines DLD-1 P=9, DLD-1 P=65 and 
in DLD-1 OXA resistant subline. 






MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value       
1 NQO1 P15559 30.8 36.5 467 12 7156 2.98 0.001
2 BABAM1 Q9NWV8 36.5 17.6 14 4 55 2.77 0.001
3 RHBDD1 Q8TEB9 35.8 11.1 7 2 254 2.68 0.001
4 COA6 Q5JTJ3 14.1 32.0 9 3 45 2.51 0.003
5 CUX1 P39880 164.1 12.6 44 4 170 2.47 0.003
6 TRIP4 Q15650 66.1 27.4 36 8 316 2.28 0.004
7 KLK6 Q92876 26.8 41.8 70 6 908 2.14 0.006
8 UBP1 Q9NZI7 60.5 9.6 13 2 343 2.12 0.004
9 TSSC4 Q9Y5U2 34.3 13.4 19 4 76 2.09 0.005
10 POM121C A8CG34 125.0 10.5 23 6 309 1.93 0.006
11 MPP5 Q8N3R9 77.2 23.0 51 9 813 1.89 0.004
12 PNPLA2 Q96AD5 55.3 12.5 38 4 554 1.86 0.009
13 LOC107984056 P54278 95.7 3.8 9 2 131 1.85 0.006
14 MOCOS Q96EN8 98.1 18.1 43 9 309 1.85 0.019
15 SLC2A1 P11166 54.0 17.5 376 12 5632 1.84 0.008
16 FSCN1 Q16658 54.5 57.2 307 22 5241 1.79 0.064
17 EHBP1 Q8NDI1 139.9 14.4 46 10 735 1.79 0.010
18 NFAT5 O94916 165.7 12.5 37 11 1300 1.78 0.017
19 FOXRED1 Q96CU9 53.8 18.9 17 6 191 1.78 0.034
20 GCLM P48507 30.7 36.1 76 7 1379 1.76 0.014
21 MED21 Q13503 15.6 13.9 9 1 201 1.76 0.033
22 SHROOM3 Q8TF72 216.7 23.6 126 25 1164 1.74 0.012
23 MZT1 Q08AG7 8.5 32.9 6 2 76 1.73 0.006
24 KMT2A Q03164 431.5 1.9 8 4 33 1.72 0.031
25 OS9 Q13438 75.5 7.9 12 3 45 1.69 0.015
26 ZNF638 Q14966 220.5 18.1 94 21 1162 1.68 0.066
27 NGDN Q8NEJ9 35.9 19.7 20 3 165 1.68 0.033
28 GOLPH3 Q9H4A6 33.8 36.2 66 5 1682 1.60 0.010
29 MYADM Q96S97 35.3 12.1 39 3 1015 1.57 0.011
30 Hsp40 O75190 36.1 23.0 34 6 558 1.56 0.031
31 CPTP Q5TA50 24.4 16.4 6 2 115 1.53 0.032
32 C1orf122 Q6ZSJ8 11.5 33.6 4 2 69 1.52 0.030
33 TNFRSF1A Q9NXR7 43.5 18.0 12 4 86 1.49 0.012
34 TERF2IP Q9NYB0 44.2 34.8 48 8 1039 1.47 0.020
35 INPP4A Q96PE3 109.9 11.2 25 6 338 1.44 0.006
36 LASP1 Q14847 29.7 41.4 282 8 1700 1.43 0.020
37 C1orf116 Q9BW04 63.9 35.6 99 12 1235 1.42 0.005
38 Hsp70 P48723 51.9 8.5 9 3 80 1.42 0.006
39 ZYX Q15942 61.2 30.1 86 10 684 1.41 0.022
40 NOL3 O60936 22.6 60.6 58 7 848 1.41 0.013
41 PSMG2 Q969U7 29.4 11.0 18 3 145 1.40 0.101
42 NUDT4 Q9NZJ9 20.3 60.6 52 6 567 1.38 0.017




43 OCLN Q16625 59.1 27.0 97 10 1094 1.38 0.018
44 TJP3 O95049 101.3 13.6 50 8 508 1.37 0.005
45 SPCS2 Q15005 25.0 17.3 46 5 563 1.34 0.018
46 STK39 Q9UEW8 59.4 32.3 50 7 853 1.32 0.064
47 TDP2 O95551 40.9 22.9 29 5 685 1.32 0.056
48 G6PD P11413 59.2 80.6 1626 36 19800 1.32 0.005
49 GCLC P48506 72.7 46.5 178 23 1895 1.32 0.028
50 APOBEC3B Q9UH17 45.9 31.2 87 9 878 1.31 0.009
51 TNFRSF10A O00220 50.1 13.7 28 4 434 1.30 0.028
52 PARD6B Q9BYG5 41.2 28.2 53 8 269 1.27 0.007
53 ANXA6 P08133 75.8 62.3 486 34 7421 1.26 0.026
54 BAIAP2 Q9UQB8 60.8 44.2 134 16 2339 1.26 0.036
55 IGF2BP3 O00425 63.7 33.5 142 12 2359 1.25 0.015
56 SEC24D O94855 112.9 24.61 79 14 777 1.24 0.013
57 STIM1 Q13586 77.4 40.73 167 18 3519 1.24 0.010
58 TBC1D17 Q9HA65 72.7 5.556 4 3 117 1.23 0.007
59 SMG9 Q9H0W8 57.6 12.88 14 4 152 1.23 0.103
60 CHTF18 Q8WVB6 107.3 18.77 57 11 348 1.20 0.062
61 CORO7 P57737 100.5 18.59 37 8 455 1.19 0.021
62 EPS8L3 Q8TE67 66.8 26.14 90 11 809 1.19 0.048
63 KRT80 Q6KB66 50.5 35.62 222 11 3782 1.18 0.005
64 PTPN1 P18031 49.9 30.11 135 11 2621 1.18 0.010
65 FHL2 Q14192 32.2 58.42 171 15 3061 1.17 0.028
66 TENM3 Q9P273 300.8 7.929 26 11 285 1.17 0.213
67 ALKBH5 Q6P6C2 44.2 17.51 16 4 90 1.16 0.212
68 AGRN O00468 217.1 9.386 40 12 614 1.14 0.093
69 ITGA3 P26006 116.5 17.41 99 12 1505 1.12 0.006
70 CPNE1 Q99829 59 23.84 156 9 2187 1.12 0.011
71 LIMCH1 Q9UPQ0 121.8 28.9 110 23 2217 1.12 0.012
72 RNF213 Q63HN8 591 18.76 229 63 1885 1.12 0.034
73 CD81 P60033 25.8 25 135 3 2472 1.11 0.065
74 LPCAT2 Q7L5N7 60.2 26.47 63 9 684 1.11 0.079
75 TAP1 Q03518 87.2 20.67 90 9 1954 1.11 0.033
76 UBE2R2 Q712K3 27.1 18.91 7 2 34 1.10 0.163
77 NXT1 Q9UKK6 15.8 25.71 22 3 543 1.09 0.172
78 CPPED1 Q9BRF8 35.5 48.09 96 9 2079 1.07 0.031
79 FECH P22830 47.8 30.73 46 9 402 1.07 0.073
80 PIK3C2A O00443 190.6 14.12 69 17 680 1.07 0.063
81 XRCC4 Q13426 38.3 27.68 32 6 908 1.07 0.257
82 NDUFS5 O43920 12.5 41.5 14 4 192 1.06 0.068
83 STAU1 O95793 63.1 47.8 280 25 3323 1.06 0.141
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Table 5.4: Results of high SILAC-ratios for single SILAC DLD-1 OXA 
experiment. p-value from multi SILAC dataset analysed by LIMMA is included. 
 
84 MTHFD2 P13995 37.9 52.6 156 11 2010 1.05 0.042
85 ERBIN Q96RT1 158.2 30.3 100 24 801 1.04 0.080
86 ESF1 Q9H501 98.7 10.2 58 7 769 1.02 0.200
87 STAT2 P52630 97.9 9.8 26 5 201 1.02 0.104
88 PYGO2 Q9BRQ0 41.2 9.1 11 2 330 1.01 0.103




MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value       
1 VPS45 Q9NRW7 65.0 17.2 58 7 620 -3.89 0.000
2 GON7 Q9BXV9 10.9 18.0 5 1 39 -3.40 0.001
3 SYTL2 Q9HCH5 104.9 7.6 14 4 87 -3.04 0.001
4 FAM175B Q15018 46.9 10.4 13 3 110 -2.82 0.008
5 SATB2 Q9UPW6 82.5 14.7 56 7 706 -2.57 0.002
6 TOMM20 Q15388 16.3 31.0 19 3 227 -2.45 0.001
7 ACSL5 Q9ULC5 75.9 43.0 85 19 923 -2.44 0.018
8 HDHD2 Q9H0R4 28.5 20.8 27 4 200 -2.35 0.016
9 STX6 O43752 29.2 23.1 21 4 199 -2.31 0.003
10 AMACR Q9UHK6 42.4 33.2 29 7 313 -2.29 0.028
11 PPWD1 Q96BP3 73.5 21.7 30 8 412 -2.26 0.006
12 DPYSL3 Q14195 61.9 50.2 278 15 4484 -2.09 0.042
13 RAB27B O00194 24.6 31.2 64 5 780 -2.03 0.033
14 NCOA5 Q9HCD5 65.5 35.1 94 10 504 -2.01 0.012
15 ANKFY1 Q9P2R3 128.3 24.6 122 17 1444 -1.99 0.003
16 ARHGAP32 A7KAX9 230.4 10.7 56 11 1079 -1.96 0.003
17 L1RE1 Q9UN81 40.0 7.1 18 2 335 -1.92 0.002
18 GBAS O75323 33.7 19.9 29 4 126 -1.86 0.014
19 USP4 Q13107 108.5 7.4 23 4 127 -1.79 0.050
20 EIF4EBP2 Q13542 12.9 25.8 15 1 184 -1.77 0.005
21 EDC4 Q6P2E9 151.6 21.8 77 17 812 -1.75 0.008
22 MFF Q9GZY8 38.4 20.5 18 4 173 -1.73 0.014
23 DHRS1 Q96LJ7 33.9 8.6 10 1 122 -1.71 0.009
24 EGLN1 Q9GZT9 46.0 12.0 4 3 44 -1.66 0.003
25 EPM2AIP1 Q7L775 70.3 13.2 14 5 79 -1.64 0.067
26 CMAS Q8NFW8 48.3 43.5 153 13 2527 -1.62 0.121
27 ACOT11 Q8WXI4 68.4 14.3 13 5 55 -1.56 0.063
28 CNOT10 Q9H9A5 82.3 18.7 20 9 129 -1.55 0.034
29 SORL1 Q92673 248.3 2.5 8 4 76 -1.55 0.004
30 TLN2 Q9Y4G6 271.4 6.3 94 4 1196 -1.54 0.075





31 CUL4B Q13620 103.9 25.6 149 14 1370 -1.53 0.088
32 ARFGAP1 Q8N6T3 44.6 20.0 27 5 500 -1.51 0.012
33 DLGAP5 Q15398 95.1 11.3 16 6 215 -1.51 0.041
34 TAGLN2 P37802 22.4 72.4 269 12 5529 -1.50 0.044
35 MTR Q99707 140.4 10.6 39 9 482 -1.50 0.055
36 YTHDF1 Q9BYJ9 60.8 14.3 33 3 334 -1.49 0.005
37 TRAF2 Q12933 55.8 6.0 2 2 32 -1.48 0.023
38 STAT1 P42224 87.3 37.9 333 21 5080 -1.48 0.016
39 ALDH5A1 P51649 57.2 18.3 38 6 984 -1.47 0.074
40 SLC7A1 P30825 67.6 6.8 19 3 279 -1.47 0.087
41 SLC26A6 Q9BXS9 82.9 4.5 9 2 75 -1.47 0.113
42 STT3B Q8TCJ2 93.6 9.1 87 7 1183 -1.44 0.061
43 CTSC P53634 51.8 19.0 57 6 579 -1.42 0.011
44 BLMH Q13867 52.5 29.0 37 8 358 -1.40 0.143
45 FANCD2 Q9BXW9 164.0 1.8 15 2 302 -1.37 0.012
46 KDELC2 Q7Z4H8 58.5 22.1 21 7 140 -1.37 0.068
47 NIPSNAP3A Q9UFN0 28.4 15.0 15 2 63 -1.37 0.136
48 RAB8B Q92930 23.6 29.5 71 1 616 -1.37 0.043
49 ATP2B1 P20020 138.7 23.4 176 14 2986 -1.37 0.026
50 MRPL17 Q9NRX2 20.0 18.9 24 4 315 -1.36 0.101
51 CSE1L P55060 110.3 32.5 388 25 5659 -1.35 0.039
52 TRIM24 O15164 116.8 8.1 23 5 280 -1.33 0.023
53 DNPEP Q9ULA0 52.4 47.8 151 17 1367 -1.32 0.014
54 RPS9 P46781 22.6 29.9 134 9 1075 -1.31 0.127
55 ABCD3 P28288 75.4 34.6 248 17 2887 -1.31 0.080
56 HSD17B11 Q8NBQ5 32.9 49.33 74 10 567 -1.31 0.121
57 COX20 Q5RI15 13.3 22.03 18 2 391 -1.29 0.068
58 HSD17B7 P56937 38.2 3.519 11 1 235 -1.29 0.053
59 OXR1 Q8N573 97.9 15.79 35 7 708 -1.28 0.050
60 SH3BGRL2 Q9UJC5 12.3 56.07 61 4 748 -1.28 0.178
61 MDN1 Q9NU22 632.4 2.77 36 10 146 -1.25 0.054
62 ATPAF2 Q8N5M1 32.8 21.11 19 4 127 -1.25 0.027
63 CIRBP Q14011 18.6 26.74 18 3 401 -1.23 0.027
64 ELMO2 Q96JJ3 82.6 12.22 25 5 267 -1.23 0.070
65 NDUFA4 O00483 9.4 27.16 24 2 362 -1.22 0.136
66 LYPLAL1 Q5VWZ2 26.3 29.96 48 5 153 -1.22 0.038
67 NPTN Q9Y639 44.4 7.035 15 2 134 -1.21 0.045
68 PRKDC P78527 468.8 35.56 1582 126 23795 -1.21 0.050
69 HMGCS1 Q01581 57.3 49.62 269 17 4377 -1.21 0.011
70 SDCBP O00560 32.4 52.68 127 7 1579 -1.20 0.059
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Table 5.5: Results of low SILAC-ratios for single SILAC DLD-1 OXA 
experiment. p-value from multi SILAC dataset analysed by LIMMA is included. 
 
71 MESDC2 Q14696 26.1 18.38 33 3 194 -1.20 0.170
72 AK3 Q9UIJ7 25.6 35.24 81 8 1381 -1.20 0.297
73 CHDH Q8NE62 65.3 8.923 16 3 76 -1.19 0.018
74 FKBP5 Q13451 51.2 35.45 163 13 2191 -1.19 0.111
75 LONP2 Q86WA8 94.6 16.78 29 9 124 -1.19 0.182
76 OSGEP Q9NPF4 36.4 34.63 13 6 44 -1.18 0.017
77 GNPDA1 P46926 32.6 47.06 59 4 893 -1.17 0.098
78 PATJ Q8NI35 196.2 20.6 103 19 1584 -1.15 0.042
79 NNT Q13423 113.8 23.3 163 16 1878 -1.14 0.150
80 PIN1 Q13526 18.2 43.56 78 5 1296 -1.14 0.047
81 ACOT13 Q9NPJ3 15.0 37.9 29 4 309 -1.14 0.109
82 MIF P14174 12.5 36.52 322 4 5042 -1.14 0.351
83 HSD17B4 P51659 79.6 46.2 528 25 10523 -1.14 0.050
84 TBCE Q15813 59.3 33.4 63 11 802 -1.13 0.206
85 PKN1 Q16512 103.9 13.1 17 8 52 -1.13 0.019
86 NUP210 Q8TEM1 205.0 14.9 131 16 1466 -1.13 0.092
87 FABP5 Q01469 15.2 65.2 576 12 10680 -1.12 0.056
88 SLC12A2 P55011 131.4 29.9 342 25 4255 -1.11 0.005
89 PSPC1 Q8WXF1 58.7 34.8 125 11 1965 -1.11 0.153
90 PEX3 P56589 42.1 25.7 30 5 308 -1.11 0.025
91 NOA1 Q8NC60 78.4 14.3 11 6 32 -1.10 0.012
92 SLC12A9 Q9BXP2 96.0 3.2 7 2 102 -1.10 0.033
93 CPOX P36551 50.1 44.1 404 21 4526 -1.10 0.076
94 TBC1D9B Q66K14 140.4 6.8 20 6 164 -1.09 0.057
95 CPT2 P23786 73.7 34.0 79 14 714 -1.09 0.362
96 THNSL1 Q8IYQ7 83.0 22.9 37 11 785 -1.09 0.052
97 MYO5C Q9NQX4 202.7 1.5 13 2 100 -1.08 0.080
98 TRMT10C Q7L0Y3 47.3 39.0 132 13 1002 -1.08 0.104
99 LSS P48449 83.3 24.7 101 14 1681 -1.08 0.425
100 RPL9 P32969 21.9 62.5 274 11 3582 -1.07 0.144
101 FAM136A Q96C01 15.6 42.8 41 5 547 -1.07 0.311
102 MOGS Q13724 91.9 33.1 235 19 3441 -1.04 0.066
103 NADK2 Q4G0N4 49.4 12.9 18 3 169 -1.04 0.136
104 SCCPDH Q8NBX0 47.1 24.5 22 7 281 -1.03 0.248
105 NAGA P17050 46.5 21.2 19 6 268 -1.03 0.047
106 FAM162A Q96A26 17.3 24.68 55 4 638 -1.03 0.156
107 VPS13C Q709C8 422.1 7.4 64 18 387 -1.03 0.101
108 SEPT8 Q92599 55.7 25.1 92 7 700 -1.02 0.347
109 GSTO1 P78417 27.5 45.2 125 12 1234 -1.01 0.227
- 232 - 
 
Cluster analysis results for KM 12 OXA are shown in Figure 5.8. Detailed 
results for significantly altered proteins in KM 12 OXA resistant subline are 
summarized in Tables 5.6 and 5.7. Log2 SILAC results for DLD-1 OXA / DLD-1 
SILAC P=9 ratio and p-values from R-LIMMA analysis of resistant and control 
cell lines are included. 
Cluster analysis for KM 12 OXA resistant subline showed similar results to 
those observed during “R” LIMMA analysis (see Fig. 5.6b). The highest number 
of proteins remain unaltered in both parent cells lines, whilst KM 12 OXA shows 
a higher number of down-regulated proteins than up-regulated proteins altered.  
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Figure 5.8: Cluster analysis of KM 12 OXA. Proteins were classified using 5
th
 
percentile threshold for significantly (a) up-regulated proteins; (b) unaltered proteins; 
(c) down-regulated proteins in sensitive parent cell KM 12 with 9 passages, in sensitive 
parent cell KM 12 with 55 passages and in KM 12 OXA resistant subline. 






MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value            
1 Hsp110 Q92598 96.8 48.1 384 33 6285 4.00 0.032
2 LIMA1 Q9UHB6 85.2 31.8 133 18 2041 3.08 0.048
3 CHMP2A O43633 25.1 11.7 25 3 1006 3.03 0.052
4 ACACA Q13085 265.4 31.3 204 47 2179 2.96 0.050
5 GPRC5A Q8NFJ5 40.2 21.0 87 5 893 2.91 0.052
6 TAP1 Q03518 87.2 16.6 40 6 762 2.78 0.065
7 TCF12 Q99081 72.9 5.1 4 2 80 2.65 0.066
8 ASMTL O95671 68.8 22.4 26 9 324 2.55 0.052
9 B2M P61769 13.7 27.7 47 3 327 2.54 0.052
10 EPPK1 P58107 555.3 54.7 669 62 9270 2.47 0.052
11 ABCC3 O15438 169.2 9.4 25 8 202 2.45 0.052
12 SPOUT1 Q5T280 42.0 9.8 27 2 253 2.41 0.062
13 MYO6 Q9UM54 149.6 30.8 172 30 2407 2.41 0.052
14 ASAP2 O43150 111.6 17.1 32 9 453 2.41 0.052
15 TIA1 P31483 42.9 16.8 38 3 365 2.40 0.064
16 SRC P12931 59.8 34.0 57 9 875 2.35 0.052
17 MGLL Q99685 33.2 12.9 18 2 264 2.34 0.052
18 ECSIT Q9BQ95 49.1 21.1 25 4 318 2.33 0.052
19 MET P08581 155.4 18.8 68 16 1226 2.32 0.052
20 HPCAL1 P37235 22.3 31.1 38 5 472 2.31 0.052
21 CHCHD6 Q9BRQ6 26.4 17.9 22 2 164 2.30 0.052
22 IPO7 O95373 119.4 22.6 185 20 1997 2.28 0.052
23 MYH14 Q7Z406 227.7 41.1 650 62 11857 2.26 0.052
24 DAG1 Q14118 97.4 6.7 10 3 76 2.18 0.082
25 FAM96B Q9Y3D0 17.7 57.1 46 6 527 2.16 0.066
26 TMEM43 Q9BTV4 44.8 43.8 54 10 629 2.12 0.052
27 CDK4 P11802 33.7 18.5 35 3 242 2.10 0.055
28 KPNA1 P52294 60.2 20.4 41 5 452 2.06 0.127
29 RAC1 O96013 64.0 22.2 45 5 307 2.04 0.063
30 SLC9A3R1 O14745 38.8 42.5 134 9 1544 2.02 0.052
31 HTATIP2 Q9BUP3 27.0 25.6 38 5 264 2.02 0.052
32 ACAD9 Q9H845 68.7 21.7 58 9 966 2.01 0.052
33 WDR55 Q9H6Y2 42.0 41.0 65 10 558 1.99 0.052
34 CD59 P13987 14.2 19.5 20 3 144 1.97 0.052
35 GNS P15586 62.0 23.4 37 7 421 1.97 0.084
36 CLPTM1L Q96KA5 62.2 7.2 28 2 78 1.96 0.074
37 PARP4 Q9UKK3 192.5 16.5 74 16 719 1.94 0.052
38 GNAI2 P04899 40.4 39.7 92 8 790 1.93 0.055
39 BAIAP2 Q9UQB8 60.8 42.2 84 15 1157 1.93 0.073
40 ENDOD1 O94919 55.0 25.6 46 7 509 1.92 0.057
41 STAT1 P42224 87.3 37.2 208 21 3560 1.91 0.052
42 NSDHL Q15738 41.9 44.2 66 12 1044 1.90 0.053
43 GEMIN5 Q8TEQ6 168.5 20.6 109 17 1494 1.89 0.052
44 NDUFS6 O75380 13.7 29.0 15 2 206 1.89 0.062
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45 RNMT O43148 54.8 20.8 39 7 576 1.89 0.073
46 TP53 P04637 43.6 30.8 63 5 806 1.88 0.064
47 AHNAK Q09666 628.7 72.4 3013 256 31662 1.86 0.054
48 LIG3 P49916 112.8 18.1 56 13 581 1.84 0.052
49 RAP2C Q9Y3L5 20.7 43.2 21 2 270 1.84 0.054
50 REPIN1 Q9BWE0 63.5 2.6 6 1 143 1.83 0.052
51 APLP2 Q06481 86.9 8.8 24 4 285 1.83 0.059
52 SH3KBP1 Q96B97 73.1 25.7 69 9 1060 1.82 0.052
53 ARHGAP18 Q8N392 74.9 19.6 41 8 530 1.81 0.055
54 ST14 Q9Y5Y6 94.7 17.0 59 9 631 1.80 0.069
55 ERMP1 Q7Z2K6 100.2 16.9 48 9 283 1.79 0.059
56 IVD P26440 46.3 27.0 69 6 1141 1.78 0.059
57 STIM1 Q13586 77.4 23.8 37 9 619 1.76 0.057
58 CLN6 Q9NWW5 35.9 11.3 26 3 391 1.72 0.052
59 NUP153 P49790 153.8 29.0 95 19 1027 1.69 0.059
60 MRE11 P49959 80.5 30.4 93 17 733 1.69 0.055
61 ACOT13 Q9NPJ3 15.0 30.7 24 3 326 1.69 0.091
62 ITGB5 P18084 88.0 23.8 50 10 475 1.69 0.063
63 CETN2 P41208 19.7 44.2 17 4 537 1.68 0.058
64 IDE P14735 117.9 18.5 58 12 291 1.68 0.074
65 USP14 P54578 56.0 46.8 207 16 2918 1.68 0.052
66 NPC2 P61916 16.6 25.8 50 2 293 1.67 0.064
67 ASL P04424 51.6 22.2 50 9 333 1.62 0.062
68 PPP1R13L Q8WUF5 89.0 23.6 50 11 329 1.61 0.052
69 UFD1L Q92890 34.5 28.7 27 5 422 1.61 0.052
70 METAP2 P50579 52.9 38.1 76 12 1066 1.61 0.052
71 CHRAC1 Q9NRG0 14.7 51.1 29 4 683 1.59 0.055
72 PTK2 Q05397 119.2 24.7 63 14 526 1.59 0.061
73 CNDP2 Q96KP4 52.8 44.8 134 15 1283 1.58 0.052
74 AGK Q53H12 47.1 21.3 38 5 518 1.58 0.059
75 UBA2 Q9UBT2 71.2 44.5 169 22 2640 1.57 0.052
76 TFAM Q00059 29.1 15.9 31 4 440 1.54 0.088
77 REXO2 Q9Y3B8 26.8 30.4 18 7 66 1.54 0.059
78 FAM49B Q9NUQ9 36.7 40.7 164 10 3076 1.53 0.052
79 FAM129B Q96TA1 84.1 49.9 394 22 4044 1.52 0.052
80 CEP131 Q9UPN4 122.1 6.6 10 4 108 1.50 0.090
81 AAGAB Q6PD74 34.6 22.5 25 4 296 1.50 0.052
82 PDCD6 O75340 21.9 37.7 74 5 1144 1.49 0.055
83 FAM21A Q641Q2 147.1 19.0 42 5 581 1.49 0.075
84 ABCF2 Q9UG63 71.2 18.0 68 9 583 1.49 0.075
85 VAPA Q9P0L0 27.9 20.1 91 4 1021 1.48 0.054
86 SRPRA P08240 69.8 26.0 69 11 971 1.48 0.063
87 RTN4 Q9NQC3 129.9 10.4 131 6 1358 1.48 0.062
88 ABCF1 Q8NE71 95.9 17.8 51 10 1143 1.48 0.168




Table 5.6: Results of high SILAC-ratios for single SILAC KM 12 OXA 




89 USP8 P40818 127.4 9.7 35 7 334 1.47 0.167
90 ABHD12 Q8N2K0 45.1 42.5 77 10 538 1.47 0.084
91 ABLIM1 O14639 87.6 21.6 41 9 305 1.46 0.061
92 NUDT3 O95989 19.5 29.7 20 3 132 1.46 0.118
93 RAD50 Q92878 153.8 19.0 93 16 1124 1.46 0.091
94 SYAP1 Q96A49 39.9 37.8 79 12 1200 1.46 0.052
95 CNPY3 Q9BT09 30.7 13.3 33 2 318 1.45 0.063
96 ADAM10 O14672 84.1 20.3 66 10 1061 1.44 0.052
97 CUTA O60888 19.1 40.8 65 5 780 1.43 0.060
98 ARHGAP35 Q9NRY4 170.4 19.1 59 16 439 1.42 0.074
99 Hsp70 P0DMV9 70.0 52.4 1009 22 14270 1.42 0.054
100 RALB P11234 23.4 33.5 87 3 1322 1.42 0.108
101 TXLNG Q9NUQ3 60.5 22.2 25 6 207 1.40 0.178




MW                                           
[kDa]
SC %  PSMs
Unique 
Peptides
Score           
Mascot
Normalized 
Log2             
Ratio:  L/H
p-value          
1 CBR3 O75828 30.8 30.7 85 3 1459 -7.54 0.000
2 PPP1R1B Q9UD71 22.9 54.9 57 6 656 -7.54 0.000
3 THBS2 P35442 129.9 5.9 32 4 401 -7.40 0.000
4 ARG2 P78540 38.6 23.7 11 4 212 -7.05 0.000
5 OXCT1 P55809 56.1 36.3 99 13 2050 -6.61 0.000
6 VIM P08670 53.6 27.3 36 8 306 -6.54 0.001
7 CA2 P00918 29.2 43.5 80 8 777 -6.10 0.000
8 BDH2 Q9BUT1 26.7 24.9 14 4 314 -6.00 0.000
9 PHGDH O43175 56.6 43.5 419 21 6051 -5.57 0.000
10 TFF3 Q07654 8.6 22.5 9 1 97 -5.00 0.000
11 GAA P10253 105.3 15.1 20 8 276 -4.93 0.000
12 FSCN1 Q16658 54.5 46.5 152 16 1974 -4.73 0.000
13 MISP3 Q96FF7 24.0 34.7 9 4 102 -4.61 0.000
14 CRYM Q14894 33.8 10.8 10 2 166 -4.48 0.000
15 NIFK Q9BYG3 34.2 25.6 26 6 555 -4.47 0.000
16 CNN3 Q15417 36.4 25.5 22 6 76 -3.93 0.000
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17 ULBP2 Q9BZM5 27.4 13.0 6 2 80 -3.79 0.002
18 HMGN5 P82970 31.5 21.6 31 4 578 -3.77 0.000
19 MUC5AC P98088 585.2 11.1 71 21 746 -3.70 0.000
20 MAPRE2 Q15555 37.0 17.7 21 4 94 -3.61 0.000
21 ALDH2 P05091 56.3 49.9 237 19 4557 -3.44 0.000
22 PRAF2 O60831 19.2 16.9 20 3 218 -3.42 0.000
23 CD109 Q6YHK3 161.6 14.6 45 12 750 -3.30 0.001
24 PPOX P50336 50.7 18.9 15 5 89 -3.29 0.001
25 S100A14 Q9HCY8 11.7 77.9 66 5 843 -3.22 0.000
26 MTX3 Q5HYI7 35.1 5.8 2 1 79 -3.17 0.001
27 PLIN2 Q99541 48.0 9.8 4 2 59 -3.08 0.001
28 FUT8 Q9BYC5 66.5 5.0 4 2 30 -3.07 0.001
29 ASB9 Q96DX5 31.8 6.5 13 1 68 -3.01 0.003
30 CKAP4 Q07065 66.0 40.2 127 16 2846 -3.00 0.000
31 PTER Q96BW5 39.0 10.0 8 3 67 -2.96 0.001
32 ALCAM Q13740 65.1 33.1 105 13 1567 -2.92 0.001
33 RIDA P52758 14.5 45.3 25 4 479 -2.92 0.001
34 SOD2 P04179 24.7 42.8 152 6 1942 -2.81 0.001
35 TESC Q96BS2 24.7 18.2 23 3 202 -2.65 0.004
36 TRIM2 Q9C040 81.5 16.5 25 6 221 -2.65 0.001
37 BLMH Q13867 52.5 25.3 19 6 290 -2.64 0.002
38 IQGAP2 Q13576 180.5 15.9 38 11 365 -2.55 0.001
39 PAPOLA P51003 82.8 13.0 24 5 131 -2.52 0.001
40 METTL26 Q96S19 22.6 7.4 2 1 33 -2.52 0.001
41 DECR1 Q16698 36.0 34.3 109 8 1116 -2.50 0.001
42 TRIOBP Q9H2D6 261.2 2.5 6 4 77 -2.48 0.001
43 C1orf35 Q9BU76 29.4 10.3 4 2 29 -2.46 0.002
44 APOO Q9BUR5 22.3 17.7 22 2 349 -2.44 0.001
45 OAT P04181 48.5 63.8 300 19 4539 -2.44 0.001
46 LACTB P83111 60.7 5.5 7 2 222 -2.39 0.001
47 AGR2 O95994 20.0 57.1 382 8 7254 -2.36 0.001
48 BPNT1 O95861 33.4 29.5 87 7 1756 -2.35 0.001
49 COQ5 Q5HYK3 37.1 17.1 18 3 212 -2.30 0.006
50 DPYSL2 Q16555 62.3 68.9 414 29 7557 -2.30 0.001
51 ACADM P11310 46.6 34.0 55 9 789 -2.27 0.001
52 MVD P53602 43.4 34.3 53 6 497 -2.27 0.002
53 RAP1GDS1 P52306 66.3 17.1 48 6 881 -2.23 0.003
54 DDT P30046 12.7 50.0 211 7 2052 -2.21 0.002
55 TAMM41 Q96BW9 51.0 19.5 44 6 586 -2.18 0.002
56 ALDH6A1 Q02252 57.8 15.0 24 4 88 -2.18 0.004
57 ACADS P16219 44.3 28.6 37 6 766 -2.18 0.011
58 HCCS P53701 30.6 20.5 13 4 93 -2.16 0.001
59 PACSIN3 Q9UKS6 48.5 14.4 7 4 180 -2.16 0.001
60 MPC2 O95563 14.3 22.8 15 2 81 -2.12 0.008





61 S100P P25815 10.4 49.5 49 4 899 -2.10 0.002
62 ABHD6 Q9BV23 38.3 8.3 10 2 82 -2.09 0.002
63 KIF2C Q99661 81.3 28.6 52 12 649 -2.08 0.002
64 SLC25A11 Q02978 34.0 27.1 42 6 873 -2.07 0.001
65 PHLDA1 Q8WV24 45.0 2.2 3 1 30 -2.07 0.003
66 GPHN Q9NQX3 79.7 9.8 16 4 160 -2.05 0.002
67 FABP5 Q01469 15.2 71.1 454 14 6909 -2.05 0.003
68 PARP2 Q9UGN5 66.2 4.5 16 2 164 -2.04 0.003
69 ATP1B1 P05026 35.0 30.4 111 8 1420 -2.02 0.001
70 LYN P07948 58.5 10.5 38 3 142 -2.02 0.001
71 SLC16A1 P53985 53.9 4.0 6 1 42 -2.00 0.001
72 MYO1E Q12965 127.0 8.5 14 6 156 -2.00 0.001
73 LONP1 P36776 106.4 36.4 291 26 4044 -1.99 0.001
74 MIA2 Q96PC5 159.7 1.0 4 1 40 -1.96 0.001
75 MGST3 O14880 16.5 15.8 55 2 184 -1.96 0.014
76 SLK Q9H2G2 142.6 15.4 60 12 441 -1.94 0.003
77 CORO7 P57737 100.5 19.4 51 8 578 -1.93 0.012
78 CYCS P99999 11.7 56.2 59 7 341 -1.93 0.002
79 SLC25A4 P12235 33.0 37.2 139 2 2153 -1.92 0.003
80 VDAC3 Q9Y277 30.6 50.5 223 10 3029 -1.91 0.002
81 PLEK2 Q9NYT0 39.9 30.3 38 5 244 -1.90 0.020
82 KIF20A O95235 100.2 10.7 13 5 265 -1.88 0.002
83 HMGCS2 P54868 56.6 42.3 209 11 3218 -1.88 0.004
84 GLOD4 Q9HC38 34.8 50.2 133 10 2362 -1.88 0.003
85 PGM1 P36871 61.4 44.1 98 17 1512 -1.87 0.002
86 HAX1 O00165 31.6 32.3 16 5 53 -1.87 0.003
87 GEMIN2 O14893 31.6 7.1 5 2 115 -1.86 0.001
88 MYO1D O94832 116.1 16.6 66 10 400 -1.85 0.002
89 NUCB2 P80303 50.2 21.0 30 6 85 -1.85 0.002
90 S100A16 Q96FQ6 11.8 29.1 19 2 491 -1.85 0.002
91 PRPSAP2 O60256 40.9 39.6 97 8 806 -1.82 0.007
92 ACO2 Q99798 85.4 38.1 308 22 4323 -1.82 0.003
93 PYGL P06737 97.1 41.9 319 23 3192 -1.81 0.001
94 VDAC1 P21796 30.8 69.6 501 17 9879 -1.80 0.002
95 STOM P27105 31.7 11.1 6 2 29 -1.80 0.004
96 UROD P06132 40.8 26.2 38 7 606 -1.79 0.003
97 PEPD P12955 54.5 29.8 106 13 1588 -1.79 0.004
98 PYCR2 Q96C36 33.6 36.9 81 8 1582 -1.78 0.003
99 PDE6D O43924 17.4 20.7 10 2 44 -1.78 0.007
100 GLUL P15104 42.0 10.2 7 2 86 -1.76 0.002
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Table 5.7: Results of low SILAC-ratios for single SILAC KM 12 OXA 
experiment. p-value from multi SILAC dataset analysed by LIMMA is included. 
 
 
101 USP13 Q92995 97.3 4.4 13 1 160 -1.76 0.003
102 PRDX2 P32119 21.9 66.7 316 14 3613 -1.76 0.003
103 MTFR1 Q15390 37.0 3.6 2 1 35 -1.76 0.003
104 DNA P11388 174.3 29.1 290 27 3751 -1.76 0.003
105 S100A6 P06703 10.2 16.67 10 2 123 -1.73 0.003
106 SFN P31947 27.8 48.8 265 8 2975 -1.73 0.008
107 PBK Q96KB5 36.1 30.7 48 6 697 -1.71 0.007
108 PAPSS2 O95340 69.5 35.7 94 13 1437 -1.71 0.002
109 MVK Q03426 42.4 18.2 25 3 183 -1.71 0.021
110 LBR Q14739 70.7 13.3 77 4 858 -1.70 0.002
111 PFKFB2 O60825 58.4 11.7 10 4 248 -1.68 0.009
112 SRSF4 Q08170 56.6 10.9 23 4 328 -1.68 0.012
113 TERF2IP Q9NYB0 44.2 15.5 32 3 541 -1.67 0.004
114 COPS7A Q9UBW8 30.3 9.5 11 2 224 -1.67 0.004
115 HACL1 Q9UJ83 63.7 14.7 20 4 368 -1.65 0.003
116 HSP90AA1 P07900 84.6 60.8 2582 37 41847 -1.65 0.006
117 DOCK6 Q96HP0 229.4 3.3 12 4 89 -1.65 0.001
118 ALDH1B1 P30837 57.2 42.7 215 15 3440 -1.63 0.003
119 GTPBP3 Q969Y2 52.0 12.8 7 3 147 -1.63 0.008
120 HSD17B11 Q8NBQ5 32.9 29.0 29 6 410 -1.63 0.043
121 ANP32E Q9BTT0 30.7 23.1 70 4 1544 -1.62 0.004
122 ATP2B1 P20020 138.7 21.1 106 17 1523 -1.61 0.002
123 HEATR3 Q7Z4Q2 74.5 10.7 35 6 276 -1.61 0.007
124 DDI2 Q5TDH0 44.5 41.6 41 9 450 -1.60 0.004
125 GOT1 P17174 46.2 50.6 373 12 5053 -1.60 0.004
126 ACSL1 P33121 77.9 27.1 61 12 469 -1.59 0.003
127 ABCB10 Q9NRK6 79.1 1.2 7 1 127 -1.58 0.009
128 LUC7L Q9NQ29 43.7 18.9 120 4 692 -1.58 0.003
129 ISG15 P05161 17.9 26.1 40 3 694 -1.58 0.006
130 KRI1 Q8N9T8 82.5 8.1 33 4 350 -1.57 0.015
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5.3.5.4 Bioinformatics analysis of proteins significantly changed due to 
resistance 
Only proteins classified in the altered group using the 5th percentile cluster 
analysis and with a significant p-value (p<0.05) obtained from LIMMA analysis 
were selected to develop protein network models by STRING (Protein-Protein 
Interaction Network) which will be discussed in the section 5.4.2.2. Finally, 
significantly altered proteins discussed were used to build up the Venn 
diagrams that show common significantly up-regulated and significantly down-
regulated protein in resistant sublines to OXA. These commonly up-regulated 
and down-regulated proteins presented at the intersection of the Venn diagrams 
will be discussed in detail further in section 5.4.2.1. 
 
 
Figure 5.9: Venn diagrams of OXA resistant sublines. Common significantly (a) up-
regulated; (b) down-regulated proteins using 5
th
 percentile threshold in two different 
resistant CRC sublines to OXA. 
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Figure 5.10: The figure shows a proteomic network model for DLD-1 OXA. Significantly altered proteins obtained by modification on 
EnrichNet and GO from the initial bubble map obtained in STRING. Proteins were classified into different biological processes groups 
represented with a circle.  Dotted arrows indicate the most relevant altered proteins and its main function as mediator of drug resistance.    
Key: Green arrow: significantly down-regulated protein; Red arrow: significantly up-regulated protein. 
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Figure 5.11: The figure shows a proteomic network model for KM 12 OXA significantly altered proteins obtained by modification on 
EnrichNet and GO from the initial bubble map obtained in STRING. Proteins were classified into different biological processes groups 
represented with a circle.  Dotted arrows indicate the most relevant altered proteins and its main function as mediator of drug resistance.  
Key: Green arrow: significantly down-regulated protein; Red arrow: significantly up-regulated protein. 
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5.3.5.5 Verification of experimental fold changes using housekeeping-control proteins  
 
 
Table 5.8: Commonly significantly altered proteins in two resistant sublines to OXA and which were used to identify new 
mechanisms of resistance involved in resistance to OXA. Key: Red: up-regulated, Green: down-regulated proteins. 
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Table 5.9: Control proteins that are unaltered by drug effects and which were used to evaluate the success of SILAC approach and 
statistical analysis applied to OXA resistant sublines. Log2 fold change of all control proteins were found close to zero in both OXA 
resistant sublines when they were compared to its respective parent-control cell lines. A Log2 fold change proximaly to 0, means that levels 
of the proteins quantified  were similar in light and heavy samples.  
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5.4 Discussion  
5.4.1 Evaluation of cross-resistance in the KM 12 OXA resistant subline 
To shed some light on the cross-resistance problem in CRC patients, a study of 
cross-resistance mechanisms using KM 12 resistant subline to OXA was done. 
Initially, two cross-resistance MTT screenings were done using KM 12 resistant 
subline to OXA (Fig. 5.3).  
Due to a significant cross-resistant effect observed for KM 12 OXA [30] resistant 
subline to doxorubicin, the OXA and doxorubicin combinational therapy should 
be avoided (Fig. 5.3d),   
Researcher partnerships could create data platforms using CRC cell lines and 
cross-resistance studies in vitro and in vivo, that may help to understand the 
cross-resistance process. Establishment of cross-resistance guides of 
successful combinational therapies would avoid cross-resistance problems and 
it will promote working on personalized combinational therapies based on the 
presence of specific mechanisms of resistance in each patient. 
5.4.2 Mechanisms of resistance to OXA identified by proteomics  
5.4.2.1 Significantly altered proteins seen in more than one OXA resistant 
subline 
The total number of commonly quantified proteins  in parent cell lines, DLD-1 
OXA and KM 12 OXA samples were 3716 and 3441 respectively, a similar 
number of the quantified proteins in all 5-FU resistant samples (see Chapter 3, 
section 3.3.7.1).  
From histograms, volcano plots and cluster analysis obtained from parent cell 
lines and resistant sublines analysis, it was observed that the OXA resistant 
subline with the highest number of significantly altered proteins was KM 12, 
followed by DLD-1, as it was observed for resistant cell lines to 5-FU. 
Four significantly altered proteins were found in both resistant sublines to OXA 
and they are discussed below. Due to the low number of commonly altered 
proteins in OXA resistant sublines, a deeper study of uniquely altered proteins 
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in each particular resistant subline to OXA was done and discussed in section 
5.4.2.2. 
5.4.2.1.1 Up-regulated proteins of DLD-1 OXA and KM 12 OXA (3) 
STIM1 is one of the three common significantly up-regulated proteins of DLD-1 
OXA and KM 12 OXA, that was also found in KM 12 5-FU resistant subline. 
STIM1 is a protein that regulates store-operated Ca2+ entry (SOCE) in the 
endoplasmic reticulum via its EF-hand domain. High levels of STIM1 protein 
have been observed in metastatic CRC patients. STIM1 overexpression has 
been associated with tumour size and tumour invasion features using  tissue 
microarray (TMA) technology in tissue samples from CRC patients at different 
stages of disease (Wang, Sun et al. 2015). Interestingly, use of STIM1 
overexpression has been suggested as an indicator of the transaction between 
colon and rectum adenocarcinomas too. The same study showed a direct 
correlation between STIM1 expression and a poor outcome in CRC patients 
(Wong and Chang 2015). New results found in this thesis with previous findings 
of STIM1 suggest that an in-depth study of STIM1 overexpression as a 
predictive biomarker involved in MDR to 5-FU and OXA should be carried out.  
A second significantly up-regulated protein in DLD-1 OXA and KM 12 OXA was 
the brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2). 
BAIAP2 mediates the interaction of membrane-bound small G-proteins with 
their effector proteins.  The main role BAIAP2 occurs during filipodia formation 
that is required for neurite growth (Oda, Shiratsuchi et al. 1999),  although its 
role in cancer is completely unknown. 
The third significantly up-regulated protein presented in DLD-1 OXA and KM 12 
OXA resistant sublines was the antigen peptide transporter 1 (TAP1). TAP1 is a 
transporter used by cells to remove antigens and xenobiotics molecules that 
cause damaging to cells. TAP1 transports harmful particles from the cytoplasm 
to the endoplasmic reticulum to be associated with MHC class I molecules (Ritz, 
Momburg et al. 2001). TAP1 can be considered as a drug transporter from the 
ATP-binding cassette (ABC) transporters family (ter Beek, Guskov et al. 2014). 
Role of TAP1 in resistance is known and it causes drug resistance to 
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gemcitabine in pancreatic ductal adenocarcinoma (Xu, Li et al. 2013) and 
mitoxantrone resistance in lung cancer cell lines (Boonstra, Timmer-Bosscha et 
al. 2004). In CRC, the expression of TAP1 seems to have a crucial role during 
early steps of carcinogenesis (Andersen, Vogel et al. 2015). However, its 
contribution to CRC resistance is completely unknown. 
5.4.2.1.2 Down-regulated proteins of DLD-1 OXA and KM 12 OXA (1) 
The unique significantly down-regulated protein commonly found in DLD-1 OXA 
and KM 12 OXA was the plasma membrane calcium-transporting ATPase 1 
protein (ATP2B1). ATP2B1 catalyses the hydrolysis of ATP coupled with 
calcium efflux from cells to the extracellular space. Nothing is known about 
ATP2B1 activity in CRC, however, it has been observed that  platinum 
compounds disturb calcium homeostasis within cells and downregulation of 
PMCA1 appears to be one of the first consequences (Piccolini, Bottone et al. 
2013). 
5.4.2.2  Significantly altered proteins unique to one of the OXA resistant 
sublines 
A summary table containing unique proteins altered in OXA resistant sublines 
derived from DLD-1 and KM 12 is shown below. Most relevant up-regulated 
proteins were classified based on the specific literature background of the 
protein in two groups:  
1) Altered proteins by direct effect of OXA exposure related to apoptotic 
pathways and stress proteins. 
2) Altered proteins by indirect effect of OXA exposure such as proteins involved 
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 Indirect effect of  OXA  Direct effect of  OXA  
DLD-1 OXA 
NOL3, FLH2, BABAM1, 
NQO1, G6PD, PARD6B, 
TJP3, OCLN, SEC24D, 
SLC2A1 
BRISC, BRE, TNFRSF10A, 
FAM175B, PMS2 
KM 12 OXA BET1, TFRC GATA6 
Table 5.10: Up-regulated proteins identified in OXA resistant sublines 
Detailed discussion of uniquely altered proteins showed in Table 5.10 is shown 
below. 
5.4.2.2.1 DLD-1 OXA 
5.4.2.2.1.1 Apoptotic process (1) 
Tumour necrosis factor receptor superfamily member 10A (TNFRSF10A) was 
found significantly up-regulated in DLD-1 OXA resistant subline. TNFRSF10A is 
the receptor of APO-2 ligand protein, the main function of TNFRSF10A is to 
mediate the extrinsic apoptotic signalling pathway via death domain receptors 
(Walczak, Degli‐Esposti et al. 1997). Contrary, high levels of nucleolar protein 3 
(NOL3) were found in DLD-1 OXA too. NOL3 inhibits extrinsic apoptotic 
pathways (Gustafsson, Tsai et al. 2004). Once tumour cells have been treated 
with an anticancer agent like OXA, cancer cells evolve and develop resistance 
to chemotherapy sometimes through disruption of the extrinsic apoptotic 
pathways. So, alterations of extrinsic apoptotic pathways may be a 
consequence of a direct drug effect that promotes apoptosis in treated cells, but 
also may product of an extrinsic apoptotic pathway evolution that acts as a 
mechanism of resistance like NOL3 up-regulation that inhibits cell death (Fulda 
and Debatin 2006). 
Four and a half LIM domains protein 2 (FHL2) mediates transcriptional 
regulation through various signalling pathways. Overexpression of FLH2 
decreases forkhead box protein O1 (FOXO1)-induced apoptosis by inhibition of 
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FOXO1 transcriptional process in prostate cancer cells (Yang, Hou et al. 2005). 
Inhibition of FOXO1 transcription occurs when FLH2 interacts with the amino 
terminus by DNA binding of FOXO1, blocking the interaction of FOXO1 with 
transcriptional coactivators (Puigserver, Rhee et al. 2003). Although FHL2 was 
significantly up-regulated in DLD-1 OXA, FOXO1 was not detected during 
protein quantification. So, it cannot be confirmed that FLH2 is promoting 
resistance to OXA by inhibition of FOXO1-induced apoptosis. 
5.4.2.2.1.2 DNA repair process (2) 
BRISC and BRE are two members of the BRCA1-A complex that were found 
significantly up-regulated in DLD-1 OXA resistant subline. BRCA1-A recognizes 
double-strand breaks (DSBs) that occur during DNA damage. DSBs are 
recognized by BRCA1-A through a specific recognition of Lys-63-linked 
ubiquitinated histones H2A and H2AX at DNA damage sites. Additionally, 
BABM1 is necessary during mitotic spindle assembly and microtubule 
attachment to kinetochores mediating its role by deubiquitinating of NUMA1, a 
protein that keeps nuclear matrix structure during non-mitotic phases (Wang, 
Hurov et al. 2009). BRE is essential for DNA DSBs repair by helping BRCA1-A 
complex to localize DNA damage sites, avoiding premature senescence and 
cell death (Shi, Tang et al. 2016). The role of the complex BRCA1-A is crucial 
during DNA repair after DNA damage that occurs during chemotherapy 
treatments. DLD-1 OXA resistant subline shows high levels of BABAM1 can 
control cell cycle checkpoint and maintenance of genomic stability that is 
affected during DLD-1 cell line exposition to OXA (Kim and Chen 2008).  
Additionally, BRE and BRISC up-regulation in DLD-1 OXA cell line enable DNA 
repair after OXA damage, promoting cell proliferation in adverse conditions as 
occurs during chemotherapy treatments. A significantly down-regulated protein 
of DLD-1 OXA subline that is related with DNA repair process is the BRISC 
complex subunit Abro1 (FAM175B). FAM175B interacts with NUMA1 
independently of BRISC complex. FAM175B promotes deubiquitination of 
p53/TP53, preventing p53/TP53 degradation and increasing apoptosis 
response of p53/TP53 in response to DNA damage.  A down-regulation of 
FAM175B in DLD-1 OXA lets p53/TP53 degradation that will decrease 
- 250 - 
 
p53/TP53 response to DNA damage, keeping tumoural cells alive in culture 
medium with OXA (Zhang, Cao et al. 2014). 
PMS2 was found significantly up-regulated in DLD-1 OXA and DLD-1 5-FU 
resistant sublines. This mismatch repair endonuclease protein forms part of the 
post-replicative DNA mismatch repair system (MMR) and it has been previously 
described in Chapter 3 (section 3.4.3.3.1). Although no evidence of OXA 
resistance by PMS2 overexpression has been found yet. Losing and inhibition 
of PMS2 increases p53-deficient cells apoptosis by losing of tumoural cell ability 
to arrest at the G2/M upon cisplatin treatment in mice primary fibroblasts. So, 
PMS2 inhibition increases the cytotoxic effect caused by cisplatin, doxorubicin, 
etoposide, docetaxel, and 5-FU. In conclusion, PMS2 may be studied as a 
complementary strategy to improve chemotherapy treatments (Fedier, 
Ruefenacht et al. 2002).  
5.4.2.2.1.3 Drug and small molecules metabolism (3) 
A significantly up-regulation of enzymes involved in redox homeostasis was 
observed in DLD-1 OXA resistant subline. One of the most significantly up-
regulated proteins was NAD(P)H dehydrogenase [quinone] 1 (NQO1). NQO1 is 
a very effective protector of cells by its antioxidant activity by decreasing 
cytology damage associated with oxidative stress induced by cytotoxic drugs. 
NQO1 is involved in detoxification pathways that occur during  drug treatments. 
NQO1 polymorphisms and NQO1 overexpression have been proposed as a 
resistance marker to OXA and 5-FU treatments in breast and gastric cancer 
patients (Geng, Chen et al. 2014, Yang, Zhang et al. 2014). This antioxidant 
effect of NQO1 is inherent in its catalytic mechanism: the obligatory two-
electron reduction of a broad array of quinones to their corresponding 
hydroquinones by using either NADPH or NADH as the hydride donor 
(Bianchet, Faig et al. 2004). Use of NQO1 has shown good results in cancer 
patients under a cisplatin treatment. Particularly, NQO1 shows a protective 
effect of renal failure nephrons in patients under a cisplatin chemotherapy 
(Gang, Kim et al. 2013). In breast, colorectal and cervical cancers, the high-
level expression of NQO1 was found to be associated with the late clinical stage 
of the disease, poor differentiation and lymph node metastasis (Ma, Kong et al. 
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2014, Yang, Zhang et al. 2014) Interestingly under stress conditions like 
exposure to drugs, NQO1 acts as protector of p53 protein. In 2001, Asher et al., 
described NQO1 overexpression as the main mechanism of p53 degradation 
inhibition in HCT 116 CRC cell lines (Asher, Lotem et al. 2001). NQO1 kidnaps 
p53 protein by a physical direct binding that protects p53 from 20S proteasomes 
degradation (Asher, Tsvetkov et al. 2005). In DLD-1 resistant subline to OXA, 
both p53 and NQO1 proteins were found significantly up-regulated. So, a 
possible mechanism of resistance could be behind the up-regulation of both 
proteins. The overexpression of p53 has been previously described as 
biomarker of poor prognosis in lymphoma cancer patients, oesophageal 
squamous cell carcinoma (ESCC) in advanced stages of cancer (Fu, Shao et al. 
2013, Yao, Qin et al. 2014).  Up-regulation of p53 has been described as a 
mediator of cisplatin resistance in non-small cell lung cancer (Tung, Lin et al. 
2015). Overexpression of p53 mediates resistance to cisplatin compounds by 
Nrf2 protein. Nrf2 is a key transcription factor for genes coding for antioxidants, 
detoxification enzymes, and MDR. Although Nrf2 was not detected in any of 
DLD-1 study samples, an up-regulated protein by Nrf2 was found 
overexpressed in DLD-1 OXA resistant cell line. This protein is the apoptosis 
regulator Bcl-2 protein that participates in apoptosis suppression and it has 
been related to drug resistance (Niture and Jaiswal 2012). 
Together with NQO1, GCLM and GCLC are other two redox homeostasis 
significantly up-regulated enzymes also observed in DLD-1 OXA resistant 
subline. GCLM and GCLC are two enzymes that metabolise the synthesis of 
glutathione from L-cysteine and L-glutamate. Glutathione maintains redox 
homeostasis that occurs during drug treatments. Different studies have shown 
that high levels of glutathione are presented in the IGROVCDDP cisplatin-
resistant ovarian cell line. This cisplatin-resistant cell line shows also an 
increased expression of the DNA repair gene BRCA1 that has been previously 
associated with cisplatin resistance (Stordal and Davey 2009). In the same way, 
BRISC and BRE components of BRCA1 have been found significantly up-
regulated in DLD-1 OXA resistant subline too (Stordal, Hamon et al. 2012). Due 
to the high similarity of cisplatin and OXA drugs, may be possible that up-
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regulation of the biosynthesis of glutathione and up-regulation of BRCA1 DNA 
repair system are taking part in a common mechanism of resistance to OXA in 
DLD-1. In breast cancer patients with poor prognosis, new studies suggest a 
new potential role of glutathione as a biomarker of cancer resistance (Gamcsik, 
Kasibhatla et al. 2012). High levels of glutathione have been found in the 
resistant human leukaemia cell line K562 too. K562 showed also 
overexpression of Glucose-6-phosphate 1-dehydrogenase (G6PD). G6PD is an 
enzyme that provides a reducing power of (NADPH) and pentose phosphates 
for fatty acid and nucleic acid synthesis (Tsukamoto, Chen et al. 1998). G6PD 
was found also significantly up-regulated in DLD-1 OXA. So, up-regulation of 
glutathione biosynthesis and up-regulation of G6PD may be a consequence of a 
similar mechanism of resistance in K562 resistant cell lines to cisplatin and 
DLD-1 OXA. 
5.4.2.2.1.4 Intracellular protein transport (4)  
In DLD-1 OXA cell line, one of the most interesting significantly up-regulated 
proteins due to its multifactorial role was the transcription factor p65. p65 is the 
most abundant component of the NF-kappa-B transcription factor. The NF-
kappa-B-p65 complex is involved in invasin-mediated activation of IL-8 
expression (Duckett, Perkins et al. 1993). Although NFκB-p65 function in CRC 
is not understood, it looks clear that high expression of NFκB-p65 in CRC 
patients is a common issue that plays an important role in colorectal 
tumourigenesis (Rezapour, Bahrami et al. 2016). Finally, it has been observed 
that the use of ursolic acid in CRC cell lines used in vitro and in vivo, enhance 
the cytotoxicity effect of OXA and this synergistic process occurs by inhibition of 
p65 phosphorylation (Shan, Xuan et al. 2016). 
A second significantly up-regulated protein in DLD-1 OXA and involved in 
intracellular protein transport was the transport protein Sec24D. Sec24D is a 
transporter protein that promotes transport of vesicles from the endoplasmic 
reticulum to the Golgi complex and its role as a mechanism of chemoresistance 
in CRC has been described in the Chapter 4, section 4.4.1.4 (Tang, Kausalya et 
al. 1999). 
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Other significantly up-regulated protein in DLD-1 OXA was the Golgi 
phosphoprotein 3 (GOLPH3). GOLPH3 is a protein involved in the anterograde 
transport of vesicles from Golgi membrane to plasma membrane, mediating in 
vesicle secretion process. GOLPH3 is involved in the modulation of mTOR 
signalling. GOLPH3 has been described in resistance of rapamycin (Scott, 
Kabbarah et al. 2009) in non-small cell lung cancer and colon 
adenocarcinomas. Furthermore, overexpression of GOLPH3 in CRC patients 
has shown to be a poor prognosis marker (Zhou, Wang et al. 2016). 
5.4.2.2.1.5 Cellular membrane transporters and cell membrane 
organization (5) 
Among all proteins involved in cell membrane organisation, there are four 
significantly up-regulated proteins that may be taking part of the same 
resistance pathway in DLD-1 OXA. These four proteins were the partitioning 
defective 6 homolog β (PARD6B), the MAGUK p55 subfamily member 5 
(MPP5), the tight junction protein ZO-3 (TJP3) and the occluding protein 
(OCLN). All these proteins mediate polarization processes and they increase 
tight junctions of epithelial cells (Hurd, Gao et al. 2003, Aho, Lupo et al. 2009). 
Additionally, MPP5 was found significantly up-regulated in DLD-1 IRI resistant 
subline (Tobioka, Isomura et al. 2002). It would be interesting to study the 
importance of tight junctions in colorectal cells as an able mechanism of 
resistance against OXA. There is no evidence of mechanisms of resistance 
development through increasing of tight junctions. However, some researchers 
have previously proposed as consequence of up-regulation findings in groups of 
genes related to cell-cell contact through tight junctions which may favor tumour 
survival. Finally, transmembrane proteins have been proposed to be more likely 
to remodel the tumour microenvironment increasing drug resistance (Morin 
2003).  
A singular and important up-regulated protein quantified in DLD-1 OXA resistant 
subline was the solute carrier family 2, facilitated glucose transporter member 1 
(SLC2A1) (GLUT1) protein. GLUT protein family consists of 12 members. 
Overexpression of glucose transporters has been broadly studied during the 
fight against cancer resistance. High levels of the GLUT protein family have 
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been found in patients with poor prognosis in all type of cancers (Szablewski 
2013). The role of GLUT1 is to transport glucose into the cells to be used as an 
energy source during cell proliferation and other cellular processes (Young, 
Lewis et al. 2011). An increase in glucose transport is also required for high cell 
proliferation rates of tumoural cells that express the EGFR (Weihua, Tsan et al. 
2008). Specifically, in CRC GLUT1 overexpression has been related to 5-FU 
resistance in vitro and in vivo. Use of GLUT1 inhibitors such as WZB117 
reverse resistant phenotype to 5-FU in CRC (Liu, Fang et al. 2014). 
Furthermore, in CRC patient levels of GLUT proteins are used as indicators to 
select preoperative chemo-radiotherapy (CRT) treatments (Saigusa, Toiyama et 
al. 2012). Overexpression of GLUT1 transporter is being studied as anticancer 
therapy to prevent increasing of tumour cells proliferation that leads to drug 
resistance (Calvo, Figueroa et al. 2010). Down-regulation of GLUT1 has been 
demonstrated to overcome the sensitive phenotype of cisplatin and 
daunorubicin in resistant cell lines of head and CRC respectively (Cao, Fang et 
al. 2007, Brophy, Sheehan et al. 2009, Wang, Li et al. 2013) However, the 
mechanism behind these results is unknown and it is not proposed to be by 
GLUT1 direct transport of neither cisplatin nor OXA.  
5.4.2.2.2 KM 12 OXA 
KM 12 OXA was one of the resistant cell lines with lowest resistance fold- 
change. Most of the significantly altered proteins using 5th percentile threshold 
were found down-regulated. This issue complicates the identification of target 
proteins to be used as resistant biomarkers and to avoid drug resistance. 
5.4.2.2.2.1 Apoptotic process (1) 
Only the transcription factor GATA-6 (GATA6) protein was found significantly 
up-regulated and involved in apoptotic processes of KM 12 OXA. Additionally, a 
significant up-regulation of GATA6 was also found in HT 29 5-FU resistant 
subline. GATA6 is a specific protein that regulates intestinal and gastric 
epithelial cell differentiation. Overexpression of GATA6 has been identified in 
undifferentiated and proliferating HT 29 cell line (Gao, Sedgwick et al. 1998). 
Another study with HT 29 and HT 55 showed that levels of GATA6 increase 
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after radiotherapy exposure and that the effect of irradiation may be increased 
after inhibition of GATA6, suggesting a key role of GATA6 in cell survival to 
radiotherapy (Cai, Shen et al. 2014). 
5.4.2.2.2.2 DNA repair process (2) and Drug and small molecules 
metabolism (3) 
No up-regulated proteins were found involved neither in DNA repair process nor 
in drug and small molecules metabolism in KM 12 OXA resistant subline.  
5.4.2.2.2.3 Intracellular protein transport (4)  
The unique significantly up-regulated protein involved in intracellular protein 
transport of KM 12 OXA was BET1 homolog (BET1). BET1 was also found 
significantly up-regulated in HT 29 5-FU. BET1 is a protein that mediates 
vesicle transport along the cytoplasm from the endoplasmic reticulum (ER) to 
the Golgi apparatus, playing its key role during vesicle fusion to the Golgi 
apparatus membrane. So, the activity of vesicles transport from ER to the Golgi 
apparatus may be involved in resistance development to OXA in KM 12 cell line 
(Petrosyan 2015). Inhibition of transporting activity of vesicles from ER to Golgi 
apparatus has been previously used as a strategy to reverse fludarabine 
resistance phenotype in resistant chronic lymphocytic leukemia (CLL) cells in 
vitro. The mechanism behind this overcome resistance resides in blocking 
protein trafficking by brefeldin A treatment leads to activation of caspases and 
increases sequestration of the survival factors APRIL and VEGF (Carew, 
Nawrocki et al. 2006). 
5.4.2.2.2.4 Cellular membrane transporters and cell membrane 
organization (5) 
Only transferrin receptor protein 1 (TFRC) was found significantly up-regulated 
in cell membrane transport and cellular membrane organization group. TFRC 
was found significantly up-regulated in HT 29 5-FU too. TFRC is involved in iron 
uptake via endosomes internalization after ligand binding to the transferrin 
receptor that activates endocytosis of endosomes (Rothenberger, Iacopetta et 
al. 1987). In CRC cells levels of TFRC are related with proliferation rate of 
tumour cells (Okazaki, Matsunaga et al. 2010) and it has been considered 
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TFRC as enhancer of platinum drugs delivery (Daniels, Delgado et al. 2006), 
especially for OXA (Suzuki, Takizawa et al. 2008). Additionally, use of 
liposomes for platinum drugs delivery is having success in animal models, 
where drugs are maintained inside interstitial space during a long time 
(Maruyama 2011). Finally, it has been observed in a human cervical cancer cell 
line resistant to OXA that resistance it was mediated by TFRC expression and 
maintained in xenograft animal models (Chen, Kuo et al. 2016). However, the 
mechanism behind TFRC overexpression to mediate OXA resistance is 
completely unknown. Thus, keeping in mind these previous publications about 
TFRC overexpression and the new findings presented, TFRC may be involved 
in endosome encapsulation of OXA decreasing free OXA inside cells and 
reducing cytotoxic effects of the drug. 
5.4.3 Conclusion 
The development of OXA resistant sublines was carried out by continuous drug 
exposure. From the three initial parent cell lines, only HT 29 cell line was not 
able to develop a resistant phenotype. Differences in resistance fold change 
between DLD-1 OXA (10.7) and KM 12 OXA (2.06) may be because initial 
parent cell lines have different genomic background and cellular sensitivity to 
OXA effects. A similar number of proteins (3500-4000) in both set of resistant 
sublines (DLD-1, KM 12) were quantified (Fig. 5.5). 
The main difference between DLD-1 OXA and KM 12 OXA resistant sublines 
was the large amount of down-regulated proteins seen in KM 12 OXA. 
According to resistance fold change results, DLD-1 OXA showed a higher 
resistance fold change. However, DLD-1 OXA showed fewer altered proteins 
than KM 12 OXA too. These proteomic results suggest that the type of altered 
proteins and their potential roles as a mediator of drug resistance are more 
relevant than the number of altered proteins that may not be directly related with 
cell survival under drug effects. Among the most significant up-regulated 
proteins in  DLD-1 OXA, PMS2 involved in DNA mismatch repair system may 
be studied as future targeted protein to avoid acquired resistance in CRC 
(Fedier, Ruefenacht et al. 2002). Among up-regulated proteins in KM 12 OXA, 
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GATA6 involved in intestinal epithelial cell differentiation process is known by its 
role during radiotherapy resistance (Cai, Shen et al. 2014) and its inhibition may 
be studied as target therapy during acquired resistance to OXA too. 
In summary, heterogeneity between both OXA resistant sublines was found and 
some potential mechanisms of resistance were identified by proteomics.                   
All these different changes in protein expression of DLD-1 OXA and KM 12 
OXA resistant sublines act together to increase survival of cells by being more 
resistant to OXA effects. This may explain difficulties in developing new drugs to 
avoid mechanisms of resistance against tumour cells able to develop multiple 
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6 Identification of new MDR mechanisms in CRC 
6.1 Introduction 
In addition to utilising the data to identify drug-specific mechanisms of 
resistance, results can also be used to identify potential mechanisms of MDR. 
However the analytical metrics used for investigating a single drug are not 
necessarily appropriate for studying 2 or more compounds as explained below. 
DLD-1 resistant sublines were used to find commonly altered proteins. These 
commonly altered proteins might not be so significantly relevant as commonly 
altered proteins found in different resistant sublines to the same drug. This is 
due to few limitations regarding the quantitative proteomics and SILAC 
approach and it is explained below.  
During protein fold change calculation, SILAC ratios from both parent sensitive 
cell lines were used as a reference control to be compared to the resistant 
subline. SILAC ratios from parent cell lines are product of three independent 
readings in the mass spectrometer. It is important to keep in mind that the 
resistant subline fold change is calculated with these same control SILAC ratios. 
Therefore, a standard deviation of a specific protein in SILAC parent cell lines 
will affect to the protein fold change estimation in all resistant cell lines 
compared to these controls. Consequently, fold changes of proteins found 
commonly altered in resistant sublines derived from the same original cell line 
(e.g., DLD-1 5-FU and DLD-1 OXA) have been calculated using the same two 
parent-control cell lines (e.g., DLD-1 P=9, DLD-1 P=65). Using the same two 
controls to estimate fold change of a protein in resistant sublines, the probability 
to find a similar fold change for the same protein is increased. However, fold 
changes of proteins found commonly altered in different resistant sublines 
derived from different parent cell lines (e.g., DLD-1 5-FU and KM 12 5-FU) have 
been calculated using different parent-control cell lines (e.g., DLD-1 P=9, DLD-1 
P=65 and KM 12 P=9, KM 12 P=55, respectively). So, their fold changes were 
calculated based on their respective controls, which are independent of each 
specific cell line. 
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All previous results showed in this thesis have been discussed under a high 
level of statistical significance. To be discussed all previously proteins have 
satisfied two requirements: 1) they are presented in the 10% group of the most 
altered proteins of each resistant subline and 2) differences in protein 
expression between resistant subline and its parent cell lines are significant in 
fold change terms. All these results previously described support the hypothesis 
of the existence of specific proteins that play individual roles to mediate 
resistance to drugs among different CRC cell lines. Although proteins discussed 
in Chapters 3-5 showed a high significance change at the expression level, 
most of these altered proteins have not shown any connection between different 
resistant sublines. These proteins have been described individually and they 
have not been grouped into a common cellular pathway that may explain the 
CRC resistance in global terms.  To identify altered proteins associated with a 
common cellular pathway presented in different resistant sublines, the whole list 
of proteins was studied, independently of 5th criteria. So, the fold-change 
difference between each resistant subline with its control parent cell lines was 
the unique factor analysed. This new and extended study that included also 
proteins with high significant fold change and not only proteins included in the 
10% of the most altered proteins, enable to extend the chance to identify new 
common pathways altered in more than one resistant subline. Hence, the aims 
of this chapter are to establish analytical metrics for identifying MDR candidates 
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6.2 Results 
6.2.1 Overall strategy 
An overall strategy flow chart followed during identification of proteins involved 
in MDR is shown below. 
 
Figure 6.1: Flowchart describing quantitative screening analysis used to identify 
altered proteins in MDR by SILAC approach. Initially, 200 μg of light sample and 
200 μg of heavy sample were mixed to get 400 μg (Light/Heavy) sample. L/H sample 
was separated in 12 L/H subsamples by SCX using 12 different EB. Each eluted 
subsample was analysed by MS in triplicate and all identified peptides were used for 
protein identification. From all peptides detected during MS analysis, only the three best 
peptides were used for peptides quantification in triplicate. After protein quantification 
three filters were applied: 1) Only proteins quantified from unique peptides with 2 or 
more PSMs were used 2) Only master proteins were considered 3) Mascot score applied 
for p<0.05. Proteins only quantified in heavy or light sample were removed. Finally, 
after LIMMA  analysis, proteins with highest Log2 fold change were used to identify the 
most commonly altered molecular pathways between the six different resistant sublines 
established using EnrichNet and GO analysis. 
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A new study with EnrichNet and GO was carried out using the Log2  fold change 
results obtained from LIMMA analysis.  
6.2.2 Overall view of altered proteins in MDR 
The most abundant and altered biological processes identified in resistant 
sublines were related to endosome compartments and multivesicular bodies 
(MVBs) formation. Alteration of the vacuolar protein sorting-associated protein 4 
(VSP4) was the most relevant. VPS4 is a mediator of cellular stress response 
found up-regulated in resistant sublines but not in parent cell lines. Additionally, 
the proto-oncogene SRC was found up-regulated in four resistant sublines too. 
So, a model containing these most relevant up-regulated proteins found in at 
least two resistant sublines was developed and a summary of these up-
regulated protein data is included in table 6.1. Additionally, CD63 was found up-
regulated in HT 29 5-FU and it was included in the model due to its known role 
as marker of MVB-derived vesicles and during endosome biogenesis 
(Ostrowski, Carmo et al. 2010). Furthermore, CD63 was included in the model 
as it has been described previously its interaction with Timp1 protein developing 
anoikis resistance in melanoma and Timp1 protein was found significantly up-
regulated in KM 12 5-FU and KM 12 OXA resistant sublines (Toricelli, Melo et 
al. 2013).  
Proteins VPS4, CD63, TIMP1 and SRC, shown in Table 6.1 were found up-
regulated among resistant sublines and are discussed in detail in section 6.3.1. 
Following validation of VPS4 expression in sensitive and resistant cell lines, 
evidence for involvement was investigated by studying expression of VPS4 and 
CD63 following treatment of parent cells with 5-FU. A WB study of VPS4 using 
the three parent cell lines DLD-1, KM 12 and HT 29 after three passages under 
5-FU exposure were done, to check if drug exposure increases VPS4 levels as 
it was predicted in the model. 
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Table 6.1: Most commonly altered proteins in six resistant sublines to 5-FU, OXA, IRI. Key: Red – Up-regulated proteins. # unquantified 
protein 
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6.2.2.1 WB validation of the proteomics findings for VPS4 expression in 
sensitive and resistant sublines 
The MDR model proposed is based on the idea that VPS4 regulates lysosome 
homeostasis that is altered under drug treatments, where cells are growing in 
metabolic stress conditions. Additionally, it is known that VPS4 is involved in 
late steps of the endosomal MVBs pathways, which have been discussed to 
play resistance to multiple drugs as it will be discussed below section 6.3.1. To 
confirm if increasing of VPS4 levels occurs during drug treatments, initially, new 
parent cell lines DLD-1, KM 12 and HT 29 were cultured under 5-FU conditions 
during three passages using IC50 of the drug for each cell line. Secondly, WB 
analysis was done to compare if levels of VPS4 had increased in the three cell 
lines after drug exposure and these results are shown below (Fig. 6.6). 
Furthermore, and immunocytofluorescence microscopy study was done for 
CD63 in DLD-1 5-FU to confirm results obtained from mass spectrometry. In 
order to validate proteomics results, expression of VPS4 (Fig. 6.2) was further 
analysed using WB. Validation of quantitative proteomics results was necessary 
to support the initial outcomes from SILAC-approach and LIMMA analysis. 
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6.2.2.1.1 VPS4 in resistant sublines to 5-FU 
 
Figure 6.2: WB of VPS4 in 5-FU sublines. On the left side, (a) (d) (g) WB results for 
VPS4 and ß-actin in parent cell lines and 5-FU resistant sublines. In the middle and 
right side, bar graph comparisons between WB results and SILAC-approach results for 
5-FU resistant sublines are shown. (*p≤0.05) 
SILAC  WB  
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VPS4 Western blot analysis of DLD-1 parent and 5-FU resistant subline showed 
a single band of 50 kDa molecular weight, which was slightly most intense in 
DLD-1 5-FU resistant subline sample. Band intensities were adjusted relative to 
ß-actin, which was analysed as a house-keeping protein. After correction for 
cross-experiment variations, the ratios for VPS4, closely matched the SILAC 
data (Fig. 6.2b,c). Similar results were obtained for VPS4 Western blot analysis 
of KM 12 parent and resistant sublines which showed the most intense single 
band of 50 kDa molecular weight in KM 12 5-FU and matched between WB 
results with previous SILAC data (Fig. 6.2e,f).  However, no differences were 
found in intensity bands for VPS4 in HT 29 resistant and sensitive sublines to              
5-FU (Fig. 6.2h,i). MDA-MB 231 cell line was used as positive control for VPS4 
during immunoblotting. Bar graphs were obtained from SILAC approach with 
Log2 (SILAC-ratios) data for each sample and tables show p-values obtained 
from SILAC approach by LIMMA statistics analysis. Data are presented as 
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6.2.2.1.2 VPS4 in OXA resistant sublines 
 
Figure 6.3: WB of VPS4 in OXA sublines. On the left side, (a) (d) WB results for 
VPS4 and ß-actin in parent cell lines and OXA resistant sublines. In the middle and 
right side, bar graph comparisons between WB results and SILAC-approach results for 
OXA resistant sublines are shown. 
VPS4 Western blot analysis of DLD-1 parent and OXA resistant subline showed 
a single band of 50 kDa molecular weight, which was slightly most intense in 
DLD-1 5-FU resistant subline sample. Band intensities were adjusted relative to 
ß-actin, which was analysed as a house-keeping protein (Fig. 6.3a). After 
correction for cross-experiment variations, the ratios for VPS4, closely matched 
the SILAC data (Fig. 6.3b,c). For VPS4 Western blot analysis of KM 12 parent 
and resistant sublines, a single band of 50 kDa molecular weight and similar 
intensity was found in all samples in KM 12 OXA, which showed a poor 
matched with previous results from SILAC approach  (Fig. 6.3e,f).  MDA-MB 
231 cell line was used as positive control for VPS4 during immunoblotting. Bar 
graphs were obtained from SILAC approach with Log2 (SILAC-ratios) data for 
each sample and tables showing p-values obtained from SILAC approach by 
SILAC  WB  
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LIMMA statistics analysis. Data are presented as mean; an asterisk represents 
significant differences (P≤0.05). 
6.2.2.1.3 VPS4 in resistant sublines to IRI 
VPS4 Western blot analysis of DLD-1 parent and IRI resistant subline showed a 
single band of 50 kDa molecular weight, which showed a similar intensity in all 
samples. Band intensities were adjusted relative to ß-actin, which was analysed 
as a house-keeping protein (Fig. 6.4a). Once cross-experiment variations were 
corrected, the ratios for VPS4, closely matched the SILAC data (Fig. 6.4b,c). 
MDA-MB 231 cell line was used as positive control for VPS4 during 
immunoblotting. Bar graphs were obtained from SILAC approach with Log2 
(SILAC-ratios) data for each sample and tables showing p-values obtained from 
SILAC approach by LIMMA statistics analysis. Data are presented as mean; an 
asterisk represents significant differences (P≤0.05). 
 
 
Figure 6.4: WB of VPS4 in DLD-1 IRI subline.  On the left side, (a) WB results for 
VPS4 and ß-actin in DLD-1 parent cell lines and DLD-1 IRI resistant subline.                  
(b) (c) Comparisons between WB results and SILAC-approach results for DLD-1 IRI 
resistant subline. Matched between WB and SILAC results is observed in all samples. 
6.2.2.2 ICF validation of VPS4 results identified by proteomics in DLD-1       
5-FU resistant subline 
After validation of VPS4 levels by WB in all samples, an additional ICF assay 
was done for VPS4 in DLD-1 5-FU and DLD-1 parent cell line.  
SILAC  WB  
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Figure 6.5: Subcellular localization of VPS4. Labelling of VPS4 in (a) DLD-1 5-FU 
resistant subline and (c) DLD-1 high generation control. Negative controls for (b) DLD-
1 5-FU and (d) DLD-1 high generation control. Cells were defrosted and grown during 
24 h in 6-well plates, fixed and analysed by fluorescence microscopy. For each well, 
1x10
4
 cells/ml were seeded and observed under microscope at 40x magnification. 
From results is clearly observed that labelling of VPS4 protein in DLD-1 5-FU 
resistant sublines was higher than in DLD-1 parent cell lines, confirming results 
previously obtained by both SILAC-approach and WB results (Fig. 6.2). 
Additionally, differences in size were observed, DLD-1 5-FU size was higher 
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than DLD-1 parent cell line and it was previously shown in Figure 3.14 in 
Chapter 3, section 3.3.1. Some of these differences in cell size, were observed 
between cells can be due to different cell cycle step between different cells and 
different depths of field during picture acquisition too. 
6.2.2.2.1 VPS4 levels are unaltered during short-term exposure to 5-FU  
According to previous results of VPS4 in resistant sublines, a model was 
developed. Model was based on the idea that VPS4 level is increased during 
drug exposure. Hence, after five passages of parent cell lines under 5-FU 
exposure during three generations, the expression of VPS4 protein was 
analysed. A single band of 50 kDa molecular weight was found in all samples 
and after intensities were adjusted relative to ß-actin, VPS4 expression was 
shown in bar graphs below. 
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Figure 6.6: VPS4 levels after 5-FU short-term exposure. (a) WB results for VPS4 
and ß-actin in DLD-1, KM 12 and HT 29 parent cell lines and parent cell lines grown 
during five passages under 5-FU exposure conditions. (b) Bar graphs showing 
comparisons between WB results for parent cell lines grown in normal RPMI media and 
parent cell lines grown in media with 5-FU during three passages. No significant 
differences were found among any of the all 7 samples analysed.  
No significant changes were found in VPS4 expression after five passages of    
5-FU exposure. Hence, overexpression of VPS4 observed in resistant sublines 
during SILAC experiments can be the result of other molecular processes 
alteration or the result of drug effects during long-term exposure. 
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6.2.2.3 CD63 expression patterns are similar to VPS4  
CD63 protein has been described as mediator of resistance in melanoma. 
Additionally, CD63 was found overexpressed in HT 29 5-FU resistant cell line 
but it was not quantified in the remaining samples during mass spectrometry 
analysis. Due to its important interaction with MVBs and VPS4 protein 
previously studied, an ICF study of CD63 was done in DLD-1 parent cell line 
and DLD-1 5-FU resistant subline. 
Labelling of CD63 was almost exclusively for DLD-1 5-FU resistant subline, and 
DLD-1 parent cell line did not show labelling. An additional graph bar was done 
containing the percentage of cells with high and low levels of CD63 expression 
(Fig. 6.8). Disperse internal vesicles (endosomes, MVBs) were observed under 
microscope within DLD-1 5-FU resistant subline but absent in DLD-1 parent cell 
line. These vesicles could be acting as drug storage bodies to decrease 
cytotoxic effect of free 5-FU inside the cells (Fig. 6.7). 
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Figure 6.7: Subcellular localization of CD63 in (a) DLD-1 5-FU resistant subline 
and in (c) DLD-1 high generation control. Negative control of CD63 in (b) DLD-1 5-
FU resistant subline and (d) DLD-1 high generation control. Cells were defrosted, 
growth during 24 h in 6-well plates, fixed and analysed by fluorescence microscopy. 
For each well, 1x10
4
 cells/ml were seeded and observed under microscope at 40x 
magnification. Internal vesicles containing CD63 expression were observed in (a) DLD-
1 5-FU resistant sublines but not in (c) DLD-1 parent cell lines. 
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Figure 6.8: Bar graph showing percentage of cells with strong and weak CD63 
labelling.  DLD-1 5-FU subline showed an increase in 22% of cells with internal 
vesicles (endosome/MVBs) which were observed under microscope at 40x 
magnification. 
6.2.3 DLD-1 resistant sublines to identify MDR mechanisms 
Two Venn diagrams showing commonly altered (a) up-regulated (b) down-
regulated proteins found in three different DLD-1 resistant sublines were done.  
These results may be affected by the limitation during quantification of SILAC-
ratio as same two control samples were used to calculate the fold change of the 
three DLD-1 resistant sublines during quantification data. However, it cannot be 
ruled out that some of these altered proteins may be playing an important role in 
MDR resistance. 
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Figure 6.9: Common significantly (a) up-regulated and (b) down-regulated 
proteins using 5
th
 percentile threshold in DLD-1 resistant sublines to 5-FU, OXA, 
and IRI. 
6.3 Discussion  
6.3.1 Discussion of MDR model established  
From altered proteins identified across the 3 drug types, the vacuolar protein 
sorting-associated protein 4 (VPS4) is of most interest. It is known that VPS4 
promotes autophagy and tolerance of specific proteins and receptors during the 
metabolic stress in cancer cells. Cellular stress is a normal cellular response 
during drugs exposure and it is mediated by different proteins. Drugs cause 
stress at different biological processes within cells. Main effects of drugs over 
cells depend on the mechanism of action of the specific drug. Additionally, there 
are some additional alterations such as lysosome alterations or metabolic 
changes that normally are caused by homeostasis imbalance inside cells. 
These issues occur when cells are unable to remain in equilibrium between the 
internal and external microenvironment. Four of the common altered proteins 
shown in Table 6.1 were used to develop a protein network model based on 
VPS4 expression to explain MDR problem in established resistant sublines. 
Model is shown and explained in detail below.  
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Figure 6.10: MDR model proposed for MDR in CRC. Under drug stress conditions VPS4 involved in MVBs and endosome 
formation is up-regulated. High levels of VPS4 and high late endosome activity would increase CD63 releasing. CD63can act as cell 
surface receptor for TIMP1.  SRC and SDCBP are known proteins that under TIMP1 conditions play crucial role in cancer survival 
and proliferation. Additionally, high levels of SDCBP increase binding to the cytoplasmic tail of CD63 at the plasma membrane.
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The main role of VPS4 is to regulate lysosome homeostasis that is altered 
under drug treatments, which increase metabolic stress conditions (Li, Zhang et 
al. 2011). Additionally, VPS4 is involved in late steps of the endosomal MVBs 
pathway and it may promote autophagy and tolerance of specific proteins and 
receptors during the metabolic stress in cancer cells (Adell, Vogel et al. 2014). 
VPS4 recognizes membrane-associated ESCRT-III assemblies and catalyses 
their disassembly, possibly in combination with membrane fission. VPS4 
redistributes the ESCRT-III components to the cytoplasm for further rounds of 
MVB sorting (Herlevsen, Oxford et al. 2007). The main complex of MVB is 
formed by three proteins: namely major vault protein (MVP), v-PARP, and 
TEP1. In connection with this matter, present thesis shows up-regulation of 
MVP in all resistant sublines. Also, TEP1 was found up-regulated in all resistant 
cell lines to 5-FU, confirming a possible up-regulation of VPS4 protein. The 
function of drug transporter by vault proteins was published in 2003 and it is 
discussed to be involved in drug transport (Mossink, van Zon et al. 2003). 
Recent studies show that VPS4 overexpression promotes autophagy and cell 
proliferation during in vitro starvation increasing tumour growth and poor 
prognosis in human hepatocellular carcinoma. Whilst, regarding CRC, 
overexpression of VP4S has been found in intestinal epithelial cells with a high 
presence of apoptotic markers in patients with Crohn's disease and colorectal 
HT 29 cell line (Zhang, Wang et al. 2015). With respect to drug resistance in 
cancer, VPS4 overexpression was linked to anthracycline resistance in patients 
with primary breast cancers and it is associated with poor prognosis. This 
mechanism of resistance to anthracycline is mediated by cytosolic retention of 
the drug anthracycline in lysosomes (Li, Zhang et al. 2011). 
VPS4 overexpression observed by SILAC approach was validated by WB in all 
DLD-1 resistant sublines. Initial WB results for VPS4 expression obtained 
indicate that differences in bar graphs distribution between all resistant sublines 
studied by WB correlated with previous results from SILAC approach (Fig. 
6.4b,c). Unique differences observed may be due to the use of different 
experimental approaches and statistics analysis that may increase differences 
between both results. However, the general trend and profile of samples are 
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maintained between SILAC and WB results, confirming validity of SILAC 
approach. Unique difference was observed in KM 12 5-FU that showed up-
regulation of VPS4 only under SILAC approach (Fig. 6.2e,f). Hence, after 
validation by WB of VPS4 results obtained during SILAC approach, next step 
was to confirm that VPS4 overexpression is a direct consequence of drug 
exposure. After five passages of parent cell lines DLD-1, KM 12 and HT 29 
under 5-FU conditions levels of VPS4 were measured by WB (Fig. 6.6) to verify 
if drug treatments may increase levels of VPS4 as was shown in the MDR 
model developed. However, no significant alterations in VPS4 levels were found 
for any parent cell lines after five passages under 5-FU exposure. No difference 
seen in terms of expression for the parent line experiment with 5-FU may be 
due to the short-term of drug exposure. Establishment of resistant sublines is a 
long-term experiment which requires genomic changes that will lead into an 
adaptation process, which will lead into proteome changes by cell line evolution.   
Apart from the previous role of VPS4 regulating homeostasis under abnormal 
metabolic conditions, VPS4 is required for the exosomal release of syntenin-1 
(SDCBP) and the melanoma 1 antigen (CD63) proteins (Scott, Gaspar et al. 
2005, Baietti, Zhang et al. 2012, Colombo, Moita et al. 2013, Jackson 2016). 
Both SDCBP and CD63 proteins showed high levels of expression in most of 
the resistant sublines established. So, a high level of VPS4 might be required 
by tumour cells to increase releasing of CD63 and SDCBP proteins. SDCBP is 
a protein that binds to the cytoplasmic tail of CD63 at the plasma membrane 
and it is, therefore, part of the tetraspanin-enriched microdomains. 
Overexpression of SDCBP can limit internalisation of CD63, suggesting a role 
for SDCBP as inhibitor of CD63 endocytosis, increasing membrane levels of 
CD63 (Latysheva, Muratov et al. 2006).  
The other protein released by VPS4 was CD63. CD63 is a molecule encoded 
by the CD63 gene on human chromosome 12q13. CD63 was found 
overexpressed in all resistant cell lines with the exception of DLD-1 OXA, where 
it was not quantified. CD63 is associated with the membrane of intracellular 
vesicles and it may be expressed on the cell surface. CD63 is a protein of the 
tetraspanin family also known as transmembrane 4 superfamily. Tetraspanin 
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proteins participate in numerous physiological processes like cell adhesion, 
motility, and proliferation. Localization and expression of CD63 are mediated by 
the enzyme dolichyl-diphosphooligosaccharide-protein glycosyltransferase 
subunit 2 (RPN2) that mediates CD63 glycosylation in breast cancer cell lines 
(Tominaga, Hagiwara et al. 2014). However, no significant changes in 
expression of RPN2 were found in resistant sublines during proteomics 
analysis. CD63 may be variably glycosylated and it shows three main N-linked 
glycosylation sites, two sites relate to internalization or intracellular localization 
and another site of glycosylation (hCD63N172A) responsible for CD63 cell 
surface localization. The molecular weight of CD63 has been identified in WB to 
be 32, 35 and 50kDa depending on the glycosylation. A previous study of CD63 
overexpression at mRNA level has been linked high levels of CD63 mRNA to 
metastasis and invasiveness in ovarian cancer (Zhijun, Shulan et al. 2006). 
An interesting role has been described for CD63 as a metastatic marker which 
acts as a signal transduction factor in exosomes (Ji, Greening et al. 2013). After 
these findings, CD63 has been considered also as endosome late endocytic 
compartments marker and exosome differentiation marker (Ostrowski, Carmo et 
al. 2010, Andreu and Yáñez-Mó 2014). CD63 show multiple roles in cancer 
development. CD63 plays a role in melanoma cell growth regulation and it is 
overexpressed in breast cancer cell lines resistant to doxorubicin (Turton, Judah 
et al. 2001).  Moreover, CD63 mRNA expression is positive in most of the 
breast cancer patients according to Huang et al. (Tominaga, Hagiwara et al. 
2014). 
However, the role of CD63 in CRC is still unknown and the only data available 
in CRC is that CD63 and α3-Integrin show different expression in human colon 
carcinoma cells with high and low metastatic properties (Sordat, Decraene et al. 
2002).  Additionally, alterations in expression of CD63 have been observed to 
occur in apoptotic peripheral blood leukocytes (PBL) of CRC patients after 5-FU 
drug administration. Although results of 5-FU effect on CD63 are contraries, it is 
clear that there exist a direct effect of the drug on the CD63 protein. However, 
the mechanisms behind the effects that 5-FU and other drugs have on CD63 
are unknown (Kimhi, Drucker et al. 2004). 
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To validate SILAC results for CD63 overexpression, ICF of CD63 in DLD-1 5-
FU subline was carried out. CD63 was found overexpressed in the resistant 
subline but not in DLD-1 sensitive cell line.  Additionally, an increase of 22% in 
number of cells with internal vesicles (endosome/MVBs) was observed.  
The hypothesis of overexpression of CD63 as a potential mechanism of MDR 
was reinforced by the finding of some up-regulated proteins related with CD63 
activity and which are discussed below. 
First protein related to CD63 activity is the proto-oncogene tyrosine-protein 
kinase Src (SRC) (Iizuka, Kudo et al. 2011). It has been observed that CD63 
promotes osteogenesis in osteosarcoma cell lines via SRC pathways. SRC has 
been described to be one of the proto-oncogenes with more relevance during 
chemotherapy resistance development, including resistance to 5-FU in CRC 
(Ahn, Lee et al. 2015).  During the proteomics study, SRC was found 
overexpressed in all resistant cell lines but not in parent cell lines. This fact, 
together with its interaction with CD63 suggests a common mechanism of 
resistance involving CD63 and SRC proteins. 
A second protein that is also known for its interaction with CD63 is the laminin 
subunit α-5 (LAMA5). LAMA5 is a ligand that interacts with the α3ß1/CD63 
complex and it was found overexpressed in DLD-1 5-FU, KM 12 5-FU, KM 12 
OXA and KM 12 5-FU resistant sublines, but also in HT 29 P=9. So, it cannot 
be deducted it LAMA5 is playing a role in the new mechanism of resistance 
discussed (Sordat, Decraene et al. 2002).  
A last known protein that interacts with CD63 is the metalloproteinase inhibitor 1 
(TIMP1).  CD63 acts as the surface cellular receptor of the growth factor TIMP1. 
TIMP1 regulates cell differentiation, migration and activates cellular signalling 
cascades via CD63 and ITGB1. In melanoma CD63 and TIMP1 interaction has 
been related with anoikis resistance by PI3-K signalling pathway (Toricelli, Melo 
et al. 2013). Multiple activities of TIMP1 have been described in different kind of 
cancers. TIMP1 has been associated with poor prognosis in breast cancer 
patients and it has been considered as predictive biomarker for fulvestrant 
resistance in breast cancer (Bjerre, Vinther et al. 2013). In CRC patients with 
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liver metastases, patients with high levels of TIMP1 showed poor response to 
palliative 5-FU treatment. (Gentner, Wein et al. 2009). These results have been 
complemented by recent studies about the role of TIMP1 in CRC progression, 
where TIMP1 is described as a marker of poor prognosis and metastasis 
mediated by MAPK pathway (Song, Xu et al. 2016). A similar situation has been 
found in human neural stem cells (hNSCs) with overexpression of TIMP1. 
These hNSCs cells showed a high capacity of migration during intracranial 
glioma development. This increasing of migration and proliferation was 
mediated by interaction of CD63 and TIMP1 that modulates cell spreading and 
the rearrangement of the cytoskeleton of hNSCs cells (Lee, Kim et al. 2014). 
TIMP1 was found also up-regulated in all five resistant sublines to 5-FU, OXA, 
and IRI. 
6.3.2 DLD-1 resistant sublines to identify MDR mechanisms 
Cancer is the result of an imbalance in protein expression levels and it is not 
just the product of a single protein overexpression. In the same way, drug-
resistance occurs through changes at protein expression level that can have a 
little or high impact depending on other related proteins. Hence, a small 
alteration in a single protein expression would be enough to carry forward drug-
resistance since other related proteins would foster the resistance process. 
Each cancer cell line shows diverse genomics and proteomics profiles and the 
unique common characteristic among different cancer cell lines is that they exist 
because, after an alteration in apoptosis and proliferation balance, the cell 
division process has been stronger than apoptosis. Disruption of the apoptotic 
and anti-apoptotic balance is a consequence of heterogeneous and constant 
evolution by a huge fund of mutations, where different proteins increase and 
decrease their levels influenced by other proteins expression. In summary, at 
the end of the tumorigenic process, proliferation pathways are predominant over 
the pro-apoptotic via. Therefore, both cancer and drug-resistance development 
would depend primarily on the expression level of a protein under a specific 
proteome and cellular microenvironment context. Hence, resistance phenotype 
development may happen through a complex proteome unbalance and not due 
to a single protein expression threshold exceeded. Based on this approach, 
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where a specific balance between proteins would be presented in more than 
one resistant subline, a MDR model in CRC cell lines was developed. 
6.3.2.1 Common significantly up-regulated proteins found in at least two 
of the resistant DLD-1 sublines 
Proteins significantly up-regulated in more than two resistant DLD-1 sublines 
were summarised in Table 6.2 below. 





















vesicles to the 
Golgi complex 
Unaltered Up-regulated   Up-regulated 
Table 6.2: Commonly up-regulated proteins quantified in more than two resistant 
DLD-1 sublines. 
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Only the upstream-binding protein 1 (UBP1) was found simultaneously as 
significantly up-regulated in the DLD-1 5-FU and DLD-1 OXA samples. UBP1 is 
a transcriptional activation factor that acts on different genes promotors such as 
CYP11A1 and TFCP2 (Miller and Auchus 2010). However, CYP11A1 was not 
found during proteomics analysis and TFCP2 was quantified but it did not show 
any change at expression level in resistant sublines. 
Between DLD-1 5-FU and DLD-1 IRI resistant sublines proteins, two proteins 
were found significantly up-regulated. The probable helicase with zinc finger 
domain (HELZ) and the NADH dehydrogenase [ubiquinone] 1 α-subcomplex 
assembly factor 3 (NDUFAF3). HELZ acts as helicase during mRNA 
metabolism and its induced expression in thymus and brain cell lines is 
associated with growth inhibition (Nagai, Yabe et al. 2003).  In relation to 
NDUFAF3, is involved in mitochondrial respiratory chain (Saada, Vogel et al. 
2009). 
Among DLD-1 OXA and DLD-1 IRI, seven different proteins were found 
significantly up-regulated. RHBDD1, SEC24D and MPP5 which have been 
previously described in Chapter 4, section 4.4.1, and four new up-regulated 
proteins not previously described: 1) Protein TSSC4 that is a candidate tumour-
suppressing subchromosomal transferable fragment candidate protein (Zaitoun 
and Khatib 2008). 2) Neuroguidin (NGDN) involved in the translational 
repression of cytoplasmic polyadenylation and its up-regulation in myeloid 
leukaemia cells has been associated with poor response to vincristine (VCR), 
etoposide (VP-16), and epirubicin (EPI) drugs (Chen, Lü et al. 2015). 3) Nuclear 
envelope pore membrane protein POM 121C and 4) Heat shock 70 kDa protein 
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6.3.2.2 Common significantly down-regulated proteins found in at least 
two of the resistant DLD-1 sublines 
Proteins significantly down-regulated in more than two resistant DLD-1 sublines 
were summarised in Table 6.3 below. 
Protein name Main function DLD-1 5-FU DLD-1 OXA DLD-1 IRI 
AMACR Lipids metabolism Down-regulated Down -regulated Down -regulated 
VPS45 
Chapter 3, in 
section 3.4.3.2.3 
















Down-regulated Down -regulated Unaltered 
GPD1L 
Chapter 3, in 
section 3.4.3.2.3 








Table 6.3: Commonly down-regulated proteins quantified in more than two 
resistant DLD-1 sublines. 
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The protein α-methylacyl-CoA racemase (AMACR) was the unique significantly 
down-regulated protein that was commonly found in the three DLD-1 sublines 
resistant to the three different drugs 5-FU, OXA and IRI. AMACR is involved in 
the biosynthesis of bile acid and lipids metabolism. Additionally, AMACR may 
play a role in cancer drug resistance through increasing the expression of 
enzymes such as cyclooxygenase-2 (COX-2) (Nakamura, Komiya et al. 2002). 
Between common significantly down-regulated proteins found, just four proteins 
were found in samples DLD-1 5-FU and DLD-1 OXA. One of these proteins was 
VPS45, previously described in Chapter 3, in section 3.4.3.2.3. Remaining three 
proteins are described below.  
Mitochondrial import receptor subunit TOM20 homolog (TOMM20) that 
mediates transport of mitochondrially synthesised pre-proteins from the 
cytoplasm (Yano, Terada et al. 2003). Interestingly, in Korean CRC patients, it 
has been found a correlation between the genetic variation of the gene 
TOMM20 and CRC susceptibility (Lee, Park et al. 2016). Second protein was 
the Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) whose main 
activity is to produce HMG-CoA a molecule that acts as limiting enzyme during 
cholesterol formation (Gillespie and Hardie 1992). Third protein was the Rho 
GTPase-activating protein 32 (ARHGAP32). This protein may promote cell 
growth regulation through Rho-regulated signalling pathways, especially during 
the development of neurons (Nakamura, Komiya et al. 2002). 
Two significantly down-regulated proteins were found in DLD-1 5-FU and DLD-1 
IRI. One was the protein GPD1L, which has been previously described in 
Chapter 3, section 3.4.3.2.3. The second protein was the serine 
palmitoyltransferase 3 (SPTLC3) that is involved in sphingolipids biosynthetic 
process and it has an unknown role in cancer. 
Finally, six proteins were found down-regulated among DLD-1 OXA and DLD-1 
IRI samples:  
1) Syntaxin-6 (STX6) involved in intracellular transport of vesicles to mediate 
endocytic recycling (Simonsen, Gaullier et al. 1999).  2) Rabankyrin-5 
(ANKFY1) also implicated in vesicle transporting and early endosomes 
- 286 - 
 
formation. Overexpression of Rabankyrin-5 has been link with the increase of 
the uptake process of solutes from the extracellular space (Schnatwinkel, 
Christoforidis et al. 2004). So, maybe down-regulation of Rabankyrin-5 may 
decrease this drug uptake from extracellular space into the cells and 
concentration of drug inside cells would decrease. 3) α-N-
acetylgalactosaminidase (NAGA) also involved in the metabolism of glycolipids 
and with an unknown role in cancer.  4) Protein NipSnap homolog 2 (GBAS) 
that metabolises oxidative phosphorylation process (Martherus, Sluiter et al. 
2010). 5) Lysophospholipase-like protein 1 (LYPLAL) with lysophospholipase 
activity. 6) Dehydrogenase/reductase SDR family member 1 (DHRS1) with 
oxidoreductase as its main molecular function. 
The use of resistant sublines from same original parent cell line by SILAC 
approach helps gather information about cell line evolution under different types 
of drugs. However, this information about altered proteins in different resistant 
sublines has the problem of using the same controls during proteomic SILAC 
ratios calculation. Hence, expression of the proteins in SILAC control samples 
will affect fold change estimation in different resistant sublines from the same 
parent cell line, increasing false discoveries. False discoveries would be 
consequence of a low or high protein during quantification of the SILAC heavy 
sample. 
Studies of different resistant sublines from different origin, leads into an overall 
view of the MDR process that can be used to collect data in the MDR model. 
Results presented in this model show a crucial role of CD63 in CRC resistance 
that has never been described before in DLD-1 5-FU resistant subline. An 
increase of CD63 may be caused by increase in VPS4 under drug stress 
conditions which promote releasing of CD63 protein and exosomes. So, it is 
proposed a new pathway involving VPS4 up-regulation as long-term drug 
response. Consequently, VPS4 function as a mediator for CD63 exosomal 
release and by TIMP1 binding, may together regulate cell-cell signalling 
processes and drug resistance responses in CRC. 
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7 General Discussion & Future Objectives 
Despite therapeutic advances, CRC still has a 5-year relative survival rate of 
45% (stage II-III), with the development of acquired resistance to treatment with 
anticancer drugs a major problem (Kufe, Pollock et al. 2003). There is a paucity 
of molecules which can be utilised as predictive biomarkers for drug response. 
Biomarkers have been discovered in CRC as a predictor of resistance to anti-
EGFR therapy, such as KRAS and PIK3CA mutations that now are part of 
routine testing in clinical practice (Zhang, Zheng et al. 2015). However, there 
are no biomarkers for predicting resistance to chemotherapeutic agents. 
Discovery of new mechanisms of resistance and predictive biomarkers would 
improve treatments and help decrease unnecessary toxicity and therapy and in 
addition these mechanisms could be investigated as therapeutic targets for 
modulation of acquired drug resistance. Tumours present molecular 
heterogeneity that must be considered when developing therapeutic strategies 
for a particular patient. Predictive biomarkers of drug response based on DNA 
sequences or RNA characterisation are not always easy to translate into the 
clinic. This is due to mutations identified from mRNA transcription strategies 
which in many cases show a low correlation with the amount of protein 
expressed (Seo and Lee 2004). Hence, the present thesis proposes both a new 
screening strategy based on proteomics using drug resistant CRC cell lines and 
a consequently multidrug model developed in vitro from CRC cell lines.   
Thus, an initial chemosensitivity panel of eight CRC cell lines was investigated 
to select three cell lines for the establishment of  resistant sublines. Based on 
the best correlations between drug doses and cell survival DLD-1, KM 12 and 
HT 29 were analysed. Development of CRC resistant sublines in vitro by 
continuous increasing of drug exposure is a complex process whose success 
depends on multiple factors. The main two factors that lead to success or failure 
of resistant subline establishment are: the respective genetic background of the 
cell line used and the nature of the drugs used and its mechanism of action.  
For the three drugs used to establish resistant sublines, 5-FU showed the 
lowest chemotoxicity and consequently, three different resistant sublines were 
established to this drug (DLD-1 5-FU, KM 12 5-FU, HT 29 5-FU). Two different 
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resistant sublines were developed for OXA (DLD-1 OXA, KM 12 OXA) and 
finally one resistant subline was developed with resistance to IRI (DLD-1 IRI). 
Mice xenograft models were developed using DLD-1 5-FU and relative 
sensitivity to 5-FU was seen to be maintained in vivo matching the results 
observed in vitro for DLD-1 5-FU and DLD-1 parent cell lines.  
The results described above support the hypothesis of the existence of different 
genetic backgrounds in CRC cell lines (Woerner, Yuan et al. 2010). Taking into 
account some available background from online sources such as ATCC, CLDB, 
ICLAC and ColonAtlas about the eight CRC cell lines used, microsatellite 
instability (MSI) information has been discussed as the most relevant (Sinicrope 
and Sargent 2012). It is known that the MSI is considered in CRC as the main 
source of hypermutable phenotype caused by the loss of DNA mismatch repair 
activity. Both DLD-1 and KM 12 have an MSI state that will drive somatic 
mutations, increasing development of resistant sublines (Ahmed, Eide et al. 
2013). However, HT 29 presents as a microsatellite stable (MSS) state, 
decreasing its potential to mutate and evolve to a resistant phenotype. Due to 
the lack of information available about cell line background, future experiments 
should be done to confirm the initial staging of these cell lines, as well as the 
cell line origin and treatments used in patient from were obtained. Next step 
was to identify what mechanisms of resistance are involved in the resistance of 
CRC established sublines. 
Identification of new mechanisms of resistance by a SILAC approach has been 
a useful technique to quantify differences in relative protein abundance between 
sensitive and resistant cell lines. As a metabolic labelling approach, the best 
advantage of SILAC over chemical-labelling methods is that samples can be 
mixed in an early stage during the sample processing, decreasing experimental 
errors (Lau, Suh et al. 2014). 
In terms of robustness, the SILAC approach has shown a high sensitivity, able 
to detect a high number of significant changes in protein expression using a 
small amount of sample. In comparison with other proteomics techniques such 
as WB, with the same amount of sample (around 100 μg of proteins lysate), the 
SILAC approach using an Orbitrap Analyser is able to produce quantification 
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results on average for ~3500 proteins, while WB with the same amount of 
sample shows results for ~ 4-5 proteins. Due to the large quantity of results 
obtained by this methodology, data  must be ordered from the highest level of 
significance that corresponds to a low level of noise under normal operating 
conditions. On the other hand, WB is based on the labelling of a single specific 
protein and the main noise occurs due to human errors during manual work in 
the laboratory. 
Reproducibility was similar under both proteomics techniques used with  
consistency from SILAC and WB results, which correlated for most of the 
validated proteins.  
Thus it can be considered that the SILAC-approach is an available technique to 
be used as a screening method to compare proteome expression between 
similar biological samples and a further analysis by WB may be used as 
validation technique to confirm the most relevant results obtained by mass 
spectrometry during initial screening. 
The latest trends in SILAC and proteomics studies are focused on super-SILAC 
methodology development. The main goal of super-SILAC is to achieve 
metabolic labelling in tissues and model organisms for its application to the 
study of clinical samples, and not just in cell culture. Hence, initial studies with 
Super-SILAC are based on stable-isotope labelling of organoids derived from 
human carcinoma tissues (Shenoy and Geiger 2015). This Super-SILAC mix 
achieves superior quantification accuracy compared with single cell line 
labelling from SILAC (Geiger, Wisniewski et al. 2011). 
Giving the complexity and heterogeneity of the tumoural cells, identification of 
what proteomic changes enable cells to develop resistant phenotypes is a 
highly challenging task. Proteome analysis complexity resides in the high 
number of proteins that are differently expressed among different tumoural 
cells. Hence, the challenge is to identify specific proteins involved in 
mechanisms of resistance. Subsequently, six resistant sublines were 
established in vitro and were analysed by SILAC approach.  
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An average of 3500 proteins were quantified for each sample and analysed by 
two different methods (R-LIMMA analysis and Cluster analysis) after median 
normalization and Log2 transformation of raw SILAC-ratio data. Lack of 
consensus about the best hypothesis test methodology for SILAC data 
measuring led to Nguyen et al., to compare the most used hypothesis test 
methodologies in SILAC data measurement (Nguyen, Wood et al. 2012). In 
their paper from 2012, the superiority of applying permutation test over t-test, z-
test, robust z-test and Wilcoxon signed-rank test to analyse SILAC proteomics 
results was demonstrated. Permutation testing has been broadly used in 
microarray gene analysis, network analysis and biomarker discovery (Al-
Shahrour, Díaz-Uriarte et al. 2004, Goeman and Bühlmann 2007, Walther and 
Mann 2011). 
A common response from treated resistant sublines was a trend of upregulation 
of proteomes from CRC cell lines. In all cases, the number of altered proteins 
was higher in resistant cells than in both parent control cell lines, independently 
of the number of passages. This can be explained through the drug effect on 
cell lines that after a long exposure may develop new genomic alterations, DNA 
damage, mutations and chromosome alterations caused by the chemotherapy. 
These alterations increase the variance of changes in protein expression of 
resistant sublines that were higher than in the non-treated cells. During 
comparison of control samples, no significant differences were found. However, 
the overlay for altered proteins was always higher in the long generation control. 
This is due to the changes in protein expression which occur during long-term 
cell culture passaging. Some passaging effects on the expression profile of 
efflux proteins and proliferation rates have been described (Hughes, Marshall et 
al. 2007, Siissalo, Laitinen et al. 2007).  
Chemotherapy resistance is a multifactorial process that depends on different 
variables like cell and tumour genetic variability and different genetic alterations. 
Tumour resistance is the main weakness of chemotherapy and this resistance 
may be acquired or intrinsic if it presents before drug treatment. Resistance 
limits the efficacy of chemotherapy agents and it is thought to be responsible for 
90% of treatment failure in metastatic cancer patients (Longley and Johnston 
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2005). Although intrinsic resistance has been a global problem during 
chemotherapy resistance history, developing more efficient new chemotherapy 
treatments based on personal therapy have been a factor in the increasing 
acquired resistance problem in CRC treatment (Gottesman 2002). Currently, 
specific treatments which are having success in clinical trials, such as Gefitinib 
and Erlotinib, are based on attacking target proteins to avoid resistance 
development problem. Gefitinib and Erlotinib are reversible inhibitors of tyrosine 
kinase activity of EGFR by blocking the ATP binding site (Chen, Solimando et 
al. 2013). Gefitinib and Erlotinib have shown a better prognosis during CRC 
treatment in patients that have tumours with overexpression of EGFR 
(Dienstmann, De Dosso et al. 2012). These results highlight that it is crucial to 
identify new genetic alterations and tumour proteome changes in each patient. 
The new knowledge about CRC heterogeneity is leading the development of 
new personalized therapies which are more effective against specific tumoural 
cells and with fewer side effects. Identification of altered protein expression 
among the resistant sublines has been used to establish different CRC resistant 
models based on the up-regulated and down-regulated proteins quantified that 
may be used to identify new proteins to be targeted for CRC therapy.  
Depending on the mechanism of action of the compound used, there are 
considerable differences in proteins altered during the establishment of resistant 
sublines. Cytotoxicity from compounds such as 5-FU that targets specific 
enzymes e.g. thymidylate synthase, to block synthesis of the pyrimidine 
thymidine avoiding DNA replication, may be avoided by different alterations of 
protein expression. These proteins can be involved in avoiding apoptotic 
pathways, DNA repair and metabolic pathways including 5-FU metabolism and 
5-FU transport. This broad range of proteins enables tumour cells to develop 
different altered protein networks with resistance activity. The data presented 
here show eleven common altered proteins with a potential role for the 
development of resistance to 5-FU. These proteins were MYADM, DDAH2, 
SARG (up-regulated) and SLC3A2, TAMM41, GPD1L, VPS45, RAP1GDS1, 
NCDN, BPNT1 (down-regulated). 
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Secondly, platinum compounds like OXA that binds covalently with 
macromolecules may block different processes such as DNA synthesis and 
transcription, being cell-cycle nonspecific compounds. This wide range of 
available targets makes survival of tumour cells harder. This occurs because 
cancer cells must develop multiple and different genomic and proteomic 
changes to cover the damage caused by different biological cellular processes. 
The presence of a high number of up-regulated proteins involved in multiple 
metabolisms pathways of resistant sublines to OXA may be a consequence of 
OXA disturbance within cells. The commonly altered proteins found in resistant 
sublines to OXA were BAIAP2, TAP1, STIM1 (up-regulated) and ATP2B1 
(down-regulated). 
Finally, there are more recent drugs like IRI that target crucial proteins which 
are required for cell survival such as topoisomerase I. IRI causes both lethal 
double-stranded breaks in DNA and inhibition of DNA replication, activating 
apoptotic pathways. This serious and direct mechanism of action that may 
activate pro-apoptotic pathways is the hardest mechanism of action to be 
avoided by tumour cells. So, the development of resistant sublines to IRI was 
the most difficult with only one cell line (DLD-1) successfully developed. 
Additionally, the fold change of this unique resistant cell line established (DLD-1 
IRI) was the lowest among all resistant sublines established to the three drugs 
and this can be due to the high chemotoxicity of this compound. 
The majority of the mechanisms of drug resistance identified in this thesis are 
mechanisms acquired by overexpression and down-regulation of proteins 
involved in apoptotic process (NOL3, TAOK1, PAWR, WRAP53, CYCS, 
GATA6, FHL2, PDCD4), DNA repair process (JUND, MMR, PARP2, BRCA1, 
PMS2, SMCs), drug and small molecules metabolism (DDAH2, TAMM41, 
GPD1L, BPNT1), and intracellular protein transport and cell membrane 
organization (MYADM, SAGR, APLP2, NCDN, BAIAP2, TAP1, STIM1, 
ATP2B1, CD44, LGALS3BP).   
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Among the significantly altered proteins quantified in resistant sublines, this 
thesis highlights results for commonly significantly altered proteins that were 
identified in more than one resistant subline. Based on these results new 
potential biomarkers of drug response in CRC to 5-FU and OXA are suggested 
for the first time. New mechanisms of CRC resistance suggested in this thesis 
include resistance to 5-FU by both up-regulation of MYADM, SARG, APLP2 and 
down-regulation of  SLC3A2, TAMM41, GPD1L, VPS45, RAP1GDS1, NCDN, 
BPNT1. For OXA new mechanisms of resistance in CRC involve both up-
regulation of BAIAP2, TAP1, STIM1 and down-regulation of ATP2B1. For 
validation in further studies, these proteins will be evaluated retrospectively in 
tumour biopsies from CRC patients to assess their value as predictive 
biomarkers for drug resistance or potential therapeutic targets. 
In considering MDR, commonly and not significant up-regulated proteins were 
used to design a MDR network model. The model is based on VPS4 as a 
mediator of drug resistance by regulation of lysosome homeostasis that is 
altered under drug effects (Li, Zhang et al. 2011). This mechanism of resistance 
can be related to the MVBs pathway, promoting autophagy (Adell, Vogel et al. 
2014). Additionally, these results were complemented by ICF studies of CD63 
expression in DLD-1 5-FU resistant subline which showed an increase in 
internal vesicles in resistant sublines. These internal vesicles might be acting as 
storage compartments for cytotoxic compounds, decreasing drug 
concentrations within the cells, and these studies warrant further investigation. 
In conclusion, in this study we have developed six resistant sublines to 5-FU, 
OXA and IRI, the three most common drugs used in CRC patients and analysed 
these proteomically using a SILAC-approach with Orbitrap Fusion™ Tribrid™ 
Mass Spectrometry analysis. Significantly altered proteins have been identified 
as either upregulated or downregulated in one or more of the resistant sublines, 
and thus the findings here provide a strong platform for further work to validate 
these proteins as either new biomarkers for drug resistance, or as potential 
targets for therapeutic intervention to modulate acquired drug resistance in 
CRC. 
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7.1 Future perspectives 
One of the main findings of this thesis is identification of proteins which either as 
biomarkers or therapeutic targets may be used to overcome the problem of 
acquired resistance in CRC patients. Extensive data collected in this study 
gives a good starting point to explore the drug resistance problem in CRC.                
It can be seen from the heterogeneity observed and generated with just 3 cell 
lines that development of additional resistant sublines derived from different 
parent cell lines would be useful to identify new commonly altered proteins. 
Some specific proteins have been identified, e.g. VPS4 for MDR and CD44, 
UMPS, CD63 for 5-FU and these can be studied through further experimental 
investigations using established models. Proteomics characterisation of 
resistant sublines leads to the identification of common proteins and molecular 
pathways that are relevant in drug resistance of different samples. Hence, 
alteration of these common proteins might be associated with a poor drug-
response. Therefore, after validation of results obtained in vitro and after the 
validation of some proteins results here presented as potential biomarkers in 
vivo a more heterogeneous range of CRC cell types predict tumour response to 
the different drugs will be investigated. Up-regulation and down-regulation of 
these same proteins in vivo and in biopsy of the tumour tissue or a sample of 
cells from the CRC patient can be used to study the potential role in resistance 
to a specific drug, or multiple drugs.  
Matching proteomic profiles from tumours and drug-response outcomes would 
reduce the resistance problem in the clinic, decreasing the risk of recurrence 
and resistance development. Characterisation of tumours based on proteomics 
and genomics features will be able to shed some light on the selection of the 
correct chemotherapy treatment. For example, proteins altered and involved in 
MDR must be represented in CRC tumours from CRC patients to be validated 
as good target candidates.  Additionally, the use of xenograft models derived 
from cancer cells of CRC patients may complement these studies and offer a 
choice to recapitulate tumour characterisation under different drug conditions 
before using the drug in the patient. In addition to the use of altered proteins as 
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new biomarkers of drug-response, these altered proteins can be used as target 
molecules for chemo/immunotherapies.  
After selection of the best proteins to be targeted as responsible for the partial 
phenotype of resistance, current drugs and inhibitors could be used to reverse 
the resistance phenotype in vitro. In cases established drugs are not available 
to target the specific proteins, new small molecules and novel drug 
combinations may be developed. Once, results in vitro have shown success 
with the drug, studies in vivo and xenograft models should be done before 
moving to clinical trials.  
This knowledge will allow researchers to develop new treatments for cancer and 
with technological advances such as new mass spectrometry analysers with 
even greater sensitivity; this will also allow further proteomic investigation of 
these drug resistant cell lines. This should allow lead even more information on 
the proteome to be obtained and improve the chances of a strong identification. 
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